Investigating the role of Rac1 in cardiovascular development by Dodds, Rebecca
  
Institute of Genetic Medicine 
 
Newcastle University  
 
 
 
 
 
 
 
 
 
 
 
 
Investigating the role of Rac1 in 
cardiovascular development 
 
 
 
 
 
 
Rebecca Dodds 
 
 
Submitted in accordance with the requirement for the 
degree of Doctor of Philosophy 
September 2016 
 
Supervisors: Dr Helen Phillips 
Professor Deborah Henderson 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Abstract 
 
Rac1 is a Rho GTPase which is involved in a variety of fundamental cellular 
processes, such as cell proliferation, adhesion and migration. In the adult heart, 
Rac1 is upregulated in cardiovascular disease and is required for the 
development of hypertrophy through production of oxidative stress. However, its 
expression and function during cardiovascular development remains unclear.  
Rac1 gene expression was characterised during mouse cardiac development, 
and using Cre-loxP technology it was identified that Rac1 is essential in the 
cardiomycoytes within the myocardium, but not in the epicardium, for the normal 
development of the mouse embryonic heart. Deletion of Rac1 specifically in the 
cells of the myocardium, the cardiomyocytes, using the TnT-Cre transgenic 
mouse line, resulted in severe defects of the ventricular myocardial wall as well 
as disrupted cardiac outflow tract alignment. Rac1TnTCre mutants displayed 
disrupted formation of ventricular trabeculae early in development. This resulted 
in abnormalities in the mature structures that form from the trabeculae, including 
the compact myocardial wall and interventricular septum. As a consequence of 
these myocardial defects, Rac1TnTCre mutant hearts become dilated and 
ballooned in shape leading to malalignment of the cardiac outflow tract, but with 
no overall loss of cardiomyocytes. This thesis shows that Rac1 and interacting 
partners, Mena and Vav2, are required for the organisation and movement of 
cardiomyocytes in the ventricular myocardial wall during early trabeculae 
formation.  
Congenital heart defects, including those affecting the myocardium and outflow 
tract, are the most common form of birth abnormalities. Additionally, defects 
occurring in utero can predispose to heart disease in later life. Therefore, 
understanding the role of genes that regulate myocardial wall and outflow tract 
formation could facilitate the development of preventative measures and 
treatments for congenital heart defects and cardiovascular disease.  
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Chapter 1. Introduction 
 
1.1 Mammalian adult heart and cardiovascular disease 
The mammalian adult heart is a four-chambered muscular organ that pumps 
blood through the blood vessels of the circulatory system to supply the body 
with oxygen and nutrients and to remove metabolic waste (Figure 1; adult heart 
schematic in A and dissected mouse heart in B). The muscular wall of the heart, 
or ventricular myocardium, is enveloped in a thin endocardial layer on the 
inside, and an epicardial layer on the outside (Figure 1A). The muscular wall 
contains contractile cardiomyocytes supplemented with connective tissue, and 
is innervated and vascularised. Cardiomyocytes account for around 30% of the 
total cells in the adult heart however they occupy around 75% of the total 
volume (Vliegen et al., 1991). The remaining cells and space is comprised of 
cardiac fibroblasts, endothelial cells and vascular smooth muscle cells which 
form the blood vessels and contribute to the interstitium surrounding 
cardiomyocytes (Camelliti et al., 2005) (Figure 1C).  
 
Figure 1: Adult heart structure.  
The mammalian adult heart is a four-chambered pump (schematic in A). The 
muscular wall of the heart is enveloped in a thin endocardial layer on the inside 
and an epicardial layer on the outside (A). The mouse heart is similar to the 
human heart (dissected mouse heart in B) and the muscular wall, or ventricular 
myocardium, is comprised of contractile cardiomyocytes supplemented with 
connective tissue and is innervated and vascularised (C). Cardiomyocytes (anti-
troponin red) are joined by intercalated discs (anti-connexin43, bright green) 
and are interspersed with fibroblasts (anti-vimentin, blue) (C). DAPI to label 
nuclei (yellow–green) (C) (Camelliti et al., 2005).  
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Cardiovascular disease (CVD) is the main cause of death in the United 
Kingdom (UK), accounting for over a quarter of all deaths and includes all 
diseases of the heart and circulation, including coronary heart disease, 
cardiomyopathy, atrial fibrillation (AF) and heart failure (British Heart Foundation 
(BHF)). Risk factors for CVD include genetic and environmental factors such as 
diabetes, smoking and poor diet. Furthermore, there is increasing evidence 
suggesting that abnormalities occurring in utero can predispose to CVD in adult 
life, therefore understanding the role genes play during development can help 
elucidate their role in disease development. 
1.2 Congenital heart disease 
Congenital heart defects (CHD) are the most common form of birth 
abnormalities, diagnosed in 1 out of 180 babies in the UK (BHF Statistics). 
There are many types of CHD and they can be grouped into three main 
categories; cyanotic heart disease, left sided obstructive defects and septation 
defects. The individual CHDs are listed in Table 1. 
 
Table 1: Types of congenital heart defects.  
Table adapted from Bruneau et al. (Bruneau, 2008). 
 
Several genetic and environmental risk factors for CHD have been identified but 
the majority of cases have no obvious cause. Genetic disorders such as Down’s 
syndrome can include CHD (Mortensen et al., 2012; Roberts et al., 2013; Stoll 
et al., 2015). Alternatively, maternal factors can increase the risk of CHD 
including diabetes, infections such as Rubella, and folate deficiency (Lee and 
Lupo, 2013; Cai et al., 2014; Shi et al., 2014; Simeone et al., 2015).  
Cyanotic Heart  Left Sided Obstructive 
Defects  
Septal Defects 
Transposition of the great 
arteriesTetralogy of fallot 
Tricuspid atresia 
Pulmonary atresia 
Ebstein’s anomaly of tricuspid 
valve 
Double outlet right ventricle  
Common arterial trunk 
Total anomalous pulmonary 
venous connection 
Hypoplastic left heart 
syndrome 
Mitral stenosis 
Aortic stenosis  
Aortic coarctation 
Interrupted aortic arch  
Atrial septal defect 
Ventricular septal  
defect 
Atrioventricular septal defect  
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Treatment for CHD is defect dependent. Mild defects, such as muscular 
ventricular septal defect (VSD), often heal independently and may not cause 
any further problems. However, surgery or interventional procedures are 
normally required for more severe defects. For example, in double outlet right 
ventricle (DORV) prostaglandin infusions are required to keep the ductus 
arteriosus open to allow oxygenated blood to enter the systemic circulation, 
followed by surgical repair (Lagopoulos et al., 2010). Current surgical 
techniques can often restore cardiac function, with 80% survival into adulthood 
(BHF statistics). However, patients with treated congenital heart disease often 
develop problems with heart rhythm or valves in adulthood, thus, requiring 
lifelong treatment and review. Therefore, it is important to understand the 
underlying causes of CHD to develop better treatments and preventions of CHD 
and adult cardiovascular disease.  
1.3 Embryonic heart development 
1.3.1 Overview of mammalian embryonic heart development  
Across vertebrates, cardiac development follows the same basic pattern; 
formation of a linear heart tube which undergoes lengthening and looping to 
form a four-chambered pump. Zebrafish, chick and mouse models have been 
extensively studied to dissect the pathways that initiate and regulate embryonic 
heart development. In mice, heart development is initiated at embryonic day (E) 
6.5, when the earliest cardiac precursors are positioned in bilaterally paired 
cardiogenic fields around the midline in the splanchnic mesoderm of the 
epiblast (Tam et al., 1997) (Figure 2A). These two fields, containing endocardial 
and myocardial precursor cells, converge on the midline to form the cardiac 
crescent (Figure 2B). The cardiac crescent then fuses at the midline to form the 
linear heart tube (DeRuiter et al., 1992; Buckingham et al., 2005), which 
consists of an inner endocardial tube, surrounded by a single layer of 
myocardial cells separated by cardiac jelly (Figure 2C). The linear heart tube 
undergoes a complex process of looping, and lengthens by the addition of both 
myocardial and endocardial cells to the outflow tract (OFT) pole. As the 
myocardial layer thickens and matures, myocardial cells begin to contract, the 
cardiac jelly between the endocardium and myocardium allows the contraction 
to pass to the endocardial tube, and the heart begins to beat at around E8.5. 
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During the process of looping, the heart loops to the right towards the midline 
forming the primordial atria, primordial ventricles and truncus arteriosus (Figure 
2D). The atria are positioned above the ventricles and ventricular bulging 
occurs, forming the right and left sides of the ventricle (Moorman and 
Christoffels, 2003) (Figure 2E). Cardiac jelly dissipates from the chambers and 
accumulates at the atrioventricular (AV) canal and in the OFT to form 
endocardial cushions (Figure 2F). The endocardial cushions are infiltrated by 
mesenchymal cells from the endocardium that have undergone epithelial to 
mesenchymal transition (EMT). The endocardial cushions at the AV junction are 
required for the formation of the AV septum and AV valves (tricuspid and mitral 
valves) (Anderson et al., 2003a). Similarly, the OFT endocardial cushions are 
necessary for OFT septation (septation of the truncus arteriosus into the 
pulmonary and aortic trunk) and formation of aortic and pulmonary valves 
(Anderson et al., 2003b). During development of the thickening myocardial wall, 
two main processes occur; trabeculation and compaction of the myocardium. 
Ridges of myocardium covered in endocardium extend into the atrial or 
ventricular lumen; initiating at around E9.5 (Kruithof et al., 2013) (Figure 2G). 
Trabeculation aids to increase myocardial oxygen and nutient exchange in the 
absence of coronary circulation, and also to enhance myocardial force 
generation (Sedmera et al., 2000). The trabeculae coalesce to form the 
interventricular septum (IVS) and are thought  to compact later in development, 
resulting in further thickening of the compact myocardium, during which 
ventricular septation occurs, followed by atrial septation (Anderson et al., 
2003a). By E13.5 the four-chambered heart is formed (Figure 2I).  
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Figure 2: Schematic of mouse embryonic heart development.  
Heart development is initiated at E7.0 when bilateral cardiogenic fields are 
positioned either side of the midline (A). These cardiogenic fields converge to 
form the cardiac crescent which then fuses to form the linear heart tube (B,C). 
At around E8.5 the linear heart tube loops rightwards towards the midline 
forming the primordial atria, primordial ventricles and truncus arteriosus (D,E). 
At E9.5 cardiac jelly accumulates at the atrioventricular (AV) canal and in the 
OFT to form endocardial cushions which are involved in AV and OFT septation 
(F). Trabeculation of the myocardium begins at around E9.5 where ridges of 
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myocardium covered in endocardium extend into the atrial or ventricular lumen 
(G).  NCC migrate into the aortic arch arteries and OFT contributing to the 
septation and remodelling of the OFT (J). Pro-epicardial cells spread over the 
surface of the heart in a monolayer and form the epicardium by E10.5 (K) and 
by E13.5 the four-chambered heart is formed (L). E; embryonic day. Figure 
adapted from (High and Epstein, 2008). 
1.3.2 Extracardiac cell populations  
The primary, or first heart field (FHF) is responsible for the formation of the 
initial linear heart tube. In addition to the FHF, several extra-cardiac cell 
populations contribute to the development of the heart after the formation of the 
linear heart tube, including cells originating in the second heart field (SHF), 
neural tube and pro-epicardium (PE).  The FHF contributes to cells in the left 
ventricle (LV) and atria, whereas the SHF contributes to the right ventricle (RV), 
OFT and atria. The cells from the PE form the epicardium.  
1.3.2.1 Second heart field  
Both the FHF and SHF populations originate in the cardiogenic fields, however 
these two populations do not differentiate into myocardium and endocardium 
simultaneously. The FHF is defined by the first cells to express cardiac markers, 
Mesp1, T-box transcription factor (Tbx)5 and Nkx2.5, and forms the initial linear 
heart tube. A later wave in Mesp1 expression defines the SHF, which also 
expresses LIM-homeodomain protein (Islet1), fibroblast growth factor (Fgf)8 and 
Fgf10. SHF cells contribute to the lengthening of the heart tube by their addition 
to the inflow and outflow region (Kelly et al., 2001; Mjaatvedt et al., 2001; Waldo 
et al., 2001; Waldo et al., 2005b) (Figure 3). SHF progenitors display 
differentiation delay and continued elevated proliferation relative to FHF 
progenitors (Buckingham et al., 2005). The continued proliferation and 
differentiation of SHF cells is regulated by FGF, bone morphogenetic protein 
(BMP), Hedgehog (Hh), Wnt signalling and Notch signalling pathways 
(Goddeeris et al., 2007; Prall et al., 2007; Cohen et al., 2008; Park et al., 2008) 
(Figure 4).  Conditional loss-of-function analysis of these signalling pathways in 
the SHF results in shortening of the cardiac OFT, leading to subsequent 
septation defects. FGF ligands implicated in SHF deployment include FGF3, 
FGF8 and FGF10 and are expressed in pharyngeal mesoderm and epithelia 
(Ilagan et al., 2006; Watanabe et al., 2010; Urness et al., 2011). Wnt and Hh 
signalling pathways are required to maintain proliferation and regulate 
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deployment of SHF cells (Klaus et al., 2012; Xie et al., 2012). Wnt/β-catenin 
signalling operates downstream of Notch in the regulation of progenitor cell 
differentiation and OFT morphogenesis (Klaus et al., 2012). SHF can give rise 
to three major cell lineages of the heart: cardiomyocytes, smooth muscle cells 
(SMC) and endothelial cells (Moretti et al., 2006). Endocardial cells lining the 
OFT are thought to derive from SHF progenitors (Laugwitz et al., 2008).  
 
 
Figure 3: The contribution of the second heart field (SHF) to the 
developing mouse heart.  
The relative position and contribution of the SHF progenitors (green) including 
anterior heart field (AHF) and posterior second heart field (pSHF) relative to the 
first heart field (FHF) cells (red) from the cardiac-crescent through to the looping 
stages of mouse heart development. SHF gives rise to three major cell lineages 
of the heart: cardiomyocytes, smooth muscle cells and also endothelial cells 
(Moretti et al., 2006). SHF cells contribute to the lengthening of the heart tube 
by their addition to the heart tube through the inflow and outflow region, and 
ultimately form the myocardium of the OFT, right ventricle and parts of the atria 
(Kelly et al., 2001; Mjaatvedt et al., 2001; Waldo et al., 2001; Waldo et al., 
2005b). cNCC; cardiac neural crest cells, PA; pharyngeal arches, PEO; 
proepicardial organ, OFT; outflow tract, LA; left atrium; LV, left ventricle; RA, 
right atrium; RV, right ventricle, Ao; Aorta, Pt; pulmonary trunk, AA; Aortic arch, 
Epi; epicardium, EPDCs; epicardial derived cells, IVS; Intraventricular septum, 
Tr; trabeculae, E; embryonic day (Zaffran et al., 2014). 
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Figure 4: Signalling pathways involved in proliferation and progressive 
differentiation of second heart field (SHF) cardiac progenitor cells in the 
early embryo.  
SHF cell proliferation and differentiation is regulated through various signalling 
pathway, including FGF, Notch, Hh, BMP and Wnt signalling (Francou et al., 
2013). CM; Cardiomyocyte.  
 
1.3.2.2 Cardiac neural crest cells  
Cardiac neural crest cells (NCC), originating in the dorsal neural tube, play an 
early role in restricting proliferation and controlling deployment of the SHF by 
modulating local FGF signalling (Waldo et al., 2005a) (Figure 4). Additionally, 
NCC migrate into and stabilise the endothelial cells of the pharyngeal arch 
arteries, contributing to the remodelling into the great vessels of the OFT 
(Waldo et al., 1996; Jiang et al., 2000) (Figure 2J). NCC also migrate into the 
endocardial cushions of the distal OFT and are involved in OFT septation (Kirby 
et al., 1983) (Figure 2J). As NCC enter the distal OFT, endothelial cells in the 
proximal region of the OFT undergo a process of EMT in response to 
myocardial-derived signals, to form, together with invading NCC, OFT cushions 
between the myocardial and endothelial layers (Sugishita et al., 2004). 
Convergence of OFT cushions in a spiral structure separates laminar flow from 
the embryonic left and right ventricles. 
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Figure 5: Neural crest cell (NCC) regulation of second heart field (SHF) 
proliferation and differentiation. 
NCC play a regulatory role in controlling SHF cell proliferation and 
differentiation through FGF signalling (Francou et al., 2013). CM; 
cardiomyocyte. 
 
1.3.2.3 Epicardial cells  
The proepicardium (PE) is a transient extra-cardiac cluster of cells, which form 
a cauliflower-like protrusion at the base of the developing heart (Viragh and 
Challice, 1981; Manner et al., 2001). The PE forms villi which protrude towards 
the myocardium of the looping heart tube. In mice, PE cells migrate as clusters 
of cells and adhere to the surface of the myocardium at E9.5, forming an 
epicardial layer that spreads over the surface of the heart in a monolayer, 
covering the ventricles and atria by E10.5 (Komiyama et al., 1987) (Figure 2K). 
Once the epicardium has completely enveloped the myocardium, a subset of 
epicardial cells delaminate from the epicardium and migrate into the sub-
epicardial space, from E11.5 to E12.5 (Mikawa and Gourdie, 1996; Dettman et 
al., 1998; Perez-Pomares et al., 2002).These epicardial derived cells (EPDCs) 
then migrate into the myocardium and also populate the AV cushions where the 
cells undergo EMT and differentiate into SMC, endothelial cells and fibroblasts 
(Figure 6) and contribute to the formation of coronary vessels and heart valves 
(Mikawa and Gourdie, 1996; Dettman et al., 1998; Perez-Pomares et al., 2002). 
FGFs and transforming growth factor beta (TGF) promote and inhibit EMT 
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respectively, and play a critical role in balancing the number of cells leaving the 
epithelial layer as mesenchymal cells (Morabito et al., 2001). Various signalling 
pathways regulate EPDC differentiation; Vascular endothelial growth factor 
(VEGF) and FGF signalling are required for endothelial cell differentiation; 
Tcf21, TGF-β and platelet derived growth factor (PDGF) signalling are required 
for cardiac fibroblast differentiation, and TGF-β and PDGF are required for 
smooth muscle differentiation (Figure 6). EPDCs have also been found to 
contribute to the cardiomyocyte lineage (Zhou et al., 2008). 
 
Figure 6: Epicardial epithelial to mesenchymal transition (EMT) during 
cardiac development. 
Epicardial cells undergo EMT and enter the subepicardial space. FGFs and 
TGF-β promote and inhibit EMT respectively, and play a critical role in 
balancing the number of cells leaving the epithelial layer as mesenchymal cells. 
Epicardial derived cells (EPDC)s then invade the myocardium, differentiate and 
populate the myocardium with endocardial cells (EC)s, smooth muscle cells 
(SMC)s and cardiac fibroblasts (CF). Various signalling pathways regulate 
EPDC differentiation; VEGF and FGF signalling are required for endothelial cell 
differentiation, Tcf21, TGF-β and PGDF signalling are required for cardiac 
fibroblast differentiation and TGF-β and PDGF are required for smooth muscle 
differentiation.  
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1.4 Outflow tract development and conotruncal heart defects  
Septation of the primitive cardiac chambers, the atrioventricular canal (AVC) 
and the OFT is necessary for the correct formation of the four-chamber heart. 
The morphogenic events that regulate these processes are described below.   
1.4.1 Cushion and valve formation  
Cardiac jelly that is secreted by the myocardium, concentrates itself into two 
pairs of bulges between the myocardial and endocardial layers of the primary 
heart tube. One pair lines the OFT, continuous through the proximal and distal 
regions, forming the OFT cushions (Figure 7). The second pair forms the AV 
cushions between the atrial and ventricle chambers. At E12.5 the cushions 
have fully formed and mainly consist of ECM proteins such as proteoglycans. 
Cushion mesenchyme is derived from the endocardium through EMT.  Various 
signalling pathways are involved in the initiation of EMT including Wnt, BMP, 
TGF-β and Notch (Timmerman et al., 2004; Wang et al., 2013). Wnt signalling 
from myocardial cells to endocardial cells initiates EMT and is central to cardiac 
cushion formation (Hurlstone et al., 2003). TGF-β, BMP and Notch signalling act 
to downregulate Vascular endothelial (VE)-cadherin pre EMT (Brown et al., 
1996; Jiao et al., 2006). In response to these signals from the myocardium and 
ECM, a subset of endothelial cells delaminate from the surface epithelium and 
transdifferentiate into mesenchymal cells. These mesenchymal cells migrate 
into the cardiac jelly and proliferate to cellularise the cushions (Eisenberg and 
Markwald, 1995). EMT requires down-regulation of cadherins, leading to cell 
detachment from laminin and the basement membrane. The OFT cushions are 
subsequently remodelled into semi-lunar valves at the angular junction of the 
proximal and distal regions of the OFT (Anderson et al., 2003b). The AV 
cushions are remodelled into the AV valves.  
1.4.2 OFT development  
The cardiac OFT forms at the arterial pole of the heart and connects the 
embryonic ventricles to the aortic sac. OFT morphogenesis is a complex 
process involving differentiation and proliferation of multiple cell types and is 
regulated by various signalling pathways, making it prone to abnormalities. 
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1.4.2.1 OFT formation  
After formation of the linear heart tube by the FHF, myocardial and endocardial 
cells are added to the arterial pole from the SHF progenitor population in the 
pharyngeal mesoderm. SHF cells are continuously added, leading to elongation 
of the heart tube (Kelly and Buckingham, 2002; Cai et al., 2003; Buckingham et 
al., 2005) (Figure 3). Deployment of SHF cells and regulation by NCC is critical 
for correct vessel formation. NCC and SHF cells work in coordination and NCCs 
regulate proliferation of SHF cells (Waldo et al., 2005a) (Figure 5).  
1.4.2.2 OFT remodeling  
Alongside AV septation and pharyngeal arch artery (PAA) remodeling, the OFT 
undergoes remodeling involving septation and rotation. OFT remodeling is a 
complex process with contributions from both genetics and haemodynamics, 
and occurs between E10.5 and E14.5 of mouse gestation (Yashiro et al., 2007). 
1.4.2.3 OFT Septation  
The OFT is septated into the base of the ascending aorta and the base of the 
pulmonary trunk, while both outflow vessels remain associated with the RV. 
OFT septation requires the ingrowth of the aorticopulmonary septum between 
the 4th and 6th PAA and the formation of the OFT cushions, and is regulated by 
NCCs. By E10.5, NCCs have invaded the distal region of the OFT and the 
transient aorticopulmonary septum is visible in the dorsal wall of the aortic sac 
(Anderson et al., 2003b). By E11.5, there is a rapid increase in the number of 
NCCs, due to their continuous migration into the outflow cushions and 
proliferation of cells already in the cushions (Sugishita et al., 2004; Kirby and 
Hutson, 2010), filling the distal outflow cushions and the dorsal wall of the aortic 
sac (Figure 7B). As a consequence, the dorsal wall of the aortic sac comes in 
contact with the most distal regions of the expanded outflow cushions and 
fuses, along with the fusion of the two cushions with each other, initiating 
outflow septation and separating the systemic and pulmonary circulations 
(Anderson et al., 2003b) (Figure 7C). Once septation is initiated by the fusion of 
the dorsal wall of the aortic sac with the distal OFT cushions, it proceeds in a 
distal to proximal direction (Waldo et al., 1998).  
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1.4.2.4 Rotation of the OFT and wedging of the aorta  
OFT cushion convergence is accompanied by rotation of the OFT wall in an 
anticlockwise direction, resulting in alignment of the aorta with the LV and 
pulmonary trunk with the RV (Bajolle et al., 2006) (Figure 7). This process 
requires hypoxia-driven programmed cell death in part of the distal OFT 
myocardial wall (Sugishita et al., 2004; Rana et al., 2007). The remaining distal 
OFT myocardial wall is incorporated into the right ventricular subpulmonary 
myocardium. It has been shown that the myocardium at the base of the aorta 
and pulmonary trunk is prefigured in the OFT of the heart and in subdomains of 
the SHF (Bajolle et al., 2008). ‘Wedging’ is the movement of the aorta behind 
the pulmonary trunk, between AV valves during OFT alignment and septation. 
The process of wedging is dependent on the retraction and rotation of the 
truncal myocardium and without rotation and wedging the aorta overrides the 
ventricular septum leading to DORV. 
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Figure 7: Cardiac OFT Septation. 
The OFT is septated into the base of the ascending aorta and the base of the 
pulmonary trunk. OFT cushions form through infiltration of NCC and 
proliferation of cells present within the cushions (A).  The two OFT cushions 
spiral around each other (B) and then fuse with each other, initiating outflow 
septation and separating the systemic and pulmonary circulations (C). Once 
septation is initiated it proceeds in a distal to proximal direction.  
 
1.4.2.5 Muscularisation of the OFT by myocardialisation  
At around E12.5, as the most proximal part of the cushions fuse, 
cardiomyocytes migrate and invade the flanking mesenchymal OFT cushions, 
leading to a gradual replacement of mesenchymal tissue with myocardium 
(Sugishita et al., 2004; Waldo et al., 2005b). This process is known as 
myocardialisation and leads to muscularisation of the OFT cushions and 
produces smooth muscular walls at the base of the pulmonary trunk and 
ascending aorta by E17.5 (van den Hoff et al., 2001; Rana et al., 2007). This 
process depends on multiple intercellular signalling pathways, including TGF-β, 
FGF, BMP, VEGF, Notch and non-canonical Wnt signalling (Wagner and 
Siddiqui, 2007). The fusion of cushions and muscularisation continues and 
completes the separation between the aorta and the pulmonary trunk (van den 
Hoff et al., 1999; Kruithof et al., 2003). 
1.4.3 Conotruncal congenital heart defects 
Genetic or environmental factors affecting initial formation or remodeling of the 
OFT contribute to the spectrum of conotruncal congenital heart defects seen in 
humans, accounting for 30% of all congenital heart defects (Srivastava and 
Olson, 2000; Bruneau, 2008). The most common OFT defects are shown in 
Figure 8. Tetralogy of Fallot (TOF) includes pulmonary stenosis, overriding 
aorta (OA), VSD, and right ventricular hypertrophy (Figure 8B). DORV occurs 
when both of the great arteries, the pulmonary artery and aorta, arise from the 
RV (Figure 8C). However, DORV represents a spectrum of congenital heart 
defects that ranges from VSD with 50% of the blood entering the aorta coming 
from the RV, to complete origin of the aorta from the RV. DORV is always 
associated with a VSD and can be classified by the location of the VSD; DORV 
with a committed (underlying) VSD or DORV with a non-committed VSD. A 
milder form of this CHD is OA where the aorta does not wedge properly 
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between the AV valves and is positioned above a VSD. More severe defects of 
the OFT include transposition of the great arteries (TGA) where the aorta and 
the pulmonary trunk are swapped in position (Figure 8D) and persistent truncus 
arteriosus (PTA) where the truncus arteriosus fails to separate into the aorta 
and pulmonary trunk (Figure 8E).  
 
 
Figure 8: Schematic of conotruncal heart defects.  
Tetralogy of Fallot (TOF) includes pulmonary stenosis, overriding aorta, VSD, 
and right ventricular hypertrophy (B). Double outlet right ventricle (DORV) 
occurs when both of the great arteries, the pulmonary artery and aorta, arise 
from the right ventricle (C). Transposition of the great arteries (TGA) is where 
the aorta and the pulmonary trunk are swapped in position (D). Persistent 
truncus arteriosus (PTA) is where the truncus arteriosus fails to separate into 
the aorta and pulmonary trunk (E). Adapted from (Neeb et al., 2013).  
 
As discussed above, the cardiac OFT is highly susceptible to malformations. 
Disruption in either SHF or NCC cell populations contributes to a spectrum of 
OFT defects in humans and animal developmental models. Abnormalities in 
SHF progenitors leads to impaired elongation of the OFT, resulting in disruption 
of OFT rotation and remodelling causing alignment defects, including TGA, 
DORV and OA (Abu-Issa and Kirby, 2007). Impaired elongation of the OFT can 
result from a failure of migration or addition of SHF cells to the developing OFT, 
or from defective arrangement, proliferation and maturation of these cells once 
they reach the OFT. For example, a combination of premature differentiation 
and defective cardiomyocyte polarity was shown to lead to defective OFT 
rotation, causing DORV in Vangl2SHF mutants (Ramsbottom et al., 2014). SHF 
deficiency is linked to OFT rotation defects, whereas abnormalities in NCCs 
commonly lead to a septation defect such as PTA. NCC deficiency can also 
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indirectly affect SHF development, resulting in a composite septation and 
alignment defect (Neeb et al., 2013).  
Alignment defects can be caused by an early disruption in either NCC and SHF 
contributions (Yelbuz et al., 2002), however myocardial and endocardial 
populations have also been shown to be important during OFT alignment. 
Failure of rotation of the OFT myocardial wall during OFT remodeling results in 
alignment defects, including TGA, DORV and OA (Bamforth et al., 2001; Bajolle 
et al., 2006). For example, in Pitx2deltac mutant embryos, PTA and DORV are 
associated with a myocardial rotation defect (Bajolle et al., 2006). Defects in 
formation of the OFT septum can also result from later failure of myocardial wall 
differentiation and anomalies in processes essential for remodeling, such as 
programmed cell death or myocardialisation. Compaction and rotation of truncal 
myocardium requires hypoxia driven apoptosis (Watanabe et al., 2001). In TGF-
β(2)-knockout mice, DORV and overriding tricuspid valve result from 
disturbances of myocardialisation, endocardial cushion differentiation, and 
apoptosis (Bartram et al., 2001). Intrinsic defects in OFT endocardial cells have 
been demonstrated to lead to OFT cushion anomalies (Zhang et al., 2009).  
Coordinated proliferation, migration and differentiation of the cell lineages 
involved is required for correct OFT morphogenesis. Identification of causative 
genetic mutations and modifiers of conotruncal CHD will provide further insight 
into the signalling pathways and cellular processes that drive OFT 
morphogenesis.  
1.5 Cardiac septation and septation defects  
1.5.1 Atrial and AVC septation  
Four mesenchymal tissues are required for atrial and AVC septation: the 
superior and inferior AV endocardial cushions, the mesenchymal cap (MC), and 
the dorsal mesenchymal protrusion (DMP) (Webb et al., 1998; Snarr et al., 
2008). By E11.5 all components of the AV septal complex are formed (Figure 
9). The muscular primary atrial septum (PAS) grows from the atrial roof towards 
the AVC, with the MC at its leading edge (Figure 9A). The PAS and secondary 
artial septum (SAS) then fuses to complete the septation of atrial chamber 
(Figure 9B) (Anderson et al., 2003a).  
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1.5.2 Ventricular septation  
Septation of the ventricle chambers occurs through three continuous processes; 
formation of the primitive IVS, growth of the IVS and subsequent closure of IVS. 
The IVS is initially formed from the coalescence of trabeculae branches which 
requires the absence of Hand2 in the developing IVS to inhibit regular 
trabeculae formation in this region (Togi et al., 2006) (Figure 9A). Growth and 
elongation of the IVS follows (Contreras-Ramos et al., 2009), leading to fusion 
of the IVS with AV cushions, dividing the ventricular chamber into left and right 
ventricle (Anderson et al., 2003a; Moorman and Christoffels, 2003) (Figure 9B). 
The IVS also connects with the endocardial cushions to separate the ventricular 
outlets of the OFT. The septation process is completed by convergence of the 
OFT, AV and ventricular septa. The RV initially holds the whole OFT, but fusion 
of the cushions separates the aorta and pulmonary trunk and the septum joins 
the wall of RV, pushing the aorta to the LV, and leaving the pulmonary trunk 
exiting from the RV (Waldo et al., 1998).  
 
 
Figure 9: Atrioventricular (AV) septation during cardiac development. 
Formation of the major cushions between the IVS and AS is essential as all 
components of the AV septum fuse to them. The muscular PAS grows from the 
atrial roof towards the AVC, with the MC at its leading edge (A). This muscular 
outgrowth partially septates the atrial chamber and leaves an opening (the 
ostium primum) between the MC and the AVC (A). The MC then merges 
anteriorly with the AV cushions and posteriorly with the DMP, to seal the ostium 
primum (B). Septation of the ventricle chambers occurs through formation and 
growth of the IVS (A). Subsequent closure of IVS, as it fuses with AV cushions, 
divides the ventricular chamber into left and right ventricles (B). RA; right atria, 
LA; left atria, RV; right ventricle, LV; left ventricle, IVS; interventricular septum, 
PAS; primary atrial septum, AS; atrial septum, AVS; atrioventricular septum, 
MC; mesenchymal cap, DMP; dorsal mesenchymal protrusion.  
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1.5.3 Septal defects 
Abnormal chamber septation results in CHD, including atrial septal defects 
(ASD), VSD and atrioventricular septal defects (AVSD). These defects cause 
abnormal cardiac shunting and may lead to congestive heart failure (Brickner et 
al., 2000). ASD and VSD are a defect in the septum that separates the right and 
left atria and ventricle, respectively (Figure 10, B and C). The ventricular septum 
consists of an inferior muscular portion and superior membranous portion. 
Membranous VSD is more common than muscular VSD, and is the most 
common CHD in humans (BHF statistics). There are also many subtypes of 
VSD depending on the position of the septation defect, for example, subaortic 
or subpulmonary. AVSD occurs when there is an incomplete fusion between the 
atrial and ventricular septum and can either be complete or partial (Figure 10D). 
Complete AVSD allows blood to flow between all four chambers through the 
central opening and contains a single, malformed valve. In a partial AVSD there 
are usually two valves between the atria and ventricles, however one of the 
valves (usually the mitral valve) is leaky.  
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Figure 10: Septal defects.  
Perturbations in the processes that lead to chamber septation can result in 
congenital heart diseases, including ventricular septal defects (VSD) (B), atrial 
septal defects (ASD) (C) and atrioventricular septal defects (AVSD) (D). ASD 
and VSD are a defect in the septum that separates the right and left atria and 
ventricle respectively and AVSD occurs when there is an incomplete fusion 
between the atrial and ventricular septum. RA; right atria, LA; left atria, RV; right 
ventricle, LV; left ventricle, IVS; interventricular septum, AS; atrial septum, AVS; 
atrioventricular septum.  
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1.6 Ventricular development  
1.6.1 Ventricular development overview 
The developing ventricle wall consists of three main layers; outer epicardium, 
myocardium and inner endocardium. The myocardium is separated from the 
endocardium and epicardium by cardiac jelly, and interstitial fibroblasts, 
endothelial cells and ECM surround the cardiomyocytes of the myocardium.  
Following the formation of the linear heart tube, myocardial cells undergo 
continued maturation and differentiation to become mature ventricular 
cardiomyocytes (Sedmera et al., 2000) (Figure 11). A subset of myocardial cells 
protrude into the ventricular lumen and form trabeculae, beginning at E9.5 
(Kruithof et al., 2013). In addition, ventricular myocardial cells proliferate rapidly, 
resulting in expansion of the compact myocardium (Figure 11C). Trabeculae 
cardiomyocytes become more differentiated than those in the compact 
myocardium, with reduced proliferative capacity (Harvey, 2002). Compared to 
compact layer cardiomyocytes, trabeculae cardiomyocytes are elongated and 
polarised with increased sarcomeric organization and clear myofibrils (Hirschy 
et al., 2006; Henderson and Chaudhry, 2011). At later stages in development, it 
is proposed that the trabeculae cardiomyocytes undergo compaction, from 
around E12.5, leading to further thickening of the compact layer, although 
evidence of this is lacking (Captur et al., 2016). Even after birth cardiomyocytes 
undergo structural changes; elongating into the characteristic rod-shaped 
structure, with fully aligned myofibrils and fully formed intercalated discs (ICD) 
restricted to myofibril anchorage (Hirschy et al., 2006; Martin-Puig et al., 2008) 
(Figure 12).  
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Figure 11: Ventricular cardiomyocyte formation and maturation. 
Cardiac progenitors from the FHF and SHF form the linear heart tube (E7.5–
8.5), which consists of an outer layer of myocardium (pink cells) and an inner 
layer of endocardium (green cells) separated by cardiac jelly (yellow) (A). The 
ventricular cardiomyocytes from the myocardial layer proliferate and form the 
compact zone (pink square-shaped cells) at around E10.5 (B). Furthermore 
epicardial cells from the proepicardium adhere to the myocardial layer and 
spread over the heart (blue cells) (B). Proliferation, differentiation, and migration 
of the inner layer myocardium leads to trabeculated cardiomyocytes (light 
orange cells) which protrude into the lumen of the ventricles at E12.5 (B). These 
trabeculated cardiomyocytes have a slower proliferative rate and show more 
organized sarcomeric structure. At later stages these cells undergo trabecular 
compaction (C) before becoming neonatal cardiomyocytes (D). Several weeks 
after birth the mature ventricular cardiomyocytes acquire the characteristic rod-
shaped structure with intercalated discs (red cells) (E). Figure adapted from 
(Martin-Puig et al., 2008). 
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Figure 12: Changes in cardiomyocytes morphology throughout embryonic 
and postnatal development. 
Cryosections are immunostained with anti-VE-cadherin to visualize adherens 
junctions (AJ) (green), sarcomeric marker titin 9D10 to show myofibrils (red) 
and DAPI to visualize nuclei (blue). During embryonic development (E14.5) (A) 
the AJ are distributed all around the cell, whereas during postnatal development 
(P2 - 6 months) (B-C) the AJ are restricted to the sites of myofibril anchorage, 
at the intercalated discs. At P2 and 6 month the cardiomyocytes are also larger 
and more elongated, and become polarised. Figure from (Hirschy et al., 2006). 
 
1.6.2 Cardiomyocyte structure 
Mature cardiomyocytes are characterised by binucleation, highly organised 
cytoskeletal structure and the appearance of mature ICD as well as high 
numbers of mitochondria, due to high energy demand. The actin and myosin 
fibres extend along the length of the cell and ICD are positioned between 
adjacent cardiomyocytes, to allow the transmission of contraction between 
cardiomyocytes. 
1.6.3 Cardiomyocyte cytoskeleton and adhesion  
1.6.3.1 Sarcomeric cytoskeleton 
The main components of the sarcomeric cytoskeleton are thin filaments, thick 
filaments and the Z-discs, and are crucial for cell contractility. One sarcomeric 
unit consists of intermingling thin and thick filaments, flanked by two Z-discs and 
repeats of these sarcomeric units form a myofibril (Figure 13A). The thin actin 
filaments are attached to the Z-discs and extend in the opposite direction from 
both sides of the Z-disc. Among the actin filaments are thick myosin filaments. 
The thin actin filaments consist of cardiac actin, α-tropomyosin and C-, Ι- and Τ- 
troponins (Figure 13B). Cardiac actin fibrils are formed from two chains of G-
actin monomers. Cardiac actin fibrils twist around each other, forming the 
double helix, sarcomeric F-actin. Each G-actin monomer has a binding area for 
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myosin and regulatory proteins, including tropomyosin, are also connected to 
the actin. There are two tropomyosin polymers per actin filament and these act 
to stabilise the thin filament, preventing its de-polymerisation (Mudry et al., 
2003). Cardiac troponin is a complex of three subunits; Troponin T (TnT), 
Troponin I (TnI) and Troponin C (TnC). TnT forms a complex with tropomyosin 
and allows protein kinase C (PKC) to regulate cardiomyocyte function 
(Sumandea et al., 2003). TnI is a key regulatory protein involved in cardiac 
muscle contraction and relaxation, and suppresses the actin-myosin interaction 
(Layland et al., 2005), and TnC binds calcium (Putkey et al., 1989).  
The thick filaments consist mainly of myosin and C-, H- and X-myosin binding 
proteins (Figure 13C). Myosin is a large complex comprised of two myosin 
heavy chains (MHC) and two pairs of myosin light chains (MLC1 and MLC2). 
Myosin heavy chains are thin molecules composed of two chains twisted 
around each other and contain myosin heads on one end of each chain. These 
myosin heads connect to the MLC and actin (Mornet et al., 1979; Sutoh, 1982), 
and also contain ATP binding sites (Szilagyi et al., 1979).  
The Ζ-disc structure is highly complex and functions to accumulate the 
mechanical energy produced by the interaction between myosin and actin and 
then transfer it to focal adhesions at the cell membrane (Frank et al., 2006). 
Anti-parallel actin thin filaments of opposing polarity begin from each side of the 
Z-disc, and are connected and stabilised in the Z-disc, through actin binding 
protein, α-actinin (Figure 13A) (Sjoblom et al., 2008). In cardiomyocytes, α-
actinin is localised in the Z line of cardiac myofibrils, as well as distributed at 
focal adhesions and along the cell-cell junctions (Yang and Xu, 2012).  
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Figure 13: Sarcomere composition.  
The main components of the sarcomeric cytoskeleton are thin filaments, thick 
filaments and the Z-discs. One sarcomeric unit consists of intermingling thin and 
thick filaments, flanked by two Z-discs and repeats of these sarcomeric units 
form a myofibril (A). Thin actin filaments are attached to the Z-discs through 
actin binding protein, α-actinin and extend from both sides of the Z-disc. The 
thin actin filaments consist of cardiac actin, α-tropomyosin and C-, Ι- and Τ- 
troponins (B). Among the actin filaments there are thick myosin filaments. The 
thick filaments consist mainly of myosin and myosin-binding protein C (C). 
Myosin is a large complex comprised of two myosin heavy chains and two pairs 
of myosin light chains (MLC). Myosin heavy chains contain myosin heads on 
one end of each chain that connect to the MLC and actin. Myosin binding 
protein C (MBP-C) plays an important structural and regulatory role between 
actin and myosin. Adapted from (Gautel and Djinovic-Carugo, 2016). 
 
1.6.3.2 Generic cytoskeleton  
The major and best-characterised generic cytoskeletal filaments are 
intermediate filaments (polymeric filaments composed of intermediate filament 
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proteins from a family of over 60 members), microfilaments (polymeric filaments 
of actin) and microtubules (polymers of tubulin dimers). 
Desmin is the main protein of the intermediate filaments in cardiac muscle. 
Desmin intermediate filaments provide structural integrity to the cell and tissues 
in the form of a three-dimensional (3D) skeleton that covers the entire 
cytoplasm (Figure 14). Desmin intermediate filaments play an important role in 
the preservation and unity of the myofibrils, extending from one Z-disc to 
another and also to the ICD at the cell membrane. The desmin intermediate 
filaments are also connected to the actin filaments, the nuclear membrane and 
cell organelles such as microtubules (reviewed in (Lowery et al., 2015)). 
In addition to functioning as part of the sarcomeric cytoskeleton, actin 
microfilaments, consisting of polymeric filaments of actin, are also present in 
cardiomyocytes. Similar to the desmin, intermediate filaments, the actin 
microfilaments form a 3D structure connecting the Z-disc, through α-actinin, with 
the focal adhesions and the ICD, to provide an additional connection between 
the intracellular and the extracellular environment (Figure 14). Several 
regulatory proteins are located at the sites of actin microfilament attachment to 
the costameres, such as α-actinin and Rho GTPases.  
Microtubules are tubular structures created by the polymerisation of α- and β-
tubulin heterodimers and align along the cell’s longitudinal axis (Goldstein and 
Entman, 1979) (Figure 14). In cardiomyocytes, only 25% of the total tubulin is 
polymerised in the form of microtubules, while the remaining 75% exists in the 
form of a non-polymerised protein in the cytoplasm (Palmer et al., 1998; 
Yamamoto et al., 1998). Microtubules are very dynamic elements with the 
capacity to de-polymerise and re-polymerise rapidly, therefore they can 
efficiently transmit chemical and mechanical stimuli within the cell and between 
cells leading to alterations in cytoskeleton flexibility and contraction capacity 
(Desai and Mitchison, 1997). Microtubule organising centre (MTOC) are 
polarised cell organelles and are apically expressed (Magdalena et al., 2003). 
The two most important types of MTOCs are the basal bodies associated with 
cilia and the centrosome associated with spindle formation (Figure 14). 
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 1.6.3.3 The sarcolemma  
The sarcolemma is the membrane of muscle cells. During embryonic heart 
development, two specialised regions of the sarcolemma develop; ICD for cell-
cell interaction and extracellular matrix (ECM)-integrin-cytoskeletal connections 
for cell-ECM contacts. 
1.6.3.4 ECM-cytoskeleton interactions  
Costameres (focal adhesions in vitro (Geiger and Bershadsky, 2001)) are lateral 
cell membrane attachments for many cytoskeleton networks, intercalating 
communication between the ECM, sarcolemma and the cytoskeleton (Hilenski 
et al., 1992) (Figure 14) and form as dense focal adhesion plaques at the cell 
membrane (Terracio et al., 1990). In addition to their structural role in cell 
attachment to the ECM, costameres transmit mechanical force between the Z-
discs of the actin cytoskeleton and the ECM, regulating mechanosignal 
transduction during cardiomyocyte growth and differentiation (Danowski et al., 
1992). The interactions at costameres requires transmembrane cell surface 
receptors, α- and β- integrins. The extracellular part of integrins interacts with 
the collagens, laminin and fibronectin of the ECM. The cytoplasmic domain of 
integrin receptors can directly bind actin-cytoskeleton proteins including talin, 
vinculin, paxillin, focal adhesion kinase (FAK) and α-actinin. These proteins, in 
turn, interact with the actin filaments and connect the costameres with the Z-
discs (Sharp et al., 1997). 
During the establishment of the costameres in early cardiac development, 
fibroblast-secreted collagens attach to cardiomyocyte cell surface and are 
consistent with the distribution of β1 integrin receptors at the sarcolemma and 
also with the formation of de novo premyofibril Z-bands internally (Markwald, 
1973; Borg et al., 1983; Tokuyasu, 1989; Carver et al., 1994; Sharp et al., 
1997). Additionally, focal adhesions are important during the de novo formation 
of premyofibrils near the cell membrane at the leading edge of migrating cells 
(Dabiri et al., 1997). Disruption of the costameres results in abnormal myofibril 
alignment (Shiraishi et al., 1997). These findings suggest that costameres and 
focal adhesions play an important role in the earliest steps in myofibrillogenesis 
in myocyte development and in cell migration.  
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1.6.3.5 Cell-Cell adhesion 
Cardiomyocytes are attached to each other through ICD. The ICD is exclusive 
to cardiomyocytes and functions to connect adjacent cells to enable the 
transmission of cell contraction and allow communication between cells. The 
ICD consists of different types of adhering cellular junctions including 
desmosomes, adhesions junctions (AJ) and gap junctions (Figure 14). 
Desmosomes and AJ allow transmission of mechanical signals, whereas gap 
junctions allow the passage of electrical signals. All three types of junctions are 
restricted to the ICD postnatally, however, desmosomes and AJ show polarised 
expression more rapidly than gap junctions (Angst et al., 1997; Hirschy et al., 
2006).  
The desmosomes bind intermediate filaments and join cardiomyocytes together 
to prevent detachment of cells during normal contraction (Figure 14). The 
desmosomes are formed by desmoglein-2 and desmocollin-2 transmembrane 
proteins, which establish a transcellular connection (reviewed in (Harmon and 
Green, 2013; Patel and Green, 2014).  
The AJ are attachment points for sarcomere actin filaments at cell-cell contacts 
and thus transmit contraction between neighbouring cardiomyocytes (Zuppinger 
et al., 2000) (Figure 14). The main proteins of the AJ comprise of 
transmembrane proteins including E- and N-cadherin and β1D integrin and 
cytoplasmic proteins including α-, β-, γ- (plakoglobin) and p120-catenins, 
vinculin, metavinculin, and a GTPase activating protein (GAP family protein) 
(Tepass et al., 2000). In the AJ, cadherins recruit β-catenin molecules onto their 
intracellular regions. β-catenin then associates with another catenin protein, α-
catenin which directly binds to the actin filaments, through α-actinin. The 
cadherin/β-catenin/α-catenin complex is weakly associated to actin filaments, 
therefore is a dynamic, link to the actin cytoskeleton (Itoh et al., 1997; Muller et 
al., 2005). 
The gap junctions are key structures for ion transportation between adjacent 
cardiomyocytes as well as non-muscle cells of the myocardium (Severs et al., 
2001) (Figure 14). Gap junctions are formed by six connexin molecules in the 
cell membrane. There are many types of connexins (Cx). In the ventricle 
myocardium, Cx-43 dominates and is essential for cell-cell coupling and normal 
cardiac function (Kolcz et al., 2002; Heinzel et al., 2005; Boengler et al., 2006; 
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Boengler et al., 2007), while Cx-40 and Cx-45 are associated with the cardiac 
conduction system (Severs et al., 2001).  
An additional cell junction in cardiomyocytes is the tight junction (TJ) (Hartsock 
and Nelson, 2008). TJ bind cells together and maintain the organisation of the 
plasma membrane of epithelial cells in an apical and a basolateral compartment 
(Figure 14). TJ are comprised of occudin and claudin membrane proteins 
(Furuse et al., 1998). Additional proteins, zona occludens (ZO), links claudins to 
the actin cytoskeleton, as well as recruiting signalling components, like atypical 
PKC (Itoh et al., 1999; Muller et al., 2005).  
 
 
Figure 14: Cardiomyocyte cell-cell and cell-ECM junctions.  
The major cytoskeletal filaments are intermediate filaments (polymeric filaments 
composed of intermediate filament proteins) (blue lines), microfilaments 
(polymeric filaments of actin) (pink lines) and microtubules (polymers of tubulin 
dimers) (green circles). During embryonic heart development, specialised 
regions of the sarcolemma develop. Intercalated discs (ICD) for cell-cell 
interaction, consisting of different types of adhering cellular junctions including 
desmosomes (blue), adhesions junctions (orange) and gap junctions (black). 
ECM-integrin-cytoskeletal connections (focal adhesions) (yellow) allow cell-
ECM interaction. Tight junctions (purple) bind cells together and maintain the 
organisation of the plasma membrane in an apical and a basolateral 
compartment. 
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1.6.3.6 Alterations in cytoskeletal, ICD or FA components cause cardiac 
abnormalities 
Studies investigating cytoskeletal and adhesion components in mice have 
suggested an important role of both the cytoskeleton, ICD and focal adhesion 
structures during cardiac development. For example, mice lacking α-
tropomyosin-1, a regulatory protein of the actin thin filaments, are embryonic 
lethal at E9.5 with severe cardiac defects (McKeown et al., 2014). The hearts of 
these mice were enlarged, misshapen and non-beating, with a thinned 
myocardium and fewer trabeculae. (McKeown et al., 2014). Desmin knockout 
mice show evidence of haemorrhage and have fibrotic, ischemic hearts with 
defective mitochondria composition and function (Li et al., 1996; Linden et al., 
2001). An alternative study found that Desmin null mice display cardiomyocyte 
cell death and abnormal cardiomyocyte ICD, sarcolemma and myofibrils 
(Thornell et al., 1997). A more recent study showed that Desmin null mice 
develop cardiomyocyte hypertrophy and dilated cardiomyopathy with 
cardiomyocyte cell death, calcific fibrosis and multiple ultrastructural defects 
(Weisleder et al., 2004).  Additionally, mutations in DESMIN have been 
identified in patients with Desmin-related cardiomyopathy (Goldfarb et al., 
1998). Cx-43 null mice die at birth (Zhao et al., 2005) and display delayed OFT 
myocardialisation, as well as delayed α-smooth muscle actin (α-SMA) 
expression in the proximal OFT septum (Qi et al., 2011).  
1.6.4 Cardiomyocyte cell cycle  
During embryonic development, cardiomyocytes proliferate rapidly and the rates 
of karyokinesis and cytokinesis are equal. Embryonic cardiomyocyte 
proliferation peaks at a rate of around 30% at E12.5 in the developing 
ventricles. The overall rate of cardiomyocyte proliferation gradually declines 
during later stages of embryogenesis. Following birth, cardiomyocytes lose the 
ability to proliferate and withdraw from the cell cycle. There is a final round of 
karyokinesis without the accompanied cytokinesis, resulting in binucleated 
cardiomyocytes. The initiation of binucleation is associated with downregulation 
of positive cell cycle regulators such as cyclins and cyclin dependent kinases 
(Cdk), as well as an increase in negative cell cycle regulators such as Cdk 
inhibitors p21 and p27 (Soonpaa et al., 1996). Cell death in the developing 
31 
 
heart is rare and has been shown to be restricted to specific areas in the chick, 
with very low occurrence in the ventricular myocardium (van den Hoff et al., 
2000; Cheng et al., 2002).  
During early cardiac development, cardiomyocyte cell cycle activity is closely 
associated with cardiac differentiation and morphogenesis. The onset of 
cardiomyocyte differentiation during the formation of early linear heart tube is 
accompanied by a transient reduction in proliferation. This reduced proliferation 
rate recovers by E11 and contributes to the ballooning of ventricular chambers 
from the linear heart tube (Meilhac et al., 2003).  
1.6.5 Myocardial morphogenesis   
The early vertebrate embryonic heart is a two layered, linear heart tube with a 
luminal endocardial layer and an immature myocardial layer. Maturation of the 
linear heart tube involves myocardial thickening, trabeculation and 
establishment of the coronary vasculature and cardiac conduction system, with 
the contribution of the epicardial layer.  
The growth of the myocardium can be divided into two overlapping and parallel 
processes; trabeculation and expansive growth of the compact myocardial wall.  
During expansive growth, the compact layer undergoes extensive proliferation 
and thickening. This is concurrent with the formation of the coronary vasculature 
and maturation of the cardiac conduction system. Compact myocardial cells 
remain immature and highly proliferative. Endocardial and epicardial cells 
invade the developing compact myocardium and differentiate into coronary 
endothelial cells, SMCs and fibroblasts to form the coronary vasculature. 
Factors regulating compact myocardial growth include FGFs, Wnts, and retinoic 
acid (Merki et al., 2005). 
Trabeculation occurs after cardiac looping and results in a network of luminal 
projections of myocardial cells covered by the endocardial layer. The early 
function of trabeculae is to allow for efficient myocardial oxygen and nutrient 
exchange and greater contractile function in the absence of coronary circulation 
(Sedmera et al., 2000). Several models of trabeculation have been described, 
detailing trabeculae initiation, growth and remodelling.  
The first stage in trabeculation is the emergence of trabeculae; after the 
formation of the linear heart tube, myocardial protrusions begin to appear 
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extending into the lumen, beginning on the outer curvature of the ventricle. The 
cellular and molecular mechanisms of how initial trabeculae are formed are still 
unclear; proposed mechanisms include buckling of myocardial wall (Figure 15, 
1), invagination of cardiomyocytes into the lumen (Figure 15, 2) (Liu et al., 2010; 
Peshkovsky et al., 2011) and evagination of the endocardium (Figure 15, 3).  
 
 
Figure 15: Three proposed mechanisms for initiation of trabeculation.  
(1) Buckling of myocardial wall where the myocardial cells fold in towards the 
lumen (dark pink) which leads to movement of the endocardial cells into the 
lumen (dark green). (2) Invagination of cardiomyocytes into the lumen, where 
some of the cardiomyocytes move into the lumen and again leads to movement 
of endocardial cells into the lumen. (3) Evagination of the endocardium where 
movement of endocardial cells leads to subsequent movement of 
cardiomyocytes in adjacent areas.   
 
In zebrafish, a 2-step process of trabeculation has been proposed; firstly, 
cardiomyocytes extend protrusions that invade luminally along neighbouring 
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cell-cell junctions. These protrusions can interact within the trabeculae layer to 
form new cell-cell contacts. Secondly, cardiomyocytes constrict their abluminal 
surface, moving their cell bodies into the trabeculae layer whilst extending more 
protrusions (Staudt et al., 2014). Clonal analysis in zebrafish showed that 
trabeculae cardiomyocytes are clonally unrelated to adjoining compact 
cardiomyocytes, suggesting they delaminate from the compact myocardium and 
attach at a second site in the ventricle. Additionally the trabeculae are clonally 
mixed, meaning they do not arise solely from a single cardiomyocyte (Gupta 
and Poss, 2012). Trabeculation in mice has been less well defined. 
Trabeculation initiates after cardiac looping at E9.0 and proliferation of a single 
myocyte in the tubular heart is thought it give rise to early trabeculae 
protrusions (Staudt et al., 2014).  
The second step in trabeculation is the growth of trabeculae; trabecular 
projections propagate radially to form a network and increase in length 
(Sedmera et al., 2000; Peshkovsky et al., 2011) (Figure 11B). However, the 
mechanisms which control the directionality of the trabeculae growths have not 
been well defined. Genes that are currently thought to be involved in the 
trabeculation process are Notch, Wnt, VEGF and Semaphorin genes (Toyofuku 
et al., 2004b; Grego-Bessa et al., 2007; Nagy et al., 2010; Wu et al., 2012). 
Proliferation is approximately 2-fold greater in cardiomyocytes of the compact 
myocardium, as compared with those in the inner trabeculae (Harvey, 2002). 
The trabeculae cardiomyocytes increase in maturity and decrease in 
proliferative capacity as the distance increases from the compact myocardium, 
creating a gradient from base to tip (Pasumarthi and Field, 2002; Buikema et 
al., 2013; Samsa et al., 2013).  
The last step in trabeculation is remodelling of the trabecular network. 
Trabeculae are suggested to compact or collapse at the base to become 
incorporated into the compact myocardial layer (Figure 11C). Some endocardial 
cells surrounding trabeculae are proposed to become incorporated into the 
compact myocardium as the trabeculae compact which then contribute to the 
endothelial layer of coronary capillaries and vessels (Wu et al., 2012; D'Amato 
et al., 2016). However, the efficiency and specificity of various Cre lines makes 
interpretation of this data particularly difficult and subjective leading to 
contradictory evidence (Zhang et al., 2016).  
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Some trabeculae protrusions within the ventricle free wall are remodelled to 
become part of papillary muscle, IVS and cardiac conduction system. In mice, 
this late phase of trabeculation occurs post E13.5, when Notch2 expression and 
BMP10 expression ceases in the compact myocardium and trabeculae 
myocardium respectively. During this phase, coronary vasculature is 
established and there is a switch from dependence on trabeculae to coronary 
circulation for oxygenation of the myocardium (Captur et al., 2015). 
Defective formation and/or remodelling of the trabeculae leads to cardiac 
abnormalities in mice. Failure of trabeculae formation results in a hypoplastic 
myocardial wall and embryonic lethality due to heart failure, for example Notch1 
mutant embryos die between E9.5 and E10.5 with impaired ventricular 
trabeculation (Grego-Bessa et al., 2007). Conversely, the excessive 
trabeculation or abnormal/absent remodelling typically causes a 
hypertrabeculated, non-compaction phenotype which can cause embryonic 
lethality or can lead to cardiomyopathy in adulthood (Oechslin and Jenni, 2011). 
Excessive trabeculation is associated with dilated cardiomyopathy, CHD and 
left ventricular non-compaction (LVNC) in patients.  
Trabeculae form as a result of interaction between the primitive myocardium 
and endocardium. Various signalling pathways have been identified as being 
crucial for the formation and/or remodelling of ventricular trabeculae including 
Notch, Wnt, Semaphorin and VEGF signalling (Toyofuku et al., 2004b; Grego-
Bessa et al., 2007; Nagy et al., 2010; Wu et al., 2012).  
1.6.6 Signal pathways regulating myocardial proliferation and 
trabeculation  
1.6.6.1 Notch signalling  
Notch signalling is an evolutionary conserved signalling pathway which allows 
for communication between cells and can determine cell fate, as well as being 
able to initiate cell proliferation and apoptosis (Kopan and Goate, 2002) (Figure 
16). The Notch pathway is one of the main signalling pathways between the 
endocardium and myocardium known to regulate the development of the 
ventricular wall (Grego-Bessa et al., 2007). 
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Figure 16: Notch signalling.  
Notch receptors (1-4) have a large extracellular domain and an intracellular 
domain. The extracellular domain of the Notch receptor interacts with delta like 
and jagged ligands. Proteolytic cleavage of the receptor by gamma-secretase 
results in nuclear translocation of the Notch intracellular domain (N1ICD). 
N1ICD interacts with the transcriptional repressor, recombining binding protein 
suppressor of hairless (RBP-Jk), leading to the transcription/repression of Notch 
target genes such as Hes and Hey. Figure adapted from (High and Epstein, 
2008). 
 
In humans, mutations in Notch receptor and ligand genes can cause congenital 
heart defects and LVNC, and have also been associated with adult CVD. (Li et 
al., 1997; Oda et al., 1997; Krantz et al., 1999; Eldadah et al., 2001; Garg et al., 
2005; McDaniell et al., 2006; Luxan et al., 2013). Notch gene and protein 
expression within the developing myocardium has been extensively investigated 
in mouse and zebrafish models, and is summarised in (Figure 17). In mice, 
Notch1 and N1ICD expression is restricted to the endocardium by E8.0, with 
highest expression at the base of the developing trabeculae (Williams et al., 
1995). Notch2 protein is highly expressed in the myocardium and absent from 
the endocardium (McCright et al., 2001). Notch ligands, Jagged and delta like, 
are differentially expressed. Jagged1 is expressed in the myocardium from 
midgestation (Loomes et al., 2002), whereas delta like ligands, Dll1 and Dll4, 
are restricted to endocardial cells, with highest expression at the base of the 
trabeculae, similar to N1ICD (Del Monte et al., 2007) (Figure 17). 
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Figure 17: Notch receptor and ligand expression in the developing 
myocardium. 
Notch1 and activated Notch1 (N1ICD) expression is restricted to the 
endocardium by E8.0, with highest expression at the base of the developing 
trabeculae. Notch2 protein is highly expressed in the myocardium and absent 
from the endocardium. Notch4 is expressed in the endocardium. Notch ligand, 
Jagged1 is expressed in the myocardium from midgestation, whereas delta like 
ligands, DLL1 and DLL4, are restricted to endocardial cells, with highest 
expression at the base of the trabeculae, similar to N1ICD.  
 
Gene inactivation studies in mice have allowed investigation of Notch signalling 
during ventricular development. Notch receptors 1 and 2 are crucial for 
trabeculation and myocardial development (McCright et al., 2001; Watanabe et 
al., 2006; Grego-Bessa et al., 2007). Global or endothelial deletion of Notch1 
results in defective trabeculation, impaired compact myocyte and trabeculae 
markers, and reduced cardiomyocyte proliferation (Grego-Bessa et al., 2007) 
(Figure 18). Deletion studies of Notch ligands, jagged and delta-like, and 
modifier Mib1 confirm the role of Notch signalling in myocardial development 
(Xue et al., 1999; McCright et al., 2002; Luxan et al., 2013). Since a similar 
phenotype is observed after alteration of Notch ligands receptors in the 
endocardium and Notch ligands or modifiers in the myocardium, this suggests 
myocardial-endocardial Notch signalling is critical for normal myocardial 
development (Luxan et al., 2013). Poor trabeculae formation in either global or 
endothelial Notch1 mutants was attributable to both proliferation and 
differentiation defects (Grego-Bessa et al., 2007) (Figure 18).  
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A recent paper decribes sequential Notch 1 receptor activation in the 
endocardium (D'Amato et al., 2016). Initial signalling from endocardially 
expressed delta like-4 to endocardial Notch1 is involved in cardiomyocyte 
proliferation and differentiation, resulting in trabeculation at E9.5. Later in 
development, Jagged1/2 signalling from the myocardium to Notch1 in the 
endocardium is involved in myocardial patterning, maturation and compaction at 
E11.5. This sequential Notch 1 receptor activation was found to be determined 
by Manic fringe expression (D'Amato et al., 2016).  
 
 
Figure 18: Defective Trabeculation in E9.5 Notch1 Mutants.  
H+E-stained transverse sections of representative wt (B) and Notch1 
(N1KO)(D) mutants, details of left ventricle (E and G). SEM photomicrographs 
of wt (H) and Notch1 (J) in left ventricle. In wt, note developing trabeculae with 
myocardium (E, H, arrows) and endocardium (arrowheads). Notch1 embryos 
show collapsed endocardium (arrowheads in J), disorganized myocardium 
(arrows in J) and poorly developed trabeculae. Arrowheads indicate 
endocardium. la, left atrium; oft, outflow tract; ra, right atrium; lv, left ventricle 
and rv, right ventricle. Figure taken from (Grego-Bessa et al., 2007). 
 
Hey genes, Hey1 and Hey2, are downstream effectors of the Notch pathway 
and are known to be expressed during embryonic heart development. Hey2 is 
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expressed in the ventricle compact myocardium, IVS and endocardial cells of 
the AV cushions at E10.5 (Leimeister et al., 1999; Nakagawa et al., 1999; 
Kokubo et al., 2005a) and is crucial for normal cardiac development. Cardiac 
abnormalities in Hey2 deficient embryos include perimembranous VSD, and 
ASD, (TOF), thin myocardium and abnormal trabeculae (Kokubo et al., 2004). 
Increased expression of atrial markers in the LV were also observed (ANF, 
Tbx5, Mlc1a, Mlc2a) in Hey2 mutants, suggesting that Hey2 acts to maintain 
compact ventricular phenotype and suppresses atrial phenotype (Xin et al., 
2007). Knockout studies have shown that Hey1 is dispensable for heart 
development (Fischer et al., 2004). 
Two parallel Notch-dependent cardiac developmental processes have been 
described during trabeculation, contributing to cardiomyocyte proliferation and 
trabeculation, independently. The first is the differentiation of primitive 
myocardial cells into trabeculae and compact myocardium, which is mediated 
by ephrinB2-neuregulin (Nrg) signalling in the endocardium. EphrinB2/EphB4 is 
a ligand-receptor pair that is expressed in the ventricular endocardium. 
Endocardial ephrinB2/EphB4 expression and activity is impaired in Notch 
mutants (Grego-Bessa et al., 2007). EphrinB2 is a direct transcriptional target of 
N1ICD/RBPJk and is upstream of Nrg-1. Deficiency in either EphrinB2 or 
EphB4 is embryonic lethal and hearts show defective trabeculae formation 
(Wang et al., 1998; Gerety et al., 1999). Nrg-1 is expressed in endocardial cells 
and signals to ErbB2/4 receptors in the myocardium to initiate trabeculation of 
the ventricular wall (Gassmann et al., 1995; Lee et al., 1995; Meyer and 
Birchmeier, 1995; Hertig et al., 1999). Nrg-1, ErbB2 and ErbB4 deficiency all 
result in embryonic lethality and defects in trabeculae development; mutants 
display a hypoplastic wall and abnormal trabeculae (Zhang et al., 2013). 
Cardiomyocyte proliferation is unaffected in Nrg-1 and ErbB2/4 mutants, but 
cardiomyocyte differentiation is impaired. Nrg-1 and ErbB2 have been shown to 
have a role in directional delamination of cardiomyocytes to initiate ventricular 
trabeculation (Lai et al., 2010; Liu et al., 2010). In zebrafish, ErbB2 is involved in 
the formation of myocardial protrusions (Zhao et al., 1998; Liu et al., 2010; 
Staudt et al., 2014; Wang and Huang, 2014; Rupert and Coulombe, 2015).  
The second is maintenance of BMP-dependent proliferation of trabeculae 
cardiomyocytes. Impaired proliferation marker BMP10 and differentiation 
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marker Nrg-1 expression was observed in Notch mutants (Grego-Bessa et al., 
2007). BMP10 is expressed transiently in mouse developing trabecular 
myocardium from E9.0-E13.5. Later in mouse embryonic development, at 
E16.5-E17.5, BMP10 is only expressed in the atria. Notch signalling in the 
endocardium acts to conserve BMP10 expression in trabeculae cardiomyocytes 
to maintain proliferation. Target genes of Notch and BMP10 in the myocardium 
include Tbx20, Hey2 and p57kip2 (Zhang et al., 2011). BMP10 activates BMP 
signalling via smad phosphorylation and maintains trabeculae cardiomyocyte 
proliferation via p57kip2 (Pashmforoush et al., 2004).  BMP10 is upregulated in 
several mutant mice that display trabeculation abnormalities, such as FKBP12, 
Nkx2.5 and numb mutants (Shou et al., 1998; Pashmforoush et al., 2004; Yang 
et al., 2012). Bmp10 deficient mice have reduced cardiomyocyte proliferation at 
E9-E9.5 leading to poor cardiac function and are dead by E10.5. At E9.5-E10.5 
the hearts were growth retarded, had hypoplastic walls and failed to develop 
normal trabeculae. Endocardial cushions were acellular cushions suggesting 
defective myocardialisation (Chen et al., 2004; Grego-Bessa et al., 2007). 
Induced BMP10 expression was able to rescue the proliferation defect and 
similarly, induced Nrg1 rescued the differentiation defect in these Notch 
mutants. These results indicate that BMP10 and Nrg1 independently act 
downstream of Notch signalling to regulate cardiomyocyte proliferation and 
cardiomyocyte differentiation, respectively (Grego-Bessa et al., 2007) (Figure 
19).  
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Figure 19: Endocardial-myocardial Notch signalling. 
Two parallel Notch-dependent cardiac developmental processes during 
trabeculation. The first is the differentiation of primitive myocardial cells into 
trabeculae and compact myocardium, which is mediated by ephrinB2-
neuregulin signalling in the endocardium. The second is maintenance of BMP-
dependent proliferation of trabeculae cardiomyocytes. BMP10 and Nrg1 
independently act downstream of Notch signalling to regulate cardiomyocyte 
proliferation and cardiomyocyte differentiation, respectively.  
 
1.6.6.2 Non-canonical Wnt signalling (Wnt – PCP signalling)  
Non-canonical Wnt signalling is important for normal myocardial development. 
Wnt signalling plays an important role in several cellular processes, such as cell 
fate specification, migration and proliferation and differentiation (Nusse, 2008).   
Cardiomyocytes are not an epithelial cell, however adult cardiomyocytes are 
highly polarised, with cell-cell junctions localised at ICD with attachment to ECM 
on the lateral surface, and therefore non-canonical Wnt signalling may play a 
role in cardiomyocyte polarisation.  
Planar cell polarity (PCP) signalling is an essential mechanism by which cells 
establish apical-basal axis polarity. PCP is a key feature of epithelial cells. The 
main PCP components were defined in drosophila using genetic mutagenesis 
and clonal analysis. Core signalling components include Frizzled (Fz), 
Dishevelled (Dvl), Prickle (Pk), Vangl and Celsr1. In addition, there are a large 
number of PCP effectors such as Daam1, RhoA and Rac1. Activation of 
Wnt/PCP signalling by binding of Wnt ligands, Wnt5a and Wnt11, to Fz 
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receptors at the cell membrane causes Dvl to bind Daam1, which increases its 
affinity for downstream effectors, Rac1 and RhoA, and promotes polymerization 
of actin and regulates gene expression (Figure 20) (Habas et al., 2001; Liu et 
al., 2008; Young and Copeland, 2010). 
 
Figure 20: PCP signalling.  
Core signalling components include Frizzled (Fz), Dishevelled (Dvl), Prickle 
(Pk), Vangl and Celsr1. In addition, there are a large number of PCP effectors 
such as Daam1, RhoA and Rac1. Activation of Wnt/PCP signalling by binding of 
Wnt ligands, Wnt5a and Wnt11, to Fz receptors at the cell membrane causes 
Dvl to bind Daam1, which increases its affinity for downstream effectors, Rac1 
and RhoA, and regulates cytoskeletal organisation and gene expression.  
 
Wnt ligands, Wnt11 and Wnt5a, are associated with non-canonical Wnt 
signalling and thought to stimulate cardiogenesis (Afouda et al., 2008). 
Mutations in Wnt5a and Wnt11 disrupt cardiac development (Schleiffarth et al., 
2007; Cohen et al., 2012; Sinha et al., 2015). Wnt11 is expressed in the 
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myocardium (Sinha et al., 2015) and deletion of Wnt11 results in embryonic 
lethality between E12.5 and E13.5. These Wnt11 deficient hearts had dilated 
cardiac chambers and thin myocardial walls, with fewer, irregular trabeculae 
(Figure 21), disrupted AJ and cytoskeleton organisation and decreased 
expression of ANF, Mef2c, Nkx2.5 and Gata4 (Nagy et al., 2010). 
 
 
Figure 21: Defective trabeculation in Wnt11 mutants.  
H&E staining of wild type and Wnt-11−/− hearts at E10.5. The Wnt-11-deficient 
ventricles are dilated relative to controls at E10.5 (F compared to E) and the 
trabecular processes are hypoplastic and are located at irregular distances. The 
ventricular wall is also thinner (H compared with G, arrowheads). ra, right 
atrium; rv, right ventricle; lv, left ventricle; avc, atrioventricular cushion; Scale 
Bar: 100 µm (Nagy et al., 2010).  
 
Fz receptors are the principle receptors for Wnt ligands and are involved in 
three distinct pathways; the canonical Wnt pathway, the PCP pathway and the 
calcium pathway. There are 10 frizzled receptor genes and mutations in these 
genes cause developmental phenotypes, some including cardiac abnormalities. 
Fz1 and Fz2 are partially functionally redundant. However, double Fz1 and Fz2 
null embryos have highly penetrant VSDs. Fz1/2/7 receptor mutant mice have 
increased frequency of cardiac defects when combined with mutations in Dvl3, 
Wnt3a, or Wnt11 (Yu et al., 2012).  
Gene deletion studies in mice have revealed functional redundancy between 
the three murine Dvl proteins, as well as an essential role in cardiovascular 
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development. Dvl2 deficient embryos display OFT defects, including DORV, 
TGA and PTA (Hamblet et al., 2002), Dvl1/2 double null mutants have 
ventricular and OFT defects (Sinha et al., 2012) and Dvl3 null mice die 
perinatally with cardiac OFT abnormalities, including DORV and PTA (Etheridge 
et al., 2008). Dishevelled associated activator of morphogenesis 1 and 2 
(Daam1 and Daam2) were identified as Dvl binding proteins (Habas et al., 
2001). Daam1 is expressed in developing and adult hearts, and Daam1 mutants 
show a ventricular non-compaction phenotype with DORV and VSD, but still 
have normal proliferation and BMP10 expression (Li et al., 2011). This 
phenotype suggests that Daam1-mediated Wnt/PCP signalling may orient the 
cytoskeletons of trabecular cardiomyocytes and guide their integration into the 
compact myocardium of the adult heart. Cardiac specific deletion of Daam1 
confirmed an autonomous role of Daam1 in the polarized protrusive activity in 
cardiomyocytes.  
Vangl2 and Scrib are both expressed in developing and adult myocardium. 
Natural occurring Vangl2 mutants, Loop-tail mice, have thin ventricular walls 
and DORV (Phillips et al., 2005; Henderson et al., 2006; Phillips et al., 2008). 
Scrib mutants have altered ventricular chamber formation and DORV (Murdoch 
et al., 2003; Phillips et al., 2007). Polarisation and organisation of 
cardiomyocytes in the ventricular myocardium and outflow myocardium is 
disrupted in both Scrib and Vangl2 mutants.  
Pk1 knockout mouse embryos present with pregastrulation lethality suggesting 
Pk1 plays an important role in development (Tao et al., 2009). A novel mutation 
in Pk1 (Beetlejuice (Bj)) resulted in OFT defects; 63% DORV, 17% OA and 20% 
a simple perimembranous VSD with normally positioned great arteries (Gibbs et 
al., 2016). PCP components Scrib and Vangl2 were unchanged, however Pk1 
expression was reduced in Bj mutants and both canonical and non-canonical 
Wnt signalling was perturbed in Bj mutants (Gibbs et al., 2016).   
These studies suggest that non-canonical Wnt signalling is important in 
cardiomyocyte polarity and organisation during cardiac development.  
1.6.6.3 Semaphorin signalling 
Plexin transmembrane receptors and their semaphorin ligands, as well as co-
receptors, including Nrp1, Vascular endothelial growth factor receptor (VEGFR)-
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2 and ErbB2, are emerging as key regulators of cardiovascular development. 
Semaphorins are a large, highly structurally and functionally conserved family of 
secreted or membrane associated glycoproteins (Huber et al., 2003). There are 
8 classes of semaphorins, with classes 3-7 being expressed in vertebrates. 
Class 3 are secreted proteins, whereas class 4-6 are membrane proteins and 
class 7 are anchored proteins that turn soluble after proteolytic cleavage. 
Semaphorins contain a sema domain for receptor binding.  
Two main types of semaphorin receptors have been identified; plexins and 
neuropilins. There are 9 different plexin receptors, separated into 4 classes; 
class A (Plexin A1-A4), class B (PlexinB1-3), class C (Plexin C1) and class D 
(Plexin D1) (Tamagnone et al., 1999). Plexins contain an extracellular sema 
domain which acts as an autoinhibitory element. The sema domain maintains 
plexins in an inactive state until a semaphorin binds. Semaphorin binding 
induces receptor dimerization with either another plexin receptor or one of the 
co-receptors. Plexins also contain an intracellular Rho-binding domain (RBD), to 
which Rho GTPases can bind (Tong and Buck, 2005; Tong et al., 2007; Fansa 
et al., 2013). Plexins require both extracellular and intracellular binding to 
become activated (Hota and Buck, 2012). Semaphorins and plexins interact on 
adjacent cells and within the ECM and active, phosphorylated plexins activate 
downstream kinases. Nrp receptors are transmembrane receptors with a small 
cytoplasmic domain and multiple extracellular domains which can bind class 3 
semaphorins and VEGF ligands (Gu et al., 2003). There are two types of 
Neuropilin receptors; Nrp-1 and Nrp-2 (Takashima et al., 2002).  
Various gene inactivation studies, in chick and mice have suggested that 
semaphorin signalling is involved in cardiac development including trabeculation 
and myocardial maturation (Figure 23) (Toyofuku et al., 2004a; Toyofuku et al., 
2004b). Recently, semaphorin signalling has been shown to regulate ventricular 
chamber development in the chick (Toyofuku et al., 2004a; Toyofuku et al., 
2004b). In particular, Sema6D, acting as both a membrane bound receptor and 
a soluble ligand, signals through PlexinA1 to regulate trabeculation and 
compact layer expansion. Sema6D is expressed in the compact layer and 
trabeculae myocardium, whereas PlexinA1 is expressed in the trabeculae layer 
and endocardial cells. Knockdown of either Sema6D or PlexinA1 in the chick 
leads to a decrease in heart size, a thin compact myocardium and reduced 
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trabeculation, these changes occur in the absence of altered cardiomyocyte 
proliferation or apoptosis (Figure 22). It was shown that forward signalling 
through Sema6D-PlexinA1 is necessary for the expansion of compact layer and 
bending of the linear heart tube. Whereas, reverse signalling through PlexinA1-
Sema6D is required for migration of cardiomyocytes into the trabeculae layer 
and subsequent trabeculation, through regulation of trabeculae cardiomyocyte 
motility and directionality (Toyofuku et al., 2004b). Cardiomyocytes expressing a 
mutant version of mammalian enabled (Mena), a known Sema6d interactor, do 
not migrate into the trabeculae layer but remain in the compact myocardial layer 
(Toyofuku et al., 2004b). Surprisingly, both Sema6D and PlexinA1 KO mice do 
not have any obvious cardiac defects (Takegahara et al., 2006; Takamatsu et 
al., 2010). Several studies in mice have also suggested a role of semaphorin 
signalling during myocardial development. Sema3A is strongly expressed in the 
subendocardial regions of the trabeculae myocardium early in development, 
and is then restricted to the purkinje fibres later in development (Behar et al., 
1996; Ieda et al., 2007). Sema3A null mice die postnatally with hypertrophy of 
the RV and dilation of the RA (Behar et al., 1996). Knockout or overexpression 
of Sema3A in mice causes disruption of the cardiac innervation pattern and 
results in an increased incidence of fatal arrhythmias and sudden cardiac death 
(Ieda et al., 2007). Additionally, a polymorphism in Sema3a is a risk factor for 
cardiac arrest with ventricular fibrillation (Nakano et al., 2013).  
Plexin receptors are expressed in endothelial cells during cardiovascular 
development, with PlexinC1 and PlexinD1 in particular shown to be expressed 
in the mouse endocardium (Artigiani et al., 2004; Perala et al., 2005). An 
additional study suggested that PlexinD1 along with ErbB2 are synthesised in 
cardiomyocytes. PlexinD1 mediates class 3 semaphorin signals and PlexinD1 
null mice display PTA and VSD, and pups die shortly after birth (Gitler et al., 
2004). Endothelial specific deletion of PlexinD1 recapitulates the cardiac 
phenotype seen in the null PlexinD1 mice and also reports embryonic 
myocardial defects with a thinned myocardial wall (Zhang et al., 2009). These 
results suggest that PlexinD1 in the endocardium is important for signalling 
involved in the thickening and maturation of the ventricle wall. 
Nrp-1 is expressed in multiple cell types that contribute to development of the 
cardiovascular system including NCC and endothelial cells (Brown et al., 2001; 
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Feiner et al., 2001). Additionally, Nrp-1 has been found to be expressed in both 
neonatal rat cardiomyocytes and the adult murine heart. Nrp1 forms complexes 
with VEGFR-1 and VEGFR-2 in cardiomyocytes (Li et al., 2008). Mice with null 
mutations in Nrp-1, or in the genes encoding Nrp-1 ligands exhibit cardiac or 
vascular defects (Behar et al., 1996; Brown et al., 2001; Feiner et al., 2001; 
Takashima et al., 2002). Nrp-1 null mice die at around E10.5–E12.5 with 
cardiovascular defects (Kawasaki et al., 1999). Endothelial specific disruption of 
either VEGF/Nrp1 or Sema3C/Nrp1 signalling revealed that VEGF/Nrp1 is 
critical for the cardiac septation, while Sema/Nrp1 signalling is essential for the 
development of the atria (Gu et al., 2003). Disrupted VEGF/Nrp1 signalling 
resulted in PTA, VSD and coronary artery defects (Gu et al., 2003).  
 
 
Figure 22: Sema6D and PlexinA1 expression in mice and cardiac defects 
in knockout chick model.  
E10.5 mouse embryo (A). Cross-sections through the E10.5 mouse embryo (B-
E). Sema6D mRNA is expressed throughout the ventricular myocardium (C-E) 
including the OFT, IVS and myocardial cells in compact zone and trabeculae 
(arrowhead in E). Scale bars; A–D, 100 μm; E, 20μm (Toyofuku et al., 2004a; 
Toyofuku et al., 2004b). E10.5 mouse embryo (a). Cross-sections through the 
E10.5 mouse embryo (b-e). Plexin-A1 mRNA is expressed in the compact 
myocardial layer of cardiac ventricular wall (c and e). Scale bar C, 100 μm. 
Scale bar; E, 20 μm. H&E staining of cross-sections of HH stage 36 chick 
embryos treated with control (J) or Sema6D-expressing cells (K). In Sema6D-
treated embryos, cardiac ventricle exhibits expanded cavity and poor 
myocardial trabeculae (K, arrowhead) compared with the control embryo (J). 
Figure taken from (Toyofuku et al., 2004a; Toyofuku et al., 2004b).  
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Figure 23: Semaphorin signalling during myocardial development.  
Sema3A is strongly expressed in subendocardial regions of the trabeculae 
myocardium early in development, and is then restricted to the purkinje fibres 
later in development. Sema6D is expressed in the compact layer and 
trabeculae myocardium, whereas PlexinA1 is restricted to the compact layer 
myocardium and endocardial cells. Sema6D, acting as both a membrane bound 
receptor and a soluble ligand, signals through PlexinA1 to regulate trabeculation 
and compact layer expansion in chick. PlexinC1 and PlexinD1 are expressed in 
the mouse endocardium. Nrp-1 is expressed in multiple cell types that 
contribute to development of the cardiovascular system including NCC and 
endothelial cells.  
 
1.6.6.4 VEGF signalling 
VEGF is a major signalling pathway between the myocardium and 
endocardium. Myocardial VEGF binds to VEGF receptors expressed in 
endocardial cells. VEGFR-2 is expressed in endocardial cells and binding of 
VEGF causes phosphorylation of tyrosine (Jopling et al., 2011).  
In mice, overexpression of endogenous Vegf-a causes embryonic lethality from 
E12.5 and severe heart detects, including a thin compact myocardium, 
hypertrabeculation, and defective ventricular septation and OFT remodelling 
(Miquerol et al., 2000). Vegfr-2 deficient mice lack some endothelial lineages 
and do not form trabeculae leading to embryonic lethality at E9.5 (Shalaby et 
al., 1995; Milgrom-Hoffman et al., 2011). Deletion of Vegf-a in the myocardium 
or deletion of Vegfr-2 in the endocardium resulted in similar ventricular defects, 
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including the thin myocardial walls, and ruptured septa at E15.5 (Wu et al., 
2012). This study highlights that regulation of VEGF signalling between the 
myocardium and endocardium is essential for normal cardiac ventricular 
development (Figure 24). 
 
Figure 24: VEGF signalling during myocardial development.  
Myocardial vascular endothelial growth factor (VEGF) binds to VEGF receptor 2 
(VEGFR-2) expressed in endocardial cells. Deletion of Vegf-a in the 
myocardium or deletion of Vegfr-2 in the endocardium resulted in similar 
ventricular defects, including the thin myocardial walls and defective 
trabeculation revealing that regulation of VEGF signalling between the 
myocardium and endocardium is essential for normal trabeculation (Wu et al., 
2012).  
 
The importance of all the signalling pathways described highlights the necessity 
of the interaction between the endocardium and myocardium during 
development of the ventricular wall. Between these two layers is cardiac jelly 
consisting of ECM proteins. ECM is also present in the interstitial space 
surrounding cardiomyocytes and therefore is important component in the 
signalling between the endocardium and myocardium.  
1.6.7 Role of ECM in trabeculation  
The ECM is involved in cell signalling, differentiation and migration, and is 
crucial for the spatiotemporal regulation of these processes during the complex 
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development of the heart. Alterations in the composition of the ECM can lead to 
cardiac malformations (Table 2). 
The ECM is secreted by the myocardium and is found in all components of the 
heart. In particular, there is strong expression in mesenchymal tissues of the 
developing heart such as the AV and OFT cushions, DMP and epicardium. The 
macromolecules that make up the ECM include hyaluronan, proteoglycans, 
collagens, elastin, fibrilin, fibronectin, and laminins. The main ECM components 
currently known to be important for normal heart development are shown in 
Figure 25, and studies perturbing these ECM proteins during development have 
revealed cardiac defects similar to those seen in CHD.  
 
 
Figure 25: Main components of the ECM in heart development.  
 
Recently, it has been highlighted that the ECM is important for normal cardiac 
trabeculation, for example knockout of Has2 or Versican leads to defective 
trabeculation (Yamamura et al., 1997; Camenisch et al., 2000). Hyaluronan and 
other ECM proteins make up a pericellular matrix, which surrounds 
cardiomyocytes and provides a hydrated environment that facilitates cellular 
proliferation and motility (Toole, 2001). Since regulated cell proliferation and 
migration are critical during the process of trabeculation, it is unsurprising that 
altering the composition of the pericellular matrix can result in myocardial 
defects. Using mouse and chick animal models, the expression and function of 
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several ECM proteins during cardiac development has been investigated. 
These are summarised in Table 2.  
 
 
Table 2: Mouse knockout models of ECM proteins during heart 
development (Lockhart et al., 2011). 
 
Collagen types I, III, V, VI and XI have been shown to be expressed in the 
developing myocardium (Klewer et al., 1998; Lincoln et al., 2006). Collagen XI 
is thought to be involved in the regulation of collagen fibril assembly and is 
restricted to the trabeculated layer of the ventricular wall, with no expression in 
the compact layer (Lincoln et al., 2006). Collagen XI deficient mice display 
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cardiac abnormalities such as an increase in the thickness of the IVS and AV 
valve leaflets with increased collagen I expression, as well as a pronounced 
change in the overall shape of the heart (Lincoln et al., 2006).  
Fibronectin is a multi-domain ECM protein that interacts with multiple integrins, 
HS proteoglycans, collagens, and fibrins to mediate cellular processes. During 
cardiac development, fibronectins are expressed in the endocardium and 
mesenchyme of the endocardial cushions, where it is required for EMT (Astrof 
et al., 2007). Fibronectin null embryos die by E10 due to severe cardiovascular 
and vascular defects. The formation of the primary heart tube is affected and 
those that do form a heart tube display a thickened myocardium, lack of cardiac 
jelly, and abnormal endocardium (Astrof et al., 2007). Laminin is an ECM 
protein present at the basal side of the cell in the basal lamina of the basement 
membrane and is involved in adhesion and cell migration (Timpl et al., 1979).  
These studies implicate the complex composition of ECM as an integral 
component in ventricular development.  
1.7 Coronary vasculature development  
As described earlier, the heart is made up of three major layers; the inner 
endocardium, myocardium and outer epicardium. The coronary vasculature 
develops within the middle myocardial layer and is absent from the embryonic 
heart until the myocardium becomes thickened. During the early trabeculation 
phase, interamural vessels are yet to be formed and only subepicardial vessels 
are present in the myocardium (Captur et al., 2015). 
The coronary vasculature is made up of coronary arteries and coronary veins, 
which branch into arterioles and venules and are connected by microvessels 
and capillaries. Coronary arteries and veins have three tissue layers; an inner 
layer of endothelium, a middle layer of SMCs and an outer layer of fibroblasts. 
Capillaries are made up of a single layer of endothelial cells to allow efficient 
oxygen and nutrient exchange.   
Embryonic vascular development is established through two main processes; 
vasculogenesis and angiogenesis. During vasculogenesis, endothelial cell 
precursors, angioblasts, associate to form a primitive vascular network. This is 
followed by angiogenesis, where the primitive vascular network is remodelled 
with new vessels sprouting from pre-existing vessels. Hypoxia is required for 
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angiogenesis and hypoxic regions during development, including the atria and 
IVS, correlate with major coronary artery formation in the chick heart 
(Wikenheiser et al., 2006).  
1.7.1 Origin of coronary endothelial cells  
The origin of the coronary vessel endothelial cells which contribute to the 
coronary arteries, veins and capilaries is controversial. Studies have shown that 
pro-epicardial cells generate SMCs of both coronary arteries and veins, 
however there is conflicting evidence of the origin of endothelial cells. Fate 
mapping studies have reported contribution from both the pro-epicardial cells 
and the SV, and more recently, the endocardium (Tian et al., 2013; Chen et al., 
2014). Through nuclear factor of activated T cells cytoplasmic 1 (Nfatc1) lineage 
tracing, Wu et al. showed that the endocardium is a major source of endothelial 
cells in the coronary vasculature (Wu et al., 2012). However, recent evidence 
suggests that Nfatc1 labels both SV and vascular endocardium and that the 
endocardium only minimally contributes to the coronary endothelium of the 
ventricular free walls (Zhang et al., 2016). Through complex Nfatc1 lineage 
tracing studies, Zhang et al. have shown that the majority of coronary 
endothelium arises from the SV whereas the Nrp3 expressing endocardial cells 
contribute to the coronary vessels in the septum (~90%) and minimally to the 
coronary vessels (~3%) (Zhang et al., 2016). There are numerous markers of 
endothelial and/or endocardial cells which have been identified and utilised to 
investigate coronary endothelial contributions. These are listed in Table 3.  
Endothelial/endocardial 
marker  
Expression  
Apelin  Vascular endothelial cells but not endocardial cells 
APJ Endothelial cells 
CD31 (pecam) Endothelial cells of both coronary arteries and veins and endocardial 
cells  
CD34 Endocardial cells but not epicardial cells 
CD105 (endoglin) Endothelial and endocardial cells.  
Endomucin Endothelial cells of coronary veins and endocardial cells  
Nfatc1 Endocardial cells but absent from vascular endothelial cells 
Nrp3 Endocardial cells 
Vimentin  Endocardial and epicardial cells plus subepicardial and 
intramyocardial interstitial cells 
Table 3: Endothelial and endocardial specific proteins.   
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1.7.1.1 Pro-Epicardium 
The PE is a transient extra-cardiac cluster of cells which develops as a 
cauliflower-like protrusion from at the base of the developing heart (Viragh and 
Challice, 1981; Manner et al., 2001). The pro-epicardium forms villi which 
protrude towards the myocardium of the looping heart tube, the pro-epicardial 
cells then migrate to the surface of the heart and envelop the myocardium, 
forming the epicardium. Fate mapping of pro-epicardial cells in chick and quail 
reveal contribution to additional lineages including perivascular fibroblasts, 
SMCs and endocardial cells of the coronary vessels (Manner et al., 2001). 
Studies in mice have highlighted that PE is most likely a molecularly 
compartmentalized structure, with predetermined populations contributing 
separately to each lineage. Tbx18 and (Wilm’s tumour) WT-1-expressing cells 
give rise to vascular SMCs, cardiomyocytes and fibroblasts with little or no 
contribution to endothelial cells (Cai et al., 2008; Zhou et al., 2008; Red-Horse 
et al., 2010). Whereas, Scx- and Sema3D-expressing pro-epicardial cells give 
rise to coronary vascular endothelium including the early SV and cardiac 
endocardium (Katz et al., 2012).   
1.7.1.2 Sinus Venosus  
The SV is the main vein that returns blood to the embryonic heart. The 
endothelial cells of SV are a heterogeneous population, composed of Apelin 
receptor positive and negative cells (Chen et al., 2014). A recent study 
demonstrated that some murine coronary endothelial cells arise from both the 
endothelial lining of the SV and from the cardiac endocardium, with no 
contribution to these structures from Tbx18 expressing pro-epicardial cells 
(Red-Horse et al., 2010).  
1.7.1.3 Endocardium  
The endocardium is an epithelial layer made up of endocardial cells associated 
with the basement membrane of the trabeculae and OFT myocardium. 
Endocardial cells were initially thought to be terminally differentiated, however 
recent studies demonstrate a role of endocardial cells in the formation of 
coronary vessel endothelium. As mentioned above, a recent study discovered 
that some murine coronary endothelial cells arise from the cardiac endocardium 
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(Red-Horse et al., 2010). Tian and colleagues recently proposed a mechanism 
in which a proportion of postnatal coronary vessels arise de novo in the 
neonatal mouse heart, through conversion of endocardial cells during 
ventricular compaction after birth. Genetic lineage tracing revealed that 
postnatal endocardial cells generate a distinct population of coronary 
vasculature within the inner ventricular wall. During trabeculae compaction, 
endocardial cells become trapped within the compacting myocardium and in 
response to their new hypoxic, intramyocardial environment, the endocardial 
cells undergo angiogenesis, migrate and form coronary vessels (Tian et al., 
2014). This study also revealed waves of coronary artery formation. The first 
wave of outer compact myocardial vessels is formed by EPDCs at E10.5. The 
second and third wave of vessels are formed from conversion of endocardial 
cells to vascular endothelial cells; the second wave at E13.5 in the IVS and the 
third wave postnatally in the inner compact myocardium (Tian et al., 2014).  
A role for endocardial cells during embryonic vessel formation has also been 
reported. Interestingly, Wu and colleagues described endocardial cells that 
were not terminally differentiated but were angiogenic and contributed to the 
formation of coronary endothelial networks. Nfatc1-Cre was used to fate map 
endocardial cells. It was found that Nfatc1+ endocardial derivatives make a 
substantial contribution to arterial endothelium, however, only a small 
contribution to coronary veins (Wu et al., 2012). Additionally, in the human 
heart, it has been shown that endothelial networks in the inner myocardium are 
derived from endocardial cells and are guided by filopodia-projecting 
CD31+/CD34+/CD105+/vimentin+ endocardial tip cells, with upregulated 
CD105 expression in activated endocardial cells (Rusu et al., 2015) (Figure 26). 
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Figure 26: Endocardial contribution to the coronary endothelial networks. 
In the human heart endothelial networks in the inner myocardium are derived 
from endocardial cells and are guided by filopodia-projecting 
CD31+/CD34+/CD105+/vimentin+ endocardial tip cells at the base of 
trabeculae, with upregulated CD105 expression in activated endocardial cells 
(Rusu et al., 2015). 
 
1.7.2 Regulators of vascular development  
Several cell surface receptors and ligands have been found to play central roles 
in vascular development such as tyrosine kinase receptors and associated 
ligands. In particular, VEGF and FGF and their receptors have been extensively 
investigated.  
1.7.2.1 VEGF signalling  
As previously discussed in Chapter 1 Section 1.6.6.4, VEGF signalling is 
important for trabeculation and myocardial development, but it is also critical for 
vasculogenesis. Genetic alterations of either Vegf-a or Vegfr-2 leads to 
defective vasculogenesis (Carmeliet et al., 1996; Ferrara et al., 1996; Miquerol 
et al., 2000). Myocardial to endocardial VEGF signalling is critical for 
angiogenesis and coronary vessel formation since myocardial Vegf-a or 
endocardial and SV Vegfr-2 deletion inhibited coronary angiogenesis and 
arterial formation (Wu et al., 2012). VEGFR-1 within the endocardium negatively 
regulates angiogenesis.  Endocardial specific deletion of Vegfr-1 causes 
increased coronary plexus formation with increased VEGF-Notch signalling. 
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Additionally, Vegfr-1 null endocardial cells undergo spontaneous angiogenesis 
and generated extensive endothelial tubular networks in vitro (Zhang and Zhou, 
2013). 
 
Figure 27: Disruption of Vegf-a in the Myocardium Reveals that Myocardial 
VEGFA Is Required for Coronary Angiogenesis and Artery Formation (Wu 
et al., 2012). 
Images of E14.5 control heart show the Pecam1+ coronary arteries (ca, arrows) 
and subepicardial vessels (I–K, arrowheads). Images of E14.5 TnnT2-
Cre;Vegfaf/f heart show less and immaturely formed coronary arteries (L–N, 
arrows) but numerous and dilated subepicardial vessels (arrowheads). The null 
heart also has necrotic peritruncal and septal myocardium (L, arrows). Scale 
bars for (I) and (L), 100 μm; for all other panels, 20 μm.  
 
1.7.2.2 Notch signalling  
Notch signalling is critical for coronary vessel formation. Studies revealed 
substantial and specific expression of Notch signalling components in 
developing blood vessels as detailed in Table 4. Initial vasculogenesis is 
unaffected in Notch signalling mutants, including Hey1/2, Jagged1 and Notch1 
knockout mice, however subsequent remodelling is disrupted. Large arteries 
lack expression of common arterial endothelial markers, CD44, Nrp-1 and 
EphrinB2, displaying defective arterial differentiation (Kokubo et al., 2005b). 
Additionally, a recent paper shows that endothelial Dll4 to Fringe modified 
Notch1 receptors stimulates coronary vessel development. (D'Amato et al., 
2016). 
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Notch gene Expression Reference   
Notch1 Arterial endothelium  (Villa et al., 2001) 
Notch2 Not expressed  (Villa et al., 2001) 
Notch3 Arterial smooth muscle  (Villa et al., 2001) 
Notch4 Arterial and capillary endothelium (Villa et al., 2001) (Mailhos et al., 2001) 
Delta1/3 Not expressed (Shutter et al., 2000; Mailhos et al., 
2001) 
Delta4 Arterial and capillary endothelium  (Shutter et al., 2000; Mailhos et al., 
2001) 
Jagged1/2 Arterial endothelium and smooth 
muscle 
  
Hey1  Vascular endothelium  (Fischer and Gessler, 2003) 
Hey2 Vascular endothelium and smooth 
muscle  
(Fischer and Gessler, 2003) 
EphrinB1 Arterial and venous endothelium  (Wang et al., 1998) 
EphrinB2 Arterial  (Villa et al., 2001) (Wang et al., 1998) 
EphrinB3/4 Venous endothelium (Wang et al., 1998) 
EphB3 Venous and some arterial  (Wang et al., 1998) 
EphB4 Venous and some arterial 
endothelium and endocardium  
(Wang et al., 1998) 
Table 4: Notch gene expression in the coronary vasculature.  
 
1.7.2.3 Semaphorin-Plexin signalling during angiogenesis  
Class 3 semaphorins are expressed in endothelial cells. Sema3 reduces 
endothelial motility and thus inhibits angiogenesis. Expectedly, Sema3A null 
mice exhibit vascular detects (Serini et al., 2003), and defects in Sema3C and 
receptors PlexinA2 and Nrp-1 result in DiGeorge Syndrome like defects in the 
aortic arches and OFT septation (Zhou et al., 2012). Sema4, on the other hand, 
promotes cell migration and angiogenesis (Conrotto et al., 2005). As mentioned 
earlier, plexins are expressed in endothelial cells (Artigiani et al., 2004). 
PlexinD1 is expressed in vascular cells in developing blood vessels in mice and 
propagates Sema3A inhibitory signals and is required with Sema3A and Nrp-1 
in endothelial cells for normal cardiovascular development (Gay et al., 2011; 
Hota and Buck, 2012).  
1.7.2.4 Nfatc1 
The inactive transcription factor Nfat is localised in the cytoplasm. Once 
dephosphorylated by Calcineurin, a heteromeric Ca(2+)-dependent 
serine/threonine phosphatase, Nfat undergoes translocation to the nucleus. Nfat 
regulates numerous biological processes, including cardiac development. 
Cysteine-Rich with EGF-Like Domains 1 (Creld1) gene, a regulator 
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of calcineurin/Nfactc1 signalling,  is also essential for heart development. Creld1 
function is required for the VEGF-dependent proliferation of endocardial cells by 
promoting the expression of Nfatc1 target-genes (Mass et al., 2014). Wu and 
colleagues described a decrease in Nfatct1 expression in endocardial cells 
before migration into the compact layer (Wu et al., 2012).  
1.7.2.5 VE-cadherin 
VE-cadherin plays an important role in the cessation of sprouting in 
angiogenesis (Abraham et al., 2009). Cell-cell adhesion in endothelial cells 
increases actinomyosin contractility at cell junctions through VE-cadherin, 
suppressing VEGF stimulated Rac1-dependent migration and sprouting 
(Lampugnani et al., 2002).  
1.7.2.6 Signalling pathways common to both coronary vessel formation 
and myocardial development 
Additional known signalling pathways active between the myocardium and 
endocardium that are involved in coronary vessel development include Ang-1-
Tie2, BMP2-TGF-β and FGF-FGFR-1/2 (Shalaby et al., 1995; Suri et al., 1996; 
Arita et al., 2014; Mima et al., 1995; Lavine et al., 2005; Lu et al., 2008). The 
signalling pathways between the myocardium and endocardium important for 
myocardial development and coronary vessel development (described in 
Chapter 1 Section 1.6.6 and 1.7.2, respectively) are overlapping. Notch, VEGF, 
FGF and Semaphorin signalling pathways are crucial for both trabeculation and 
coronary vessel formation (Figure 28). Hence, disruptions in myocardium or 
endothelial lineages can affect myocardial development and/or coronary vessel 
formation. This is unsurprising since the formation of coronary vessels and the 
development of the myocardium is intrinsically linked. Trabeculation occurs to 
increase perfusion in the absence of coronary circulation. As the compact 
myocardium thickens, endothelial cells invade and form the coronary 
vasculature. Once the coronary vasculature is formed, the trabeculae are no 
longer required and regress into the compact myocardium, possibly through 
compaction at the base (Figure 11) (Tian et al., 2014). 
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Figure 28:  The signalling pathways between the myocardium and endocardium important for both myocardial 
development and coronary vessel development .  
Notch, VEGF, FGF and Semaphorin signalling pathways are crucial for both trabeculation and coronary vessel formation. 
Additional known signalling pathways active involved in coronary vessel development include Ang-1-Tie2, BMP2-TGF-β and 
FGF-FGFR-1/2, as well as PCP, VE-cadherin and Nfatc1 signalling within the endocardial layer, and PCP and β-catenin 
signalling within the myocardial layer. 
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1.8 Rac1 
1.8.1 Rho-GTPases  
Rac1 (also known as Ras-related C3 botulinum toxin substrate 1) is a member 
of the Rho family of small GTPases, which are a subgroup within the large 
superfamily of Ras-related small GTPases. Rho GTPases consist of 20 
members, acting as molecular switches that oscillate between an active GTP-
bound state, able to activate several downstream effectors, and an inactive 
GDP-bound state (Jaffe and Hall, 2005). The activation of Rho-GTPases is 
catalysed by guanine nucleotide exchange factors (GEFs) and GAPs, resulting 
in GTP hydrolysis and protein activation (Tcherkezian and Lamarche-Vane, 
2007) (Figure 29). GEFs have high affinity for the guanine nucleotide-free state 
of the GTPases and are thought to promote GDP release by stabilizing an 
intermediate transition state. Over 70 RhoGAPs and 80 RhoGEFs have been 
identified and most of them show tissue-specific expression (Jaffe and Hall, 
2005; Cherfils and Zeghouf, 2013).  
RhoA, Rac1, and Cdc42 are the best-characterized members of the Rho 
GTPase family. Previous studies have highlighted the importance of these 
proteins in cytoskeletal rearrangements (Tapon and Hall, 1997; Jaffe and Hall, 
2005).  Generally, activation of Cdc42 leads to the formation of filopodia, 
activation of Rac1 induces lamellipodia and membrane ruffles, while RhoA 
activation leads to contractile actin-myosin filaments and stress fibre formation 
(Ridley and Hall, 1992; Ridley et al., 1992; Kozma et al., 1995; Nobes and Hall, 
1995). Other molecular functions regulated by these small GTPases include 
microtubule dynamics, signal transduction, gene expression, and enzymatic 
regulation, which regulate a variety of cellular processes, such as cell migration, 
polarity, survival, morphology, proliferation, differentiation, and regulation of the 
various phases of the cell cycle (Etienne-Manneville and Hall, 2002; Jaffe and 
Hall, 2005).  
Disruption of Rho GTPase signalling, using a Rho GDP dissociation inhibitor, 
during mouse development, results in embryonic death at E10.5 with cardiac 
defects, including defective heart looping and chamber septation, hypocellular 
and dilated ventricles, and a lack of trabeculation and endocardial cushion 
formation (Wei et al., 2002). Decreased proliferation in these hearts at E9.5 
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suggests a role of Rho GTPases in cardiac cell cycle regulation (Wei et al., 
2002). 
 
Figure 29: Activation of Rac1.  
The activation of Rho-GTPases including Rac1 is catalysed by guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), 
resulting in GTP hydrolysis and protein activation. Active Rac1 is associated 
with the cell membrane, whereas inactive Rac1 resides in the cytosol.  
 
1.8.2 Rac proteins 
The Rac subfamily is composed of three members: Rac1, Rac2 and Rac3 
(Haataja et al., 1997). Rac1 is expressed ubiquitously with the strongest 
expression found in the heart, placenta and kidney (Matos et al., 2000). Rac2 
expression is limited to hematopoietic tissues and regulates the actin 
cytoskeleton and superoxide generation. Rac3 is predominantly expressed in 
the central nervous system and adult brain.  
1.8.3 Rac1 
In its active state, Rac1 is associated with the plasma membrane and binds to a 
variety of effector proteins to regulate cellular responses such as cytoskeleton 
organisation, cell adhesion, and cell migration (Ridley, 2001) (Figure 30). Rac1 
regulates focal adhesion formation and organisation of actin filaments at the 
plasma membrane, resulting in the formation of lamellipodia and ruffles at the 
leading edge of migrating cells. Additional functions include regulation of gene 
transcription, DNA synthesis, superoxide production, cell proliferation and 
apoptosis (Bosco et al., 2009) (Figure 30). 
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Figure 30: Downstream functions of Rac1 activation.   
Rac1 binds to a variety of effector proteins to regulate cellular responses such 
cell adhesion, polarity and migration. Rac1 regulates actin organisation and 
focal adhesion formation at the plasma membrane, resulting in the formation of 
lamellipodia and ruffles at the leading edge of migrating cells. Additional 
functions include regulation of gene transcription, DNA synthesis, cell 
proliferation and apoptosis.  
 
1.8.4 Rac1 gene  
The human RAC1 gene is 29kb and contains seven exons and is mapped to 
chromosome 7p22 (Matos et al., 2000). In mice, the Rac1 gene is located on 
chromosome 5p14.3. There are two protein-coding transcripts through 
alternative splicing of Rac1 exon 3b (Figure 31). The first transcript contains six 
exons and encodes a 192 amino acid protein which is expressed ubiquitously 
(Figure 31A). The second transcript contains seven exons and encodes a 211 
amino acid protein which is not known to be expressed (Figure 31A). The Rac1 
protein is shown in Figure 31C and contains a RhoGTPase domain and is 
prenylated. Humans and mice share 91.6% similarity in the nucleotide 
sequence and 100% similarity in the amino acid sequence (GeneCards).  
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Figure 31: Rac1 Coding Transcripts and Protein. 
There are two protein-coding transcripts through alternative splicing of Rac1 
exon 3b. Transcript 1 contains six exons and encodes a 192 amino acid protein 
(A). Transcript is 2,325bp contains seven exons and encodes a 211 amino acid 
protein (B). Transript 1 encodes the Rac1 protein which is ubquitously 
expressed and contains a RhoGTPase domain and is prenylated (C). The 
arrows on A represent the primers used for in situ probes; Rac1 (purple) and 
Rac1 exons 4-5 (orange).   
  
1.8.5 Rac1 in embryonic development  
Rac1 is the only Rac gene expressed both ubiquitously and early in 
embryogenesis (Wang and Zheng, 2007). Rac1 null mouse embryos die during 
embryogenesis (before E7.5) and display extensive cell death in the space 
between the endoderm and ectoderm (Sugihara et al., 1998), implying that 
Rac1 has a critical role during embryogenesis. Cell-specific knock-out studies in 
mice have shown that Rac1 is required for endoderm and mesoderm migration 
(Migeotte et al., 2010; Migeotte et al., 2011). Epiblast-specific deletion of Rac1 
caused cardia bifida (two independent heart tubes) and in vitro, Rac1 deficient 
epiblast cells failed to adhere to matrix, leading to cell death (Migeotte et al., 
2011).  
1.8.6 Rac1 in cardiovascular development  
The cardia bifida phenotype observed in the epiblast specific Rac1 deletion 
embryos highlights the importance of Rac1 in early heart formation. Additionally, 
cell-specific knock-out studies in mice have shown that Rac1 has a continued 
important role in cardiac development within endothelial, NCC and 
cardiomyocyte lineages.   
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1.8.6.1 Rac1 in endothelial cells  
During mouse embryonic development, studies have shown that Rac1 is crucial 
in the endothelial lineage. Using an endothelial specific Cre line, Tie2Cre, Rac1 
was deleted from endothelial cells. Rac1;Tie2Cre embryos die at E9.5 due to 
developmental delay, with defective development of major vessels and 
complete lack of smaller branched vessels (Tan et al., 2008). The presence of a 
complete dorsal aorta suggested that Rac1 is primarily involved in angiogenesis 
rather than vasculogenesis. However, capillary like structures were absent in 
Rac1;Tie2Cre embryos suggesting Rac1 may be required for the migration of 
angioblasts to promote establishment of these networks (Tan et al., 2008). 
Rac1+/f;Tie2Cre heterozygous mice survive to adulthood but present with 
decreased eNOS, decreased endothelium-dependent vasorelaxation and mild 
hypertension (Sawada et al., 2008). Rac1 deficient primary endothelial cells had 
reduced migration and failed to form tube-like networks, as well as displaying 
reduced focal adhesion and lamellipodia formation, and attachment to 
fibronectin in response to VEGF. Endothelial cells lacking Rac1 also had 
increased permeability and unorganised cell-cell interactions as labelled by β-
catenin, VE-cadherin and ZO1. Additionally, it was established that Rac1 is 
required for cell surface signalling to downstream effectors WAVE and PAK to 
regulate endothelial cell migration, gene expression and cell permeability (Tan 
et al., 2008). Since Tie2Cre is expressed during vasculogenesis and 
angiogenesis, the same group have since conditionally deleted Rac1 in a 
temporally controlled and endothelial-restricted fashion using Cdh5(PAC)-
iCreERT2 transgenic mice. This confirmed that Rac1 is required for embryonic 
vascular integrity and angiogenesis, and is spatially involved in endothelial cell 
migration, invasion, and radial sprouting activities in 3D in vitro models (Nohata 
et al., 2016). 
Hence, Rac1 is essential in endothelial cells for normal cardiovascular 
development mainly due to its role in the regulation of the actin cytoskeleton 
and lamellipodia protrusion formation necessary for endothelial cell migration 
(Tan et al., 2008). 
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1.8.6.2 Rac1 in neural crest cells  
Deletion of Rac1 in the neural crest stem cells (NCSC) results in reduced cell 
proliferation in differentiated NCCs, but does not affect the migration of early 
NCSCs, suggesting a role of Rac1 during NCC maturation (Fuchs et al., 2009). 
Embryos lacking in Rac1 in NCC, using Wnt1Cre, have abnormal craniofacial 
development including a cleft palate at E12.5, as well as cardiovascular defects 
comprising defective remodelling of the PAA and septation of the cardiac OFT, 
resulting in a PTA (Thomas et al., 2010). Confirming the conclusions from 
Fuchs et al, NCC migration was unaffected in Rac1 mutants, however 
postmigratory NCCs showed increased  cell death and attenuated proliferation, 
as well as a defect in smooth muscle differentiation (Thomas et al., 2010). 
Hence, Rac1 is not required for NCC migration but it is important for post-
migratory NCC survival and differentiation in craniofacial and cardiovascular 
development (Thomas et al., 2010).  
1.8.6.3 Rac1 in valve development  
Rho GTPase signalling acts to coordinate AV valve differentiation and 
morphogenesis (Gould et al., 2016). Rac1 activity is almost absent in the early 
cushions but is increased substantially as the valve matures. Through gain/loss 
of function analysis, it was found that the Rac1 pathway is necessary to induce 
matrix compaction in vitro through increased cell adhesion, elongation, and 
stress fibre alignment. Additionally, cyclic mechanical signalling coordinates the 
RhoA to Rac1 signalling transition essential for proper embryonic mitral valve 
remodelling (Gould et al., 2016).   
1.8.6.4 Rac1 in cardiomyocytes  
During the duration of this project, new publications have investigated the role 
of Rac1 in cardiomyocyte populations and are discussed in detail in Chapter 3 
(Abu-Issa, 2014; Leung et al., 2014; Leung et al., 2015). However, both Abu 
Issa and Leung and colleagues use conditional deletions of Rac1 which include 
multiple cell types, leading to difficulties separating possible differential roles of 
Rac1 in specific cell types. Additionally, neither group have investigated the role 
of Rac1 in the formation of the trabeculae and subsequent development of the 
myocardium. And therefore the work presented in this thesis addresses this.  
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1.8.7 Rac1 in the adult heart  
Rac1 was identified in a pathway-based genome-wide association analysis of 
coronary heart disease (de las Fuentes et al., 2012). Additionally, Rac1 
mutations and elevated levels of Rac1 have been associated with types of CVD, 
including AF, in human patients (Adam et al., 2007). In the adult mouse heart, 
Rac1 is known to regulate proliferation and migration of vascular SMCs, 
cardiomyocyte hypertrophy, and realignment of endothelial cells during cardiac 
pathology (Sawada et al., 2010). Knockdown of Rac1 in cultured 
cardiomyocytes, or cardiomyocyte specific deletion of Rac1 in vivo, using 
MerCreMer, reduced cardiomyocyte hypertrophy in response to angiotensin II 
(Hingtgen et al., 2006; Satoh et al., 2006). Overexpression of Rac1 in the 
myocardium can cause severe cardiac hypertrophy, heart failure or AF in mice 
(Buscemi et al., 2005; Adam et al., 2007; Elnakish et al., 2011; Elnakish et al., 
2012; Elnakish et al., 2013a; Elnakish et al., 2013b; Talukder et al., 2013). This 
data suggests that Rac1 is critical in the hypertrophic response in the adult 
heart.  
1.8.8 Rac1 activators   
The activation state of Rac1 depends on the release of GDP and the binding of 
GTP and this cycling is regulated by GEFs and GAPs. A number of GEFs and 
GAPs have been linked to Rac1 activity in the heart. GAP, G protein coupled 
receptor kinase interacting protein 1 (Git1), and GEF, Pak interacting exchange 
factor (betaPix) are both involved in Rho GTPase activation. Git1 and betaPix 
form a complex at the cell membrane and are thought to act as a scaffold to 
bring together proteins involved in cytoskeletal arrangement, cell adhesion and 
migration (Botrugno et al., 2006). The Git1/betaPix complex is particularly 
located at focal adhesions where it promotes focal complex disassembly 
(Wilson et al., 2014). Git1 is highly expressed in the mouse heart at P2-3 and 
betaPix is expressed in cardiomyocytes at E8.5, as well as being expressed in 
the mouse adult heart (Kim and Park, 2001; Pang et al., 2011; Boczonadi et al., 
2014b). Git1 knockout mice develop cardiac hypertrophy and subsequent heart 
failure, with increased cardiomyocyte apoptosis and defective cardiac 
maturation (Pang et al., 2011). Little is known about betaPix/Rac1 interaction in 
cardiomyocytes, however other Rho GTPases have been shown to interact with 
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betaPix/Git1 in cardiomyocytes (Dickover et al., 2014; Wilson et al., 2014). In 
cardiomyocytes it is proposed that Rac1, Scrib and betaPix form a protein 
complex at the cell membrane, which is essential for early ventricular 
myocardial development (Boczonadi et al., 2014b). FAK is a cytoplasmic 
tyrosine kinase that is activated and targeted to focal adhesions following cell 
attachment to ECM. FAK phosphorylates betaPix and enhances its binding to 
Rac1, which facilitates targeting of Rac1 to focal adhesions (Chang et al., 
2007). Cardiac specific deletion of FAK suggests an important role during heart 
development, particulary in OFT alignment (Hakim et al., 2007). Affixin is an 
integrin-linked kinase-binding focal adhesion protein, which is highly expressed 
in skeletal and heart muscle. Affixin regulates cytoskeletal rearrangement by 
activating Rac1 through betaPix and alphaPix in vitro (Matsuda et al., 2008) and 
activates Rac1 via betaPix in myoblasts in skeletal muscle (Matsuda et al., 
2008). 
Vav2 is an exchange factor for Rho family GTPases and is ubiquitously 
expressed (Abe et al., 2000). Vav2 is tyrosine phosphorylated upon VEGF 
treatment, which temporally correlates with Rac1 activation and requires 
VEGFR-2 signalling. Vav2 and Rac1 associate and form a complex after VEGF 
stimulation, to initiate lamellipodia formation and angiogenesis. Depleting 
endothelial cells of endogenous Vav2 with siRNA prevents VEGF-induced Rac1 
activation, impairing endothelial cell migration (Garrett et al., 2007). 
 
Figure 32: Rac1 Activators.  
GEF betaPIX and GAP Git1 bind Rac1 at the cell membrane to initiate focal 
adhesion disassembly. Affixin and FAK both activate betaPIX and enhance its 
binding to Rac1. GEF Vav2 binds Rac1 to initiate lamellipodia formation leading 
to cell migration.   
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1.9 Aims and Objectives  
The development of the myocardial wall requires proliferation and differentiation 
of FHF and SHF derived cardiomyocytes, as well as signals from epicardial 
cells and invasion of EPDCs. The role of Rac1 in myocardial cells and 
epicardial cells during ventricular wall development has not been fully 
elucidated. Preliminary data suggested that deleting Rac1 from the epicardium 
and myocardium, using Gata5-Cre, resulted in defects within the myocardial 
wall (personal communication from Dr Helen Phillips). Therefore, the aim of this 
thesis was to determine the role of Rac1 within the epicardial and myocardial 
populations during ventricular development: 
 Define the expression of Rac1 within the embyonic heart during 
development. 
 Use the Cre-LoxP system to conditionally delete Rac1 from myocardial 
and epicardial cells and determine the role of Rac1 in these populations.  
o Characterise myocardial and OFT defects due to deletion of Rac1 
in Gata5-Cre, WT1-CreERT2, Mlc2v-Cre and TnT-Cre Cre 
populations.  
o Investigate cellular processes associated with Rac1, including cell 
migration, proliferation, differentiation and polarity in the 
ventricular and OFT myocardium prior to the onset of defects.  
o Analyse expression of potential Rac1 interacting proteins in 
cardiomyocytes.  
o Define how the deletion of Rac1 affects continued development 
and remodelling of ventricles and OFT during later stages of heart 
development. 
1.10 Hypothesis  
In the developing embryonic heart it is hypothesised that Rac1 is involved in 
epithelial and myocardial cell movements through cell polarity and cell 
organisation mechanisms which are crucial for the development of the complex 
structure of the myocardial wall.  
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Chapter 2. Materials and Methods 
 
2.1 Statement of Ethics  
Ethical approval of the animal work carried out in this study has been authorised 
by the Newcastle University Ethics Committee in compliance with Directive 
2010/63/EU of the European Paliament and was covered by Project Licence 
PPL 70/7864 approved by the UK Home Office. 
2.2 Materials 
2.2.1 General  
All reagents were purchased from Sigma Aldrich unless stated otherwise.  
2.2.2 Animals 
Mice were maintained in the Institute of Genetic Medicine animal facility 
according to the Animals (Scientific Procedures) Act 1986, United Kingdom. 
Wild type CD1 mice were supplied by Charles River. Several mouse lines were 
used to generate control and mutant embryos and are described briefly below.  
2.2.2.1 Rac1flox 
Rac1flox mice were generated by inserting LoxP sites flanking exons 4 and 5 of 
the Rac1 gene. These LoxP sites are recombined by Cre recombinase, leading 
to a frame shift and as a result no functional Rac1 protein is produced 
(Walmsley et al., 2003).  Rac1flox mice were maintained on the C57BL/6 
background.  
2.2.2.2 Reporter lines  
The expression pattern of Cre was examined using either a LacZ or enhanced 
yellow fluorescent protein (EYFP) construct, introduced into the Rosa26 locus. 
These constructs contain a transcriptional stop sequence flanked by LoxP sites, 
which is removed in the presence of Cre recombinase, therefore allowing the 
expression of the LacZ and EYFP constructs in these cells. R26REYFP reporter 
mice were crossed to Rac1flox mice to allow for reporting of Cre activity in 
mutant embryos (Srinivas et al., 2001). Recombination in R26REYFP embryos 
was visualised using GFP immunostaining. R26RLacZ mice were crossed to 
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TnT-Cre mice to allow for reporting of Cre activity. Cre activity was visualised by 
X-gal staining for the expression of the LacZ construct in the R26RLacZ allele.   
2.2.2.3 TnT-Cre 
Troponin-T (TnT)-Cre, gifted by Marina Campione, is a cardiomyocyte specific 
Cre line and drives Cre expression in cardiomyocytes by E7.5. An nls-Cre-hGH 
cassette was fused with the rat TnT promotor (Jiao et al., 2003).  
2.2.2.4 Gata5-Cre 
Gata5-Cre is a mouse line that drives Cre expression in epicardial cells and a 
subset of cardiomyocytes. A fragment of the Gata5 promoter was ligated to 
cDNA encoding phage P1 Cre-recombinase (Merki et al., 2005). 
2.2.2.5 Mlc2v-Cre 
The MLC2v gene is expressed bilaterally in the embryo in the cardiac primordia 
from around E7.5 in the mouse and is restricted to ventricular precursors and 
ventricular tissue from the linear heart tube stage throughout the entire 
postnatal time window. Mlc2v-Cre is a knock-in Cre line that drives Cre 
expression in a subset of ventricular cardiomyocytes. Mlc2v exons 1 and 2 were 
removed and replaced by Cre recombinase cDNA (Chen et al., 1998). 
2.2.2.6 WT1-CreERT2 
Wilms Tumour (WT)1-CreERT2 is tamoxifen inducible Cre line that drives Cre 
expression in epicardial cells. The targeting strategy removed exon 1 of WT1 
(Zhou et al., 2008).  
2.3 Methods 
2.3.1 General 
All procedures were carried out at room temperature unless stated otherwise.   
2.3.2 Timed Matings 
Mouse matings were set up overnight and separated following successful 
mating, which was determined by the presence of a copulation plug. To allow 
embryonic staging, 12pm on the day of plug detection was assumed to be 
embryonic day (E) 0.5. 
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2.3.3 Substance injections  
2.3.3.1 Tamoxifen Injections 
Pregnant Rac1flox female mice were given two consecutive intraperitoneal 
injections of 1mg tamoxifen. The tamoxifen was dissolved in 10µl 100% ethanol 
by shaking at 37° C and then added to 90µl of peanut oil (100µl total volume per 
injection). 
2.3.3.2 BrdU injections  
Pregnant Rac1flox female mice were given one intraperitoneal injection of BrdU 
(25mg/ml). BrdU was dissolved in sterile water by shaking at 72° C.  
2.3.4 Mouse Dissection  
2.3.4.1 Embryo/embryonic heart dissection  
At the required developmental stage (between E8.5 to E17.5) pregnant females 
where sacrificed by cerebral dislocation and embryos were dissected out into 
ice cold phosphate buffered saline (PBS), unless stated otherwise for individual 
protocols.  PBS was prepared by adding 10 tablets (OXOID) to 1 litre of distilled 
water (dH20) and was autoclaved before use. Embryo yolk sacs/limbs were 
collected for genotyping. Young embryonic hearts (E8.5-E12.5) were dissected 
by firstly removing the pericardium to reveal the heart and then by gently pulling 
the heart away from the embryo and snipping the outflow tract with forceps. 
Older embryonic hearts (E13.5-E17.5) were dissected by cutting open the 
thoracic cavity to reveal the heart and then pulling the heart and lungs away 
from the embryos by holding onto the lungs with forceps. The lung lobes were 
then removed leaving the heart intact. Hearts were then rinsed in PBS.  
2.3.4.2 Neonatal and adult heart dissection  
At the required age, neonates and adults were sacrificed by cervical dislocation. 
After cervical dislocation, adult hearts were injected with 1M potassium chloride 
into the left atrium causing diastolic arrest. Hearts were then dissected out as 
for older embryonic hearts and rinsed in PBS. 
2.3.4.3 Somite matching 
Embryos were somite counted and matched within 3 somites for all 
experiments. The somite ranges for the relevant stages are shown in Table 5. 
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Age Somite number range Volume of Lysis Buffer 
(µl) (type of sample)  
E8.5 8-12 50 (yolk sac) 
E9.5 21-29 50 (yolk sac) 
E10.5 35-39 100 (yolk sac) 
E11.5 45-47 100 (yolk sac) 
E12.5 - 200 (limb) 
E13.5 - 200 (limb) 
E15.5 - 400 (limb) 
E17.5 - 400 (limb) 
P0 - 400 (limb) 
Table 5: Somite ranges for stages of embryonic development including 
the type of sample taken for genotyping and volume of lysis buffer used.  
 
2.3.5 Genotyping of Mice 
For identification of transgenic adult mice and embryos, ear notches and 
embryo limbs/yolk sacs were taken respectively and subjected to DNA 
extraction followed by polymerase chain reaction (PCR) to amplify target 
genomic regions.  
2.3.5.1 DNA lysis  
DNA extraction of adult mouse ear Notches was carried out using the ‘hot shot 
DNA lysis method’. Ear Notches were added to 75µl of 25mM sodium 
hydroxide, 0.2mM ethylenediamine tetra-acetic acid (EDTA), pH 12 and heated 
at 95˚C for 30 minutes. The lysed solution was then cooled to 4˚C for 10 
minutes and neutralised by the addition 75µl 40 mM Tris-HCl pH 5. Samples 
were vortexed and centrifuged for 2 minutes at 1500rpm. 2-4µl of each genomic 
DNA sample was used in genotyping PCR reactions. 
DNA extraction of embryo samples was carried out using proteinase K 
digestion. The lysis buffer was prepared by diluting proteinase K to a final 
concentration of 600 μg/ml in proteinase K buffer (50 mM potassium chloride 
(KCl), 1.5mM magnesium chloride (MgCl2), 10 mM Trizma base (tris) pH 8.5, 
0.45% v/v Igepal® CA-630, 0.45% v/v Tween-20). This was added to the 
samples and incubated at 56°C for 2 hours, or until the sample had completely 
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lysed. The samples were vortexed intermittently to ensure complete breakdown 
of the tissues and release of the DNA. Proteinase K was heat inactivated by 
incubating at 95°C for 10 minutes. The lysed sample was centrifuged at 
13,000rpm full speed for 1 minute to collect any debris and stored at 4°C until 
use. The sample type and volume of lysis buffer was dependent on the age of 
the embryos and are detailed in Table 5. 
2.3.5.2 Polymerase Chain Reaction 
PCR was carried out using GoTaq DNA polymerase (Promega). Primers were 
designed and optimised previously; primer sequences are listed in Table 6. 
Each reaction was prepared for PCR in 0.2ml PCR tubes (Thermo) as 
described in Table 7. PCR was carried out on a SensoQuest thermo cycler. 
Briefly, the temperature program consisted of an initial denaturising step at 
94°C for 2 minutes, followed by 35 cycles of; 94°C, annealing temperature, and 
72°C, followed by an extension step at 72°C for 10 min.The samples were held 
at 4°C before use. The annealing temperatures and cycling times were specific 
to primer sequences as detailed in Table 7.  
Table 6: Genotyping PCR primer sequences and product sizes for Rac1, 
EYFP and Cre.  
 
 
 
 
 
 
 
Gene Primer Sequence (5' to 3') Product size 
(bp) 
Rac1 Rac1 1 ATT TTG TGC CAA GGA CAG TGA CAA GCT 333bp (flox) 
300bp (WT) 
 
Rac1 2 GAA GGA GAA GAA GCT GAC TCC CAT C 
Rac1 3 CAG CCA CAG GCA ATG ACA GAT GTT C 
EYFP EYFP 316 GGA GCG GGA GAA ATG GAT ATG 320bp (flox) 
600bp (WT) EYFP 883 AAA GTC GCT CTG AGT TGT TAT 
EYFP 4982 AAG ACC GCG AAG AGT TTG TC 
Cre 
 
S1X Cre A GCA TAA CCA GTG AAA CAG CAT TGC TG  280bp 
 S1X Cre B GGA CAT GTT CAG GGA TCG CCA GGC G  
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Table 7: Genotyping PCR reaction set up and cycling conditions for Rac1, 
EYFP and Cre. 
 
2.3.5.3 Agarose gel electrophoresis 
Following PCR, 10µl of each sample was ran on a 2% agarose gel made using 
agarose (NBS biologicals) and TAE buffer  (40mM Tris, 20mM acetic acid, and 
1mM EDTA) with 0.5µg/ml ethidium bromide. A 100bp DNA ladder (Promega) 
was ran alongside samples to determine PCR product sizes. Gel 
Electrophoresis was carried out in TAE buffer typically maintained at 125 volts 
for 30 minutes. The gel was visualised using a UVP transluminator and the 
image captured. 
2.3.6 Processing of Embryos/Hearts 
2.3.6.1 Paraffin Wax Embedding   
Embryos/hearts were washed in PBS then fixed in 4% paraformaldehyde (PFA) 
in PBS, washed in PBS and dehydrated in an ethanol series. Tissues were then 
transferred to glass vials and shaken in histoclear before an equal volume of 
wax (VWR) was added and maintained at 60°C. Embryos/hearts were then 
Gene Reaction PCR cycling conditions 
Rac1 1µl 10µM Rac1 1                                                 
1µl 10µM Rac1 2   
1µl 10µM Rac1 3 
0.25µl 25mM dNTP 
4µl 5x buffer 
0.5µl MgCl2  
0.1µl taq polymerase 
8.15µl dH2O 
4µl sample 
1. 94˚C - 4 minutes 
2. 94˚C - 30 seconds 
3. 60˚C - 30 seconds 
4. 72˚C - 30 seconds 
5. 72˚C - 10 minutes 
Held at 4˚C 
 
Cycling 4-2 x35 
EYFP 1µl 10µM EYFP 1                                                 
1µl 10µM EYFP 2   
1µl 10µM EYFP 3 
0.25µl  25mM dNTP 
4µl 5x buffer 
0.1µl taq polymerase 
10.65µl dH2O 
2µl sample 
94˚C - 3 minutes 
94˚C - 30 seconds 
58˚C - 1 minute 
72˚C - 1 minute  
72˚C - 10 minutes 
Held at 4˚C 
  
Cycling 4-2 x35 
Cre 1µl 10µM S1XA                                                  
1µl 10µM S1XB 
0.25µl  25mM dNTP 
4µl 5x buffer 
0.1µl taq polymerase 
11.65µl dH2O 
2µl sample 
1. 95˚C - 2 minutes 
2. 95˚C - 30 seconds 
3. 55˚C - 30 seconds 
4. 72˚C - 30 seconds 
5. 72˚C - 10 minutes 
Held at 4˚C 
Cycling 4-2 x35 
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placed in paraffin wax moulds and heated forceps were used for positioning in 
the correct orientation for transverse sectioning. Timings for each step vary 
according to embryo/heart size and are listed in Table 8.  
2.3.6.2 Wax sections 
Wax embedded embryos and hearts were sectioned transversely at a thickness 
of 8μm using a rotary microtome. Serial or sister sections were placed on water-
covered histobond positively charged slides (Merienfeld) at 37°C and allowed to 
expand and dry. Slides were then placed in an oven to dry overnight at 37°C. 
2.3.6.3 Cryoembedding  
Following dissection, hearts/embryos were shaken in ice cold sucrose at 4˚C to 
remove water and prevent tissue damage during freezing; 15% sucrose in PBS 
until hearts/embryos had sunk then 30% sucrose in PBS until hearts/embryos 
had sunk. The hearts were placed in plastic wells and the sucrose was removed 
by pipetting. The hearts were then covered in O.C.T embedding medium (Cell 
Path) and snap frozen on dry ice. Cryoembedded hearts were stored at -80˚C.  
2.3.6.4 Cryosections 
10µm serial or sister sections were sliced using a Leica cryostat and placed 
onto histobond positively charged glass slides.  The sections were allowed to air 
dry for 1 hour, after which they were wrapped in tin foil and stored at -80°C or 
used immediately.  
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Table 8: Processing timings for embedding embryos/hearts in paraffin wax.   
PFA, paraformaldehyde; PBS, phosphate buffered saline. 
  E9.5 E10.5/embryonic 
hearts 
E11.5 E12.5 E13.5 E14.5 E15.5 E16.5 E17.5 P0/adult 
hearts 
4% PFA at 
4˚C 
1 night 1 night 1 night 1 night 1 nights 2 nights 2 nights 5 nights 5 nights 5 nights 
Wash PBS 5 mins 
(x2) 
5 mins (x2) 5 mins 
(x2) 
5 mins 
(x2) 
5 mins 
(x2) 
5 mins 
(x2) 
5 mins 
(x2) 
5 mins (x2) 5 mins (x2) 5 mins (x2) 
50% EtOH 
(shaking) 
30 mins 30 mins 1 hour 2 hours 2 hours 3 hours 3 hours 4 hours 5 hours 6 hours 
70% EtOH 
(shaking) 
30 mins 
(x2) 
30 mins (x2) 1 hour 
(x2) 
2 hours 
(x2) 
2 hours 
(x2) 
3 hours 
(x2) 
3 hours 
(x2) 
4 hours, 
O/N 
5 hours, 
O/N 
6 hours, O/N 
95% EtOH 
(shaking) 
30 mins 30 mins 1 hour 2 hours 2 hours 3 hours 3 hours 4 hours 5 hours 6 hours 
100% EtOH 
(shaking) 
30 mins 
(x2) 
30 mins, 1 hour 1 hour 
(x2) 
2 hours, 
O/N 
2 hours, 
O/N 
3 hours, 
O/N 
3 hours, 
O/N 
4 hours, 
O/N 
5 hours, 
O/N (x2) 
6 hours, O/N 
(x2) 
Histoclear 
(shaking) 
10 mins 
(x2) 
15 mins (x2) 20 mins 
(x2) 
20 mins 
(x2) 
20 mins 
(x2) 
20 mins 
(x2) 
30 mins 
(x2) 
1 hour (x2) 1 hour (x2) 1 hour (x2) 
Histoclear / 
Wax (60˚C) 
15 mins 20 mins 20 mins 30 mins 30 mins 1 hour 1 hour 1 hour 2 hours 2 hours 
Wax (60˚C) 20 mins 
(x3) 
30 mins (x3) 40 mins 
(x3) 
1 hour 
(x3) 
1 hour 
(x3) 
1 hour 
(x4) 
1 hour 
(x4) 
1 hour 
(x4), O/N 
2 hours 
(x4), O/N 
2 hours (x4) 
O/N) 
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2.3.7 Histology staining  
For all histology stains paraffin sections were first treated as follows; paraffin 
sections were dewaxed in Histoclear (National Diagnostics) for 10 minutes, 
twice. The sections were then incubated in 100% ethanol for 3 minutes, twice, 
followed by rehydration through ethanol series (90%, 70% and 50% EtOH, 2 
minutes each) and equilibrated in dH20 for 2 minutes.  
2.3.7.1 Haematoxylin and eosin staining  
Haematoxylin and eosin staining was used to identify changes in heart 
morphology in the mutant embryos. Haematoxylin stains the cell nuclei purple, 
while eosin stains the cytoplasm pink.  
After equilibration in dH20 the sections were stained in Harris’ haematoxylin 
solution for 5-10 minutes. Excess haematoxylin was washed away with running 
water for 5 minutes. Slides were then dipped in an acid alcohol solution (1% v/v 
hydrochloric acid (HCl), 70% ethanol) to remove the stain from all tissues 
except the nucleus and returned to the running water for a further 5 minutes. 
The slides were then incubated in eosin (Fisher Scientific) for 5 minutes, rinsed 
in running water and dehydrated by dipping in 50%, 70% and 90% ethanol. 
Following this, the slides were transferred to 100% ethanol for 3 minutes, twice, 
and incubated twice in Histoclear for 10 minutes. Slides were mounted in 
Histomount (National Diagnostics) and dried overnight. Sections were imaged 
using a Zeiss Axioplan2 microscope and associated Axiovision SE64 software. 
2.3.7.2 Alcian blue staining  
After equilibration in dH20 the sections were stained in Alcian blue solution for 
30 minutes. Excess alcian blue was washed away with running water for 1 
minute. The slides were then incubated in nuclear fast red for 5 minutes. 
Excess solution was removed by rinsing in running water for 1 minute, followed 
by dehydration through an ethanol series (50%, 70%, 90%, and 100%, twice). 
The slides were then incubated twice in Histoclear for 10 minutes and mounted 
in Histomount and dried overnight. Sections were imaged using a Zeiss 
Axioplan2 microscope and associated Axiovision SE64 software. 
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2.3.7.3 Sirius red Staining 
After equilibration in dH20 the sections were incubated in 0.2% 
phosphomolybolic acid for 5 minutes. Slides were then rinsed in dH20, twice, 
followed by staining in picro-sirius red for 2 hours. Slides were then rinsed, first 
in 0.01% HCl and then dH20 followed by dehydration through an ethanol series 
(50%, 70%, 90%, and 100%, twice). The slides were then incubated twice in 
Histoclear for 10 minutes and mounted in Histomount and dried overnight. 
2.3.7.4 Millers elastin Staining  
After equilibration in dH20 the sections were stained in Millers stain for 1 hour. 
Slides were then rinsed in dH20 before incubation in 3 % ferric chloride for 10 
mins. Slides were then rinsed again in dH2 before a 5 minute incubation in 
Eosin. Slides were rinsed for a final time in dH20 rinse followed by dehydration 
through an ethanol series (50%, 70%, 90%, and 100%, twice). The slides were 
then incubated twice in Histoclear for 10 minutes and mounted in Histomount 
and dried overnight. 
2.3.7.5 Toluidine blue Staining   
After equilibration in dH20 the sections were stained in toluidine blue working 
solution (10% stock solution [1% toluidine blue O in 70% EtOH] in 1% NaCl 
pH2.0-2.5) for 2-3 minutes. After staining slides were washed in dH20, three 
times then dehydrated quickly through 95% and 2 changes of 100% ethanol. 
The slides were then incubated twice in Histoclear for 10 minutes and mounted 
in Histomount and dried overnight. 
2.3.7.6 β-galactosidase staining  
For whole mount β-galactosidase staining, embryos were dissected and 
washed in ice-cold PBS followed by a light fixation in 4% PFA at 4˚C. The 
length of fixation was dependent on the size of the embryo; 5 minutes for E8.5-
E9.5, 15 minutes for E10.5-E12.5 and 40 minutes for E15.5 hearts. After 
fixation, embryos were washed in PBS for 5 mins, three times. Embryos/hearts 
were incubated in x-gal staining solution (0.1% w/v X-Gal, 5 mM potassium 
ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, 0.02% Igepal® CA-
630, 0.01% sodium deoxycholate, 0.02 M Tris pH 7.3) in the dark, shaking at 
37˚C for 4 hours to overnight. Once the stain had developed fully, the X-gal 
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staining solution was removed and embryos/hearts were washed in PBS, three 
times, and fixed in 4% PFA overnight at 4˚C. Following fixation, embryos were 
washed in PBS, photographed and dehydrated for normal wax embedding.  
2.3.8 Immunostaining  
2.3.8.1 Immuno-fluorescent (IF) staining of wax sections  
Paraffin sections were dewaxed in Histoclear (National Diagnostics) (10 
minutes, twice), rehydrated in an ethanol series (100%, 90%, 70% and 50% 
EtOH – 5 minutes each) and equilibrated in PBS for 5 minutes. Antigen retrieval 
was carried out using 1M citrate buffer (pH 6); sections were boiled in citrate 
buffer in a pressure cooker for 5 minutes, cooled for 20 minutes then rinsed in 
dH20. Non-specific epitope binding was blocked by incubation of the sections in 
10% foetal calf serum (FCS) in Tris buffered saline with 0.3% triton x (TBS-Tx) 
for 30 minutes. TBS-Tx, (Tris HCl, 0.2M NaCl, 0.3% Triton X, pH7.5) was 
prepared freshly. Primary antibodies were diluted in 2% FCS in TBS-Tx. 
Dilutions are listed in Table 9. 100µl was added to each slide and covered with 
parafilm (Fisher Scientific). Slides were then placed in a humidified chamber 
and incubated at 4°C overnight.   
Sections were washed in TBS-Tx (5 minutes, 3 times). Fluorescently-
conjugated secondary antibodies (listed in Table 10) were diluted 1:200 in TBS-
Tx then 100µl was added to each slide and covered with parafilm 
(ThermoFisher Scientific). Slides were then placed in a dark humidified 
chamber and incubated at room temperature for 1 to 2 hours. Slides were then 
washed in TBS-Tx (5 minutes, 3 times) in the dark, mounted in Vectashield with 
DAPI with a glass coverslip (Cell Path) and left at 4°C overnight before viewing. 
Sections were imaged using either a Zeiss AxioImager or a Nikon Confocal 
microscope with associated Axiovision SE64 or Nikon Elements software, 
respectively.  
2.3.8.2 Immunohistochemistry (IHC) staining of wax sections 
Paraffin sections were initially treated as for fluorescence staining except 
endogenous peroxidise activity was inhibited using 3% H2O2 for 10 minutes after 
antigen retrieval, followed by additional washing in dH20. Slides were incubated 
with biotinylated secondary antibodies (listed in Table 10) and then washed in 
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TBS-Tx (5 minutes, 3 times) before AB complex (VectorStain) was added for 30 
minutes (250µl per slide). Slides were then washed in TBS-Tx (5 minutes, 3 
times) before Diaminobenzine (DAB) was added until brown staining was 
observed, when the reaction was discontinued by placing in PBS. Slides were 
then counterstained in 0.5% methyl green for 10 minutes and washed in H20 (2 
times 5-10 dips, then 20-30 seconds) and butanol (2 times 2-5 dips, then 15-20 
seconds). Slides were then placed in Histoclear (10 mins, twice), before 
mounting in Histomount and were left overnight to dry. Sections were imaged 
using a Zeiss Axioplan2 microscope and associated Axiovision SE64 software. 
2.3.8.3 Signal amplification -  Tyramide Signal Amplification (TSA)  
Tyramide Signal Amplification (TSA) kit (PerkinEkmer) was used as per 
manufacturer’s protocol for antibodies listed in Table 9. Briefly, slides were 
dewaxed, rehydrated, antigen retrieval and washed as for fluorescent staining 
(Chapter 2 Section 2.3.8.1) and then TSA-IF protocol was followed. Slides were 
blocked in TNB blocking buffer (0.1M Tris-HCl pH7.5, 0.15M NaCl, 0.5% 
Blocking reagent) for 30 mins. Primary antibodies were diluted in TNB buffer, 
dilutions listed in Table 9.100µl was added to each slide and covered with 
parafilm (Fisher Scientific). Slides were then placed in a humidified chamber 
and incubated at 4°C overnight. Sections were washed in TBS-Tx (3 times, 5 
minutes). Biotinylated secondary antibodies (listed in Table 10) were diluted 
1:300 in TNB then 100µl was added to each slide and covered with parafilm 
(Fisher Scientific). Slides were placed in a humidified chamber and incubated at 
room temperature for 1 hour. Following antibody incubation, slides were then 
washed in TBS-Tx (5 minutes, 3 times). Streptavidin-HRP diluted in TNB buffer 
1:100, 100µl was added to each slide and covered with parafilm and incubated 
at room temperature for 30 minutes. Sections were washed again in TBS-Tx (5 
minutes, 3 times), before Cyanide 3 Tyramide, diluted 1:50 in amplification 
diluent, was added to the slides. Slides were covered in parafilm and left in the 
dark for 10 mins. Slides were then washed a final time in TBS-Tx in the dark (5 
minutes, 3 times), then mounted in Vectashield with DAPI with a glass coverslip 
(Cell Path) and left at 4°C overnight before viewing. Sections were imaged 
using either a Zeiss AxioImager or a Nikon Confocal microscope with 
associated Axiovision SE64 or Nikon Elements software, respectively. 
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2.3.8.4 Alternative antigen retrieval methods  
Anti-α-SMA staining did not require antigen retrieval as stated in Table 9.  
Anti-CD31 staining required proteinase K antigen retrieval as stated in Table 9. 
Following the 5 minutes PBS wash, 400µl Proteinase K (20µg/ml) in TE buffer 
was added to each slide and incubated for 30 minutes. The slides were then 
washed and then TSA-IF protocol was followed as described above in Chapter 
2 Section 2.3.8.3.  
2.3.8.4 Immuno-fluorescent staining of cryosections   
Frozen sections were thawed to room temperature before fixation in 4% PFA for 
10 minutes. Sections were then washed in PBS (5 minutes, twice), treated with 
detergent (0.5% Triton X in PBS, 10 minutes) before being washed again in 
PBS (5 minutes, twice). Slides were then treated as for wax sections (as 
described in Chapter 2 Section 2.3.8.1). 
Primary Antibodies  Supplier/Order 
number 
Dilution Targets Method 
Mouse anti-α-actinin GeneTex/GTX1032
19 
1:500 Cardiomyocytes IF  
Rabbit anti-cardiac-
actin 
GeneTex/GTX1018
76 
1:200 Cardiomyocytes IF 
Rabbit anti-ANF Source BioSci/ 
GTX112698S 
1:200 Trabeculae 
cardiomyocytes 
IF 
Mouse anti-α-smooth 
muscle actin 
Sigma Aldrich 
/A5228 
1:500 Cardiac smooth 
muscle cells 
IHC (No 
antigen 
retrieval), IF 
Mouse anti- β-catenin 
 
BD Bioscience/  
610153 
1:200 Adherens junctions IF 
Rat anti-BrdU Abcam/Ab6326 1:200 Proliferating cells IF  
Rabbit anti-Ccn1 Santa Cruz/ Sc-
13100 
1:100 ECM  IF 
Rat anti-CD31 BD Biosciences/ 
553370 
1: 300 Endothelial cells IF 
(Proteinase 
K antigen 
retrieval, 
TSA) 
Rabbit anti-cleaved 
caspase 3 
Cell Signalling/ 
9661 
1: 100 Apoptosis  IF (TSA) 
Goat anti-Cx-40 Santa Cruz sc-
20466 
1:50 Adherens junctions IF 
Rabbit anti-Cx-43 Sigma/C6219 1:100 Adherens junctions IF 
Rabbit anti-Delta4 Santa Cruz/sc-
28915 
1:100 Endothelial cells IF 
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Rabbit anti-Desmin Millipore 04-585 1:100 Desmosomes IF  
Mouse anti-E-cadherin  BD 
transduction/61018
1 
1:100 Adherens junctions IF 
Rabbit anti-ENAH Abcam/Ab124685 1:400  Rac1 interactor IF 
Rabbit anti-ERG Abcam/Ab92513 1:1000 Endothelial cells IF 
Rat anti-endomucin Santa Cruz/sc-
65495 
1:300 Endocardial cells IF 
Rabbit anti-FAK Abcam/ab40794 1:100 Endocardial cell focal 
adhesions 
IF 
Mouse anti-fibronectin Santa Cruz/sc8422 1:20 ECM IF 
Chicken anti-GFP Abcam/Ab13970 1: 100 EYFP IF, 
Rabbit anti-GFP Torrey Pines/TP401 1:100 EYFP IHC 
Mouse anti-Islet1  Hybridoma 1:5 SHF cells IF 
Rabbit anti-laminin Sigma/L9393 1:50 ECM basement 
membrane 
IF 
Mouse anti-MF20 Dev Hyb Bank/1-
2/21/13 
1: 500 Cardiomyocytes IF, IN+HC 
Rabbit anti-N1ICD Cell signalling/4147  1:400 Activated Notch  IF (TSA) 
Mouse anti- Neuropilin 
1 
Sigma/PA5-23306 1:100 Endocardial 
signalling 
IF 
Mouse anti-NfatC1 BD 
Bioscience/556602 
1:500 Endocardial 
signalling 
IF 
Mouse anti- N-
cadherin  
BD Bioscience/ 
610920 
1: 200 Adherens junctions  IF 
Rabbit anti-phHH3 Millipore/06-570 1: 300 Proliferating cells IF 
Rabbit anti-PKCz Santa Cruz sc-216 1:100 Apical Membrane IF 
Goat anti-scrib Santa Cruz/ sc-
11049 
1:100 PCP signalling IF 
Rabbit anti- Sema3a Abcam/Ab23393 1:100 Endocardial 
signalling 
IF 
Goat anti-Sfrp1 Abcam/Ab110113 1:100 ECM IF 
Rabbit Anti-SM22α Abcam/ab14106 1:200 Smooth muscle cells IF 
Goat anti-troponin I Hytest 1:100 Cardiomyocytes  IF 
Rabbit anti-acetylated 
tubulin 
Sigma/ T6793 
 
1:500 MTOC IF 
Rabbit anti-gamma-
tubulin 
Sigma/ T6557 
 
1:100 MTOC IF 
Goat Anti-Vav2 Santa Cruz/Sc-
8586 
1:200 Rac1 interactor IF 
Rat anti-VE-cadherin BD 
Bioscience/555289 
1:50 Endocardial cell 
adherens junctions 
IF (TSA) 
Mouse anti-VEGFA ThermoFisher//MA1
16629 
1:100 VEGF signalling IF 
Rabbit anti-VEGFR2 ThermoFisher 1:100 VEGF signalling IF 
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/MA515157 
Chicken anti –
Vimentin  
Abcam/Ab24525 1: 100 Fibroblasts IF 
WGA 594 conjugate  ThermoFisher/ 
W11262 
1:200 Binds to sialic acid 
and N-
acetylglucosaminyl 
residues in cell and 
nuclear membranes 
IF 
Rabbit anti-ZO1 Abcam/ab59720 1:100 Tight junctions IF 
Table 9: Primary antibodies for immunostainng. All on paraffin sections 
unless otherwise stated.  
Table 10: Secondary antibodies for immunostaining. 
2.3.9 RNA Isolation from hearts 
2.3.9.1 Tissue collection 
Embryonic, neonatal and adult hearts were dissected as described in Chapter 2 
Section 2.3.4 using diethylpyrocarbonate (DEPC)-treated PBS and RNase free 
plastic wear and instruments.  Hearts were transferred to RNase free eppendorf 
tubes, snap frozen in liquid nitrogen and stored at -80˚C.  
2.3.9.2 RNA extraction 
Hearts were allowed to thaw on ice before RNA extraction using the TRIzol® 
Plus RNA Purification System (Ambion) or Reliaprep RNA tissue miniprep 
system (Promega). The manufacturer’s protocols were followed for both kits 
and are briefy described below.  
The TRIzol® Plus RNA Purification System was used for RNA extraction of wild 
type hearts. Hearts were pooled as per Table 11. The heart tissue was 
homogenised in 500µl Trizol using a 2ml syringe with 21G and 27G needles. 0.2 
Secondary Antibodies Supplier/Order number Animal raised in  Dilution 
Alexa Fluor 594 anti-rabbit Life Technologies/ A11012 Donkey 1 in 200 
Alexa Fluor 594 anti-
mouse 
Life Technologies /A21203 Donkey 1 in 200 
Alexa Fluor 594 anti-goat Life Technologies /A11058 Donkey 1 in 200 
Alexa Fluor 594 anti-
chicken 
Life Technologies /A11042 Goat 1 in 200 
Alexa Fluor 488 anti-
mouse 
Life Technologies / A21201 Donkey 1 in 200 
Alexa Fluor 488 anti-rabbit Life Technologies/ A21201 Goat 1 in 200 
Alexa Fluor 488 anti-rat  Life Technologies / A21208 Donkey 1 in 200 
Alexa Fluor 488 anti-goat Life Technologies /A11055 Donkey 1 in 200 
anti-mouse biotinylated Dako Denmark/E0354 Rabbit 1 in 300 
anti-rabbit biotinylated Dako Denmark/ E0432 Goat 1 in 300 
anti-rat biotinylated Dako Denmark E0 Rabbit 1 in 300 
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volumes of chloroform were added and the sample was shaken vigorously by 
hand, then incubated at room temperature for 2-3 minutes. Samples were 
centrifuged at 12,000 x g for 15 minutes at 4°C to allow phase separation of the 
samples components. 200μl of the upper aqueous phase, containing nucleic 
acids, was transferred to a fresh tube and an equal volume of RNase-free 70% 
ethanol added. The samples were mixed and then transferred to a PureLink™ 
RNA mini kit spin column (Life Technologies) and centrifuged for 15 seconds at 
full speed to allow binding of RNA to the column. The spin column was washed 
once in the supplied wash buffer 1 before on-column DNaseI treatment to 
remove any genomic DNA within the sample. 10 units of DNaseI were diluted in 
1x DNase buffer in DEPC-H2O to a total volume of 80 μl for each sample. The 
DNaseI mix was added to the spin column and incubated for 15 minutes at 
room temperature. The column was then washed again in wash buffer 1, 
followed by multiple washes in wash buffer 2 (contains ethanol). RNA was 
eluted in 30µl of the supplied RNase free water, by centrifugation at 13,000rpm 
for 2 minute, and stored at -80°C.  
Table 11: Number of embryonic hearts pooled for RNA extraction at each 
stages. 
 
The Reliaprep RNA tissue miniprep system was used for RNA extraction of 
control and Rac1TnTCre hearts. 100µl LBA buffer containing 1-Thioglycerol was 
added to E10.5 hearts and homogenisation was carried out by pipetting 7–10 
times using a P200 pipettor. The homogenates were then centrifuged for 3 
minutes at 13,000rpm and the supernatant was transferred to a clean tube. 34µl 
Isopropanol was added to the supernatant and the mixture was vortexed and 
then added to a ReliaPrep™ minicolumn inside a collection tube. The tube was 
centrifuged at 13,000rmp for 1 minute. The flowthrough was discarded and 
500µl of RNA Wash Solution was added to the Minicolumn and centrifuged at 
13,000rpm for 30 seconds. The flowthrough was again discarded and 30µl of 
DNase I mix was added to the Minicolumn membrane and incubated for 15 
Embryo stage No. of hearts pooled 
E10.5 5 
E13.5 3 
E15.5 2 
E17.5 2 
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minutes. 200µl of Column Wash Solution (with ethanol) was added to the 
Minicolumn and centrifuged at 13,000 rpm for 15 seconds. 500µl of RNA Wash 
Solution (with ethanol) was then added and centrifuged at 13,000rpm for 30 
seconds. The collection tube was discarded and the ReliaPrep™ Minicolumn 
was placed into a new collection tube. 300µl of RNA Wash Solution was added 
and the tube was centrifuged at high speed for 2 minutes. The ReliaPrep™ 
Minicolumn was then transferred to an Elution Tube. RNA was eluted in 15µl of 
Nuclease-Free Water, by centrifugation at 13,000rpm for 1 minute and stored at 
–80°C. 
2.3.9.3 RNA quantification and quality assessment  
Quantification of RNA samples was carried out using a NanoDrop 
spectrophotometer (Thermo Scientific). The NanoDrop channels were blanked 
using elution buffer and 1 μl of each sample was loaded onto the pedestals. 
Quantifications were given in ng/μl and quality was judged based on the 
absorbance at 260 nm divided by absorbance at 280 nm (260/280 value). A 
260/280 value of 2.0 is considered high quality RNA. Quality was also tested by 
running the samples on a 1% agarose gel at 200 V for 15 minutes. Total RNA 
was then used to synthesise complementary DNA (cDNA). 
2.3.10 cDNA synthesis  
cDNA was produced from 1 µg of RNA using the high capacity cDNA reverse 
transcription kit (Invitrogen) according to the manufacturer’s instruction. A 40 μl 
cDNA synthesis reaction contained: 1µg RNA, 1 x Reverse transcriptase buffer, 
1 mM each dNTP, 1 x random primers and 100 units reverse transcriptase. The 
cDNA synthesis reaction was carried out in a thermocycler with the following 
cycling conditions: 25˚C for 10 minutes, 37˚C for 2 hours, 85˚C for 5 minutes, 
4˚C for 10 minutes. Synthesized cDNA was stored at -20°C until required. 
2.3.11 Semi-quantitative PCR 
Semi-quantitative reverse transcriptase (RT)-PCR was carried out using primers 
listed in Table 12. The same reaction mix and PCR conditions were used for all 
genes and are listed in Table 13. The number of PCR cycles was selected such 
that both the target gene and housekeeping gene PCR amplification product 
was clearly visible on an agarose gel and could be quantified. Therefore, the 
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amplification needed to be in the exponential range but not yet at the reaction 
plateau.  
Band intensities were analysed in Image J software. Target gene values were 
normalised to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) values for 
each individual sample.   
Gene Primer sequence  Product size 
(bp)  
Reference  
Rac1 CCC AAT ACT CCT ATC ATC CTC G 258 (Wells et al., 2004) 
CAG CAG GCA TTT TCT CTT CC 
Rac2 CCA GCA CCC CCA TCA TCC TGG 248 (Wells et al., 2004) 
GGG GCG CTT CTG CTG TCG TGT G 
Rac3 CAC ACA CCC ATC CTT CTG GTG 253 (Wells et al., 2004) 
CAG TGC ACT TCT TGC CTG GC 
HOP CGG GAC AGA CGT AAG GTC A 876 (Grego-Bessa et al., 
2007) TCA ACC ACC AGT GTG TTT AGT GAA 
PEG1 TGC TCC CTT CCG GCC CAA 627 (Grego-Bessa et al., 
2007) TCT GAA CAG CCA GCG GGA TGC 
Irx5 CCA CTC GCC ACC GCC ACC T 304 (Grego-Bessa et al., 
2007) GCC ATA GTT CGT GTA GCC CGG ATA 
Table 12: Primers used for semi-quantitative PCR.  
 
Reaction (20µl) PCR cycling conditions 
1µl 10µM forward and reverse primer 
mix                                        
0.25µl 25mM dNTP 
4µl 5x buffer 
0.1µl taq polymerase 
8.15µl dH2O 
2µl cDNA (100ng)  
1. 94˚C - 4 minutes 
2. 94˚C - 30 seconds 
3. 60˚C - 30 seconds 
4. 72˚C - 1 minute (Cycling 2-4 x25) 
5. 72˚C - 10 minutes 
Held at 4˚C 
Table 13: Reaction and cycling conditions for semi-quantitative PCR.  
 
2.3.12 Quantitative Real Time PCR (qPCR) 
2.3.12.1 Primer Design for qPCR 
Gene sequences were taken from the mouse database in ensembl. Primers 
were designed using Primer3 and Primer-BLAST according to parameters listed 
in Table 14. 
2.3.12.2 Quantitative Real Time PCR  
qPCR was carried out using SYBR Green Jumpstart Taq readymix kit (Sigma) 
or SYBR® Select Master Mix (Life Technologies). For both mixes, 10ng of 
cDNA was included in a 10µl reaction mix consisting of 1x SYBR green/select, 
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0.1x reference dye and 1µM primers (listed in Table 15) and remaining volume 
dH20. Samples were prepared in triplicate with water controls for each gene of 
interest. GAPDH was used as a housekeeping gene after determining 
consistent expression throughout embryonic heart development.  
For wild type gene expression analysis, quantitative real time PCR was carried 
out on at 7900HT Fast Real Time PCR system (Applied Biosystems) using SDS 
v2.4.1 software. The temperature program for the 7900HT instrument was as 
follows; 95˚C for 15 minutes, followed by 40 PCR cycles of; 95˚C for 30s (100% 
ramp rate), 60˚C for 30s (100% ramp rate) and 72˚C for 30s (100% ramp rate). 
This was followed by a melt curve of 80˚C for 10s (100% ramp rate), 68˚C for 
10s (100% ramp rate) then to 99˚C (2% ramp rate). For expression analysis in 
control and Rac1TnTCre hearts, a Quant Studio 7 (Life Technologies) system was 
used with Quant Studio 7 analysis software. The temperature program for the 
Quant Studio 7 was 95˚C for 20s (1.9˚C/s ramp rate), PCR cycling of 95˚C for 
1s (1.9˚C/s ramp rate) and 60˚C for 20s (1.6˚C/s ramp rate), 40 times. This was 
followed by a melt curve of 95˚C for 15s (1.9˚C/s ramp rate), 60˚C for 1 minute 
(1.6˚C/s ramp rate) then to 95˚C for 15s (0.05˚C/s ramp rate). For both 
instruments the samples were added to 384 well plates (Greiner Bio One/Life 
Technologies). 
Table 14: Parameters for designing qPCR primers.  
 
Variable Parameters 
Primer length (bp) 18-22bp 
Primer melting 
temperature (Tm) 
Min: 57°C, Max: 70°C, Optimum: 60°C 
Max Tm difference 1°C between primers 
Primer GC content   40-60% 
Primer details No hairpin loops or secondary structures predicted using Sigma online 
software. 
No more than three contiguous nucleotides with the same base or 
repeats of sequences of three or more bases.  
PCR product size 50-200bp 
Exon junction span Primer must span an exon-exon junction 
Database Refseq RNA (refseq_rna) 
Organism Mus musculus (taxid: 10090) 
Splice variant 
handling 
Allow primer to amplify 
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Table 15: Primer sequences with their predicted product sizes, target 
exons and primer efficiency used for all qPCR analysis.   
 
2.3.12.3 qPCR Analysis  
Primer efficiencies were calculated using the DART-PCR program and are 
listed in Table 15.  Primers with efficiencies less than 80% were discounted and 
redesigned.  
Analysis was carried out using the comparative Ct method (Schmittgen and 
Livak, 2008). Briefly, triplicate Ct values were averaged with any values differing 
more than 0.5 Ct value from the other triplicates being excluded from the 
analysis. For each gene of interest, the average expression value for each 
sample was normalised to the average GAPDH expression value of that sample 
via subtraction.  The ΔΔCt values were then calculated and an average for each 
Gene Primer sequence (5’ to 3’) Product 
size 
(bp) 
Spanning 
exons 
Primer 
efficiency 
(%) 
Gapdh 
(Dr Simon Bamforth) 
 
TGTGCAGTGCCAGCCTCGTC 80 2-3 98.3 
TGACCAGGCGCCCAATACGG 
Rac1 AGGGATGATAAGGACACCAT
TG 
121 5-6 97.8 
GAGCTGAGCACTCCAGGTAT
TT Rac1 Ex4-5 CCCTTGTGAGTCCTGCAT 164 
 
4-5 99.7 
TGGGAGTCAGCTTCTTCTCC 
Ccn1 
(Mo and Lau, 2006) 
GCAGCAAGACCAAGAAATCC  
 
 
 88.0 
TTCTGGTCTGCAGAGGTGTG 
Sfrp1 GCCCGAGATGCTCAAATGTG 181 1-3 95.3 
CATCCTCAGTGCAAACTCGC 
Afp TTTACCCAGTTTGTTCCGGAA
G 
104 2-3 99.9 
CTTTCTAAACACCCATCGCCA
G Nrg1  
(D'Uva et al., 2015) 
ATCGCCCTGTTGGTGGTCGG - 
 
- 
 
 
87.7 
AGCTTCTGCCGCTGTTTCTTG
GT ErbB2 
(D'Uva et al., 2015) 
CGCTGCCCCAGTGGTGTGAA
G 
- - 92.0 
CAGCCTCGTTCGTCCAGGT 
ErbB4 
(D'Uva et al., 2015) 
GCCCCAAAGCCAACGTGGAG
T 
- - 86.5 
GCGGCATCAGCTGCGTAACC 
Vegf-a 
(Dr Colin Miles)  
ATCTTCAAGCCGTCCTGTGT 
 
- - 88.8 
GCATTCACATCTGCTGTGCT 
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sample group was determined. Fold expression was determined and used for 
representation in a bar graph.   
2.3.13 Microarray  
2.3.13.1 Sample collection  
All surfaces and dissecting equipment were cleaned with RNase away to 
remove contaminating RNase.  Embryos were collected at E10.5 in ice cold 
DEPC PBS. Embryos were removed from yolk sacs and somites counted.  
Hearts were removed from the chest cavity and immediately snap frozen in 
liquid nitrogen. Hearts were then stored at -80°C until required for RNA 
extraction.  Remaining embryonic tissue was used for genotyping. 
2.3.13.2 RNA extraction  
Samples were allowed to thaw on ice, followed by RNA extraction using the 
RNeasy Plus Micro kit (Qiagen). The protocol was carried out as per 
manufacturer’s instructions. Briefly, four hearts were pooled in 350µl RLT-plus 
lysis buffer with 1% β-mercaptoethanol. Hearts were homogenised by pipetting 
7–10 times using a P200 pipettor. The lysate was then centrifuged for 3 minutes 
at 13,000rpm. The supernatant was transferred to a gDNA eliminator spin 
column in a 2ml collection tube and centrifuged for 30 seconds at 13,000rpm. 1 
volume of 70% RNase free ethanol was added to the flow through and mixed by 
pipetting. The mixture was then transferred to an RNeasy MinElute spin column 
and centrifuged for 15 seconds at 13,000rpm. The flow through was discarded 
and 700µl RW1 buffer was added to the columnand centrifuged for 15 seconds 
at 13,000rpm. 500µl of RPE buffer was added to the spin column, the column 
was inverted 3 times and left to stand for 2 minutes. 500µl of 80% RNase free 
ethanol was then added to the column and centrifuged for 2 minutes. The spin 
column was placed in a new collected tube and centrifuged with the lid open for 
5 minutes, before finally being placed in an elution tube. RNA was eluted in 15µl 
RNase free water, by centrifugation at 13,000rpm, and stored at -80˚C.  
2.3.13.3 Microarray Analysis  
RNA samples from somite matched control and Rac1TnTCre E10.5 embryonic 
hearts were sent on dry ice to Aros for quality control assessment. Microarray 
analysis was carried out on an Affymetrix Mouse Transcriptome Array 1.0. 
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Analysis was carried out using Transcriptome analysis console v3.0. Gene 
changes of ≥1.5 fold with a P-value of ≤0.05 were included.  
2.3.14 In situ hybridisation  
RNase free pipette tips and DEPC-treated solution were used to minimise probe 
degradation. 
2.3.14.1 Luria Bertani broth and Agar plate preparation 
Luria Bertani (LB) broth was prepared with 171 mM NaCl, 1% w/v Tryptone 
(Oxoid) and 0.5% w/v yeast extract (Fisher) in dH2O and autoclaved. 
Agar plates were prepared by the addition of 1.5% w/v of Agar (Fisher) to LB 
broth and autoclaving. Agar was then cooled to 50°C and ampicillin was added 
to a final concentration of 50 μg/ml. The agar was then poured into petri dishes 
(20-25 ml per dish) and allowed to set in the presence of a flame. Agar plates 
were made freshly and kept at 4˚C for no longer than 4 weeks. 
2.3.14.2 Probe plasmid transformation 
Probe plasmids donated by De la Pompa are listed in Table 18. Upon receipt, 
the probe plasmids were transformed, mini prepped and sent for sequencing. 
Transformations were carried out using 5-alpha subefficiency E-coli cells (NEB) 
according to the manufacturer’s instructions. 1-10 ng of plasmid DNA was 
added to a 30 μl aliquot of competent cells and gently mixed, then incubated on 
ice for 30 minutes. Competent cells were heat-shocked for 20 seconds in a 
42°C water bath to encourage uptake of the plasmid DNA, then returned to ice 
for a further 2 minutes. LB broth was preheated to room temperature and 970μl 
was added to each vial of competent cells. The competent cells were then 
incubated at 37°C in a thermomixer for 60 minutes with agitation. 100 μl of 
culture was spread onto an ampicillin containing LB agar plate and incubated at 
37°C for 16 hours. After this time plates were stored at 4°C. 
2.3.14.3 Miniprep of plasmid DNA 
For miniprep of plasmid DNA, overnight cultures were prepared by inoculating 
3ml of LB media containing ampicillin (50 μg/ml), with a single colony picked 
from an agar plate. Cultures were incubated at 37°C for 16 hours with agitation. 
The cultures were pelleted by centrifugation at 6,000 x g for 5 minutes at 4°C. 
91 
 
The miniprep protocol was then carried out using a QIAprep Spin Miniprep kit 
(QIAGEN) according to the manufacturer’s instructions. Briefly, samples were 
resuspended in 250μl buffer P1, lysed in buffer P2 and then neutralised by the 
addition of buffer N3. The sample was centrifuged at 17,000 x g for 10 minutes 
to pellet cell debris and the supernatant was applied to a QIAprep spin column 
and centrifuged for 1 minute to allow binding of the plasmid DNA. The DNA was 
washed in buffer PB, then buffer PE, with centrifugation for 1 minute after each 
step. Plasmid DNA was eluted in 30μl buffer EB. The miniprep DNA was then 
measured of a nanodrop. 
2.3.14.4 NanoDrop spectrophotometry 
Quantification of DNA samples was carried out using a NanoDrop 
spectrophotometer (Thermo Scientific). The NanoDrop channels were blanked 
using elution buffer and 1μl of each sample was loaded onto the pedestals. 
Quantifications were given in ng/μl and quality was judged based on the 
absorbance at 260 nm divided by absorbance at 280nm (260/280 value). A 
260/280 value of 1.8 is considered high quality DNA. 
2.3.14.5 DNA sequencing 
Sanger sequencing was performed to confirm that the correct plasmid DNA had 
been amplified. A 20μl volume containing between 30-100ng/μl of plasmid DNA 
was sent to GATC Biotech for sequence analysis. The sequence was returned 
in FASTA format and was analysed using a basic local alignment search tool 
(BLAST) (available online at: http://blast.ncbi.nlm.nih.gov/) to compare to all 
known sequences across the murine genome. 
2.3.14.6 Linearization 
All restriction enzymes, buffers and bovine serum albumen (BSA) were 
obtained from New England Biolabs. 4 μg plasmid DNA was digested in a 20 μl 
reaction mix containing: 20 units of restriction enzyme, 1x enzyme buffer, 1x 
BSA (not required for high fidelity enzymes). The digestion mix was incubated 
at 37°C for 2-4 hours. The restriction enzymes used for each probe are listed in 
Table 19. 
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2.3.14.7 PCR Purification 
Purification of PCR and restriction digest reactions was carried out using a 
QIAquick PCR purification kit (QIAGEN), according to the manufacturer’s 
instructions. Briefly, the sample to be purified was diluted in 5 volumes of the 
supplied buffer PB and then added to a QIAquick spin column and centrifuged 
at full speed to allow the DNA to adhere to the column surface. The column was 
washed by adding buffer PE, containing ethanol, and centrifuged again at full 
speed. The column was centrifuged a final time to ensure all of buffer PE had 
been removed then transferred to a fresh microcentrifuge tube for collection. 
The sample was eluted in 30μl of buffer EB. To confirm the size of the purified 
sample, 5μl was added to 1μl of 6x loading dye (Promega) for gel 
electrophoresis. 
2.3.14.8 NanoDrop spectrophotometry 
Quantification of DNA samples was carried out using a NanoDrop 
spectrophotometer (Thermo Scientific) as detailed in Chapter 2 Section 
2.3.14.4. 
2.3.14.9 Probe design – PCR amplification of Rac1 cDNA  
Primers designed to amplify around a 400-500bp fragment of target gene (listed 
in Table 16). PCR amplification was carried out using E10.5 heart cDNA. 
Reaction and cycling conditions are described in Table 17.  
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Gene Forward primer 
sequence 
Reverse primer 
sequence  
Product 
size (bp)  
PCR/cloning 
Afp GCAGAGTGCTGCAAA
TTACCC 
AATGTCGGCCATTCCCT
CAC 
540 Cloning  
Apob TTCTGGAGTATGCTTT
AAAAGTTGT 
TAGAAGCCTTGGGCACA
TTG 
468 Cloning  
Apoa1 CCAACAGCTGAACCT
GAATCTCC 
GTCTGGCTTTCTCGCCA
AGT 
503 Cloning  
Ccn1 TCCTCTGTGTCCCCAA
GAACTGTCTCTCCCCA
ATCTGGGC 
TAATACGACTCACTATA
GGGGGGCCGGTATTTC
TTGACAC 
535 PCR 
Erbb2 GGCTGCTGGACATTG
ATGAGACTGAATACCA
TGCAGATGG 
TAATACGACTCACTATA
GGGTAGAAGGTGCTGT
CCATGGG 
412 PCR 
Papss2 AGCAGGACTCCCGTT
CTTTG 
GTTGATGACTCCATCGT
CCAGT 
466 Cloning  
Peg1 TATTTAGGTGACACTA
TAGCACATCCCGGTG
CTTCTTCT        
TAATACGACTCACTATA
GGGCTGATGTGGTCTC
GGCTTGT        
627 PCR 
Rac1 AGTGAATCTGGGCCTA
TGGG 
ACAGCAGGCATTTTCTC
TTCC 
435 Cloning  
Rac1 
Ex4-5 
TGCTTTTCCCTTGTGA
GTCCTGCATCATTTGA
AAATGTCCG 
TAATACGACTCACTATA
GGGGTCAGCTTCTTCTC
CTTCAGC 
164 PCR 
Sema4c AGCCTCAGTGCCGGG
TAAG 
GTGACCAGCTCCCCAG
AAGATA 
508 Cloning  
Sfrp1 GTTCTTCGGCTTCTAC
TGGCCCGAGATGCTC
AAATGTGAC 
TAATACGACTCACTATA
GGGGTACTGGCTCTTCA
CCTTGC 
403 PCR 
Trf CAGGCCAGTGTGGTC
TAGTG 
GCAGGGTTCTTTCCTTC
GGT 
454 Cloning  
Ttr ATTCGCGGATGTGGTT
TTCAC 
CGGTTGGTCCACTCTGC
TTT 
479 Cloning  
Table 16: Primers used to amplify mouse E10.5 cDNA for RNA probe 
synthesis. 
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Reaction (40µl) PCR cycling conditions 
2µl 10µM forward and reverse primer 
mix                                       
0.5µl 25mM dNTP 
8µl 5x buffer (clear) 
0.2µl taq polymerase 
27.3µl dH2O 
2µl cDNA (100ng)  
1. 94˚C - 4 minutes 
2. 94˚C - 30 seconds 
3. 60˚C - 30 seconds 
4. 72˚C - 1 minute (Cycling 2-4 x35) 
5. 72˚C - 10 minutes  
Held at 4˚C 
Table 17: Reaction and cycling conditions for semi-quantitative PCR. 
 
Purification of PCR reaction was carried out using Qiagen PCR purification kit 
(QIAGEN), as described in Chapter 2 Section 2.3.14.7.  
The purified PCR product was quantified using a nanodrop. 50ng PCR product 
was then ligated into PGEM-T plasmid using PGEM-T Easy Vectors System 
(Promega). The ligation reaction was as follows; 5µl 2x rapid ligation buffer, 1µl 
PGEM-T, 1µl T4 DNA ligase, made up to 10µl with 50ng pcr product and dH2O. 
The reaction was incubated at 4˚C overnight.  
The ligation reaction was then used in a transformation using 5-alpha 
subefficiency E-coli cells (NEB) according to the manufacturer’s instructions as 
described in Chapter 2 Section 2.3.14.2. 
Miniprep of Rac1-PGEM-T plasmid DNA was carried out using a QIAprep Spin 
Miniprep kit (QIAGEN) according to the manufacturer’s instructions as 
described in Chapter 2 Section 2.3.14.3. 10 colonies were picked from the agar 
plate for mini prep.  
To determine if the miniprep DNA contained the required probe-PGEM-T, a test 
digest with an appropriate restriction enzyme was carried out. EcoRI was 
chosen as there were 2 EcoRI restriction sites within the PGEM-T therefore this 
would cut the plasmid into 2 linear fragments of DNA.  The digestion reaction 
was set up as follows; 2µl 10x sutsmart buffer, 2µl miniprep plasmid DNA, 15µl 
water and 1µl of EcoR1-high fidelity. The reaction was incubated at 37˚C for 2 
hours. 5µl of digestion reaction was added to 1µl 6x loading dye and ran on a 
1% agarose gel. The DNA containing the ligated probe-PGEM-T plasmid was 
confirmed by Sanger sequencing by GATC as described in Chapter 2 Section 
2.3.14.5. 
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2.3.14.10 Probe design - PCR 
Primers were designed to amplify a 400-500bp fragment of target gene. T7 
binding site was added to the 5’ end of the forward primer and T3 binding site 
was added to the 5’ end of the reverse primer. This allows DIG labelling of both 
antisense and sense probes.  
A 40µl PCR reaction was set up containing 50ng cDNA, 1µM primers, 1x clear 
buffer, 125µM dNTPs with 0.2µl taq polymerase and dH2O. PCR was carried 
out under general cycling conditions; 94˚C 3 mins, 35 cycles of 94˚C 30 
seconds, 60˚C 30 seconds and 72˚C 1 minute, 72˚C for 10 minutes and stored 
at 4˚C.  
Purification of PCR reaction was carried out using Qiagen PCR purification kit 
(QIAGEN), according to the manufacturer’s instructions as detailed in Chpater 2 
Section 2.3.14.7.  
Probe Plasmid
/PCP 
DNA 
Restriction 
enzyme for 
linearisation 
RNA 
polymerase 
Donated/made 
Bmp10 Plasmid BamHI T7 De la Pompa 
Hey2 Plasmid EcoRI T3 De la Pompa 
EphB4 Plasmid EcoRI T7 De la Pompa 
ErbB2 PCR - T7 Made 
Rac1 Plasmid Sal1 T7 Made 
Rac1 Ex4-5 PCR - T7 Made 
Ccn1 PCR - T7 Made 
Sfrp1 PCR - T7 Made 
Neuregulin1 Plasmid Xba1 T7 Anthony Firulli  
Neuropilin 1 Plasmid Xho1 T7 Anthony Firulli  
Vegf-a Plasmid BamHI T7 Anthony Firulli  
Vegfr-2 Plasmid EcoRI Sp6 Simon Bamforth  
Table 18: Probes used for in slide in situ hybridisation.  
 
2.3.14.11 DIG labelling of probe  
DIG labelling of the probe was carried out using DIG RNA labelling kit (Sp6/T7) 
(Roche) as per manufacturer’s protocol. Briefly, 1µg of purified linearised 
plasmid/PCR product was included in a 20µl reaction containing 1xNTP 
labelling mix, 1x transcription buffer, 20 units of RNase inhibitor and 40 units of 
required RNA polymerase diluted in RNase free water. The reaction was mixed 
gently and centrifuged briefly to collect all of reaction then incubated at 37°C for 
2 hours. DNaseI treatment was carried out to remove template DNA; 2μl 
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DNaseI was added and the reaction was incubated at 37°C for a further 15mins. 
The reaction was then stopped by adding 2μl 0.2M EDTA (pH8.0).  
2.3.14.12 Probe extraction 
The probe was extracted using Lithium Chloride. 80 μl DEPC TE, 10 μl 4M LiCl 
and 250μl 100% EtOH (ice cold) were added to the reaction and left in -80°C for 
2 hours. The samples were then centrifuge at 4°C for 30mins (in a pre-cooled 
centrifuge). The supernatant was removed and the pellet was air-dried for 10 
minutes before being redissolved in 100μl DEPC TE with 2μl RNase inhibitor. 
Probes were ran on agarose gel to check  Add 5μl to 1μl loading dye and run on 
1% agarose gel at 200V for 10 mins. Probes were stored at -80°C. 
2.3.14.13 Embryo dissection and processing 
Embryos were dissected, fixed and processed for wax embedding as described 
previously using DEPC treated solutions and RNase free plastic ware and 
instruments. PFA was prepared with DEPC-treated PBS and ethanol dilutions 
were prepared with DEPC-treated dH2O.  
Microtome sectioning was carried out as described previously using DEPC-
treated dH2O and RNase away spray to ensure microtome and hot plate were 
RNase free. Slides were kept at 4˚C until use.  
2.3.14.14 Pre hybridation 
All solutions, glassware and plastic ware were RNase free. Solutions were 
made with DEPC- treated dH20 or PBS. Glass bottles were treated with DEPC 
dH20 and autoclaved. Additional glassware and metal utensils were baked in an 
oven at 180˚C overnight. RNase away spray was used to wipe plastic ware and 
lab bench space. Slides were either placed in glass troughs containing solutions 
or in a humid chamber with on slide solutions. Slides were dewaxed using 
histoclear (10 minutes, twice) and dehydrated through an ethanol series; 100%, 
twice, 90%, 70% and 50% for 5 minutes each. Slides were placed in DEPC-
PBS for 5 minutes, followed by a postfixation with 4% DEPC PFA for 20 
minutes in a humid chamber. Slides were washed in DEPC PBS for 5 minutes, 
twice, before being incubated with 10µg/ml Proteinase K in DEPC PBS for 20 
minutes at 37˚C. Slides were then washed in DEPC PBS for 5 minutes, twice, 
and fixed again in DEPC PFA for 5 minutes. Slides were washed in DEPC PBS 
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for 5 minutes followed by 15 minutes in 0.07N hydrochloric acid whist stirring. 
Slides were then washed in DEPC PBS for 5 minutes, twice, then 0.25% acetic 
anhydride in 0.1M triethanolamine pH8 for 10 minutes whilst stirring. Slides 
were then washed in DEPC PBS for 5 minutes, twice, then DEPC dH2O. Finally, 
slides were equilibrated in hybridisation buffer (50% formamide, 0.75M NaCl, 
0.075M Na-citrate) for 2 hours at 65°C in a hybridisation chamber. 
2.3.14.15 Hybridisation  
Probes were diluted 1:300 in hybridisation buffer and heated to 70˚C for 5 
minutes before adding to slide. Slides were covered with a glass coverslip and 
incubated at 65°C overnight, in the dark.  
2.3.14.16 Posthybridisation washes and antibody detection  
Coverslips were washed from slides using prewarmed posthybridisation buffer 1 
(50% formamide, 5X SSC, 1% SDS). Slides were washed in buffer 1 at 65˚C for 
30 minutes, twice, then posthybridisation buffer 2 (50% formamide, 2X SSC, 
0.1% SDS) at 65˚C for 30 minutes, twice. Slides were then washed in MABT 
(0.5M Maleic acid, 0.75M NaCl, 0.5% Tween 20, pH7.5) for 5 minutes, 3 times 
before blocking with 20% FCS, 10mg/ml BSA in MABT for 2 hours. Slides were 
incubated with anti-dig antibody, 1:1000 diluted in 1:5 blocking buffer, overnight, 
4°C and covered with parafilm. 
2.3.14.16 Developing 
Slides were washed in MABT for 20 minutes, twice, and then for 1 hour, three 
times. Slides were then washed in AP-Buffer (0.1M Tris, 0.1M NaCl, 0.05M 
Mg2Cl, 0.1% Tween 20) for 10 minutes, three times. To develop, slides were 
incubated in NBT/BCIP (20µl/ml) in AP buffer and kept in the dark humid 
chamber until the required staining intensity was reached. Slides were washed 
in PBS for 5 minutes, twice and then postfixed with 4% PFA for 15 minutes 
washed again in PBS for 5 minutes, twice. Finally, slides were dehydratated 
through an ethanol series (50%, 70%, 90%, 100%, twice) for 5 minutes each 
then histoclear for 4 minutes, twice before being mounted in DPX. Sections 
were imaged using a Zeiss Axioplan2 microscope and associated software. 
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2.3.15 Western blotting 
2.3.15.1 Protein extraction  
E15.5 hearts were allowed to thaw on ice, then lysed using cell lytic MT cell 
lysis buffer containing 10μg/μl Proteinase inhibitors. For E15.5 hearts, 200μl 
buffer was added. The hearts were then homogenised using a 2ml syringe with 
21G and 27G needles. After the tissue was fully homogenised, the samples 
were centrifuged for 5 seconds and then spun at 4°C for 1 hour. Finally, 
samples were centrifuged at 4˚C for 20 minutes at 12000rpm and stored at -
20°C.  
2.3.15.2 Bradford assay  
Standards (2000, 1000, 500, 250, 125, 62.5, 31.25, O µg/µl) were prepared by 
a 1:1 serial dilution of BSA in cell lytic buffer with 10μg/μl protease inhibitors. 5µl 
of each standard and sample was added to clear 96 well plates, in duplicate. 
250µl Bradford reagent (warmed to room temperature) was then added to each 
well and incubated for at least 5 minutes before being read of a Multiskan. 
Sample concentration was calculated using the standard curve produced from 
the data.  
2.3.15.2 Sample preparation  
10µg protein was diluted in laemmli buffer with 5% β-mercaptoethanol and 
heated at 95˚C for 5 minutes. The samples were then centrifuged at 12000rpm 
for 5 minutes and cooled to room temperature for 5 minutes.  
2.3.15.3 Gel electrophoresis  
4-12% Tris-Glycine gels (ThermoFisher Scientific) were clamped into a tank 
(ThermoFisher Scientific), which was then filled with running buffer (2.5mM Tris 
pH8.0, 19mM Glycine, 0.01% SDS). The gel combs were removed and 20-30µl 
of sample and 10µl of protein standard were added to individual wells. The gel 
was run at 90V until the protein moved out of wells and then at 180V for around 
90 minutes, current set to 500mA.  
2.3.15.4 Transfer  
The membrane was prepared whilst the gel was running; membrane and 
blotting paper were dipped in methanol for 30 seconds, dH2O for 5 minutes and 
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then ice-cold transfer buffer (48mM Tris, 39mM Glycine, 0.04% SDS, 20% 
Methanol) for at least 20 minutes. Transfer sponges were added to the transfer 
buffer.  The transfer was carried out in a tank with transfer buffer, at 100V for 1 
hour at 4°C with a magnetic stirrer.  
2.3.15.5 Ponceau stain 
The membrane was removed and then stained with ponceau S to check for 
successful transfer of proteins; the membrane was dipped in methanol for 30 
seconds then stained with ponceau S for 5 minutes and washed in 5% acetic 
acid, twice, to remove background. The membrane was then rinsed in TBST 
and cut if necessary.   
2.3.15.6 Blocking and antibodies 
The membrane was blocked using 5% milk/TBST (TBS, 0.1% Tween 20) for 1 
hour before incubating in primary antibody, diluted in 5% milk/TBST overnight at 
4°C. To remove the primary antibody, the membrane was washed, firstly in 5% 
milk/TBST, for 10 minutes, 4 times, and secondly in TBST, for 10 minutes, 4 
times. The secondary antibody was diluted 1:10,000 in 5% milk/TBST, added to 
the membrane and incubated for 1 hour, shaking. The secondary antibody was 
removed by washing, firstly in 5% milk/TBST, for 10 minutes, 4 times, and 
secondly in TBST, for 10 minutes, 4 times. Primary and secondary antibodies 
used are listed in Table 19. 
 
Antibodies Supplier/Order no. Dilution used 
Rabbit anti-GAPDH Abcam/ab22555 1:10,000 
Rabbit anti-Rac1 Millipore/ 05-389 1:10,000 
Goat anti-Rabbit HRP  Dako/P0448 1:10,000 
Table 19: Antibodies used in western blotting.  
 
2.3.15.7 Developing  
The membrane was incubated with SuperSignal west dura extended duration 
substrate (ThermoFisher Scientific) for 5 minutes. Following this, excess 
substrate was removed from the membrane and the membrane was placed in a 
clear plastic sheet inside the developing cassette. High performance 
chemiliminescence film (GE Healthcare) was exposed to the membrane for 1 
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minute before being placed in the developer. Exposure times were then 
adjusted accordingly. 
2.3.15.8 Stripping for re-probing 
To allow sequential blotting of proteins with similar molecular weight, the 
membrane was stripped after developing of the first protein blot and then 
reincubated with a second primary antibody. The membrane was incubated with 
mild stripping buffer (0.2M glycine, 0.1% SDS, 0.1% Tween 20, pH2.2) for 10 
minutes, twice, followed by washes in PBS, for 10 minutes, twice, and TBST, for 
10 minutes, twice. The membrane was then developed to check for effective 
striping, washed in TBST and blocked again before incubation with an 
additional primary antibody. 
2.3.15.9 Western blot analysis 
Blots were scanned and band intensities were analysed in Image J software. 
Target gene values were normalised to GAPDH values for each individual 
sample. 
2.3.16 Magnetic Resonance Imaging (MRI) 
2.3.16.1 Embryo dissection for MRI 
Embryos were dissected in Hanks balanced salt solution with 5mM EDTA at 
37°C. Embryos were bled out for up to 20 minutes on a heat mat. The umbicical 
cord was repeatedly clipped to encourage pumping out of blood. Embryos were 
washed twice in cold PBS then photographed. The left forelimb was removed to 
mark the left side of the embryo and used for genotyping. Slits were made on 
either side of the abdomen to allow penetration of fixative and contrast agent. 
Embryos were transferred to tubes and immersion fixed in 4% PFA + 4μl/ml 
Magnevist® (Gd-DTPA) on ice. Magnevist® (gadopentetate dimeglumine, Gd-
DTPA) is a paramagnetic material which shortens the longitudinal relaxation 
time (T1) of water protons enhancing the contrast of the MRI scan. Embryos 
were store at 4°C for at least 4 days to allow full penetration of fixative and 
Magnevist® before being sent to for MRI.  
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2.3.16.2 MRI tube preparation  
MRI tubes were prepared as described previously (Bamforth et al., 2012). The 
MRI tube consists of a nuclear magnetic resonance tube (outer diameter 28mm; 
Fluorochem, UK) containing a teflon disk attached to a nylon rod to allow the 
embryos to be removed from the tube after scanning. 32 embryos (8 layers, 4 
embryos per layer) were loaded into the MRI tube by embedding in agarose 
(1% agarose w/v in dH2O, heated to dissolve) containing the contrast reagent 
Magnevist® (4μl/ml). The tube was sealed with a lid and parafilm to prevent the 
agarose from drying out and shipped on ice packs to Oxford for scanning. MRI 
scanning was carried out by Dr Jurgen Schneider (University of Oxford) and the 
embryos and images collected as a series of tagged image format (.tiff) files. 
2.3.16.3 MRI data analysis and 3D reconstructions  
The collected .tiff stacks can be analysed through AMIRA software (FEI 
Visualization Science Group). The voxel size used was: x-25.4, y-25.4, z-24.4. 
The .tiff stack for each layer of the MRI tube was opened separately and a 
transverse view through the embryos was analysed, using the removed left 
forelimb for orientation purposes. Embryos were analysed for morphological 
changes and 3D reconstructions were produced.  
The .tiff stack was cropped to include only the region of interest for the 
reconstruction, in order to minimise the file size. The labelling tools within the 
program were then used to label each structure of the heart for reconstruction. 
The hue, saturation and value levels for the colours used for each structure are 
shown in Table 20. A 3D model of each structure was then produced using the 
‘SurfaceGen’ option with unconstrained smoothing.  
 Hue  Saturation  Value  
Aorta 0.0000 0.859 0.859 
Pulmonary artery 0.549 0.585 0.965 
Outside surface of heart  0.500 0.127 0.800 
Left ventricular lumen  0.041 0.804 0.800 
Right ventricular lumen  0.667 0.506 1.000 
Trachea 0.376 0.161 0.949 
Table 20: Colouring for MRI 3D reconstructions using Amira. 
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2.3.17 High resolution episcopic microscopy (HREM) 
2.3.17.1 Embryo dissection and processing for HREM 
Embryos were harvested and dissected in Hanks buffer with 5mm EDTA at 
37˚C. During the dissection embryos were continuously flipped to minimise 
pooling of blood on one side of the embryo and the umbilical vessels were 
repeatedly clipped to keep blood pumping out for as long as possible. After 
most of the blood had pumped out, embryos were transferred to PBS with 
50mM KCL to ensure the heart arrested in diastole. Embryos were decapitated 
below the lower jaw and sliced around the liver region to remove the lower 
portion then left to bleed out at 37C for 5 minutes. Some of the pericardium was 
removed to reveal the heart. Torsos were then fixed in 4% PFA for 30 minutes, 
followed by several washes of dH2O whilst shaking vigorously on a rocker. 
Torsos were left in dH2O until the hearts turned completely white when all the 
blood was lysed (up to 1 hour). Torsos were transferred back to 4% PFA for 
overnight fixation and dehydrated to 70% as for normal wax embedding 
(Chapter 2 Section 2.3.6.1). Torsos were sent in 70% ethanol to Dr Tim Mohun 
for embedding, sectioning and imaging. HREM scanning was carried out by Dr 
Tim Mohun (The Francis Crick Institute) and images were collected as a series 
of .tiff files. 
2.3.17.2 HREM data analysis and 3D reconstructions  
The collected .tiff stacks can be analysed through AMIRA software (FEI 
Visualization Science Group) as detailed in Chapter 2 Section 2.3.16.1.  
2.3.18 Embryonic heart dissection and processing for Transmission 
electron microscopy (TEM) 
 To look at the sarcomeric ultrastructure of E10.5 embryonic hearts, tissue was 
analysed by transmission electron microscopy (TEM). 
Embryos were collected in ice-cold PBS and hearts were dissected as 
described in 2.3.4.1. The atria were removed to ensure only ventricle tissue was 
analysed.  The hearts were then transferred to EM fixative (4% glutaraldehyde, 
4% PFA, 0.1M sodium cacodylate, 3mM CaCl2, pH7.4) and stored at 4
°C before 
being processed by the Newcastle University EM unit, sectioned and imaged 
using a Phillips TEM. 
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2.3.19 Cardiomyocyte cell counts  
2.3.19.1 Dissociation and fixative of cardiomyocytes  
E15.5 hearts were dissected in ice-cold DEPC-PBS at low-light intensity. Hearts 
were then added to 500µl of 0.28 Wunsch units/ml Liberase TM (Roche) and 
incubated for 20 minutes at 37˚C, shaking at 300rpm. Hearts were then 
manually dissociated by pipetting up and down. 500µl of 0.2M EDTA (0.1M final 
concentration) was added to inhibit the collagenase reaction. Cells were 
washed in FACs buffer (2% FCS in PBS) by spinning down at 1500rpm for 5 
minutes. The supernatant was removed and the pellet was resuspended in 
500µl PBS and fully disaggregated by pipetting up and down. An equal volume 
(500µl) of fixation buffer (4% Formaldehyde (Polysciences) in PBS) was added 
to give a final formaldehyde concentration of 2%. The cells were incubated at 
room temperature for at least 1 hour. Formaldehyde was then removed by 
spinning down at 1500rpm for 5 minutes and the cells were stored in FACs 
buffer in the dark. The fixed cells were incubated with 0.1% Triton X-100 and 
stained with 20µl Propidium Iodine (PI) solution (Abcam) for 30 minutes before 
analysis using a Tali image based cytometer (Invitrogen).  
2.3.19.2 Cell count analysis  
The number of PI-positive and EYFP-positive cells were counted using the Tali 
image based cytometer. Parameters were set for roundness and size of cells 
counted to include the cardiomyocyte population.  
2.3.20 Measurements 
2.3.20.1 Heart size and myocardial thickness measurements 
Brightfield images were taken on a Zeiss Axioplan microscope with associated 
Axiovision SE64 software. Thoracic cavity and heart diameter were measured 
using the length tool in Axiovision SE64 software. At least 3 sections were 
measured per embryo and an average measurement was taken. For myocardial 
thickness measurements, 3 measurements were taken perpendicular to the 
outer myocardial surface of each ventricle and averaged. The myocardial 
thickness measurements were normalized for each section by dividing by the 
average heart width.  
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2.3.20.2 Trabeculae counts and directionality analysis 
Trabeculae counts were carried out on histology stained transverse sections 
from E9.5-E17.5 control and mutant embryos. The number of trabeculae 
protrusions arising from the compact myocardial wall were counted in the left 
and right ventricle in at least 3 sections per embryo.  
For measurement of the directionality of the developing trabeculae angles were 
measured from the perpendicular compact myocardium using imageJ software. 
HREM tiff images were used from E10.5 and E11.5 control and mutant 
embryos.  All trabeculae arising from the compact myocardium were measured 
in at least 5 sections per embryos.  
2.3.20.3 Cell migration measurements  
Brightfield images were taken on a Zeiss Axioplan microscope with associated 
Axiovision SE64 software. Thoracic cavity and heart diameter were measured 
using the length tool in Axiovision SE64 software. At least 3 sections were 
measured per embryo and an average measurement was taken. For cell 
migration measurements, measurements were taken perpendicular to the outer 
myocardial surface of each ventricle to the furthest Cre-positive derived 
migrating cell. The cell migration measurements were normalized for each 
section by dividing by the average heart width.  
2.3.20.4 Outflow tract length measurements 
E10.5 embryos were dissected with the head and tail removed to reveal the 
outflow tract clearly. Brightfield images of the side view of embryos were taken 
on a Leica MZ6 microscope. OFT length was measured using ImageJ software.  
2.3.20.5 Cell counts  
Fluorescent images were taken on a Zeiss AxioImager using associated 
Axiovision LE64 software. Images of both left and right ventricles and the 
interventricular septum (IVS) were taken for at least 3 sections per embryo. Cell 
count analysis was carried out using ImageJ software. Cell counts of 
phHH3/caspase3/BrdU were expressed as a ratio of total number of cells 
(DAPI).  
105 
 
2.3.20.6 Cardiomyocyte cell area  
To measure the area of cardiomyocytes the cell membrane was stained with 
wheat germ agglutinate (WGA) containing a fluorescent Alexa 594 conjugate 
(ThermoFisher W11262).  
Slides were dewaxed, rehydrated and washed with PBS. WGA was diluted 
1:200 in PBS and 95µl added to each slide before covering with a coverslip and 
incubated in a humidified chamber for 30 minutes in the dark.  Slides were then 
washed 3 times for 5 minutes in PBS and mounted in DAPI containing 
Vectorshield (Vector).   
Slides were then imaged using an AxioImager 2 (Zeiss). The area of individual 
cardiomyocytes was then measured using Image J, restricting measurements to 
cardiomyocytes in a transverse orientation found adjacent to transversely 
sectioned capillaries. The average area of cardiomyocytes was determined for 
the RV, and LV for control and mutant hearts (n=3, 3 sections per heart).  
Cardiomyocyte size was analysed in Microsoft excel and significance 
determined using a unpaired t-test (p<0.05).   
2.3.21 Co-Immunoprecipitation (Co-IP) 
2.3.21.1 Blocking beads for IP  
Dynabeades in Slurry (Life Technologies 10006D) (50µl contains 1.5mg). 
Magnet used to remove supernatant. 1ml of 1% BSA/PBS added to beads and 
mixed for 1 hour using rotary shaker. Magnet used to remove the supernatant. 
Beads washed in PBS twice by pipetting up and down. Magnet used to remove 
the supernatant. 400µl of lysis buffer and proteinase inhibitors added. Stored at 
4°C until required.  
2.3.21.2 Preclearing lysates 
Preclearing prevents non-specific binding of proteins to beads, removes 
proteins that bind to immunoglobulins non-specifically and lowers background 
and improves signal to noise ratio. 50µl of species specific serum added to 1ml 
of lysate. Incubated on ice for 1 hour. 100µl of bead slurry added to the lysate 
and incubated for 30 minutes at 4°C with gentle agitation. Supernatant removed 
using magnet and use for IP. 
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2.3.21.3 Immunoprecipitation with antibody-beads 
100µl of prepared bead slurry added to an Eppendorf with 5µl of primary 
antibody (recommended dilution on data sheet). Antibody and beads incubated 
at 4°C with gentle mixing overnight. Supernatant removed and washed twice 
with lysis buffer. Pre-cleared cell lysate added (300µl) to block beads with 
antibody conjugate. Incubated at room temperature for 4 hours, rotary mixing. 
Beads washed three times in wash buffer, removing the supernatant between 
washes (using magnet). Buffer resuspended and transferred to a clean tube. 
20µl elution buffer and 20µl of 2X laemelli buffer added and heated at 70°C for 
10 minutes to remove beads. Followed by cooling at 4°C for 5 minutes and 
centrifugation. Supernatant protein kept and store at -20°C until required. 
2.3.22 Statistics 
2.3.22.1 Unpaired t-test  
Statistical analysis was carried out using an unpaired student’s t-test in 
Microsoft Excel. Variance analysis was carried out using the F-test in Microscoft 
Excel and the type of t-test was calculated accordingly (equal or un-equal 
variance). Statistical significance was assigned when p<0.05, unless otherwise 
stated. Standard error of the mean (SEM) was used for all error bars.  
2.3.22.2 Kruskal Wallis Test  
Kruskal Wallis is a non-parametric test carried out in SPSS for statistical 
analysis of Rac1 expression data from qRT-PCR.  
2.3.22.3 Chi-sqaured  
Chi-squared is a non-parametric test carried out in SPSS for statistical analysis 
of genotype frequency data and trabeulae angle measurements.  
2.3.22.4 Two-way ANOVA 
The two-way ANOVA is a non-parametic test carried out in SPSS for statistical 
analysis of multiple grouped data; myocardial thickness measurements, 
trabeculae numbers, cell counts and cell area measurements.  
2.3.22.5 Power calculations 
Power calculations were carried out for any data requiring statistical analysis 
using the unpaired t-test using the tool available at the following site; 
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http://biomath.info/power/ttest.htm. All experiments were sufficiently powered 
unless stated.  
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Chapter 3. Early myocardial deletion of Rac1 causes embryonic 
heart defects 
3.1 Introduction  
3.1.1 Rac1 in embryogenesis  
Unlike the other members of the Rac family, Rac1 is expressed ubiquitously 
early in mouse embryogenesis (Wang and Zheng, 2007). Rac1 is critical for 
embryogenesis as Rac1 null mice die during gastrulation with extensive cell 
death observed in the space between the endoderm and ectoderm (Sugihara et 
al., 1998). Due to the embryonic lethality of Rac1 deletion, tissue specific 
functions of Rac1 could not be investigated using this mouse model. Therefore, 
conditional inactivation of Rac1 using Cre-LoxP technology has been employed 
in both previously published work and in this thesis.  
3.1.2 Cre-LoxP technology  
The Cre-LoxP recombination system was first described in 1992 and has since 
been extensively used throughout developmental biology (Lakso et al., 1992). 
The technique utilises the enzyme Cre recombinase, produced by the 
bacteriophage P1, which acts on short sequences termed ‘LoxP sites’. These 
LoxP sites can be introduced into specific regions of DNA. The Cre 
recombinase can then cause recombination between two LoxP sites, removing 
the intervening sequence. This technology can be used to cause tissue specific 
gene inactivation, by removal of important functional regions, or gene activation, 
by insertion of a floxed (flanked by LoxP sites) ‘stop’ sequence upstream of a 
gene of interest which is expressed in a specific tissue. Cre recombinase is 
expressed under the control of a promoter, allowing specific spatial and 
temporal activation of the Cre enzyme, which therefore results in tissue-specific 
activation/inactivation of the gene of interest. 
3.1.3 Rac1 in cardiac development  
Using Cre-LoxP technology, Rac1 has been shown to have critical roles in 
endothelial cells and neural crest cells during cardiac development (Tan et al., 
2008; Thomas et al., 2010).  
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Recent studies published after the onset of this project have highlighted a role 
of Rac1 in cardiomyocytes during embryonic development (Abu-Issa, 2014; 
Leung et al., 2014; Leung et al., 2015). Abu-Issa reported cardiac defects in 
mice with Rac1 deficiency in cardiac progenitors, using a precardiac mesoderm 
specific Cre line, Nkx2.5-Cre. Rac1 deficient cardiomyocytes appear to have 
reduced adhesion and Rac1Nkx2.5Cre embryos are embryonic lethal by E12.5 with 
disorganised, thin ventricular walls and defective OFT alignment (Abu-Issa, 
2014). The defects were attributed to defective cell adhesion as shown by 
disrupted β-catenin and FAK (Abu-Issa, 2014). Additionally, Leung and 
colleagues generated mice with Rac1 deficiency in SHF progenitors using 
Mef2c-Cre. Rac1 deficient cardiomyocytes have impaired elongation and 
cytoskeleton organisation and Rac1Mef2cCre embryos have cardiac defects; VSD 
and ASD as well as a thinned RV myocardium and a bifid cardiac apex (Leung 
et al., 2014). In the IVS of Rac1 SHF mutant hearts, expression of the PCP 
protein Scrib was shown to be lost and apoptosis was significantly increased. 
An overall decrease in migratory markers WAVE and Arp2/3 was also shown, 
as well as a decrease in transcription factors Gata4, Tbx5, Nkx2.5 and Hand2 in 
the RV myocardium (Leung et al., 2014). Furthermore, these mice have a 
spectrum of OFT defects ranging from OA to severe TGA with additional 
incidence of aortic atresia and abnormal right subclavian artery (ARSA). The 
OFT defects occur as a result of early defects in cell proliferation in the 
splanchnic mesoderm and reduced NCC and SHF cell migration into the 
developing OFT, leading to a shorted OFT (Leung et al., 2015). Both Abu-Issa 
and Leung have shown Rac1 is critical in cardiac progenitors and have 
suggested Rac1 functions to regulate cardiomyocyte polarity and/or adhesion 
for normal cardiac development. Despite these investigations, the role of Rac1 
in early myocardial development remains unclear. The findings of Abu-Issa rely 
on very limited phenotyping data and poor quality immunostaining in cultured 
cardiomyocytes. Isolated cardiomyocytes are not representative of the complex 
structure of the developing myocardium and do not distinguish between the 
different types of cardiomyocytes i.e compact and trabeculae cardiomyocytes 
display widely different properties including the maturation of the actin-
cytoskeleton and cell-cell junctions. Also the genetic analysis of Rac1Mef2cCre 
hearts, by Leung and colleagues, was carried out at E13.5, at this time point the 
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phenotype was already established, therefore, any gene transcriptional changes 
detected may be secondary to the phenotype. Additionally, the expression of 
Rac1 and additional PCP protein Scrib is not consistent with previously reports 
of cell membrane localisation in cardiomyocytes (Boczonadi et al., 2014b). Both 
Abu Issa and Leung and colleagues use conditional deletions of Rac1 that 
include multiple cell types, leading to difficulties separating possible differential 
roles of Rac1 in specific cell types. Additionally, neither group has investigated 
the role of Rac1 in the formation of the trabeculae and subsequent development 
of the myocardium. Thus, the aim of this project was to investigate the role of 
Rac1 in developing myocardium.   
3.1.4 Rac1flox mice 
At least two separate strains of Rac1flox mice have been generated to allow 
investigation of Rac1 in specific tissues using the Cre-LoxP system. Several 
investigators have used Rac1flox mice generated by David J. Kwiatkowski and 
produced by Jackson Laboratories (stock 5550). These mice have LoxP sites 
flanking exon 1 of the Rac1 gene (Tan et al., 2008; Thomas et al., 2010; Abu-
Issa, 2014; Leung et al., 2014; Leung et al., 2015). Reduction of Rac1 protein 
has been confirmed in these mice by western blot analysis (Tan et al., 2008). In 
the heart, Rac1 mRNA levels were reduced as well as Rac1 protein levels 
shown by western blot and immunostaining, although the immunostaining is 
inconsistent with previous reports of Rac1 localisation (Leung et al., 2014). In 
this study, Rac1flox mice were used which were generated by insertion of LoxP 
sites flanking exons 4 and 5 of the Rac1 gene (Walmsley et al., 2003). Cre-
mediated recombination between these sites results in the excision of exons 4 
and 5 and a subsequent frame shift and lack of a functional Rac1 protein in Cre 
expressing cells. 
3.2 Aims of chapter 
The primary aims of this chapter were to confirm and define Rac1 expression in 
the developing heart and subsequently determine its role within the epicardial 
and myocardial populations during ventricular development.  
The development of the myocardial wall requires proliferation and differentiation 
of FHF and SHF derived cardiomyocytes, as well as signals from epicardial 
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cells and invasion of epicardial derived cells. The role of Rac1 in myocardial 
cells and epicardial cells during ventricular wall development has not been fully 
elucidated. Preliminary data suggested that deleting Rac1 from the epicardium 
and myocardium, using Gata5-Cre, resulted in defects within the myocardial 
wall (personal communication from Dr Helen Phillips). Therefore, the aim of this 
chapter was to characterise these defects in detail.  
It was hypothesised that Rac1 is required in both epicardial and myocardial 
cells for normal heart development and its differential roles could be determined 
by conditional deletion of Rac1 from myocardial and epicardial cells using 
Gata5-Cre, WT1-CreERT2, Mlc2v-Cre and TnT-Cre  transgenic mouse lines.  
3.3 Results  
3.3.1 Rac1 expression in the embryonic heart through development   
3.3.1.1 Rac1 gene expression in the embryonic, postnatal and adult heart  
Rac1 is known to be ubiquitously expressed throughout mouse tissues, 
including the heart (Wang and Zheng, 2007). However, the temporal expression 
of Rac1 in the heart during cardiac development has not previously been 
reported. To attain a developmental series for cardiac Rac1 expression, qPCR 
was carried out on dissected wild type hearts of a series of ages covering the 
main stages of heart development. At E10.5 the four chambered heart is 
formed, followed by continued myocardial and OFT development between 
E10.5-E17.5. At postnatal stages, structural and functional changes occur within 
the myocardium to adapt to the hyperoxic environment. The adult heart 
structure is achieved by 6 weeks of age. CD1 embryonic hearts were collected 
for RNA at E10.5, E13.5, E15.5, E17.5, postnatal day (P) 0, P2, P4 P6, P8, 
P10, P12, P15, P18 and 6 weeks (n=6 for each time point). RNA was extracted 
using the Trizol Plus RNA purification system (Ambion). qPCR analysis was 
carried out using the Comparative Ct method and gene expression values were 
normalised to housekeeping gene, GAPDH, values. qPCR analysis firstly 
confirmed that Rac1 is expressed in the developing heart A). Secondly, it 
revealed that Rac1 expression levels vary significantly throughout embryonic 
and postnatal development and in the adult (Kruskal Wallis, p<0.01). Rac1 is 
consistently expressed throughout embryonic development. Kruskal Wallis 
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pairwise analysis revealed no significant changes during embryonic 
development. However, postnatally at P2 there is a significant increase in 
expression (~50%) that remains constant for 10 days. At P15 Rac1 expression 
is significantly decreased (~30%) and returns to embryonic levels that are 
sustained in the adult heart. Kruskal Wallis pairwise analysis revealed 
significant differences between P2  and both E15.5 and E17.5. Additionaly, 
significant differences are seen between P15 (as well as 6 weeks) and 
postnatal stages P2, P4, P6 and P10.  GADPH values remained constant in all 
samples (Figure 33B). The increase in Rac1 at P2 suggests Rac1 may have an 
important role in postnatal heart development. During postnatal heart 
development, cardiomyocytes undergo elongation into the characteristic rod-
shaped structure, with fully aligned myofibrils and fully formed intercalated discs 
restricted to myofibril anchorage (Hirschy et al., 2006; Martin-Puig et al., 2008). 
Therefore, the increased expression of Rac1 may have a role in the maturation 
of the cytoskeleton and polarisation of postnatal cardiomyocytes. Alternatively, 
following birth cardiomyocytes lose the ability to proliferate and withdraw from 
the cell cycle. There is a final round of karyokinesis without the accompanied 
cytokinesis, resulting in binucleated cardiomyocytes. At P4-P6, binucleation 
initiates and by P21, 85-90% of all cardiomyocytes are binucleated. Several 
studies have also proposed a wave of cardiomyocyte proliferation at P15 
(Porrello et al., 2011; Naqvi et al., 2014). Since Rac1 has a role in cell cycle 
regulation, it is plausible that Rac1 may play a role in retaining cell proliferation 
during these early postnatal stages.   
These results are in agreement with reports of ubiquitous embryonic expression 
of Rac1 including in the heart (Wang and Zheng, 2007), however they do not 
allow interpretation of cell specific expression of Rac1.  
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Figure 33: Cardiac expression of Rac1 throughout embryonic and 
postnatal development, and in the adult by qPCR.  
Quantitative real time PCR (qPCR) analysis shows that cardiac expression of 
Rac1 remains relatively stable throughout embryonic development, however 
during postnatal development Rac1 is upregulated (P2-P12) by around 50% 
then returns to embryonic levels by P15. Expression values are normalised to 
housekeeping gene GAPDH and are relative to E10.5 expression (n=6) (A). 
GAPDH expression is consistent across all ages in the samples used to 
determine Rac1 cardiac expression by qPCR (B). *P<0.05. E embryonic day; P 
postnatal day. Statistical analysis carried out using the Krustal Wallis Method.  
 
3.3.1.2 Rac1 gene expression in cardiomyocytes  
To identify the cardiac cell type(s) that express Rac1 during cardiac 
development, in situ hybridisation was carried out on E11.5, E13.5 and E15.5 
embryonic sections. The Rac1 RNA probe was designed to target the 5’ UTR. 
The Rac1 probe hybridisation showed strong expression across the whole 
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embryo section including the myocardium, endocardium and epicardium (Figure 
34). The myocardial expression of Rac1 is relatively similar at E11.5 and E13.5 
but is reduced at E15.5 (asterisk and arrow head respectively in Figure 34, A’, 
B’ and C’). Strong expression was observed in endocardial cells (arrows in 
Figure 34, A’ and A’’) and in the sub-epicardial region (arrowheads in Figure 34, 
A’ and A’’). Within the myocardium, Rac1 expression is seen in the 
cardiomyocytes and at E13.5 and E15.5 strong Rac1 expression also appeared 
around intra-myocardial and septal vessels (arrows in Figure 34, B’ and C’’). A 
sense RNA probe was used as a negative control and did not show any non-
specific hybridisation (Figure 34D-D’). These results confirm that Rac1 is 
expressed in cardiomyocytes within the developing myocardium and highlight 
that Rac1 is also expressed in additional cardiac cells including endocardial cell 
layers as well suggestive expression in endothelial cells and/or smooth muscle 
cells of the cardiac vessels.  
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Figure 34: Cardiac expression of Rac1 during development by slide in situ 
hybridisation.   
Rac1 is expressed ubiquitously in the myocardium during embryonic heart 
development (asterisk in A’, B’ and C’). High expression is observed in 
endocardial cells at E11.5 (arrows in A’ and A’’) and around intra-myocardial 
vessels at E13.5 and E15.5 (arrows in B’ and C’’). E; embryonic day, RV; right 
ventricle, LV; left ventricle, IVS; interventricular septum. Scale bars; A-D 100µm, 
A’-D’ 50µm.  
 
3.3.2 Targeted deletion of Rac1 from specific cell types in the developing 
heart  
To determine the role of Rac1 during ventricular development, Rac1 was 
deleted from specific cardiac cell types using the Cre-LoxP system. 
3.3.2.1 Cre mouse lines  
The transgenic mouse Cre lines used in this study are listed in Table 21 and an 
example of the expression pattern of each Cre line at E15.5 is shown in Figure 
35. Gata5-Cre was initially accepted as an epicardial specific Cre line but 
subsequently the Phillips’ group established it is also expressed in the 
myocardium (Merki et al., 2005). Gata5-Cre is expressed from E9.25 in all 
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epicardial cells and a proportion of myocardial cells, predominantly in the LV 
(Merki et al., 2005). WT1-CreERT2 is tamoxifen inducible and is expressed in 
epicardial cells only (Zhou et al., 2008). TnT-Cre is expressed from E7.5 in all 
myocardial cells (Jiao et al., 2003). Mlc2v-Cre is expressed in a portion of 
ventricle myocardial cells from E7.5 and shows patchy expression during 
embryonic heart development (Chen et al., 1998).  
3.3.3.2 Mouse crosses 
Rac1flox mice (as described in Chapter 3 Section 3.1.4) contain LoxP sites 
flanking exons 4 and 5 of the Rac1 gene (Walmsley et al., 2003) (Figure 36B). 
Rac1flox mice were firstly crossed to R26REYFP reporter mice to detect Cre 
activity and subsequent Rac1 deletion. R26REYFP mice contain a ‘floxed’ 
transcriptional stop sequence, which is removed in the presence of Cre, 
therefore, allowing the expression of the EYFP construct in Cre expressing cells 
(Srinivas et al., 2001) (Figure 36C). Rac1flox; R26REYFP mice were 
subsequently crossed to different Cre lines to generate Rac1f+;EYFPf+;Cre stud 
males. These stud males were then mated to Rac1ff;EYFPff females to produce 
Rac1ff;EYFPff;Cre mutant embryos (subsequently referred to as Rac1Cre) 
(Figure 36D).   
Rac1Cre mutants are homozygous for Rac1 deletion and controls are 
heterozygous or wild type for Rac1 deletion in Cre expressing cells, combined 
with expression of EYFP (cross shown in Figure 36). 
Table 21: Summary of Cre lines used to delete Rac1 from cardiac cell 
types.  
 
Cre Line Age of onset Expression Reference 
Gata5-Cre E9.25 Epicardial and Myocardial  (Merki et al., 2005) 
WT1-
CreERT2 
Tamoxifen inducible E8.5 Epicardial (Zhou et al., 2008) 
TnT-Cre E7.5 Cardiomyocyte (Jiao et al., 2003) 
Mlc2v-Cre E7.5 Patchy myocardial (Chen et al., 1998) 
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Figure 35: Cardiac expression of Gata5-Cre, WT1-CreERT2, TnT-Cre and 
Mlc2v-Cre at E15.5.  
EYFP reporting of Cre expression using IHC. Gata5-Cre is expressed 
throughout the epicardium and patchy in myocardium (A and enlarged in A’). 
WT1-CreERT2 is expressed in the epicardium only under the control of 
tamoxifen; injections were given at either E8.5-E10.5 or E9.5-E11.5 (B and 
enlarged in B’, arrow heads point to epicardial cells and arrows point to 
migrating epicardial derived cells). TnT-Cre is expressed in the myocardium 
only (C and enlarged in C’). Mlc2v-Cre is expressed in a population of ventricle 
myocardial cells (D and enlarged in D’). RV; right ventricle, LV; left ventricle, 
GFP; green fluorescent protein. Scale bars; A-D 100µm, A’-D’ 50µm.  
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Figure 36: Cre-LoxP system utilised to generate cardiac cell specific 
deletion of Rac1. 
Cre is expressed under the control of a cell-specific promoter (A). Rac1flox mice 
contain LoxP sites flanking exons 4 and 5 of the Rac1 gene; these sites are 
recombined out by Cre leading to a frame shift and subsequent lack of a 
functional Rac1 protein in Cre expressing cells (Walmsley et al., 2003) (B). 
R26REYFP mice contain a transcriptional stop sequence flanked by LoxP sites, 
which is removed in the presence of Cre, therefore, allowing the expression of 
the EYFP construct in Cre expressing cells (Srinivas et al., 2001) (C). Rac1flox 
mice were firstly crossed to R26REYFP mice to allow reporting of Cre activity 
and consequent Rac1 deficiency. Rac1flox; R26REYFP mice were crossed to 
Cre lines to generate Rac1f+;EYFPf+;Cre stud males. These stud males were 
then mated to Rac1ff;EYFPff females to produce Rac1ff;EYFPff;Cre mutant 
embryos (D).  Black arrows represent LoxP sites, EYFP; yellow fluorescent 
protein.  
 
3.3.3.3 Rac1 mRNA transcript expression in Rac1TnTCre hearts 
To confirm Rac1 deletion in the mutant embryonic hearts the Rac1 transcript 
was first examined by semi-quantitative RT-PCR. In Rac1Cre cells, the Cre 
recombinase should remove the LoxP flanked sequence containing Rac1 exons 
4 and 5, leading to production of 134bp fragment of mRNA that will be degraded 
by non-sense mediated decay. To test this principle, primers were designed 
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either side of the LoxP sites (the forward primer binding in exon 3 and the 
reverse primer binding in exon 6) to amplify a segment of cDNA containing the 
deleted sequence (Figure 37A). Control and Rac1TnTCre E12.5 hearts were 
dissected for RNA and the cDNA synthesised was used in RT-PCR. In the 
control hearts the expected wild type Rac1 band of 356bp was produced. In the 
Rac1TnTCre E12.5 hearts, in addition to the expected wild type Rac1, a smaller 
product was also produced (134bp). The size of this PCR fragment is consistent 
with the size of the wild type Rac1 fragment (356bp) without the deleted LoxP 
flanked fragment (222bp) (n=4) (Figure 37B). These results suggest that the 
recombined floxed mRNA is transcribed in the Rac1Cre hearts with Rac1 exons 
4-5 skipped and that the wild type Rac1 allele mRNA is also transcribed in the 
Rac1Cre hearts. This is a novel finiding as it is not mentioned in the orignial 
publication or in any additional publications using this mouse model. 
Quantification of Rac1 deletion was confirmed on a protein level in the orginal 
publication (Walmsley et al., 2003), therefore this was investigated in Chapter 3 
Section 3.3.3.4.   
To quantify the reduction in wild-type Rac1 mRNA transcript in embryonic 
hearts, qPCR was carried out using primers designed to target the floxed exons 
4 and 5 only (Figure 37D). RNA was extracted from E10.5 control and 
Rac1TnTCre hearts using the Reliaprep RNA tissue miniprep system (Promega) 
and the cDNA synthesised was used in qPCR. qPCR analysis was carried out 
using the ‘Comparative Ct method’ and gene expression values were 
normalised to housekeeping gene, GAPDH, values. A 52% reduction in 
expression of Rac1 exons 4 and 5 was confirmed in E10.5 Rac1TnTCre hearts 
compared to control hearts (n=6, p-value 6.77x10-5) (Figure 37C). It is 
hypothesised that the remaining 48% expression of Rac1 in E10.5 Rac1TnTCre 
hearts is from non-cardiomyocytes expressing wild type Rac1, including 
epicardial cells, smooth muscle cells and endothelial cells. However, these 
experiments do not confirm that Rac1 is deleted specifically and efficiently in 
Cre-positive derived cells (i.e. cardiomyocytes in Rac1TnTCre hearts).  
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Figure 37: Analysis of Rac1flox transcript expression in Rac1TnTCre hearts.  
A shorter mRNA transcript (134bp) is observed in the Rac1TnTCre E10.5 hearts in 
addition to the wild type band (356bp) as shown by RT-PCR (n=4) (B). RT-PCR 
primers bind either side of the LoxP sites in the Rac1flox allele (A). qPCR 
analysis of wild-type Rac1 mRNA in E10.5 embryonic hearts revealed a 52% 
reduction in Rac1 expression in Rac1TnTCre hearts compared to controls (n=4) 
(D). Primers target the floxed exons 4 and 5 only (C). qPCR analysis was 
carried out using the Comparative Ct method and gene expression values were 
normalised to housekeeping gene, GAPDH, values.  *P<0.05. Statistical 
analysis carried out using the unpaired t-test.  
 
To confirm if Rac1 is deleted specifically in Cre-positive derived cells, slide in 
situ hybridisation was carried out using a Rac1 probe designed to target the 
‘floxed’ exons, 4 and 5, only. E12.5 control and Rac1TnTCre embryos were 
embedded and sectioned for in situ hybridisation. Slide in situ hybridisation was 
carried out using a Rac1 exon 4-5 antisense RNA probe. A sense RNA probe 
was used as a negative control and did not develop any non-specific 
hybridisation (data not shown). The antisense probe showed comparable 
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hybridisation staining to the Rac1 probe exon 3-4 staining described in Figure 
34 in control E12.5 hearts. In Rac1TnTCre E12.5 hearts, reduced Rac1 expression 
was observed in the myocardial layer (Figure 38, asterisk in A’ compared to B’), 
however, Rac1 expression in other cells appeared unchanged such as 
expression in endocardial cells (Figure 38, arrows in A’ compared to arrows in 
B’) and in mesenchymal cells of the cardiac OFT cushions (Figure 38, arrows in 
C’ and D’). Staining intensity is also comparable in control tissues such as the 
oesophagus and trachea (Figure 38, arrows in C’’ and D’’). Therefore, it is 
suggested that Rac1 mRNA is efficiently and selectively deleted from 
cardiomyocytes in the Rac1TnTCre embryos.  
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Figure 38: Specific myocardial deletion of Rac1 shown by slide in situ 
hybridisation in E12.5 control and Rac1TnTCre embryo sections.   
Rac1 is expressed ubiquitously at E12.5 in control hearts with high expression 
in endocardial cells and in the OFT cushions (A’, C’). In Rac1TnTCre hearts, Rac1 
expression is reduced in the myocardial layer (asterisk in A’ and B’), however 
expression is retained in the endocardial layer of the developing myocardium 
(arrows in A’ and B’). Additionally, staining intensity is comparable in the 
mesenchymal cells of the OFT cushions (arrows in C’ and D’) and in the 
trachea/oesophagus (arrows in C’’ and D’’). E; embryonic day, RV; right 
ventricle, LV; left ventricle, Ao; Aorta, Oe; oesophagus, Tr; Trachea. Scale bars; 
A-D 100µm, A’-D’’ 50µm.  
 
3.3.3.4 Rac1 protein expression in Rac1TnTCre hearts  
Western blotting was performed to determine if the recombined mRNA 
transcript is able to produce a protein in the i mutant hearts. Control and 
Rac1TnTCre E15.5 hearts were dissected and extracted for total protein. 
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Polyclonal IgG Rac1 antibody (Millipore) was used to detect Rac1 C-terminal as 
this antibody would bind both wild type Rac1 and to the mutant Rac1 protein if it 
is produced from the mutant mRNA described in Chapter 3 Section 3.3.3.3. 
Band intensity was determined using ImageJ software and GADPH was used to 
normalise Rac1 protein expression. The western blot shown in Figure 39A 
shows that Rac1 is visually reduced in E15.5 Rac1TnTCre hearts. Quantification 
of the band intensities confirms an 80.1% reduction in Rac1 protein in 
Rac1TnTCre E15.5 hearts compared to controls (Figure 39B) (n=3, p-value 
0.016). It is proposed that the remaining Rac1 protein is attributed to Rac1 
expression in non-cardiomyocytes cardiac cells. Therefore, it is suggested that 
Rac1 protein is efficiently and selectively deleted from cardiomyocytes in the 
Rac1TnT-Cre embryos. These results suggest that mutant mRNA described in 
Chapter 3 Section 3.3.3.3 undergoes non-sence RNA medicated decay.  
 
 
Figure 39: Western blot of Rac1 protein in Rac1TnTCre hearts. 
Western blotting for Rac1 in using protein from E15.5 hearts revealed a 
reduction in Rac1 in Rac1TnTCre hearts compared to controls (n=3) (A). GAPDH 
was used as a loading control. Quantification of band intensity using ImageJ 
software showed an 80.1% reduction of Rac1 in Rac1TnTCre E15.5 hearts 
compared to controls (n=3) (*P<0.05) (B). *P<0.05. Statistical analysis carried 
out using the unpaired t-test.  
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3.3.3.5 Rac gene expression in Rac1TnTCre hearts  
Rac family members Rac1, Rac2 and Rac3 are differentially expressed. Rac1 is 
expressed ubiquitously, Rac2 expression is limited to hematopoietic tissues and 
Rac3 is predominanty expressed in the central nervous system. Therefore, 
Rac1 is the only Rac family member that is expressed in the heart. It was 
postulated that the absence of Rac1 in the heart could lead to compensatory 
ectopic expression of the other Rac family (Rac2 and Rac3) genes in the heart. 
RT-PCR was carried out using primers for Rac1, Rac2 and Rac3 to determine 
gene expression in whole embryos and in E12.5 control and Rac1TnTCre hearts 
(Figure 40) (Wells et al., 2004). Rac1, Rac2 and Rac3 are all expressed in 
E12.5 whole embryo cDNA (Figure 40A). As previously shown, Rac1 mRNA is 
expressed in E12.5 hearts in both controls and Rac1TnTCre hearts. Rac2 mRNA 
is weakly expressed in control E12.5 hearts but expression is comparable in 
Rac1TnTCre hearts and Rac3 mRNA is not expressed in either control or 
Rac1TnTCre E12.5 hearts (Figure 40B). These results confirm that there is no 
compensatory change in Rac family member gene expression in the absence of 
Rac1 in the heart.  
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Figure 40: Expression of Rac family genes in E12.5 Rac1TnTCre hearts.  
Rac1, Rac2 and Rac3 are all expressed in E12.5 whole embryo cDNA (n=3) 
(A). Rac1 mRNA is expressed in E12.5 hearts in both controls and Rac1TnTCre 
hearts (n=3) (B). Rac2 is weakly expressed in both control and Rac1TnTCre 
hearts. However, Rac3 mRNA is not expressed in E12.5 hearts, in either control 
or Rac1TnTCre hearts (n=3) (B).  
 
Rac1 expression was only assessed at a transcript and protein level in 
Rac1TnTCre hearts due to the previously mentioned issues with specific Rac1 
antibodies. For the crosses of Rac1flox mice with additonal Cre lines, Rac1 
deletion is assessed by the expression of EYFP in Cre positive dervived cells. It 
is assumed that specific Rac1 knock out in Cre postive derived cells is 
consistent in the Rac1flox model, with no resulting increase in alternative Rac 
gene expression. However, recombination efficeincy of Cre lines can be 
variable, therefore this represents a limitation in the interpretation of the data 
from Gata5Cre, WT1-CreERT2 and Mlc2vCre crosses and in comparisons 
between these crosses. 
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3.3.3 Combined myocardial and epicardial specific Rac1 deletion causes 
cardiac defects 
To identify the role of Rac1 in epicardial and myocardial cells during 
development, Rac1flox mice were initially crossed with Gata5-Cre mice. 
3.3.3.1 Gata5-Cre mice  
Gata5-Cre mice were generated as an epicardial specific Cre line with Cre 
expression observed in the septum transversum at E9.25. At E12.5, expression 
was detected in the epicardium, pericardium and body wall (Merki et al., 2005). 
Merki and colleagues also described Gata5-Cre expression in the liver and 
additional studies have shown Gata5-Cre is expressed in other tissues, 
including the lung epithelium and skin (Xing et al., 2010). 
3.3.3.2 Gata5-Cre expression  
As mentioned, Gata5-Cre mice were initially generated as an epicardial specific 
Cre line. However, the Phillips’ group have recently reported expression in the 
developing myocardium (Boczonadi et al., 2014b). Anti-GFP IHC staining of 
E9.5-E15.5 Gata5Cre;EYFP sections confirmed expression in epicardial cells 
and also patchy Cre expression within the cardiomyocytes of the developing 
myocardium (Figure 41). The LV has a consistently higher proportion of Gata5-
Cre-positive derived cells compared to the RV and Gata5-Cre cells mainly 
appear clustered together in large patches (Figure 41A-E). Gata5-Cre is also 
expressed in the pericardium and SHF cells of the developing OFT and 
pharyngeal region at E10.5 (Figure 41F-G).  
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Figure 41: Gata5-Cre expression throughout cardiac development.  
Gata5-Cre is expressed in a subset of myocardial cells from E9.5 (A and A’). 
From E10.5-E15.5, myocardial Gata5-Cre expression is predominately in the 
left ventricle (B’-E). Gata5-Cre is also detected in epicardial cells at E10.5 and 
onwards (B-E), and in the myocardial cells of the outflow tract from E9.5 (F-J). 
E; embryonic day, GFP; green fluorescent protein. MF20; myosin II heavy chain, 
LV; left ventricle, RV; right ventricle, OFT; outflow tract, Ao; aorta, PT; 
pulmonary trunk. Scale bars; 100µm.  
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3.3.3.3 Rac1flox x Gata5-Cre mouse cross 
Timed matings were set up between Rac1flox mice and Rac1flox;+;Gata5-Cre 
mice. Rac1Gata5Cre embryos were collected across developmental stages E10.5-
P0 and analysed using histological and IHC techniques.  
The expected number of Rac1Gata5Cre embryos were observed as predicted by 
Mendelian ratios across all ages (E9.5-P0), however some Rac1Gata5Cre 
embryos were found dead in utero, from E14.5 onwards, and none survived at 
birth, therefore, the mutant embryos are embryonic lethal (Table 22). Table 23 
shows a summary of the abnormalities observed in Rac1Gata5Cre mutant 
embryos. No external or cardiac defects were observed in control embryos or in 
Rac1f+Gata5Cre heterozygous mutants. The heterozygous mutants could therefore 
be used as Cre-positive controls.   
3.3.3.4 Extracardiac defects in Rac1Gata5Cre embryos 
Rac1Gata5Cre embryos presented with oedema, cranial haemorrhage, non-closure 
of the ribs and heart defects. A summary of the defects observed in Rac1Gata5Cre 
embryos is detailed in (Table 23).  
Oedema and cranial haemorrhage can be indicative of heart function failure and 
may result secondary to the heart defects. However, as Gata5-Cre is expressed 
in many tissues, including the lung epithelium and skin, the observed oedema 
and cranial haemorrhage could also result from Rac1 deficiency in non-cardiac 
tissues (Xing et al., 2010).  
At E11.5 Gata5-Cre is expressed in the pericardium (Figure 43, A and B). 
Rac1Gata5Cre mutants display an abnormally thin body wall from E12.5 (Figure 
43, C and D), leading to non-closure of the ribs later in development, at E15.5 
(Figure 43, E’ and F’). This suggests that Rac1 has an important role in the 
maturation and thickening of the pericardium and ventral body wall.   
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Embryonic 
day (E) 
Total 
embryos 
Rac1
Gata5Cre
 
embryos 
observed 
Rac1
Gata5Cre
 
embryos 
expected 
% Rac1
Gata5Cre 
embryos alive 
Chi-
squared 
E10.5 17 8 4.25 100% ns 
E11.5 70 16 17.5 100% ns 
E12.5 36 8 9 100% ns 
E13.5 64 22 16 100% ns 
E14.5 27 6 6.75 96.3% ns 
E15.5 124 32 31 97.6% ns 
E16.5 16 4 4 100% ns  
E17.5 33 7 8.25 94% ns 
P0 13 5 3.25 0% ns 
Table 22: Rac1Gata5Cre embryos observed in expected Mendelian ratios.  
The number of Rac1Gata5Cre embryos observed at dissection was within the 
expected limits at each age. Some Rac1Gata5Cre embryos were found dead at 
dissection from E14.5 onwards. Statistical analysis carried out using the Chi-
squared test.  
 
Embryonic 
day (E) 
Total 
Rac1
Gata5Cre
 
embryos 
Oedema  Cranial 
Haemorrhage  
Thin body 
wall/non closure 
of ribs 
Heart 
Defect  
E10.5  
 
5 0% 
 
0%  0%  0% 
E11.5 5 0% 
/5  
0%  0%  80%  
E12.5 6 100%  0%  0%  100%  
E13.5 6 100% 16.7% 100%  100% 
E14.5 5 100% 20%  100% 100% 
E15.5 25 100%  56%  100% 100%  
E16.5 4 100% 100%  100%  100% 
E17.5 5 100% 80% 100% 100% 
P0 5 - - 100% 100% 
Table 23: Summary of the defects observed in Rac1Gata5Cre mutant mice. 
Rac1Gata5Cre embryos display oedema, cranial haemorrhage and non closure of 
the ribs, as well as heart defects.  
 
3.3.3.5 Gata5-Cre expression in Rac1Gata5Cre hearts  
Anti-GFP staining of E11.5, E13.5 and E15.5 control and Rac1Gata5Cre sections 
showed similar expression of Gata5-Cre in controls and Rac1Gata5Cre embryos 
(Figure 44). All epicardial cells expressed Gata5-Cre at E15.5. In the ventricle, 
Gata5-Cre was expressed in the majority of LV cardiomyocytes (~90%) as well 
as in some cardiomyocytes in the RV (~40%) and IVS (~20%) (Figure 44). In 
the OFT, Gata5-Cre was expressed in the wall of both the aorta and pulmonary 
trunk (Figure 45). The number of Gata5-Cre-positive derived cells appeared to 
be reduced in Rac1Gata5Cre hearts from E13.5 (Figure 44, D compared to C). 
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Additionally, the Gata5-Cre-positive derived cells appeared more rounded in 
Rac1Gata5Cre hearts compared to controls (Figure 44, D compared to C). These 
observations are indicative of altered cell survival/proliferation and/or cell 
polarity in the absence of Rac1, which will be discussed further in Chapter 5.  
 
Figure 42: Rac1Gata5Cre embryos during development.  
Control embryos develop normally (A-D). Whereas, Rac1Gata5Cre embryos 
develop oedema by E13.5 (white arrow in F and G) and haemorrhage by E17.5 
(asterisk in ). E; embryonic day. Scale bars; 2mm. 
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Figure 43: Body wall defects in Rac1Gata5Cre embryos. 
Gata5-Cre is expressed in the body wall at E11.5 (arrows in A and B). 
Rac1Gata5Cre embryos have thin body wall from E12.5 (arrows in C and D) and 
non-closure of the ribs at E15.5 (F and white arrow in F’), as well as cranial 
haemorrhage (asterisk in F). LV; left ventricle, RV; right ventricle, E; embryonic 
day, GFP; green fluorescent protein. Scale bars; A-B 200µm, C-D 400µm, E-F’ 
1mm. 
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Figure 44: Gata5-Cre expression in control and Rac1Gata5Cre ventricles.  
Anti-GFP staining of E11.5, E13.5 and E15.5 control and Rac1Gata5Cre ventricle 
sections showed similar expression of Gata5-Cre in both control and 
Rac1Gata5Cre embryos (n=3). Additionally, the Gata5-Cre-positive derived cells 
appeared more rounded in Rac1Gata5Cre hearts compared to controls (arrows in 
D’’ and F’’ compared to C’’ and E’’). E; embryonic day, RV; right ventricle, LV; 
left ventricle, IVS; interventricular septum, GFP; green fluorescent protein. 
Scale bars; A-F 200µm, A’-F’’’ 100µm.  
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Figure 45: Gata5-Cre expression in control and Rac1Gata5Cre OFT.  
Anti-GFP staining of E11.5, E13.5 and E15.5 control and Rac1Gata5Cre OFT 
sections showed similar expression of Gata5-Cre in the aorta and pulmonary 
trunk in both control and Rac1Gata5Cre embryos (n=3) (A-F). E; embryonic day, 
Ao; aorta, PT; pulmonary trunk, GFP; green fluorescent protein. Scale bars; A-F 
200µm, A’-F’’’ 100µm. 
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3.3.3.6 Cardiac defects in Rac1Gata5Cre embryos 
From E11.5 onwards, Rac1Gata5Cre embryos display heart abnormalities (listed in 
Table 24). At E11.5 the Rac1Gata5Cre hearts have notably sparse trabeculae 
(Figure 46, D’ compared to C’). Later in development, Rac1Gata5Cre hearts have a 
significantly thinned myocardial wall compared to controls (Figure 46E’-L’). Left 
and right myocardial measurements at E12.5, E13.5, E15.5 and E17.5 show the 
myocardium becomes increasingly thinner compared to controls from E13.5 
onwards and does not recover during development (Figure 46N). In controls, 
the LV thickens more than the RV from E15.5 to E17.5. However, this difference 
is not seen in Rac1Gata5Cre hearts; both ventricles are of a similar thickness at 
E17.5 (Figure 46N). The cross-sectional diameter of the heart diameter is 
unchanged in Rac1Gata5Cre hearts compared to controls (Figure 46M). These 
results suggest the myocardium is not undergoing normal thickening and 
compaction in Rac1Gata5Cre embryos as in the controls.  
Occasional epicardial defects were also observed on the surface of the heart in 
some Rac1Gata5Cre mutants from E12.5. These defects included areas of 
detached epicardial cells filled with blood, forming blisters on the surface of the 
heart (Figure 47A-C). In some areas, the epicardial surface appeared uneven 
with small epicardial blisters and invaginations of the myocardium (Figure 47C). 
At E15.5, VSD were observed in all Rac1Gata5Cre mutants (Figure 48, A and D). 
Additionally, the aorta remained connected to the RV in the form of OA and 
DORV (Figure 48, B and E). The aorta appeared dilated with a thinner muscular 
wall (Figure 48, C’ and F’).  
The Rac1Gata5Cre cardiac phenotype confirms that Rac1 is required in the 
myocardium and/or epicardium for normal development of the ventricles and 
correct OFT alignment. It is hypothesised that the Rac1Gata5Cre embryos die 
at/before birth due to the combination of lethal body wall and heart defects 
observed during development.  
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Table 24: Summary of the cardiac defects observed in Rac1Gata5Cre mutant 
embryos.  
No defects were observed in the control embryos/pups at any age. A visible 
reduction in the thickness of the myocardium was classed as a thin 
myocardium. Abnormal trabeculae was defined as a visibly reduced number of 
trabeculae or aberrant directionality of trabeculae. VSD; ventricular septal 
defect, OA; overriding aorta, DORV; double outlet right ventricle.  
 
 
 
 
 
 
Embryonic 
day (E)  
Total 
Rac1
Gata5Cre
 
embryos 
Epicardial 
blood 
blisters 
Thin 
myocardium  
Abnormal 
trabeculae  
VSD  OA/ 
DORV  
E10.5 5 0%  0%  0% -  - 
E11.5 5 20%  40%  60%  -  -  
E12.5 6 83.3% 33.3% 100% -  -  
E13.5 5 40% 100% 100% -  -  
E14.5 5 60% 100% 100% - - 
E15.5 8 100% 100% 100% 100% 100% 
E16.5 4 50% 100% 100% 100% 100% 
E17.5 5 20% 100% 100% 100% 100% 
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Figure 46: H&E staining and myocardial measurements of control and 
Rac1Gata5Cre hearts.   
Example images of H&E stained control and Rac1Gata5Cre heart sections at 
E10.5 to E17.5 (n=5) (A-L). The heart diameter is unchanged in Rac1 Gata5Cre 
hearts compared to controls (M). Rac1Gata5Cre hearts have a significantly thinned 
compact myocardium compared to aged matched controls from E13.5 (N). In 
controls, the left ventricle is thicker than the right ventricle at E17.5, whereas the 
ventricles are of equal thickness in Rac1Gata5Cre embryos (N). E; embryonic day, 
RV; right ventricle, LV; left ventricle. Scale bars; A-J 200µm, A’-H’ 50µm, K-L 
500µm, I’-L’’ 100µm. *p<0.05. Statistical analysis carried out using a two-way 
ANOVA.  
 
 
 
138 
 
 
Figure 47: Epicardial defects in Rac1Gata5Cre hearts.  
Example images of epicardial blisters in Rac1Gata5Cre hearts at E12.5 and E15.5. 
In some areas, the epicardium is detached from the surface of the heart and the 
gap is filled with red blood cells (A’, B’ and C’). In other areas, the epicardial 
surface appears uneven with small epicardial blisters and invaginations of the 
myocardium (C’’). RV; right ventricle, Ao; aorta. Scale bars; A-C 200µm, A’-C’’ 
100µm.  
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Figure 48: OFT defects in Rac1Gata5Cre hearts. 
Rac1Gata5Cre hearts have ventricular septal defects (VSD) (asterisk in D), double 
outlet right ventricle (DORV) (asterisk in E) and dilated aorta (asterisk in F’) 
(n=5). E; embryonic day, LV; left ventricle, RV; right ventricle, Ao; aorta, PT; 
pulmonary trunk. Scale bars; A-F 500µm, C’ and F’ 100µm.  
 
3.3.4 Epicardial specific deletion of Rac1 does not affect cardiac 
development 
As both epicardial and myocardial cells were affected in the Gata5-Cre crosses, 
to dissect the roles of Rac1 in the epicardium and myocardium during cardiac 
development, Rac1 was first specifically deleted from epicardial cells by 
crossing Rac1flox mice to a tamoxifen inducible WT1-CreERT2 mouse line.  
3.3.4.1 WT1-CreERT2 mice  
The generation and validation of WT1-CreERT2 mice has been described 
previously (Zhou et al., 2008). Briefly, GFPCre complementary DNA was 
knocked into the endogenous WT1 start codon. WT1-Cre expression was 
confined to proepicardium and epicardium from E9.5 to E15.5, and was not 
detected in the myocardium. To regulate Cre-labelling temporally, a cDNA 
encoding a Cre-modified oestrogen receptor ligand-binding domain (CreERT2) 
was also knocked into the WT1 locus. CreERT2 fusion protein recombinase 
activity requires tamoxifen. Maternal injection of tamoxifen at E10.5 and E11.5 
was found to induce Cre activity whereas no expression was detected in the 
absence of tamoxifen. The frequency of WT1CreERT2 labelled cells in epicardium 
was reduced compared to constitutive labelling by WT1GFPCre, probably due to 
inefficient CreERT2 activation by tamoxifen concentrations compatible with 
maintenance of pregnancy (Zhou et al., 2008). 
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3.3.4.2 Rac1flox x WT1-CreERT2 mouse cross  
Timed matings were set up between Rac1flox mice and Rac1flox;+;WT1-CreERT2 
mice. Cre recombinase was activated in WT1-CreERT2-expressing epicardial 
cells following an intraperitoneal dose of tamoxifen administered on 2 
consecutive days at either E8.5 and E9.5 (n=4) or E9.5 and E10.5 (n=6). At this 
point in embryonic development epicardial cells are migrating from the pro-
epicardium and attaching to the surface of the myocardium to form the single 
layered epicardium. Therefore, Rac1 should be deleted in the pro-epicardial 
cells as they form the epicardial layer. This is similar to when Gata5-Cre is 
expressed in the epicardium and hence allows the dissection of the Rac1Gata5Cre 
phenotype using this model. Rac1WT1-CreERT2 embryos were collected at E15.5 
and the expected numbers of embryos were observed as predicted by 
Mendelian ratios. All Rac1WT1-CreERT2 mice were alive and appeared to have 
developed normally compared to littermate controls at E15.5 (Figure 49, A and 
D). Rac1WT1-CreERT2 embryos were analysed using histological and IHC 
techniques. No external or cardiac defects were observed in control embryos or 
in Rac1f+WT1-CreERT2 heterozygous mutants. The heterozygous mutants could, 
therefore, be used as Cre-positive controls.   
3.3.4.3 WT1-CreERT2 expression 
IHC staining with an anti-GFP antibody confirmed Cre activation in epicardial 
cells and EPDCs exclusively at E15.5 (Figure 49G-L).  
3.3.4.4 Cardiac phenotype in Rac1WT1-CreERT2 embryos 
H&E staining showed no observable defects in myocardial development in 
E15.5 Rac1WT1-CreERT2 hearts when Cre was induced at either E8.5-9.5 or E9.5-
10.5 (Figure 49A-B, D-F). Measurements of left and right myocardial wall 
thickness confirmed no differences between control and Rac1WT1-CreERT2 hearts 
(Figure 49C). Additionally, no septal or OFT defects were observed in Rac1WT1-
CreERT2 embryos. 
3.3.4.4 Migration of epicardial and EPDCs in Rac1WT1-CreERT2 embryos 
IHC staining with anti-GFP identifies the Cre-positive  epicardial cells and 
EPDCs in the Rac1WT1-CreERT2 hearts. Epicardial cells appear to have migrated 
from the proepicardium and spread over the outer surface of the heart in both 
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control and Rac1WT1-CreERT2 embryos (Figure 49G-L). The number of Cre-
positive derived epicardial cells is not significantly different in Rac1WT1-CreERT2 
compared to control hearts (Figure 49M). Furthermore, Cre-positive derived 
EPDCs are found migrating into the myocardial layer of the heart in Rac1WT1-
CreERT2 embryos as in controls (Figure 49, arrows in C and F). The number and 
distance of Cre-positive derived EDPCs is not significantly different in Rac1WT1-
CreERT2 embryos compared to controls (Figure 49M-N). However, there is a slight 
trend towards a reduced number/distance of migration of EPDCs, therefore 
analysis of additional hearts at E15.5 and additional ages, possibly E12.5 and 
E17.5, would be necessary to conclude that Rac1 has no role in EPDC 
migration. An epicardial explant and cell migration assay could also be carried 
out.  
The lack of a cardiac phenotype in Rac1WT1-CreERT2 embryos at E15.5, indicates 
that Rac1 is not required in epicardial cells for the normal thickening and 
maturation of the myocardium during embryonic development, up to this stage. 
Therefore, it was hypothesised that Rac1 is essential in myocardial cells for the 
development of the myocardial wall.  
 
Embryo 
stage 
Total 
embryos 
Rac1
WT1-CreERT2 
expected 
embryos 
Rac1
WT1-CreERT2 
observed 
embryos 
% embryos 
alive 
Chi-squared 
E15.5 59 14.75 14 100% ns 
Table 25: Expected and observed numbers and percentages for 
Rac1Mlc2vCre embryos and pups. 
The number of Rac1WT1-CreERT2 embryos observed at dissection were within the 
expected limits E15.5. No Rac1WT1-CreERT2 embryos were found dead at 
dissection. Statistical analysis carried out using the Chi-squared test.  
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Figure 49: Rac1WT1-CreERT2 phenotype.  
Rac1WT1-CreERT2 embryos do not have any external phenotype (A and D) (n=14). 
Rac1WT1-CreERT2 hearts are normal compared to controls (B and E) (n=6). 
Statistical analysis carried out using an unpaired t-test. Rac1WT1-CreERT2 
epicardial cells correctly form the epicardium as in the control and the EPDCs 
successfully migrate into the myocardium as in the control (n=6) (C and F, 
arrows point to migrating EPDCs). RV; right ventricle, LV; left ventricle, EPDCs; 
epicardially derived cells, GFP; green fluorescent protein. Scale bars; A-B 2mm, 
D-F 500µm, G-L 100µm. Statistical analysis carried out using a two-way 
ANOVA.  
 
3.3.5 Patchy myocardial deletion of Rac1 does not affect cardiac 
development 
To further dissect the roles of Rac1 in the epicardium and myocardium during 
cardiac development, Rac1 was specifically deleted from myocardial cells by 
crossing Rac1flox mice to a Mlc2v-Cre mouse line.  
3.3.5.1 Mlc2v-Cre mice  
The Mlc2v-Cre mice have been generated by a gene knock-in approach, with 
Cre recombinase being inserted into exons 1 and 2 of the Mlc2v gene (Chen et 
al., 1998).  
3.3.5.2 Mlc2v-Cre expression  
Mlc2v-Cre is exclusively expressed in cardiomyocytes, therefore, it allows 
investigation of gene function specifically in the myocardium without 
interference from extra-cardiac defects or additional cardiac cell functions (as in 
Rac1Gata5Cre embryos). Dual IF staining of E9.5, E10.5 and E15.5 EYFP;Mlc2v-
Cre embryo sections using anti-GFP and anti-MF20 confirmed patchy 
expression in cardiomyocytes of the developing ventricular myocardium (Figure 
50, A, C and  E). At E15.5, Cre expression was highest in the IVS (~80%), and 
less in the myocardium of the ventricles, at around 50% and 30% in the right 
and left ventricles, respectively. Expression was absent from the developing 
atria and OFT (Figure 50, B and D).   
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Figure 50: Mlc2v-Cre expression during cardiac development.  
Dual IF staining of E9.5, E10.5 and E15.5 EYFP;Mlc2v-Cre sections using anti-
GFP and anti-MF20 confirmed patchy expression in cardiomyocytes of the 
developing ventricular myocardium. Expression was absent from the developing 
atria and OFT.  E; embryonic day. GFP; green fluorescent protein. LV; left 
ventricle, RV; right ventricle, OFT; outflow tract. Scale bars; A-E’’ 200µm, 
except A’-A’’ 50µm.  
 
3.3.5.3 Rac1flox x Mlc2v-Cre mouse cross 
Rac1 and Mlc2v genes are found close together on Chromosome 5 (20.06cM 
apart) (Figure 51A), consequently, mutants could only be generated via genetic 
recombination (Figure 51C versus D). The frequency of mutant offspring 
observed was 20.7% and this is consistent with the predicted recombinant 
frequency of 20.06% (Figure 51B). Timed matings were set up between Rac1flox 
mice and Rac1flox;+;Mlc2v-Cre mice. All Rac1Mlc2vCre mice survived to at least 21 
days and appeared to develop normally compared to littermate controls (Figure 
52A-B). Rac1Mlc2vCre embryos were collected at E15.5 and analysed by histology 
and IHC techniques.  
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Figure 51: Recombination explanation of Rac1flox x Mlc2v-Cre cross.  
Rac1 and Mlc2v genes are found close together on Chromosome 5 (20.06cM 
apart) (A), consequently, mutants could only be generated via genetic 
recombination (C versus D). The frequency of mutant embryos and neonates 
observed was 20.7% and this is consistent with the predicted recombinant 
frequency between Rac1flox and Rac1WT;Mlc2v-Cre alleles of 20.06% (B).  
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Embryo 
stage 
Total 
embryos 
Rac1
Mlc2vCre
 embryos 
expected 
Rac1
Mlc2vCre
 embryos 
observed   
% 
embryos 
alive 
Chi-
squared 
Number  Percentage Number Percentage 
E9.5 26 6.5 25% 1 3.8% 100% 0.013 
E15.5 75 18.75 25% 8 10.6% 100% 1.01E-6 
Weaned 
pups 
15 3.75 25%  3 20% 100% 0.033 
Table 26: Expected and observed numbers and percentages for 
Rac1Mlc2vCre embryos and pups.  
The number of Rac1Mlc2vCre embryos observed at dissection were within the 
expected limits at each age. No Rac1 Mlc2vCre embryos were found dead at 
dissection. Statistical analysis carried out using the Chi-squared test.  
 
3.3.5.4 Cre expression in Rac1Mlc2vCre embryos  
IHC staining of E15.5 wax sections with anti-GFP antibody confirmed Cre 
activation in a subset of ventricle myocardial cells in both control and 
Rac1Mlc2vCre embryos (Figure 53). Expression was patchy in both ventricles and 
IVS but was absent from the atria and OFT.  
3.3.5.5 Cardiac phenotype in Rac1Mlc2vCre embryos  
E15.5 sections were stained with H&E to examine cardiac morphology in 
Rac1Mlc2vCre embryos. Rac1Mlc2vCre hearts were grossly normal with a thickened 
ventricle myocardium, confirmed by myocardial thickness measurements of the 
left and right ventricle (Figure 52C-D). The thickened and compact myocardium 
consisted of mostly unaffected wild type cells or Cre expressing Rac1 mutant 
cardiomyocytes which were interspersed with unaffected wild type cells. (Figure 
53E-F). Interestingly, in 3 out of 8 Rac1Mlc2vCre hearts, a small region of the 
compact myocardial wall appeared thinner and less compacted compared to the 
rest of the myocardial wall (Figure 53E-F). These areas of thin and less 
compact myocardium correlated with regions of densely packed Cre expressing 
Rac1 mutant cardiomyocytes. Rac1Mlc2vCre embryos did not have any septal or 
OFT defects. 
3.3.5.6 Cardiomyocyte maturation  
E15.5 sections were immunostained using an anti-α-SMA antibody to examine 
cardiomyocyte maturation in Rac1Mlc2vCre embryos. Reduction in α-SMA 
expression is associated with cardiomyocyte differentiation and therefore at 
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E15.5, α-SMA becomes restricted to the compact myocardium and is relatively 
absent from the trabeculated myocardium. α-SMA expression appeared normal 
in Rac1Mlc2vCre hearts compared to controls, implying myocardial wall maturation 
is unaffected in Rac1Mlc2vCre embryos (Figure 53E-F). In conclusion, deleting 
Rac1 from a subset of cardiomyocytes leads to mild myocardial defects, but 
does not recapitulate the defects seen in Rac1Gata5Cre embryo hearts. Therefore 
it was hypothesised that the high percentage of Rac1 expressing 
cardiomyocytes (50% and 70% in the right and left ventricles, respectively) are 
able to compensate for the lack of Rac1 in the interspersed mutant cells. In 
regions where mutant cells are clustered mild myocardial defects are observed, 
similar to that seen in the Rac1Gata5Cre embryos (Figure 53F).  
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Figure 52: Rac1Mlc2vCre embryos show no abnormal phenotype.  
Rac1Mlc2vCre embryos develop normally and do not show any external defects at 
E15.5 (n=8) (A-B). H+E staining of transverse sections shows that there are no 
structural heart defects in Rac1Mlc2vCre hearts and myocardial development is 
normal compared to controls at E15.5 (n=6) (C-D) and α-SMA IHC staining 
reveals normal cardiomyocyte maturation compared to controls at E15.5 (n=6) 
(E-F). LV; left ventricle, RV; right ventricle. Scale bars; A-B 2mm, C-F 500µm, 
C’-F’’ 50µm.  
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Figure 53: IHC anti-GFP staining of E15.5 control and Rac1Mlc2vCre heart 
sections.  
IHC staining of E15.5 wax sections with anti-GFP antibody confirmed Cre 
activation in a subset of myocardial cells in both control and Rac1Mlc2vCre 
embryos. Mlc2v-Cre expression was patchy in both ventricles and IVS (A-D, G-
H).  In regions of densely packed Cre expressing mutant cells, the compact 
myocardial wall appeared thinner and less compacted compared to the rest of 
the myocardial wall in Rac1Mlc2vCre hearts. Whereas, wild type cells or 
interspersed Cre expressing mutant cells were found in areas of compacted 
ventricular wall (E’-F’). LV; left ventricle, RV; right ventricle, IVS; interventricular 
septum. Scale bars; A-B 500µm, C-H 200µm, E’-F’ 50µm.  
 
3.3.6 Rac1 is required in the myocardium for normal myocardial and 
outflow tract development  
As shown in Chapter 3 Section 3.3.4 Rac1 is not required in the epicardium for 
ventricular wall development, therefore it was hypothesised that deletion of 
Rac1 in cardiomyocytes is the source of the myocardial phenotype observed in 
Rac1Gata5Cre embryos. Therefore, Mlc2v-Cre was used to delete Rac1 from 
cardiomyocytes. However, as discussed in Chapter 3 Section 3.3.5, the 
percentage of cardiomyocytes expressing Mlc2v-Cre was too low to give a 
myocardial phenotype and did not recapitulate the Gata5-Cre cardiomyocyte 
expression. Deletion of Rac1 in ventricular wall myocardial cells (~30% of 
myocardial cells in LV and ~50% of myocardial cells in RV, calculated using % 
GFP IHC staining of Mlc2v-Cre derived cells at E15.5) did not recapitulate the 
myocardial and OFT defects seen in Rac1Gata5Cre embryos (~90% of myocardial 
cells in LV and ~40% of myocardial cells in RV, calculated using % GFP IHC 
staining of Gata5-Cre derived cells at E15.5). It was therefore hypothesised that 
Rac1 deletion in the majority of ventricular cardiomyocytes may recapitulate the 
Rac1Gata5Cre phenotype. To test this hypothesis, Rac1 was deleted from all 
developing cardiomyocytes by crossing Rac1flox mice to a myocardial specific 
TnT-Cre line.  
3.3.6.1 TnT-Cre mice 
Similar to Mlc2v-Cre, TnT-Cre is exclusively expressed in cardiomyocytes, 
therefore it allows investigation of gene function specifically in the myocardium 
without interference from extra-cardiac defects or additional cardiac cell 
functions (as in Rac1Gata5Cre embryos). However, TnT-Cre is expressed in all 
cardiomyocytes rather than a small subset (as in Mlc2v-Cre) (Jiao et al., 2003). 
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In TnT-Cre mice, Cre recombinase is expressed under the control of Troponin-T 
promoter which is expressed in all differentiated cardiomyocytes from E7.5.  
3.3.6.2 TnT-Cre expression  
R26RLacZ and R26REYFP mice were crossed to TnT-Cre mice to allow for 
reporting of Cre activity (Figure 54K-M). Cre activity was visualised by X-gal 
staining for the expression of the LacZ construct in the R26RLacZ allele (Figure 
54M). IF staining using anti-GFP was used to visualise EYFP expressing cells 
(Figure 54L). X-gal staining of R26RLacZ;TnT-Cre embryos confirms TnT-Cre 
expression is restricted to the cardiomyocytes in the heart at E8.5 and E10.5 
(Figure 54A-B). The X-gal stained E10.5 embryos were sectioned and 
counterstained with eosin to confirm expression is restricted to the myocardial 
layer of the heart; expression is absent in epicardial, endocardial and 
mesenchymal regions (Figure 54E). At E13.5 and onwards, X-gal staining of 
R26RLacZ;TnT-Cre hearts shows TnT-Cre expression is restricted to heart and 
is absent in the OFT vessels (Figure 54C-D). Additionally, IHC staining of E13.5 
and E15.5 R26REYFP;TnT-Cre using anti-GFP, confirmed expression in the 
myocardial layer and expression is absent in epicardial, endocardial and 
mesenchymal regions (Figure 54F-G). 
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Figure 54: TnT-Cre expression  
TnT-Cre mice express Cre recombinase under the control of the Troponin-T 
promoter (A). EYFP and LacZ reporter mice have a lox-stop-lox site that allows 
the regulation of expression of EYFP and LacZ under the control of Cre 
recombinase (B and C, respectively). TnT-Cre is expressed in the heart at E8.5 
and onwards as shown by X-gal staining (D-G). Transverse sections of E10.5 
X-gal stained embryos show TnT-Cre is exclusively expressed in the myocardial 
cells and is absent from other cardiac cells such as the mesenchymal cells of 
the developing cardiac cushions (H). This data is confirmed by anti-GFP 
immunostaining at E13.5 and E15.5 (I-J). TnT-Cre is expressed exclusively in 
cardiomyocytes as shown by dual IF with GFP and MF20, a cardiomyocyte 
marker (K-N). LV; left ventricle, RV; right ventricle, OFT; outflow tract. Scale 
bars A-P; 200µm Q-S; 50µm. 
 
3.3.6.3 Rac1flox x TnT-Cre cross  
Timed matings were set up between Rac1flox mice and Rac1flox;+;TnT-Cre mice. 
Rac1TnTCre embryos were collected across developmental stages E9.5-P0 and 
analysed using histological and IHC techniques.  
The expected numbers of Rac1TnTCre embryos, as predicted by Mendelian 
ratios, were observed up to E17.5. However, some Rac1TnTCre embryos were 
found dead in utero, from E12.5 onwards and none were alive at birth. Only 1 
Rac1TnTCre pup was collected at birth, and was deceased. Any additional 
Rac1TnTCre pups were most likely cannibalised by the dam at birth, after the 
pups had died. Rac1TnTCre embryos do not have an external phenotype (Figure 
56A-B). No external or cardiac defects were observed in control embryos or in 
Rac1f+TnTCre heterozygous mutants. The heterozygous mutants could therefore 
be used as Cre positive controls.   
3.3.6.4 Cardiac phenotype in Rac1TnTCre embryos  
All Rac1TnTCre embryos have visible heart abnormalities from E11.5 onwards; a 
summary of the heart defects is detailed in Table 28. The cardiac phenotype in 
Rac1TnTCre embryos recapitulates that seen in the Rac1Gata5Cre mutants. At E11.5 
the Rac1TnTCre hearts have notably sparse trabeculae (Figure 55, B’ compared 
to A’), and from E13.5 the Rac1TnTCre hearts have a significantly thinned 
myocardium (Figure 55, D’ compared to C’ and J). Poor septum formation is 
also observed from E11.5 onwards (Figure 55, B compared to A). Rac1TnTCre 
hearts appear irregular in shape with large ventricular lumens compared to 
controls from E12.5 (Figure 55C-H). At E15.5, the Rac1TnTCre hearts are 
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significantly increased in diameter compared to controls (Figure 55, G, H and J) 
and appear to be positioned at an abnormal angle within the thoracic cavity. At 
E15.5 all Rac1TnTCre embryos have a muscular VSD (Figure 56E). Additionally, 
the aorta remains associated with the RV and displays DORV/OA (Figure 56F). 
 
Embryo 
stage 
Total 
embryos 
Rac1
TnTCre
 embryos 
observed 
Rac1
TnTCre 
embryos 
expected 
Alive (%) 
Rac1
TnTCre 
embryos 
Chi-squared 
E9.5 208 43 52 100% ns 
E10.5 336 96 84 100% ns 
E11.5 183 44 45.75 100% ns 
E12.5 164 40 41 85% ns 
E13.5 98 20 24.5 80% ns  
E14.5 23 8 5.75 100% ns 
E15.5 141 27 35.25 88.89% ns 
E17.5 25 7 6.25 85.71% ns 
P0 34 1 8.5 0% 1.75E-07 
Table 27: Rac1TnTCre embryos observed in expected Mendelian ratios. 
The number of Rac1TnTCre embryos observed at dissection were within the 
expected limits at each age. Some Rac1 TnTCre embryos were found dead at 
dissection from E12.5 onwards. Statistical analysis carried out using the Chi-
squared test.  
 
Embryo 
stage 
Total 
Rac1
TnTCre
 
embryos 
Thinned 
myocardium  
Abnormal 
trabeculae 
VSD DORV/
OA 
Abnormal 
position of heart 
E9.5  3 0/3 0/3 - - - 
E10.5 3 0/3 3/3 - - - 
E12.5 2 2/2 
 
2/2 
 
- - 
 
2/2 
E15.5 6 6/6 
 
6/6 
 
6/6 6/6 6/6 
E17.5 4 4/4 4/4 4/4 4/4 4/4 
P0 0 - - - - - 
Table 28: Summary of the cardiac defects in Rac1TnTCre embryos.  
Rac1TnTCre embryos display thinned myocardium, abnormal trabeculae, VSD, 
DORV/OA and abnormal position of the heart. No defects were noted in the 
control embryos at any age. VSD; ventricular septal defect, DORV; double 
outlet right ventricle, OA; overriding aorta. 
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Figure 55: H&E staining of control and Rac1TnTCre hearts with myocardial 
measurements.  
Myocardial abnormalities are observed from E11.5 including thin compact 
myocardium and irregular trabeculae (A-B).  Rac1TnTCre hearts have a 
significantly thinned compact myocardial layer compared to controls at  E13.5 
(n=4), E15.5 (n=4) and E17.5 (n=4) (J). At E17.5 in Rac1TnTCre hearts, the left 
ventricle is more compacted compared to the right ventricle, whereas the 
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thickness is similar between left and right ventricles in controls. The diameter of 
the Rac1TnTCre hearts is significantly increased compared to controls at E15.5 
(I). LV; left ventricle, RV; right ventricle. Scale bars; A-F 200µm, G-H 500µm, A’-
F’’ 50µm, G’-H’’ 100µm. *p<0.05. Statistical analysis carried out using a two-
way ANOVA.  
 
 
Figure 56: OFT defects in Rac1TnTCre embryos.  
Rac1TnTCre embryos do not have an external phenotype (A-B). At E15.5 all 
Rac1TnTCre embryos have a muscular VSD (Asterisk (*) in E) and the aorta 
remains associated with the right ventricle causing displays DORV/overriding 
aorta (OA) (Asterisk (*) in F) (n=4). LV; left ventricle, RV; right ventricle. Scale 
bars; A and D 2mm, B-C, E-F 500µm.  
 
3.3.7 The epicardium forms normally in Rac1TnTCre hearts.  
To confirm that the epicardium is unaffected in Rac1TnTCre hearts, 
immunostaining using an anti-WT1 antibody marker of epicardial cells was 
carried out. At E11.5 the epicardium has completely enveloped the 
myocardium, this can be seen in both control and Rac1TnTCre hearts (arrows 
point to WT1-postive epicardial cells in Figure 57). 
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Figure 57: Epicardium forms normally in Rac1TnTCre hearts.  
Immunostaining using an anti-WT1 antibody marker of epicardial cells shows 
the epicardium is formed by E11.5 in both control (A-D’) and Rac1TnTCre hearts 
(E-H’) (n=3) (arrows point to WT1-postive epicardial cells). 
 
To summarise, deletion of Rac1 from all myocardial cells during development 
results in severe and lethal myocardial and OFT defects during embryonic 
development. This suggests that Rac1 is crucial in the development of the 
myocardial wall and in the alignment of the OFT. Further analysis of the OFT 
and ventricular cardiomyocytes in Rac1TnTCre and Rac1Gata5Cre will help elucidate 
the specific role of Rac1 in these tissues during cardiac development in 
Chapters 4 and 5 respectively.  
3.4 Discussion  
This chapter aimed to firstly confirm expression of Rac1 in the developing heart 
and secondly to dissect its role within the development of the myocardium. 
Preliminary data suggested that deleting Rac1 from the epicardium and 
myocardium, using Gata5-Cre, resulted in defects within the myocardial wall 
(personal communication Dr Helen Phillips). Therefore, the aim was to 
characterise these defects in detail and dissect the role of Rac1 in the 
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epicardium and myocardium during myocardial development, using additional 
Cre lines.  
3.4.1 Rac1 expression  
In this chapter Rac1 expression was confirmed within the developing embryonic 
heart at both the mRNA transcript level and protein level and this is consistent 
with previous studies (Wang and Zheng, 2007). It was shown through slide in 
situ hybridisation that Rac1 mRNA is expressed in the myocardium and 
epicardium as well as being strongly expressed in the endocardium. 
Confirmation of these in situ hybridisation results at the protein level was tried 
through immunostaining, however non-specificity of the Rac1 antibodies tested 
within the heart meant this was not possible. Several alternative 
immunostaining techniques were tried but none of the three Rac1 antibodies 
tested gave specific staining for Rac1. Rac1 is known to be expressed in the 
heart and previous reported expression of Rac1 in the heart shows Rac1 
antibody staining at the cell membrane of cardiomyocytes (Boczonadi et al., 
2014b). The three antibodies tested all gave different staining patterns, one was 
the same as the secondary antibody only control showing specific expression 
within the heart. This may be attributed to the nature of myocardial tissue which 
is particularly susceptible to non-specific binding of antibodies. The other two 
gave ubiqutous expression which was unchanged in Rac1 deleted cells, i.e 
cardiomyocytes in Rac1TnTCre sections.  
3.4.2 Role of Rac1 in cardiac development 
Using Cre-LoxP technology it was demonstrated that Rac1 can be deleted 
within specific cell types during cardiac development. This tool has allowed 
investigation of the role of Rac1 in the epicardium and/or myocardium, and 
consequently it was shown that Rac1 is required in myocardial cells for normal 
cardiac development. Combined deletion of Rac1 in epicardial cells and 
myocardial cells, using Gata5-Cre, resulted in lethal myocardial and OFT 
defects. Dissection of the Rac1Gata5-Cre phenotype using epicardial and 
myocardial specific Cre lines revealed that Rac1 is critical in myocardial cells 
but may not be required in epicardial cells for normal myocardial thickening and 
subsequent OFT alignment during embryonic development.  
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3.4.2.1 Rac1 in the ventral body wall  
Extra-cardiac defects were observed in Rac1Gata5Cre mutants including non-
closure of the ribs and an open ventral body wall. Both Rac1 and Gata5-Cre are 
expressed in the developing ventral body wall mesenchyme and Rac1Gata5Cre 
embryos have a thin body wall from E12.5. This data suggests that Rac1 is 
deleted from the body wall at an early stage in embryonic development and has 
a role in the thickening of the body wall mesenchyme. Ventral body wall defects 
have been observed in other Gata5-Cre mutants. For example, Alk5;Gata5Cre  
mutants have a body wall closure defect with extrusion of visceral organs 
through the ventral body wall (Sridurongrit et al., 2008). Alk5 is one of the co-
receptors for TGF-β signalling and this signalling pathway is known to be 
involved in regulation of numerous cellular processes. Additionally, secretion of 
Wnt ligands from the developing ventral body wall mesenchyme play a critical 
role in fusion of the sternum and closure of the secondary body wall (Snowball 
et al., 2015). Since these developmental processes are affected in Rac1Gata5Cre 
mutants, Rac1 deletion may disrupt TGF-β or Wnt signalling in the ventral body 
wall mesenchyme. Rac1 is downstream of non-canonical Wnt signalling and is 
also linked with canonical Wnt signalling. Alternatively, cadmium exposure 
induces ventral body wall defects in the chick and is associated with an 
increase in Rac1 causing dissociation of cadherin-mediated AJs (Doi et al., 
2011). Therefore, deregulated AJ in Rac1 deficient mesenchymal cells 
represents a potential cause of the ventral body wall defects in Rac1Gata5Cre 
embryos. The primary cause of the body wall defects in Rac1Gata5Cre embryos 
was not the focus of this thesis, however determining the role of Rac1 in 
cardiomyocytes during development may help elucidate its role in body wall 
development.  
3.4.2.2 Rac1 in the epicardium 
Rac1 is expressed in migrating cells and is required for the formation of the 
lamelipodia and filopodia that are necessary for cell movement (Duquette and 
Lamarche-Vane, 2014). Thus it was surprising that deletion of Rac1 in the 
epicardium, using WT1-CreERT2, did not result in any significant defects in 
epicardial cell migration. In normal development, epicardial cells form an 
uninterrupted epicardial layer over the surface of the myocardium and EPDCs 
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migrate into the compact layer. The Rac1 deficient epicardial cells in Rac1WT1-
CreERT2 hearts were not significantly reduced in number or in average compact 
myocardial migration distance, however additional ages would be useful in 
drawing conclusions from this result. Additionally, epicardium explants and 
epicardial cell migration assays could be used to confirm that the loss of Rac1 
does not affect epicardial cell migration. These results may suggest that 
epicardial Rac1 is not required in epicardial cells for the formation of the 
epicardium, epicardial cell migration or for the normal thickening of the compact 
layer during early heart development. However, some defects seen in 
Rac1Gata5Cre hearts are suggestive of an epicardial phenotype, particularly the 
epicardial blisters consisting of a detached epicardial cell layer filled with blood, 
and an uneven epicardial surface. Since no significant defects were observed in 
the epicardial specific Rac1 knock-out, it may suggest that the epicardial 
phenotype observed in Rac1Gata5Cre is secondary to the myocardial phenotype, 
or alternatively that the efficiency of Rac1 knock-out is reduced in WT1-
CreERT2 compared to Gata5-Cre. This cannot be determined from the work in 
this thesis since Rac1 knock-out was only validated in the TnT-Cre model.  
Additionally, Rac1 may be required for the later migration and differentiation of 
epicardial cells and development of the myocardium. This would be similar to 
the role of Rac1 in NCC’s where no migration defect was observed, however, 
differentiation defects were apparent. EPDCs migrate into the compact 
myocardium and differentiate into smooth muscle cells and endothelial cells of 
the coronary vessels, as well as fibroblasts (Mikawa and Gourdie, 1996; 
Dettman et al., 1998; Perez-Pomares et al., 2002). Defective EPDC 
differentiation is known to affect coronary vasculature development and 
therefore may possibly lead to defective cardiovascular development during 
later embryonic and postnatal developmental stages (Rhee et al., 2009). 
However, in the context of this thesis, Rac1 in epicardial cells is not required for 
the normal maturation of the ventricular myocardium or OFT alignment.  
3.4.2.3 Rac1 in the myocardium 
The phenotype observed in the different Cre line crosses suggests that Rac1 is 
required in the myocardium for the normal maturation of the ventricles. The 
cellular and molecular mechanism by which cardiomyocyte specific Rac1 
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deficiency leads to OFT and myocardial defects are discussed in Chapter 4 and 
Chapter 5, respectively. The role of Rac1 in other cell types suggests that Rac1 
could be regulating many processes during development such as cell 
proliferation and/or survival, cell adhesion, cell polarity and cytoskeletal 
arrangement.  
Previous work suggests that Rac1 is required for normal polarity in cardiac 
progenitors (Abu-Issa, 2014). Nkx2.5-Cre specific deletion of Rac1 results in 
heart failure at E12.5-E13.5 due to thin disorganised myocardial walls and OFT 
alignment defects similar to Rac1TnTCre and Rac1Gata5Cre mutants. Nkx2-5-Cre 
expressing progenitors are shown to primarily give rise to the cardiomyocyte 
lineage, therefore, it is not surprising that our Rac1TnTCre hearts closely model 
the Nkx2.5-Cre phenotype. However, there is additional but infrequent 
contribution to the endothelial lineage (Moses et al., 2001; Stanley et al., 2002) 
and Nkx2.5-Cre deletes Rac1 from early cardiac progenitors. Additionally, Rac1 
is thought to be required for polarity in SHF progenitors (Leung et al., 2014). 
Rac1Mef2Cre embryos exhibited ventricular and atrial septal defects, a thinner RV 
myocardium, and a bifid cardiac apex. Markers of the SHF include Islet1 and 
Mef2c and hence Islet1-Cre and Mef2c-Cre are commonly used for targeted 
SHF gene deletion. Islet1-Cre progenitors were found to contribute to SHF 
cardiomyocytes as well as SMCs, and endothelial cells (Cai et al., 2003; Moretti 
et al., 2006; Yang et al., 2006; Sun et al., 2007). Mef2c-Cre progenitors 
represent a more restricted population than Islet1-Cre progenitors, but also 
contribute to SHF cardiomyocytes, SMCs and ECs. Specifically, Mef2c-Cre 
progenitors also contribute to the endocardial cells of the RV, the smooth 
muscle of the pulmonary trunk and the endothelium of the OFT (Verzi et al., 
2005). Similar to Rac1Mef2Cre hearts, our Rac1TnTCre mutants display thin 
myocardial walls and VSD. Taking this into consideration, our Rac1TnTCre model 
is more appropriate for investigating the role of Rac1 in cardiomyocytes as it 
specifically targets cardiomyocytes during myocardial development and is not 
affected by the deletion of Rac1 in additional cell types. 
Therefore, despite the investigations discussed above, the role of Rac1 in early 
myocardial development remains unclear. Both Abu Issa and Leung and 
colleagues use conditional deletions of Rac1 which include multiple cell types, 
leading to difficulties separating possible differential roles of Rac1 in specific cell 
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types. Additionally, neither group have investigated the role of Rac1 in the 
formation of the trabeculae and subsequent development of the myocardium. 
Therefore the aim was to investigate the role of Rac1 specifically in the 
cardiomyocytes during myocardial trabeculation and thickening.  
Our Rac1Mlc2vCre hearts did not display any major myocardial defects. Mlc2v-Cre 
is expressed in a subpopulation of ventricle cardiomyocytes, often surrounded 
by unaffected cardiomyocytes. These findings suggest that interactions 
between cardiomyocytes and/or other cell types are important for myocardial 
development and can be compensated for by the majority of unaffected 
cardiomyocytes in Rac1Mlc2vCre hearts, compared to severe defects when Rac1 
is deleted from all cardiomyocytes. The observations of subtle myocardial 
defects in areas highly populated by Cre-positive derived cardiomyocytes 
supports this hypothesis. However, since the effciency of the Cre recombination 
in the Rac1Mlc2vCre cross was not assessed, it can not be directly compared to 
that of the Rac1TnTCre model.  
Our Rac1TnTCre model allows analysis of a more restricted population of 
cardiomyocytes during ventricular development compared to published 
Rac1Nkx2.5Cre and Rac1Mef2cCre mutants and also our Rac1Gata5Cre mutants.  
Therefore, further analysis of Rac1 function in cardiomyocytes descibed in this 
thesis was carried out in Rac1TnTCre hearts and occasionally complemented by 
analysis of Rac1Gata5Cre cardiomyocytes.  
Both Rac1TnTCre and Rac1Gata5Cre mutants display an apparent reduction in 
ventricular cardiomyocytes and disrupted cardiomyocyte morphology. Therefore, 
cardiomyocyte cell cycle and polarity were primarily investigated in mutant 
hearts, to determine if similar mechanisms were occurring to that which have 
been reported in the alternative Rac1 mutant models. These are discussed in 
Chapters 4 and 5 in relation to the OFT defects and myocardial defects, 
respectively.  
3.4.3 Conclusions 
In conclusion, in this chapter expression of Rac1 in the developing heart was 
confirmed and deletion of Rac1 within epicardial and myocardial populations 
using Cre-LoxP technology was validated. Using various Cre lines it was 
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determined that Rac1 is crucial within the developing myocardium for normal 
maturation of the ventricles and for correct OFT alignment.  
164 
 
Chapter 4. Outflow tract alignment defects in Rac1 mutants  
4.1 Introduction  
4.1.1 Overview of OFT development 
The cardiac OFT forms at the arterial pole of the heart and connects the 
embryonic ventricles to the aortic sac. During heart looping, myocardial cells are 
added to the arterial pole from the SHF progenitor population in the pharyngeal 
mesoderm (Kelly and Buckingham, 2002; Cai et al., 2003; Buckingham et al., 
2005). The OFT undergoes remodeling, consisting of OFT rotation, septation 
into the aorta and the pulmonary trunk and subsequent alignment of the two 
vessels with left and right ventricles, respectively. Deployment of SHF cells and 
cardiac NCC and subsequent remodeling of the OFT are critical for correct 
vessel formation and alignment and are regulated by various signalling 
pathways.  
4.1.2 OFT formation 
The OFT elongates by addition of SHF progenitor cells from the pharyngeal 
mesoderm to the myocardial and endocardial layers of the distal OFT (Kelly and 
Buckingham, 2002; Cai et al., 2003; Buckingham et al., 2005). The SHF cells 
migrate together forming an epithelial-like sheet. SHF cells remain in their 
precursor state for a longer duration, with a differentiation delay and higher level 
of proliferation, compared to FHF cells. Additionally, SHF cells have prolonged 
expression of Islet1 whereas Islet1 is expressed only transiently in the FHF (Cai 
et al., 2003). The processes regulating remodeling of the OFT are critical for 
correct OFT septation and alignment.  
4.1.3 OFT remodelling 
The OFT is septated into the base of the ascending aorta and base of the 
pulmonary trunk while both outflow vessels remain associated with the RV. OFT 
septation is accompanied by retraction and rotation of the truncal myocardium 
in an anticlockwise direction, resulting in alignment of the aorta with the LV and 
pulmonary trunk with the RV (Bajolle et al., 2006). The septation process is 
completed by convergence of the OFT septum with AV and ventricular septa, 
separating the systemic and pulmonary circulation. The movement of the aorta 
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behind the pulmonary trunk, between the AV  valves during OFT alignment and 
septation is known as ‘wedging’, and without ‘wedging’ the aorta overrides the 
ventricular septum. As the OFT cushions fuse, a process of invasive 
myocardialisation leads to muscularisation of the OFT cushions and produces 
smooth muscular walls at the base of the pulmonary trunk and ascending aorta 
(van den Hoff et al., 2001; Sugishita et al., 2004; Waldo et al., 2005b; Rana et 
al., 2007).   
4.1.4 Cell polarity in the OFT  
Cell polarity regulates both collective and individual cell movements during 
embryonic development (Munoz-Soriano et al., 2012). Epithelial cells exhibit 
apical-basolateral polarity and PCP, both of which are required for normal 
embryonic development. Cardiomyocytes are not an epithelial cell, however 
they display features of epithelial cell polarity, including PCP signalling and 
apical-basal polarity (ABP). Adult cardiomyocytes are highly polarised with cell-
cell junctions localised at ICD with attachment to the ECM on their lateral 
surface. The role of the two types of polarity in cardiomyocytes during 
development has been investigated but requires further studies.  
4.1.5 Apical basal polarity in the OFT  
Like epithelial cells, cardiomyocytes display ABP. The apical side is at the 
luminal side of the cell. The basal side of the cell is attached to the basement 
membrane and the lateral side of the cell is where it is attached to adjoining 
cells. The apical, lateral and basal sides of the cell are regulated by the 
presence of AJ and TJ (Kaplan et al., 2009) (Figure 14). MTOC are polarised 
cell organelles and are apically expressed (Magdalena et al., 2003) (Figure 14). 
ECM proteins such as laminin are present at the basal side of the cell in the 
basal lamina of the basement membrane and are involved in adhesion and cell 
migration (Timpl et al., 1979) (Figure 14).    
4.1.6 PCP signalling in the OFT  
Disruptions in PCP signalling components can lead to OFT defects (Murdoch et 
al., 2003; Phillips et al., 2005; Henderson et al., 2006; Phillips et al., 2007; 
Phillips et al., 2008; Gibbs et al., 2016). Polarisation and organisation of 
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cardiomyocytes in the outflow myocardium is disrupted in both Scrib and Vangl2 
mutants. 
4.1.7 Conotruncal congenital heart defects  
Coordinated migration, proliferation and differentiation of multiple cell lineages 
is required for correct OFT morphogenesis. Disruption in either SHF or NCC cell 
populations contributes to a spectrum of OFT defects in humans and animal 
developmental models (Yelbuz et al., 2002; Abu-Issa and Kirby, 2007; 
Ramsbottom et al., 2014).  Myocardial and endocardial populations have also 
been shown to be important during OFT rotation and alignment (Bamforth et al., 
2001; Bajolle et al., 2006; Zhang et al., 2009), as well as cellular processes 
essential for remodeling such as programmed cell death and myocardialisation 
(Bartram et al., 2001; Watanabe et al., 2001).  
4.2 Aims of Chapter 4  
As identified in Chapter 3, myocardial deletion of Rac1 during embryonic 
development results in OFT defects including DORV and OA with VSD. These 
phenotype data suggests that Rac1 plays an important role within the 
development of the myocardium, which is critical for normal ventricular 
septation and alignment of the OFT. The aim of this chapter was therefore to 
dissect the cellular mechanism which is disrupted in the absence of Rac1, 
during the formation and remodelling of the OFT.  
It can be hypothesised that defective OFT development and/or OFT remodelling 
causes the DORV/OA phenotype observed in both the Rac1Gata5Cre and 
Rac1TnTCre embryos. The aim was, therefore, to investigate each stage of OFT 
development to identify the primary defect in Rac1 myocardial mutant hearts, 
focussing on Rac1TnTCre mutants.  
Firstly, the expression of Gata5-Cre and TnT-Cre will be examined to define the 
boundary of affected cardiomyocytes within the OFT myocardium. Secondly, 
early development of the OFT will be studied in Rac1TnTCre heart, including 
addition of SHF cells, myocardial cell proliferation and cell polarity. Thirdly, OFT 
remodelling will be analysed, looking at OFT myocardialisation and wedging of 
the aorta in Rac1TnTCre hearts.  
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Rac1 is implicated in the regulation of cell proliferation and cell polarity in 
cardiomyocytes as well as additional cell types. Thus, it is additionally 
hypothesised that alterations in these cellular processes within the developing 
OFT myocardium is the primary defect in Rac1 myocardial mutant hearts. 
Therefore, the aim was to focus on analysis of cell proliferation and polarity in 
Rac1 deficient OFT cardiomyocytes, using the Rac1TnTCre model.   
4.3 Results  
Rac1 is expressed in the developing OFT myocardium (Figure 38) and 
myocardial deletion of Rac1, as well as published SHF and cardiac progenitor 
deletion of Rac1, has been shown to result in OFT defects, suggesting a role of 
Rac1 in OFT formation and/or remodelling.  
4.3.1 Early OFT formation and cellular morphology in Rac1TnTCre mutant 
hearts  
The key processes in OFT formation were examined in Rac1TnTCre embryos with 
an aim to ascertain the primary defect causing the observed DORV/OA 
phenotype.  
4.3.1.1 Addition of SHF progenitors and OFT lengthening  
The OFT elongates by addition of SHF progenitor cells from the pharyngeal 
mesoderm to the myocardium of the distal OFT. To assess this process in the 
Rac1TnTCre embryos, analysis of SHF progenitor addition and also OFT length 
was carried out. 
To determine if addition of SHF progenitor cells occurs normally in the 
Rac1TnTCre embryos, immunostaining for a SHF specific marker, Islet1, was 
carried out on E10.5 sections. At E10.5, the OFT is undergoing elongation by 
addition of SHF cells at the arterial pole. In controls, Islet1 expression appeared 
strong in the nucleus of distal OFT cells (arrows in Figure 58) and was 
decreased in a gradient towards the ventricular myocardium (Figure 58A-A’’). 
No expression was observed in ventricular cardiomyocytes (arrow heads). The 
Rac1TnTCre hearts showed comparable expression pattern of Islet1 (n=3) (Figure 
58B-B’’). From these results, it was concluded that SHF progenitors correctly 
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migrate from the pharyngeal mesoderm and contribute to the arterial pole of the 
OFT in Rac1TnTCre hearts.   
To analyse OFT length, E10.5 Rac1TnTCre embryos were dissected and the 
hearts and OFT were imaged (Figure 59A-B). OFT length was measured using 
ImageJ software in control (n=6, average somite number 33.8) and Rac1TnTCre 
(n=6, average somite number 34.1) embryos. There was no significant 
difference in OFT length between the control and Rac1TnTCre embryos (Figure 
59C).  
 
 
Figure 58: Islet1 expression in control and Rac1TnTCre OFT at E10.5. 
In controls, Islet1 expression appears strong in the nucleus of distal OFT cells 
(arrows in A’’ and A’’’) and is decreased in a gradient towards the ventricular 
myocardium. No Islet1 expression was observed in ventricular cardiomyocytes 
(arrow heads in A’’ and A’’’). The Rac1TnTCre hearts showed equivalent 
expression of Islet1 compared to controls (n=3). OFT; outflow tract. Scale bars; 
100µm. 
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Figure 59: Rac1TnTCre OFT length is normal at E10.5.  
E10.5 control and Rac1TnTCre embryos were dissected and the hearts and OFT 
were imaged (A-B). OFT length was measured using ImageJ software and 
found to be in equivalent in Rac1TnTCre embryos compared to controls (C) (n=6). 
Scale bars 1mm. Statistical analysis carried out using the unpaired t-test. 
 
4.3.1.2 OFT morphology  
The shape and angle of the OFT was also investigated using 3D Amira 
reconstructions of heart sections and HREM data.  
E9.5 (n=3) and E10.5 (n=3) hearts were reconstructed from section images 
using Amira software. These 3D models indicate that the overall morphology of 
the OFT is normal in Rac1TnTCre hearts at E9.5 (Figure 60A-B) and E10.5 
(Figure 60C-D).  
Additionally, E10.5 (n=6) and E11.5 (n=5) embryos were sent for HREM 
imaging. This allowed visualisation of the OFT in the form of tiff videos and 3D 
erosion models that were produced from the HREM images by Dr Tim Mohun, 
Francis Crick Institute. Figure 61 and Figure 62 show example stills of tiff videos 
and 3D erosion videos respectively. Analysis of the HREM data confirmed that 
the OFT morphology is normal in Rac1TnTCre embryos at E10.5 and E11.5. In 
addition, the OFT cushions appeared to have formed normally at E11.5 (Figure 
61E-J). At E11.5 the RV appears smaller in the HREM tiffs of the Rac1TnTCre 
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hearts (Figure 61H-J) compared to controls (Figure 61E-G), however this is due 
to the angle of the section and was not noted in the 3D reconstructed hearts 
(Figure 62).  
 
 
Figure 60: 3D Amira reconstructions of E9.5 and E10.5 control and 
Rac1TnTCre hearts.  
The size and shape of the OFT and ventricles is normal in Rac1TnTCre hearts 
compared to controls at E9.5 (B) and E10.5 (D) (n=3). OFT; outflow tract, A; 
atria, V; ventricle, RA; right atria, LA; left atria, RV; right ventricle and LV; left 
ventricle. Red; myocardium, yellow; PAA and green; pharynx. 
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Figure 61: HREM images of E10.5 and E11.5 control and Rac1TnTCre hearts. 
The size and shape of the OFT is normal in Rac1TnTCre hearts compared to 
controls at E10.5 (C-D) (n=6) and E11.5 (H-J) (n=5). In addition, the OFT 
cushions appeared to have formed normally at E11.5 (E-J). OFT; outflow tract, 
RA; right atria, RV; right ventricle and LV; left ventricle.  
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Figure 62: Cut-ventricle view of 3D reconstructions of E11.5 control and 
Rac1TnTCre hearts. 
The size and shape of the OFT is normal in Rac1TnTCre hearts (C-D) compared 
to controls E11.5 (A-B) (n=5). OFT; outflow tract, RA; right atria and RV; right 
ventricle. 
 
Taken together, Islet1 staining of SHF cells and 3D models of Rac1TnTCre hearts 
suggest that deficiency of Rac1 does not affect the addition of SHF cells to the 
developing OFT or the subsequent OFT lengthening.  
4.3.1.3 Rac1 deficient cardiomyocytes in the OFT ‘transition zone’  
As SHF progenitor cells are incorporated into the OFT myocardium, they 
progressively differentiate into cardiomyocytes. The region of the OFT where 
this differentiation process initiates is called the ‘transition zone’ (Ramsbottom 
et al., 2014). Both Gata5-Cre and TnT-Cre are expressed in differentiated 
cardiomyocytes and therefore are expected to be expressed in the developing 
OFT myocardium. Since Rac1Gata5Cre and Rac1TnTCre embryos display OFT 
defects similar to those seen in SHF mutants, it was hypothesised that Gata5-
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Cre and TnT-Cre may be more widely expressed in SHF cells outside of the 
differentiated myocardium. Consequently, investigation of the boundaries of 
Gata5-Cre and TnT-Cre expression in the OFT in relation to the transition zone 
was carried out.  
The transition zone can be marked by the gradual reduction in SHF-specific 
gene, Islet-1, expression and the initiation of myosin heavy chain (MF20) 
expression. As described earlier, at both E9.5 and E10.5, Islet-1 is strongly 
expressed in the nucleus of the distal OFT SHF cells. Islet1 expression is 
reduced as cells differentiate into cardiomyocytes, creating a gradient of Islet-1 
expression in the OFT (Figure 58). Islet-1 is not expressed in the ventricular 
myocardium. MF20 is a component of the actin-myosin cytoskeleton and is 
specifically expressed in the myocardium. At E9.5 and E10.5, MF20 expression 
is initiated in differentiated cardiomyocytes of the distal OFT and is strongly 
expressed in the ventricular myocardium. This myocardial expression is 
retained throughout development.  
E9.5 and E10.5 embryos EYFP;Gata5-Cre and EYFP;TnTCre embryos were 
dissected, embedded in paraffin and sectioned. Dual staining with anti-GFP, to 
label Cre expressing cells, and a cardiomyocyte marker, MF20 or SHF marker, 
Islet-1, was carried out.  
Dual staining with GFP and Islet1 or MF20 shows TnT-Cre becomes active as 
cardiomyocytes begin to differentiate. The expression of TnT-Cre, as marked by 
GFP, shows an overlapping expression pattern with MF20 in the OFT at E9.5 
and E10.5 (Figure 63, B and D). Additionally, as TnT-Cre expression is initiated, 
Islet1 expression is reduced in a gradient towards the ventricular myocardium 
(Figure 64, B and D).  
Similar to TnT-Cre, dual staining with GFP and MF20 shows Gata5-Cre is 
active in differentiated cardiomyocytes, since GFP shows an overlapping 
expression pattern with MF20 in the OFT at E9.5 and E10.5. However, Gata5-
Cre also appears to be active in the pharyngeal mesenchyme and SHF 
progenitors before they begin to differentiate into cardiomyocytes and prior to 
the onset of MF20 expression (arrows in Figure 63, A and C). The GFP 
expression overlaps with some SHF progenitors (arrows in Figure 64, A and C).  
These results highlight that Gata5-Cre is more widely expressed within the SHF 
compared to TnT-Cre. Therefore, the extent of Rac1 deletion within the 
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developing OFT varies between Rac1Gata5Cre and Rac1TnTCre mutants. However, 
despite this the OFT phenotype observed in the Rac1Gata5Cre and Rac1TnTCre is 
comparable. Therefore, it is suggested that the expression of Gata5-Cre within 
the SHF derived cells of the pharyngeal mesoderm does not contribute to the 
observed phenotype in Rac1Gata5Cre embryos. Consequently, it can be 
hypothesised that Rac1 deletion in differentiated cardiomyocytes is responsible 
for the OFT defects observed in Rac1Gata5Cre and Rac1TnTCre mutants. 
Gata5-Cre and TnT-Cre lineage tracing overlaps within the ‘transition zone’ 
(Figure 65) therefore, the aim was to assess the characteristics of the Rac1 
deficient cardiomyocytes in this region including cardiomyocyte differentiation, 
proliferation, polarity and adhesion.  
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Figure 63: Gata5-Cre and TnT-Cre expression in the OFT in relation to 
cardiomyocyte marker, MF20. 
Dual staining with GFP and MF20 shows TnT-Cre becomes active as 
cardiomyocytes begin to differentiate. The expression of TnT-Cre, as marked by 
GFP, shows an overlapping expression pattern with MF20 in the OFT at E9.5 
and E10.5 (B and D).  However, Gata5-Cre is also active in the pharyngeal 
mesenchyme and SHF progenitors before they begin to differentiate into 
cardiomyocytes and prior to the onset of MF20 expression (arrows in A and C). 
LV; left ventricle, RV; right ventricle, OFT; outflow tract. Scale bars; 100µm.  
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Figure 64: Gata5-Cre and TnT-Cre expression in the OFT in relation to SHF 
marker, Iselt1. 
Dual staining with GFP and Islet1 shows TnT-Cre becomes active as 
cardiomyocytes begin to differentiate. As TnT-Cre expression is initiated, Iselt1 
expression is reduced in a gradient towards the ventricular myocardium (B and 
D). However, Gata5-Cre is also active in the pharyngeal mesenchyme and SHF 
progenitors before they begin to differentiate into cardiomyocytes and prior to 
the onset of MF20 expression (arrows in A and C). The GFP expression 
overlaps with SHF progenitors (arrows in A and C). LV; left ventricle, RV; right 
ventricle, OFT; outflow tract Scale bars; 100µm. 
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Figure 65: Gata5-Cre and TnT-Cre expression in the OFT in relation to 
cardiomyocyte marker, MF20. 
Dual staining with GFP and MF20 shows TnT-Cre becomes active as 
cardiomyocytes begin to differentiate (D). The expression of TnT-Cre, as 
marked by GFP, shows an overlapping expression pattern with MF20 in the 
OFT at E10.5 (D). However, Gata5-Cre shows a wider expression pattern than 
MF20 expression, with additional expression in the pharyngeal mesoderm 
(arrows in A). Gata5-Cre is more widely expressed within SHF compared to 
TnT-Cre, Gata5-Cre and TnT-Cre expression overlaps within in the ‘transition 
zone’ (B and C compared to E and F).  
 
4.3.1.4 OFT cardiomyocyte differentiation  
As shown in Figure 64 and Figure 66, SHF cells begin to express Cre as they 
are undergoing cardiomyocyte differentiation, and it was hypothesised that this 
process could be altered in the absence of Rac1. To determine if cardiomyocyte 
differentiation occurs normally in the transition zone in Rac1TnTCre hearts, 
immunostaining with MF20 was carried out on E9.5 and E10.5 sections. In 
controls, MF20 expression appeared strong in the myocardial cells of the OFT. 
The Rac1TnTCre hearts had normal expression pattern of MF20 in the OFT 
compared to controls (E9.5 n=3, E10.5 n=3) (Figure 66). These results suggest 
that deficiency of Rac1 does not affect the differentiation of SHF cells into 
cardiomyocytes in the transition zone. 
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Figure 66: MF20 IHC on E9.5 and E10.5 control and Rac1TnTCre heart 
sections. 
Anti-MF20 IHC staining shows that cardiomyocyte differentiation within the OFT 
is normal in Rac1TnTCre hearts compared to controls at E9.5 (A-B) and E10.5 (C-
D) (n=4). LV; left ventricle, OFT; outflow tract. Scale A-B 200µm, A’-D’’ 50µm.  
 
4.3.1.5 OFT cardiomyocyte proliferation and apoptosis  
Since regulated cell proliferation and apoptosis is crucial for normal OFT 
development, it can be hypothesised that either increased cell death or reduced 
proliferation in the developing OFT following its initial formation could explain 
the OFT defects observed later in development. Therefore, cell death and 
proliferation was examined in the OFT myocardial cells in control and 
Rac1TnTCre hearts, by IF with apoptosis marker, caspase-3 and proliferation 
marker, BrdU.  
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To analyse proliferation in the developing OFT, BrdU incorporation was utilised 
to identify cells undergoing DNA synthesis. Administration of BrdU into pregnant 
females results in BrdU incorporation into all embryonic cells that are 
undergoing DNA synthesis (S phase) during the exposure time. E9.5 embryos 
were exposed to BrdU for 1 hour prior to dissection. Embryos were then 
dissected, processed and sectioned. Dual immunostaining staining using anti-
MF20 and anti-BrdU allowed identification of proliferating cardiomyocytes. Cell 
count analysis revealed proliferation levels in the OFT myocardium was 
relatively high, however was not altered in Rac1TnTCre hearts (n=5) (Figure 67B). 
Similarly, immunostaining with anti-caspase 3 was utilised to identify cells 
undergoing apoptosis. Dual staining with anti-caspase-3 and anti-MF20 was 
carried out on E9.5 sections of control and Rac1TnTCre hearts. Cell count 
analysis revealed the level of apoptosis in the developing OFT in controls was 
minimal and was unchanged in the Rac1TnTCre hearts (n=5) (Figure 67C). 
Furthermore, the number of cells in the OFT was equivalent between controls 
and Rac1TnTCreembryos (Figure 67A). Therefore, Rac1 deficiency does not 
affect OFT cardiomyocyte apoptosis or proliferation and hence there is no 
difference in cell number.   
It can be proposed from these results that SHF progenitors are undergoing 
progressive differentiation into cardiomyocytes and the subsequent 
cardiomyocytes are undergoing regulated proliferation and cell death.  
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Figure 67: Cell proliferation and apoptosis analysis of E9.5 control and 
Rac1TnTCre OFT sections.  
No significant differences were observed in the total cardiomyocyte cell number 
(A-B, G), BrdU detected cardiomyocyte proliferation (C-D, H) or caspase-3 
detected cardiomyocyte apoptosis (E-F, I) (n=6). Positive control for caspase-3 
immunofluorescent staining in OFT (J-K). OFT; outflow tract. Scale bar 100µm. 
Statistical analysis carried out using the unpaired t-test. Large SEM is seen in 
the caspase analysis, in both the control and Rac1TnTCre hearts. Statistical power 
calculations suggest the experiment may be underpowered.   
 
4.3.1.6 Outflow tract cardiomyocyte adhesion and polarity 
In addition to cardiomyocyte differentiation and proliferation, continued OFT 
development requires regulated cardiomyocyte adhesion and polarity 
(Ramsbottom et al., 2014). Therefore, some of the main markers of 
cardiomyocyte adhesion and polarity were investigated in Rac1TnTCre mutant 
hearts.  
E9.5 and E10.5 embryos were dissected, embedded in paraffin and sectioned. 
Immunostaining for AJ, desmosome, gap junction, and TJ markers were carried 
out in control and Rac1TnTCre hearts. Images of left and right sides of the OFT at 
the transition zone were taken as shown in Figure 68 and analysed for Figure 
69 to Figure 75.  
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Figure 68: Transition zone in OFT investigated for markers of 
cardiomyocyte adhesion and polarity.  
Example of N-cadherin staining in E9.5 control (A-A’) and Rac1TnTCre (B-B’) 
transverse sections. Images of left and right sides of the OFT at the transition 
zone were taken and analysed for Figure 69 to Figure 75. LV; left ventricle, 
OFT; outflow tract. Scale bar 100µm.  
 
AJ markers, β-catenin and cadherins were all restricted to the membrane as 
expected in both controls and Rac1TnTCre hearts (Figure 69 and Figure 70). E9.5 
expression of β-catenin (n=4) and N-cadherin E9.5 (n=4) are normal (Figure 69 
and Figure 70 respectively) as well as expression of E-cadherin at both E9.5 
(n=3) and E10.5 (n=3) (Figure 70). Desmosome marker, desmin, appeared to 
be normally expressed in the Rac1TnTCre OFT compared to controls at E9.5 
(n=4) (Figure 71). TJ have restricted expression at apical membranes, therefore 
are a useful indicator of cell polarity. TJ marker, PKC-ζ appeared to be normally 
expressed in the Rac1TnTCre OFT compared to controls at both E9.5 (n=3) and 
E10.5 (n=3) (Figure 72A-H). Additional TJ marker, ZO-1 also appeared normally 
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expressed at cell-cell junctions in E10.5 control and Rac1TnTCre OFT 
cardiomyocytes (n=3) (Figure 72I-L).  
 
 
Figure 69: β-catenin IF in OFT cardiomyocytes in control and Rac1TnTCre 
hearts. 
Adherens junction marker, β-catenin is restricted to the membrane as expected 
in both controls and Rac1TnTCre hearts at E9.5 (n=4). Scale bars; 50µm. 
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Figure 70: N-cadherin and E-cadherin IF in OFT cardiomyocytes in control 
and Rac1TnTCre hearts.  
Adherens junction marker, N-cadherin is restricted to the membrane as 
expected in both controls and Rac1TnTCre hearts at E9.5 (n=4) (A-G’). Adherens 
junction marker, E-cadherin expression is restricted to the membrane in both 
controls and Rac1TnTCre hearts at both E9.5 (n=3) and E10.5 (n=3) (H-K’). Scale 
bars; A-G’ 50µm, H-K’ 100µm. 
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Figure 71: Desmin IF in OFT cardiomyocytes in control and Rac1TnTCre 
hearts. 
Desmosome marker, Desmin, is normally expressed in the Rac1TnTCre OFT 
compared to controls at E9.5 (n=4). Scale bars; 50µm. 
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Figure 72: PKCk and ZO-1 IF in OFT cardiomyocytes in control and 
Rac1TnTCre hearts.  
Tight junction marker, PKC-z appeared to be normally expressed in the 
Rac1TnTCre OFT compared to controls at both E9.5 (n=3) and E10.5 (n=3) (A-H). 
Additional tight junction marker, ZO-1 also appeared normally expressed at cell-
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cell junctions in E10.5 control and Rac1TnTCre OFT cardiomyocytes (n=3) (I-L). 
Scale bars; 100µm. 
 
Microtubule protein, acetylated gamma (γ)-tubulin appeared normally expressed 
within the OFT cardiomyocytes in controls and Rac1TnTCre hearts (n=3) (Figure 
73).  
 
 
Figure 73: Gamma (γ)-tubulin IF in OFT cardiomyocytes in control and 
Rac1TnTCre hearts.  
Microtubule protein, acetylated gamma (γ)-tubulin appeared normally expressed 
within the OFT cardiomyocytes in controls and Rac1TnTCre hearts (n=3). Scale 
bars; 100µm. 
 
4.3.1.7 Extracellular matrix (ECM)  
ECM protein laminin is expressed in the basal lamina within the basement 
membrane in both controls and Rac1TnTCre hearts at E9.5 (n=3) (Figure 74). 
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Figure 74: Laminin IF in OFT cardiomyocytes in control and Rac1TnTCre 
hearts.  
ECM protein laminin is expressed in the basal lamina within the basement 
membrane in both controls and Rac1TnTCre hearts at E9.5 (n=3). Scale bars; 
100µm. 
 
4.3.1.8 Planar cell polarity signalling  
Scrib is a component of PCP signalling and is thought to interact with Rac1 
within embryonic cardiomyocytes (Boczonadi et al., 2014b). Scrib expression 
was restricted to cardiomyocyte cell membrane in controls and Rac1TnTCre 
hearts at both E9.5 (n=3) and E10.5 (n=3), suggesting deficiency of Rac1 does 
not affect Scrib membrane binding (Figure 75).  
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Figure 75: Scrib IF in OFT cardiomyocytes in control and Rac1TnTCre 
hearts. 
PCP signalling protein scrib was restricted to cardiomyocyte cell membrane in 
controls and Rac1TnTCre hearts at E9.5 (n=3) and E10.5 (n=3). Scale bars; A-H’ 
50µm, I-L’ 100µm. 
Immunostaining for indicators of cell polarisation such as cell-cell junction 
proteins, MTOCs and ECM proteins reveal that OFT cardiomyocyte adhesion 
and polarity is unaffected during early OFT formation in Rac1TnTCre hearts.  
4.3.2 OFT remodelling in Rac1TnTCre hearts 
OFT morphology in the early stages of heart development appears unaffected 
in Rac1TnTCre hearts, at both a tissue and cellular level. Therefore, it was 
hypothesised that the OFT alignment defects arise from abnormalities in later 
OFT remodelling.  
4.3.3.1 OFT rotation and wedging of the aorta  
Later in development, at around E12.5, the OFT septates into the aorta and 
pulmonary trunk. The OFT rotates and these vessels spiral around each other. 
‘Wedging’ then occurs where the aorta moves behind the pulmonary trunk and 
positions itself between the AV valves, to allow for OFT alignment into the 
correct ventricular chambers. This process is dependent on the retraction and 
rotation of the truncal myocardium (Watanabe et al., 2001) and without 
wedging, the aorta overrides the ventricular septum. 
To visualise OFT development in Rac1TnTCre embryos and define the 
developmental stage when the OFT defects arise, E11.5-E15.5 embryos were 
dissected with the pericardium/body wall removed to allow visualisation of the 
heart and OFT. Images were taken of control and Rac1TnTCre embryo hearts and 
OFTs and analysed (n=3 for each time point). The shape of both the heart and 
OFT appears normal at E11.5 and E12.5 (Figure 76A-D). However, by E13.5 
the heart appears to be ballooned in shape with the OFT at an aberrant angle 
(Figure 76E-F). This abnormality becomes more pronounced at E14.5 and 
E15.5 (Figure 76G-J’). Therefore, it was hypothesised that the DORV/OA defect 
in Rac1TnTCre and Rac1Gata5Cre embryos arises from a defect in the maturation 
and/or rotation of the OFT. To investigate this, the embryonic stage when the 
OFT defects become apparent will be determined and IF will be used to look at 
the process of OFT myocardialisation.  
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4.3.2.2 3D visualisation of Rac1Gata5Cre and Rac1TnTCre hearts  
Histology sections of mutant hearts revealed fully penetrant DORV/OA. To allow 
3D visualisation of the OFT defects in mutant hearts, Rac1Gata5Cre and 
Rac1TnTCre and stage matched control embryos were sent for magnetic 
resonance imaging (MRI). E15.5 Rac1Gata5Cre and Rac1TnTCre embryos were 
dissected, bled out and incubated with fixative and contrast agent for optimal 
Figure 76: Images of control 
and Rac1TnTCre dissected 
hearts during development. 
The shape of both the heart 
and OFT appears normal at 
E11.5 and E12.5 (A-D). 
However, by E13.5 the heart 
appears to be ballooned in 
shape with the OFT at an 
aberrant angle (E and F). This 
abnormality becomes more 
pronounced at E14.5 and 
E15.5 (G-J’). The heart 
appears bifid in shape with a 
prominent interventricular 
groove (arrows in F, H and J). 
Scale bars; A-J 500µm, I’-J’ 
1mm. 
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MRI imaging. Embryos were then embedded within agarose inside a MRI tube 
and sent to Dr Jurgen Schneider, University of Oxford, for imaging (Bamforth et 
al., 2012). 3D models were created from MRI image stacks using Amira 
software (Rac1Gata5Cre; n=15, controls; n=8, Rac1TnTCre; n=4, controls; n=4). MRI 
reconstructions highlight the abnormal shape of both Rac1Gata5Cre and 
Rac1TnTCre hearts, with severely dilated and rounded ventricular chambers. The 
reconstructions also show thin myocardial walls and OFT alignment defects 
(Figure 77).  
 
 
Figure 77: 3D reconstructions of E15.5 Rac1Gata5Cre and Rac1TnTCre hearts 
MRI data. 
Example images of 3D models created from MRI image stacks using Amira 
software. Orange; left ventricle, purple; right ventricle, red; aorta, blue; 
pulmonary trunk, white; trachea.  
 
4.3.2.3 OFT myocardialisation  
At E12, myocardialisation initiates and leads to a muscularisation of the base of 
the aorta and pulmonary trunk. To determine if myocardialisation of the OFT 
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cushions occurs normally in Rac1TnTCre embryos, staining for ECM and 
myocardial specific proteins was carried out on E11.5-E14.5 control and 
Rac1TnTCre wax sections (n=3). Alcian blue stains ECM in blue and was 
counterstained with eosin. IHC staining for myocardial markers, anti-α-SMA and 
anti-MF20, with DAB was counterstained with methyl green. Alcian blue staining 
confirms a high density of ECM within the endocardial and OFT cushions at 
E12.5 and E13.5 as expected (Figure 78A-D). By E14.5, the majority of ECM is 
confined to the AV and semilunar valves (Figure 78E-F). The composition of the 
endocardial and OFT cushions appears normal in Rac1TnTCre hearts from E12.5-
E14.5 (Figure 78A-F). Also, initial cushion formation is unaffected in Rac1TnTCre 
hearts, shown at E12.5. However, the positioning of the OFT cushions appears 
to be disrupted from E13.5 onwards. The complete fusion of the endocardial 
cushions, OFT and IVS is not seen in Rac1TnTCre hearts as in controls. It was 
hypothesised that this could be as a result of the shortened IVS and dilated 
ventricle chambers.  
Anti-α-SMA and anti-MF20 immunostaining highlights the myocardial cells 
migrating into the OFT cushions and confirms that the OFT cushions are 
undergoing myocardialisation in both controls and in Rac1TnTCre hearts (Figure 
79A-D, Figure 80A-D). By E14.5 the cushions have fully myocardialised (Figure 
80E-F). At E12.5 these invading myocardial cells are projecting inwards, into 
the OFT cushions, in the Rac1TnTCre hearts as in controls (Figure 81).   
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Figure 78: Alcian blue staining of E12.5, E13.5 and E14.5 control and 
Rac1TnTCre heart sections.  
Alcian blue staining confirms a high density of ECM within the endocardial and 
OFT cushions at E12.5 and E13.5 as expected (A-D) (n=4). By E14.5, the 
majority of ECM is confined to the AV and semilunar valves (E-F) (n=3). The 
composition of the endocardial and OFT cushions appears normal in Rac1TnTCre 
hearts from E12.5-E14.5 (A-F). Also, initial cushion formation is unaffected in 
Rac1TnTCre hearts, shown at E12.5. However, the positioning of the OFT 
cushions appears to be disrupted from E13.5 onwards. The complete fusion of 
the endocardial cushions, OFT and IVS is not seen in Rac1TnTCre hearts as in 
controls (C-D). LV; left ventricle, RV; right ventricle, Ao; aorta, PT;pulmonary 
trunk. Scale bars; A-D’’’ 200µm, E-F’’’ 500µm. 
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Figure 79: α-SMA IHC on E12.5 and E13.5 control and Rac1TnTCre hearts. 
Anti-α-SMA IHC staining highlights the myocardial cells migrating into the OFT 
cushions and confirms that the OFT cushions are undergoing myocardialisation 
in both controls and in Rac1TnTCre hearts (A-D) (n=4). LV; left ventricle, RV; right 
ventricle, Ao; aorta, PT;pulmonary trunk. Scale bars 200µm. 
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Figure 80: MF20 IHC on E12.5, E13.5 and E14.5 control and Rac1TnTCre 
hearts. 
Anti-MF20 IHC staining highlights the myocardial cells migrating into the OFT 
cushions and confirms that the OFT cushions are undergoing myocardialisation 
in both controls and in Rac1TnTCre hearts (A-D) (n=4). By E14.5 the cushions 
have fully myocardialised (E and F) (n=3). LV; left ventricle, RV; right ventricle, 
Ao; aorta, PT;pulmonary trunk. Scale bars; A-D’’ 200µm, E-F’’ 500µm. 
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Figure 81: MF20 IFon E12.5 control and Rac1TnTCre hearts sections. 
Anti-MF20 IHC staining shows the invading myocardial cells are projecting 
inwards, into the OFT cushions at E12.5, in the Rac1TnTCre hearts as in controls 
(white arrows) (n=4). Scale bars; 100µm. 
 
4.4 Discussion  
This chapter aimed to dissect the cellular mechanism(s) which is/are disrupted 
in the absence of Rac1 in cardiomyocytes, during the formation and/or 
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remodelling of the OFT. Myocardial deletion of Rac1 during embryonic 
development results in OFT defects including DORV and OA with VSD, 
suggesting that Rac1 plays an important role within the development of the 
myocardium, which is critical for normal ventricular septation and alignment of 
the OFT.   
In summary, it was shown that both Gata5-Cre and TnT-Cre are expressed in 
the distal OFT at the ‘transition zone’ at E9.5, however early OFT formation is 
unaffected in Rac1TnTCre hearts, with normal addition of SHF cells and OFT 
lengthening, cardiomyocyte differentiation and proliferation. Additionally, 
Rac1TnTCre cardiomyocytes in the OFT appear correctly polarised with regular 
cell-cell junctions. Interesting, despite the lack of OFT formation defects, later in 
cardiac development the OFT is positioned at an aberrant angle to the 
ventricles and leads to misalignment of the OFT vessels resulting in DORV/OA 
with VSD.  
4.4.1 Cre expression in the OFT  
Firstly the aim was to characterise the expression boundary of both Gata5-Cre 
and TnT-Cre within the OFT myocardium. Both Gata5-Cre and TnT-Cre are 
expressed in the transition zone between Islet-1-expressing SHF progenitors 
and MF20-expressing differentiated cardiomyocytes. TnT-Cre becomes active 
as cardiomyocytes begin to differentiate and shows an exclusive overlapping 
expression pattern with MF20 and coincides with reduced Islet-1 expression in 
the OFT myocardium. In addition to the ‘transition zone’, Gata5-Cre is also 
active in the pharyngeal mesenchyme, in Islet-1-expressing SHF progenitors 
before the onset of MF20 expression. However, despite the expanded 
expression of Gata5-Cre in the developing OFT compared to TnT-Cre, the OFT 
phenotype observed in the Rac1Gata5Cre and Rac1TnTCre is comparable. 
Therefore, it can be implied that the expression of Gata5-Cre within the SHF 
derived cells of the pharyngeal mesoderm does not contribute to the observed 
OFT phenotype in Rac1Gata5Cre embryos. Hence subsequent analysis focussed 
on the deletion of Rac1 in differentiated myocardium.  
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4.4.2 OFT development in Rac1TnTCre hearts 
Next each stage of OFT development in Rac1TnTCre hearts was characterised 
and investigation of the key regulatory cellular processes involved at each stage 
was carried out. It was hypothesised that defective OFT development and/or 
OFT remodelling causes the DORV/OA phenotype observed in both the 
Rac1Gata5Cre and Rac1TnTCre embryos.  
4.4.2.1 OFT formation 
Early development of the OFT was investigated in Rac1TnTCre hearts, including 
addition of SHF cells, myocardial cell differentiation, proliferation and cell 
polarity.  
Expectedly, SHF addition and OFT lengthening was normal in Rac1TnTCre 
hearts. Additionally, cardiomyocyte differentiation was unchanged.   
Rac1 is implicated in the regulation of cell proliferation and cell polarity in 
cardiomyocytes as well as additional cell types (Abu-Issa, 2014; Leung et al., 
2014). Hence it was surprising that these cellular processes appeared to be 
occurring as normal within the developing OFT myocardium in Rac1TnTCre 
hearts. The levels of cell proliferation and apoptosis was unchanged in 
Rac1TnTCre hearts, along with total cardiomyocyte number. Polarised cell-cell 
junctions including AJ, desmosomes and TJ were expressed and localised at 
the cell membrane in Rac1TnTCre hearts as in controls. Additional markers of cell 
polarity, MTOCs and ECM proteins, were also unaffected.  
The absence of early OFT defects is contrasting to observations in SHF Rac1 
mutants. Rac1;Mef2cCre mice develop a spectrum of OFT defects ranging from 
OA to severe TGA with additional incidence of aortic atresia and ARSA. In this 
study it was proposed that the OFT defects occur as a result of early defects in 
cell proliferation in the splanchnic mesoderm and reduced cardiac NCCs and 
SHF cell migration into the developing OFT, leading to a shorted OFT (Leung et 
al., 2015). Mef2c-Cre progenitors contribute to SHF cardiomyocytes, SMCs and 
ECs including endocardial cells of the RV, the smooth muscle of the pulmonary 
trunk and the endothelium of the OFT (Verzi et al., 2005). Gata5-Cre and TnT-
Cre expression is restricted to SHF-derived cardiomyocytes and Rac1 mutant 
hearts do not display early OFT defects. The phenotypic differences between 
these mutants highlights the importance of defining Cre expression within the 
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OFT and reveals that different regions of the OFT are required for OFT 
lengthening, OFT septation and OFT rotation and alignment.  
It is interesting that the OFT malformations observed in both Rac1TnTCre and 
Rac1Gata5Cre embryos later in development are similar to classic SHF mutants 
where all SHF derived cardiac cells are affected, suggesting that it is the 
cardiomyocytes of the OFT which are required for OFT rotation and remodelling 
and supports evidence that OFT malformations can have multiple causes and 
origins (Neeb et al., 2013).  
4.4.2.2 OFT remodelling 
Finally, OFT remodelling was then analysed, including OFT myocardialisation 
and wedging of the aorta, in Rac1TnTCre hearts.  
Visualisation of the OFT throughout embryonic development in Rac1TnTCre 
hearts revealed abnormalities arising from E13.5. The rotation and alignment of 
the OFT is disrupted in Rac1 myocardial mutants. OFT cushion formation and 
composition appears normal in Rac1TnTCre hearts. Additionally, subsequent 
myocardialisation of the cushions is unaffected with myocardial cells observed 
invading and replacing the ECM in the underlying cushions.  
The ventricle myocardium is severely thinned in both Rac1TnTCre and 
Rac1Gata5Cre hearts from E12.5. Interestingly, the OFT myocardium and IVS is 
relatively thick in both Rac1TnTCre and Rac1Gata5Cre mutants compared to control 
hearts. This suggests possible differences between ventricular cardiomyocytes 
and those in the OFT myocardium and IVS. In situ hybridisation for Rac1 did not 
reveal any differences in Rac1 expression between these areas, suggesting this 
difference does not occur as a result of increased or decreased expression of 
Rac1 but possibly due to differences in cardiomyocyte morphology and 
development in the IVS and OFT myocardium. This theory is supported by the 
fact that cardiomyocytes in these regions have a different origin. The IVS is 
known to form as the trabeculae coalesce during early cardiac development and 
regulatory pathways include the absence of Hand2 signalling in the IVS region  
(Togi et al., 2006). In addition, the OFT myocardium is involved in 
myocardialisation of the OFT cushions. This suggests that Rac1 is not required 
for the processes occurring in the IVS or OFT myocardium, however is crucial 
for development of the ventricular free wall myocardium.  
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It has been shown that correct alignment of the OFT requires rotation of the 
OFT myocardium. Failure of rotation of the OFT myocardial wall during OFT 
remodeling results in alignment defects, including TGA, DORV and OA 
(Bamforth et al., 2001; Watanabe et al., 2001; Bajolle et al., 2006).  
In Rac1TnTCre and Rac1Gata5Cre hearts, the combination of a thinned ventricle 
myocardium with a thick developed OFT myocardium could lead to defective 
OFT positioning later in development - without the support of the ventricle 
myocardium, the OFT myocardium cannot correctly rotate to facilitate OFT 
alignment.  
At E10.5 the shape and structure of the Rac1TnTCre heart is comparable to 
controls (Figure 82). By E13.5 the myocardium is significantly thinned and the 
ventricles are slightly ballooned in shape in Rac1TnTCre embryos, however OFT 
positioning is unaffected (Figure 82). By E15.5 the myocardium is severely 
thinned, and the heart is significantly dilated and ballooned in shape and 
significantly increased in size (Figure 82). The ballooned shape of the ventricles 
interrupts cardiac rotation and prevents AV septation, meaning the aorta 
remains associated with the RV (Figure 82).    
These results suggest Rac1 has a specific role in ventricle cardiomyocytes 
during embryonic development and the severe myocardial defects result in 
defective OFT positioning later in development.  
 
 
 
 
 
202 
 
 
Figure 82: The shape of the ventricles affects the alignment of the OFT at 
E15.5.   
At E10.5 the shape and structure of the Rac1TnTCre heart is comparable to 
controls. By E13.5 the myocardium is significantly thinned and the ventricles are 
slightly ballooned in shape in Rac1TnTCre embryos, however OFT positioning is 
unaffected. By E15.5 the myocardium is severely thinned and significantly 
ballooned in shape and significantly increased in size. The ballooned shape of 
the ventricles interrupts cardiac rotation and prevents atrioventricular septation, 
meaning the aorta remains associated with the RV.    
 
4.4.3 Conclusions  
In this chapter, it is concluded that myocardial deletion of Rac1 does not affect 
initial OFT formation but leads to defects in OFT remodelling and alignment. It is 
proposed that DORV/OA defects arise as a consequence of the severe 
abnormalities in ventricular chamber maturation and disrupted ventricular 
septation, rather than from direct defects in the OFT. These defects in the 
ventricle myocardium cause cardiac dilation with rounded ventricles and 
abnormal positioning of the aorta above the IVS. The underdeveloped IVS is not 
sufficient to complete ventricular septation; therefore, the aorta overrides the 
septum. This is an example of early myocardial defects causing later OFT 
defects without disruption of the OFT formation. 
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Chapter 5. Trabeculation and compaction is disrupted in Rac1 
mutants 
5.1 Introduction 
5.1.1 Ventricular development  
As discussed in Chapter 1 Section 1.6.1, the development of a mature 
thickened myocardial wall requires signalling and interaction between cells in all 
three cardiac layers, as well as interactions within the ECM surrounding the 
myocardium. 
After the formation of the linear heart tube, the myocardium undergoes 
trabeculation and compaction which requires proliferation and differentiation of 
cardiomyocytes (Sedmera et al., 2000; Harvey, 2002; Hirschy et al., 2006; 
Henderson and Chaudhry, 2011; Samsa et al., 2013) (Figure 11). Regulated 
cardiomyocyte differentiation, proliferation, polarity and cytoskeletal 
organisation is essential for correct ventricular wall development, and these can 
be influenced by interactions with the ECM and signalling to and from the 
endocardium. Rac1 is known to play a role in many of these key developmental 
processes involved in ventricular development.  
5.1.2 Cardiomyocyte differentiation   
Cardiomyocytes of both the FHF and SHF can be identified by expression of 
differentiation markers, including MF20, α-SMA and SM22α. As the ventricle 
wall undergoes maturation, both α-SMA and SM22α are increasingly restricted 
to the compact layer and become completely restricted by E15.5. At birth, both 
α-SMA and SM22α are absent from cardiomyocytes and are expressed 
exclusively within the smooth muscle cells of the coronary vessels. However, 
MF20 remains expressed in cardiomyocytes throughout development and 
postnatally. The trabeculae cardiomyocytes are more differentiated than 
compact myocytes; therefore can be distinguished by the markers previously 
described, α-SMA and SM22α, as well as additional markers such as ANF, 
BMP10 and PEG1. 
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5.1.3 Cardiomyocyte cytoskeleton  
The contractile sarcomeric cytoskeleton consists of thin actin filaments, which 
are attached to Z-discs, and thick myosin filaments interspersed between them 
(Figure 13). One of the main roles of Rac1 is regulation of the actin 
cytoskeleton. Rac1 controls cytoskeletal dynamics and is a key regulator of cell 
adhesion and migration, mediated by signalling through effector proteins such 
as p21 activated kinase (PAK), Extracellular signal-related kinase (ERK) and 
Mena . PAK1 is a serine threonine kinase which can be directly activated by 
Rac1 and plays a key role in cytoskeletal reorganisation and cell spreading 
downstream of Rac1 (Sussman et al., 2000; Parrini et al., 2002; ten Klooster et 
al., 2006; Sheehan et al., 2007). ERK/mitogen activated protein kinase (MAPK) 
activation has been shown to be both upsteam and downstream of Rac1 and is 
involved in cytoskeletal reorganization and hypertrophy in the heart (Clerk et al., 
2001; Yanazume et al., 2002; Kawamura et al., 2003; Ray et al., 2007; Elnakish 
et al., 2012). In cardiomyocytes, active Rac1 is associated with Mena (Ram et 
al., 2014). Mena, a member of the Ena/VASP family of actin regulatory proteins, 
increases actin filament assembly by its intrinsic polymerase and anti-capping 
activities. Mena is localised at the ICD and Z-disc, and co-localises with 
numerous cytoskeletal proteins in addition to Rac1 (Benz et al., 2013). Mena 
co-localises with CapZ at the Z-disc; CapZ acts as a barbed end capping 
protein for F-actin and is localised at the end of thin filaments in the Z-disc. At 
the ICD Mena co-localised with Cx-43, cadherin and vinculin. RNAi knockdown 
of Mena led to significantly increased Rac1 activity, as shown by increased 
GTP-bound Rac1 protein as well as altered localisation of Cx-43 at the ICD, 
resulting in faster intercellular communication (Ram et al., 2014). In mice 
overexpressing constitutively active Rac1, left ventricular Mena expression was 
increased  significantly, and this was associated with lateral redistribution of Cx-
43. Similar to Rac1, Mena is highly expressed during heart development but its 
expression is downregulated in the adult heart. However, Mena is upregulated 
in CVD, associated with heart failure, and is a critical regulator of cardiac 
function. Mice overexpressing Mena in the cardiomyocytes develop 
exacerbated hypertrophy, fibrosis and contractile dysfunction following TAC 
compared to controls (Belmonte et al., 2013). Mena KO mice have reduced 
cardiac performance and there are structural alterations at the ICD (Aguilar et 
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al., 2011). This suggests that Mena is a critical regulator of the ICD, in part via 
interactions with Rac1 (Ram et al., 2014). Cardiomyocytes expressing a mutant 
version of Mena remain in the compact myocardial layer, suggesting Mena is 
required for the migration of cardiomyocytes into the trabeculae layer (Toyofuku 
et al., 2004b).  
5.1.4 Cardiomyocyte polarity and adhesion 
Cardiomyocytes display features of epithelial cell polarity including PCP and 
ABP. The apical side and the basolateral side of the cell regulated by the 
presence of AJ and TJ (Kaplan et al., 2009). MTOC are polarised cell 
organelles and are apically expressed (Magdalena et al., 2003).  
Adult cardiomyocytes are highly polarised with cell-cell junctions localised at 
ICD with attachment to the ECM on their lateral surface (Borg et al., 1983). ICD 
allow connection and communication between cardiomyocytes and consist of 
desmosomes, AJ and gap junctions (Figure 14). TJ join epithelial cells near the 
apical membrane (Hartsock and Nelson, 2008) and the PAR-PKCζ complex co-
localizes with TJ protein ZO-1 and is required for the establishment of epithelial 
cell polarity (Ohno, 2001; Suzuki et al., 2001).  
Rac1 is implicated in both apicobasal polarity and PCP signalling pathways as a 
regulator of actin cytoskeleton, cell shape and morphology (Henderson and 
Chaudhry, 2011; Mack and Georgiou, 2014). The role of Rac1 in cell polarity 
has been demonstrated in convergent extension cellular movement, orientation 
of hair cells in the cochlea and anterior-posterior body axis specification during 
development (Bosco et al., 2009; Grimsley-Myers et al., 2009; Roszko et al., 
2009). 
PCP signalling has been shown to regulate cytoskeleton organisation and 
stimulate cardiogenesis through polymerization of actin (Afouda et al., 2008). 
Studies investigating the role of PCP proteins in ventricular development have 
shown expression within the developing myocardium and several PCP mutant 
mice display ventricular myocardial defects (Murdoch et al., 2003; Phillips et al., 
2005; Henderson et al., 2006; Phillips et al., 2007; Phillips et al., 2008). 
Polarisation and organisation of cardiomyocytes in the ventricular myocardium 
is disrupted in both Scrib and Vangl2 mutant mice (Murdoch et al., 2003; 
Phillips et al., 2005; Henderson et al., 2006; Phillips et al., 2007; Phillips et al., 
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2008) (Figure 20). Rac1 and fellow PCP signalling protein, Scrib, interact in 
cardiomyocytes and their combined role is linked with ventricular maturation 
(Boczonadi et al., 2014b). Scrib is a scaffolding protein that is essential for cell 
polarisation and orientation, and interacts with known Rac1 GEFs, betaPix and 
Git1 (Audebert et al., 2004; Osmani et al., 2006; Momboisse et al., 2009). Scrib 
controls recruitment of betaPix to the leading edge of migrating cells, to promote 
cell polarisation (Osmani et al., 2006). Global deletion of Scrib using PGK-Cre 
and cardiac specific deletion of Scrib using Nkx2.5-Cre resulted in myocardial 
defects, including a thinned myocardium, stunted trabeculae, VSD and poor 
formation of the IVS (Boczonadi et al., 2014b). The defects in the Scrib;Nkx2.5-
Cre embryos were attributed to an increase in cardiomyocyte apoptosis and a 
reduction in cell proliferation (Boczonadi et al., 2014b). Boczonadi and 
colleagues found that Scrib co-localises with Rac1 and betaPix at the cell 
membrane at E8.5, and that in Scrib deficient cardiomyocytes, Rac1 and 
betaPix are absent from the cell membrane. Rac1;Scrib;Nkx2.5-Cre double 
heterozygous embryos display DORV and VSD with disrupted cell adhesion as 
shown by mislocalised N-cadherin and absent Cx-43 (Boczonadi et al., 2014a). 
Additionally, Scrib is shown to be absent from the IVS in Rac1;Mef2c-Cre hearts 
(Leung et al., 2014). 
5.1.5 Signalling pathways in ventricular development   
As described in Chapter 1.6.6 there are many signalling pathways which have 
been shown to regulate the development of the ventricle wall, including Notch, 
VEGF and Semaphorin (Toyofuku et al., 2004b; Grego-Bessa et al., 2007; Nagy 
et al., 2010; Wu et al., 2012). 
5.1.5.1 VEGF signalling during ventricular development  
VEGF signalling is one of the major signalling pathways between the 
myocardium and endocardium important for both myocardial development and 
coronary vessel formation (Bruns et al., 2010; Jopling et al., 2011; Shalaby et 
al., 1995; Miquerol et al., 2000; Milgrom-Hoffman et al., 2011; Wu et al., 2012). 
Rac1 interacts with the VEGF signalling pathway in endothelial cells and 
promotes VEGF-induced endothelial cell migration by stimulating the formation 
of lamellipodia and membrane ruffles. Inhibiting Rac1 in human endothelial cells 
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led to reduced VEGFR-2 mRNA and protein expression (Meissner et al., 2009) 
and inhibition of VEGFR-2 signalling blocks VEGF-induced Rac1 activation 
(Garrett et al., 2007). VEGF signalling promotes Rac1 initiated lamellipodia 
formation and angiogenesis via Rac GEF Vav2 (Garrett et al., 2007).  
Therefore, Vav2 acts downstream of VEGF to activate Rac1 and VEGF 
signalling to VEGFR-2 is upstream of the Rac1-Vav2 interaction in endothelial 
cells (Garrett et al., 2007). Vav2 knockout adult mice develop cardiovascular 
defects, including an increase in collagen fibrosis, arterial pressure and heart 
rate, due to deregulation of the renin-angiotensin II system (Sauzeau et al., 
2007). Overexpression of either wild-type or constitutively active Vav2 results in 
prominent membrane ruffles and enhanced stress fibres in cells with elevated 
rates of cell migration and Rac1 activity (Liu and Burridge, 2000).  
VE-cadherin mediates adhesion between endothelial cells and is an important 
regulator of angiogenesis and blood vessel permeability. Rac1 controls VE-
cadherin adhesion by acting downstream of several growth factors, including 
Ang-1 and VEGF (Abe et al., 2000; Noren et al., 2000; Del Valle-Perez et al., 
2010; Jones et al., 2013; Liao et al., 2014).  
 
5.1.5.2 Semaphorin signalling during ventricular development  
Plexins are the first known transmembrane receptors that interact directly with 
Rho small GTPases. On binding to GTPases, the plexin receptor regulates the 
remodelling of the actin cytoskeleton and alters cell movement in response to 
semaphorin guidance cues (Tong et al., 2007). Mutations in the GTPase 
activation domain of PlexinD1 recapitulates the phenotype of PlexinD1 null mice 
(Worzfeld et al., 2014). PTA was also found in a patient with a mutation in the 
intracellular region of PlexinD1, which is predicted to perturb its membrane 
anchoring and catalytic GTPase-activation (Gay et al., 2011; Hota and Buck, 
2012; Ta-Shma et al., 2013). Rac1 is known to interact directly with the 
intracellular domain of PlexinA and PlexinB family members, to both regulate 
receptor activity and propagate downstream signalling processes (Vikis et al., 
2000; Vikis et al., 2002; Turner et al., 2004; Tong and Buck, 2005; Bell et al., 
2011). Additionally, over expression of Rac1 increases cell surface expression 
of Plexins and their interaction with semaphorins. Similarly, the amount of 
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Rac1.GTP is increased in the presence of PlexinA1 (Turner et al., 2004). 
Moreover, it has been proposed that Plexin sequesters Rac1 away from PAK, 
an effector protein that stimulates actin polymerization and forward movement 
of the cell front (Vikis et al., 2002). Plexins appear to have preferential binding 
affinity for certain GTPases and thus can modulate different downstream 
activities. Rho GTPase binding may also destabilize dimerization of Plexin 
effector domains (Tong et al., 2007). It appears that Rac1 plays a slightly 
different role in PlexinA signalling compared to PlexinB signalling (Vikis et al., 
2000; Vikis et al., 2002; Toyofuku et al., 2005; Tong et al., 2007). Early reports 
suggested that PlexinC1 and D1 do not bind Rho-GTPases in vitro.  
 
Figure 83: Active Rac1 interacts with numerous proteins to regulate 
several cellular processes.  
Rac1 directly interacts with Plexins and ERK in cytoskeleton rearrangement, as 
well as PAK in FA reorganisation and Mena in ICD organisation. As part of the 
PCP pathway, Rac1 interacts with Scrib to regulate cell polarity. Rac1 interacts 
with VEGFA, VE-cadherin, Vav2 and p120-catenin in the formation of 
lamellipodia during angiogenesis. Additionally, Rac1 stabilises β-catenin, 
increasing its translocation to the nucleus leading to gene transcription of Wnt 
targets.  
 
Rac1 is involved in various cellular processes, such as cell migration, polarity, 
survival, morphology, proliferation, differentiation, and regulation of the various 
phases of the cell cycle. Although the role of Rac1 in several cell types, 
particularly in endothelial cells and neurones, has been extensively 
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investigated, its role in the maturation and movement of cardiomyocytes is 
unknown. 
5.2 Aims of the Chapter  
As identified in Chapter 3, myocardial deletion of Rac1 during embryonic 
development results in myocardial defects including a thin myocardial wall and 
sparse trabeculae formation. This data suggests that Rac1 plays a crucial role 
in the development of the myocardium.   
The aim of this chapter is to dissect the cellular mechanism of Rac1 during the 
development of the ventricular myocardium. The maturation of the myocardium 
is a complex process involving regulated cardiomyocyte differentiation and the 
formation and subsequent remodelling of a trabeculated myocardial layer. Rac1 
plays a role in many of the cellular processes that are required during 
myocardial development including cell migration, proliferation and 
differentiation. In order to dissect the main function of Rac1 in embryonic 
cardiomyocytes, and to determine the primary cause of the cardiovascular 
defects in Rac1TnTCre hearts, first the hearts were characterised at the onset of 
myocardial defects and the examined the key regulatory cellular processes 
involved at this stage of embryonic development. The expression of potential 
Rac1 interactors during the onset of cardiac abnormalities was also analysed in 
Rac1TnTCre hearts. Additionally, how the deletion of Rac1 affected continued 
development and remodelling of ventricles during later stages of heart 
development was examined.  
It is hypothesised that disrupted cell polarity/cellular organisation leads to 
defective trabeculae formation and reduced compact myocardial proliferation. 
5.3 Results  
5.3.1 Trabeculation is disrupted in Rac1TnTCre hearts 
5.3.1.1 3D modelling of Rac1TnTCre hearts shows reduced trabeculae 
network from E10.5 
Both Rac1TnTCre and Rac1Gata5Cre hearts display abnormal, sparse trabeculae 
and defective myocardial thickening (Section 3.3.6.4). However, 2D images are 
a poor representation of the complex 3D trabeculae network that develops in 
the ventricles from E9.5 onwards. To analyse the abnormal trabeculae in the 
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Rac1TnTCre hearts in 3D, E10.5 and E11.5 embryos were sent to Dr Tim Mohun 
at the Francis Crick Institute for HREM imaging (Weninger et al., 2006; Captur 
et al., 2014). HREM imaging allows reconstruction of embryos and hearts using 
3D modelling software. The embryos were dehydrated in ethanol and sent for 
further processing and imaging by Dr Mohun. Tiff images, videos and 3D 
reconstructions were produced by Dr Mohun (Figure 84 and Figure 85).  
Analysis of the tiff images, videos and 3D reconstructions revealed distinct 
differences in the formation of the trabeculae in Rac1TnTCre hearts compared to 
controls, at E11.5 (n=6), with a subtle phenotype evident at E10.5 (n=5). At 
E10.5, initial trabeculae protrusions are regularly spaced on the inner layer of 
the ventricle free wall (Figure 84A-D) and form a luminal network, this can be 
seen clearly in the control 3D hearts (Figure 85A-B). In the Rac1TnTCre hearts, 
there appears to be slightly fewer trabeculae protrusions at E10.5 (Figure 84D-F 
and Figure 85C-D). At E11.5, the trabeculae continue to develop into a highly 
organised network and trabeculae coalesce to form the developing IVS. Again, 
this can be seen in the control E11.5 hearts (Figure 84G-L and Figure 85E-F). 
Whereas the trabeculae network is markedly reduced in the Rac1TnTCre hearts, 
with some areas of smooth compact myocardium completely lacking in 
trabeculae formation (arrows in Figure 84, J and K), including an 
underdeveloped IVS compared to controls (arrow heads in Figure 84G-L). In 
3D, the trabeculae network in Rac1TnTCre hearts remains simplified and 
disorganised with fewer, larger trabeculae present (Figure 85G-H). Again, areas 
of smooth compact myocardium completely lacking in trabeculae formation can 
be identified (arrows in Figure 85, G compared with H). 
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Figure 84: Trabeculae formation is visibly disrupted from E10.5 in 
Rac1TnTCre hearts. 
Example HREM images of E10.5 (n=6) and E11.5 (n=5) control and Rac1TnTCre 
hearts. At E10.5 the trabeculae appear reduced in number and disorganised (D-
F, compared to A-C). At E11.5, there appears to be fewer trabeculae 
protrusions in the Rac1TnTCre hearts with some areas of smooth compact 
myocardium completely lacking in trabeculae formation (arrows in J and K). The 
IVS appears underdeveloped in Rac1TnTCre hearts compared to controls by 
E11.5 (arrow heads in J and L). LV; left ventricle, RV; right ventricle. 
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Figure 85: Trabeculae network formation is visibly disrupted by E11.5 in 
Rac1TnTCre hearts.  
3D reconstructions of HREM images from E10.5 and E11.5 control and 
Rac1TnTCre embryos. At E10.5 in controls, initial trabeculae protrusions are 
regularly spaced on the inner layer of the ventricle free wall and form a luminal 
network (A-B). In the Rac1TnTCre hearts, there appears to be fewer and less 
organised trabeculae protrusions (C-D) (n=2). At E11.5, the trabeculae continue 
to develop into a highly organised network and trabeculae coalesce to form the 
developing IVS (E-F). Whereas the trabeculae network is markedly reduced in 
the Rac1TnTCre hearts, with some areas of smooth compact myocardium 
completely lacking in trabeculae formation compared to controls (arrows in G-H) 
(n=2). LV; left ventricle, RV; right ventricle. 
 
5.3.1.2 Angle of trabeculae formation is disrupted from E10.5 in Rac1TnTCre 
hearts 
As observed from HREM 3D models, ventricle free wall trabeculae protrusions 
typically develop perpendicular to the myocardial wall, forming a complex 
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myocardial network within the ventricular lumen. Analysis of trabeculae angle 
projections in E10.5 Rac1TnTCre control and mutant section images revealed that 
mutant trabeculae form at aberrant angles to the myocardial wall compared to 
controls. The data spread for the angles of trabeculae projections from the 
compact myocardium was significantly increased in Rac1TnTCre hearts compared 
to controls (n=5, Figure 86). In controls, the data spread was greater in the LV 
as compared to the RV, whereas it was comparable between left and right 
ventricle in Rac1TnTCre hearts (Figure 86, B compared to C). Chi squared 
statistical analysis revealed significant differences in the spread of trabeculae 
angles between controls and Rac1TnTCre hearts at 30°-39°, 40°-49°, 60°-69° and 
80°-89° (p<0.05).  
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Figure 86: Trabeculae formation angle is disrupted in Rac1TnTCre hearts at 
E10.5.  
Trabeculae projection angle measured from the compact myocardium in control 
and Rac1TnTCre E10.5 hearts (A and B) (n=5). Data separated into left and right 
ventricle (C and D, respectively). The data spread for the angles of trabeculae 
projections from the compact myocardium was significantly increased in 
Rac1TnTCre hearts compared to controls (n=5, A and B). In controls, the data 
spread was greater in the left ventricle as compared to the right ventricle, 
whereas it was comparable between left and right ventricle in Rac1TnTCre hearts 
(C compared to D). Schematic representation of the angles of trabeculae in 
control and Rac1TnTCre hearts (E). Statistical analysis carried out using the Chi-
squared test in SPSS. *P<0.05.   
 
5.3.1.3 Number of trabeculae reduced from E10.5 in Rac1TnTCre hearts 
To quantify the reduction in trabeculae, projections from the myocardium were 
counted in 10 sections per embryo using the E10.5 and E11.5 HREM data sets, 
and E9.5 H&E sections. The number of trabeculae was found to have a trend 
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for a reduction in Rac1TnTCre hearts compared to controls from E10.5, but not 
statistically significant (Figure 87A). From E12.5 the trabeculae begin to 
remodel and contribute to the IVS, papillary muscles and moderator band whilst 
the ventricular myocardium becomes thickened with fewer trabeculae. In the 
Rac1TnTCre hearts it appeared that the number of trabeculae remains high in the 
RV, while becoming markedly reduced in the LV during later stages of heart 
development, at E12.5-E17.5. To quantify this, trabeculae numbers were 
counted from H&E staining of E12.5, E15.5 and E17.5 embryos (Figure 87C). 
The total number of trabeculae is significantly higher in E15.5 Rac1TnTCre hearts 
compared to controls (Figure 87C). This suggests that the trabeculae in the RV 
do not undergo compaction as in controls, whereas the trabeculae in the LV 
possibly undergo abnormal compaction. These results highlight that the left and 
right ventricles may remodel in diverse ways during normal ventricular 
development and is investigated further in Chapter 5 Section 5.3.9. 
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Figure 87: Decreased number of ventricular trabeculae projections in 
Rac1TnTCre hearts from E10.5.  
Counts of ventricular trabeculae projections in E9.5-E17.5 control and 
Rac1TnTCre hearts (n=4). Counts are separated into right ventricle (RV), left 
ventricle (LV) and the combined total for each ages (TOTAL). The number of 
trabeculae was unchanged in the Rac1TnTCre hearts compared to controls at 
E9.5 (A), however a trend for a reduction in trabeculae was seen in the left 
ventricle from E10.5-E11.5, but this was not statistically significant (B).  The 
myocardium begins to compact at E15.5 in controls, as shown by a trend for a 
reduction in the number of trabeculae (C), this trend is not seen in the 
Rac1TnTCre hearts and conversely shows a significant increase in the total 
number of trabeculae at E15.5 (C). In the Rac1TnTCre hearts, the number of 
trabeculae remains high in the right ventricle, becoming markedly reduced in 
the left ventricle during later stages of heart development, at E17.5 (C). 
Statistical analysis carried out using a two-way ANOVA, *p<0.05.  
 
From the HREM data and trabeculae analysis it can be concluded that the 
development of the trabeculated myocardium is disrupted from E10.5 onwards, 
consisting of reduced formation and directionality of the trabeculae. The 
development and maturation of the ventricular myocardium is a complex and 
poorly defined process, involving regulated cardiomyocyte differentiation, 
proliferation and maturation. Each of these processes were investigated in 
Rac1TnTCre (and some Rac1Gata5Cre) hearts to determine the primary defect in 
myocardial development.  
5.3.2 Early cardiomyocyte markers are expressed in Rac1 deficient 
cardiomyocytes 
To investigate early cardiomyocyte differentiation in Rac1TnTCre embryos, 
immunostaining using antibodies against early cardiomyocyte markers was 
carried out. MF20 and SM22α markers are both expressed in differentiated 
cardiomyocytes in the early developing heart at E9.5 and E10.5. As shown in 
Figure 88, at E9.5 MF20 is uniformly expressed in the myocardial wall in 
Rac1TnTCre hearts as in controls (Figure 88A-F). Normal expression of MF20 is 
continued at E10.5 and additionally, SM22α is expressed as expected in the 
myocardial wall, developing trabeculae and IVS in Rac1TnTCre hearts (Figure 
88G-J). These results suggest that Rac1 is not required for the initial 
differentiation of cardiomyocytes during embryogenesis.  
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Figure 88: Normal expression of cardiomyocyte markers, MF20 and 
SM22α, in E9.5 and E10.5 Rac1TnTCre hearts.  
Immunostaining using anti-MF20 (A-H) and anti-SM22α (I-J) shows expression 
of these differentiated cardiomyocyte proteins in the myocardial layer of the 
heart in controls and Rac1TnTCre hearts (n=4). LV; left ventricle, RV; right 
ventricle. Scale bars; A-J 200µm, A’J’’ 100µm. 
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5.3.3 Cell cycle is not altered in E10.5 Rac1TnTCre hearts 
As previous analysis has shown, Rac1TnTCre mutant hearts have fewer 
trabeculae and a thinner myocardial wall, implying that cell proliferation or cell 
survival may be affected.  
Rac1 is known to play a role in cell cycle regulation and has been shown to 
delay entry into M phase (Moore et al., 1997; Mamidipudi et al., 2004). 
Therefore, to determine if cell cycle is affected in Rac1TnTCre hearts, analysis of 
key cell cycle genes and markers of proliferation was carried out by qPCR and 
IF,  respectively.  
5.3.3.1 Key cell cycle genes CIP/KIP group proteins; p21, p27 and p53 are 
unchanged in Rac1TnTCre hearts 
p21, p27 and p53 are CIP/KIP group proteins which are selectively expressed 
during different phases of the cell cycle (Ahuja et al., 2007). p21 prevents cells 
from entering the S-phase by blocking cyclin/CDK-complex activity, resulting in 
an accumulation of cells in G0/G1, altering cell morphology and differentiation, 
without triggering apoptosis. In addition, p21 mediates the p53-induced G1 cell 
cycle arrest resulting from DNA damage. p53 tumour-suppressor gene activity 
results in cell cycle arrest in G1 and initiation of DNA repair. If repair fails, p53 
induces Bax gene apoptosis. p27 regulates cell progression from the G1- to S-
phase by mediating G1 arrest through inhibiting cyclin/CDK-complex activities, 
in response to a variety of growth inhibitory cytokines including transformation 
growth factor. Overexpression of p27 leads to apoptotic cell death in all cell 
types (Wang et al., 1997).  
qPCR analysis of key cell cycle gene expression was carried out in E10.5 
hearts  as this time point is before the onset of myocardial defects (n=6). There 
was no change in expression of p21, p27 and p53 in E10.5 Rac1TnTCre hearts 
compared to controls (Figure 89).  
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Figure 89: Cell cycle gene p21, p27 and p53 have unchanged expression 
in E10.5 Rac1TnTCre whole hearts.  
qPCR analysis of cell cycle gene expression in E10.5 control and Rac1TnTCre 
whole hearts. p21, p27 and p53 no significant differences in expression in 
Rac1TnTCre hearts compared to controls (n=6). Expression was normalised to 
housekeeping gene, GAPDH. Statistical analysis carried out using the unpaired 
t-test. 
 
5.3.3.2 Cell proliferation is not significantly altered in Rac1TnTCre hearts 
To investigate proliferation in Rac1TnTCre compact and trabeculae 
cardiomyocytes, BrdU in utero injection combined with immunostaining of 
embryonic sections was carried out. Administration of BrdU in pregnant females 
results in BrdU incorporation into all embryonic cells that are undergoing DNA 
synthesis (S phase) during the exposure time. E9.5, E10.5, E11.5, E12.5 and 
E13.5 embryos were exposed to BrdU in utero for 1 hour before dissection. 
Embryos were then dissected, processed and sectioned. Dual 
immunofluorescence staining using anti-MF20 and anti-BrdU allowed 
identification of proliferating cardiomyocytes. Cell counts were carried out and 
the data is presented in Figure 90 and Figure 91. Cell counts were separated 
into compact layer and trabeculae layer cardiomyocytes and left and right 
ventricles were analysed separately, except at E9.5 when the whole ventricle 
was included due to small numbers of cells and lack of a clear boundary 
between ventricles. At E9.5 and E10.5 the number of cells in the compact layer 
and trabeculae layer is comparable between control and Rac1TnTCre hearts (n=5) 
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(Figure 90A-F). At E11.5 there is a reduction in trabeculae cardiomyocytes in 
the LV, as well as in IVS, with the RV unchanged (n=5) (Figure 90G-I). At E12.5 
there is a reduction in trabeculae and total cardiomyocytes in the LV, as well as 
the total cardiomycytes in the RV (Figure 90J-L). From E13.5 the first significant 
reduction in compact cardiomyocyte number is observed, as well as a decrease 
in total cell numbers in both the right and left ventricles (n=3) (Figure 90M-O). 
Additionally at E13.5, cell number is decreased in the trabeculae layer in the LV 
(n=3) (Figure 90M-O). This data suggests that the Rac1 deficient trabeculae 
cardiomyocytes in the left ventricle are either unable to survive or have a slower 
proliferation rate compared to control cells.  
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Figure 90: Cardiomyocyte cell number is reduced in Rac1TnTCre ventricles 
compared to controls in transverse heart sections.  
Immunostaining with anti-MF20 for cardiomyocytes (red) and DAPI nuclear 
stain (blue). Cells were counted in at least 3 sections per embryo and separated 
into left and right ventricle and IVS, and for the ventricle myocardium the counts 
were also separated into trabeculae, compact and total. At E9.5 and E10.5 the 
number of cells in the compact layer and trabeculae layer is comparable 
between control and Rac1TnTCre hearts (n=5) (A-F). At E11.5 there is a reduction 
in trabeculae cardiomyocytes in the LV, as well as in IVS, with the RV 
unchanged (n=5) (G-I). At E12.5 there is a reduction in trabeculae and total 
cardiomyocytes in the LV, as well as the total cardiomyocytes in the RV (J-L). 
From E13.5 the first significant reduction in compact cardiomyocyte number is 
observed, as well as a decrease in total cell numbers in both the right and left 
ventricles (n=3) (M-O). Additionally at E13.5, cell number is decreased in the 
trabeculae layer in the LV (n=3) (M-O). LV; left ventricle, RV; right ventricle, IVS; 
interventricular septum. Scale bars; 100µm. Statistical analysis carried out using 
a two-way ANOVA.  
 
Suprisingly, no significant differences were observed in the percentage of 
cardiomyocytes which had incorporated BrdU, therefore cells undergoing DNA 
synthesis during the 1 hour incubation period, at E9.5-E12.5 (Figure 91A-L, 
n=4). Unexpectedly at E13.5, there was an increase in the percentage of BrdU 
expressing LV trabeculae cardiomyocytes in Rac1TnTCre hearts, in comparison 
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with LV compact layer and trabeculae cardiomyocytes in control hearts (n=3, p-
0.0003). This may be occurring as a compensatory mechanism in response to 
the severely thinned myocardium and reduced contraction potential.  
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Figure 91: BrdU incoporation, as a marker of cell proliferation, is not 
altered in Rac1TnTCre ventricular cardiomyocytes compared to controls.  
Immunostaining with anti-BrdU for proliferating cells (green), anti-MF20 for 
cardiomyocytes (red) and DAPI nuclear stain (blue). Cells were counted in at 
least 3 sections per embryo and separated into left and right ventricle and IVS, 
and for the ventricle myocardium the counts were also separated into 
trabeculae, compact and total. No significant differences were observed in the 
percentage of cardiomyocytes that had incorporated BrdU at E9.5-E12.5 (A-L, 
n=5). Unexpectedly at E13.5, there was an increase in the percentage of BrdU 
expressing left ventricle compact layer and trabeculae cardiomyocytes in 
Rac1TnTCre hearts in comparison with left ventricle trabeculae cardiomyocytes in 
control hearts (n=3, p-0.0003) (M-O). LV; left ventricle, RV; right ventricle, IVS; 
interventricular septum. Scale bars; 100µm. Statistical analysis carried out using 
the two-way ANOVA. *P<0.05.  
 
Since cardiomyocyte cell number is reduced from E9.5 but no differences in 
BrdU incorporation were detected, it was hypothesised that Rac1 deficient 
cardiomyocytes may be undergoing DNA synthesis and incorporating BrdU 
without undergoing cytokinesis and cell division. Phospho-histone H3 (phHH3) 
immunostaining is an additional tool for analysing cell proliferation. phHH3 is 
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selectively expressed during the G2 and M phase of the cell cycle and thus 
represents a more selective window of cell proliferation during later stages of 
the cell cycle compared to BrdU incorporation. Dual immunostaining with anti-
phHH3 was carried out in E11.5, E12.5 and E13.5 embryos to address this 
hypothesis. Again, MF20 was used as a marker to identify cardiomyocytes. In 
Rac1TnTCre hearts, similar to BrdU incorporation analysis, there was no 
significant change in percentage expression of phHH3 in Rac1 deficient 
cardiomyocytes at E11.5 or E12.5 (n=3) (Figure 92).  
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Figure 92: phHH3 expression is unchanged in cardiomyocytes in 
Rac1TnTCre hearts compared to controls.  
Immunostaining with anti-phHH3 for proliferating cells (green), anti-MF20 for 
cardiomyocytes  (red) and DAPI nuclear stain (blue). Cells were counted in at 
least 3 sections per embryo and separated into left and right ventricle and IVS, 
and for the ventricle myocardium the counts were also separated into 
trabeculae, compact and total. In Rac1TnTCre hearts, similar to BrdU 
incorporation analysis, there was no significant change in percentage 
expression of phHH3 in Rac1 deficient cardiomyocytes at E11.5 or E12.5 (A-F) 
(n=3). Scale bars; 100µm. Statistical significance carried out using the two-way 
ANOVA.  
 
The combined data from BrdU and phHH3 proliferation analysis in Rac1TnTCre 
hearts shows no significant differences in the proliferation rate of 
cardiomyocytes during early cardiac development (E9.5-E13.5). It is possible 
that a small reduction in rate or a delay in proliferation may result in increasingly 
reduced cell numbers over the course of heart development. However, since 
there is no significant change in proliferation, it is likely that the cause of the 
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severe myocardial phenotype is another developmental process, such as cell 
apoptosis.  
5.3.3.3 Cell death is normal in Rac1TnTCre hearts 
To investigate if the reduction in trabeculae cell numbers was due to increased 
cell death in Rac1 deficient hearts, dual immunofluorescent staining with anti-
caspase 3 was carried out and again MF20 was used as a marker to identify 
cardiomyocytes in Rac1TnTCre hearts.   
Caspase 3 is activated by auto-proteolytic cleavage or cleavage by another 
caspase protease to initiate cellular apoptosis. During cardiac development, cell 
death is relatively rare but is required for some developmental processes, such 
as outflow tract remodelling (Watanabe et al., 1998; Watanabe et al., 2001). 
Other embryonic tissues such as the neural tube display relatively high levels of 
apoptosis and therefore were used as a positive control for anti-Caspase-3 
staining.  
In Rac1TnTCre hearts, levels of Caspase-3 positive cell death was low and not 
significantly changed compared to controls at E9.5 (n=5) (Figure 93A-C), E11.5 
(n=4, Figure 93, A and D-E) and E12.5 (n=4, Figure 93, A and F-I). These 
results show that Rac1 deficient cardiomyocytes are not undergoing abnormal 
apoptosis during the early stages of heart development. It is therefore proposed 
that the myocardial phenotype is not due to aberrant cardiomyocyte apoptosis.  
Combined results from phHH3, BrdU and Caspase-3 staining confirm that cell 
proliferation and apoptosis is unaffected in Rac1TnTCre hearts. These results are 
surprising since Rac1TnTCre hearts display a severely thinned myocardial wall 
and reduced trabeculae. However, from heart dissections, MRI 3D 
reconstructions and cross-sectional measurements it was noted that Rac1TnTCre 
hearts are dilated and larger compared to control hearts (Figure 94, C 
compared to B) (n=4). Therefore, as the cell number was counted and averaged 
in 3 transverse sections, this may not be representative of the whole heart. It 
was therefore hypothesised that Rac1TnTCre hearts may contain equivalent 
numbers of cardiomyocytes compared to control hearts but spread over a larger 
surface area, thus appears less in individual heart sections. To test this 
hypothesis, E15.5 hearts were dissociated, propidium iodide (PI) was added to 
label cell nuclei and YFP was used to identify cardiomyocytes. Control and 
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Rac1TnTCre hearts had comparable numbers of cardiomyocytes (n=4), however 
the SEM error bars suggest high variability between Rac1TnTCre hearts (Figure 
94A). Statistical power calculations suggest the experiment is underpowered.   
Due to time constraints further whole hearts cell counts were not possible in ths 
project but this is the focus of ongoing work and will be necessary to confirm 
equal cell numbers in Rac1TnTCre hearts. From this preliminary data, it is 
proposed that the decreased cell numbers counted from sections may not be 
representative of total numbers of cardiomyocytes within a whole heart and 
hence no differences were observed in proliferation, apoptosis or cell cycle 
gene expression.  
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Figure 93: Cell death is normal in Rac1TnTCre cardiomyocytes.  
Immunostaining with anti-caspase-3 to mark apoptosis (green), anti-MF20 for 
cardiomyocytes (red) and DAPI nuclear stain (blue). Cells were counted in 3 
sections per embryo and separated into trabeculae, compact and total 
cardiomyocytes. The level of Caspase-3 positive cell death was low and not 
significantly changed compared to controls at E9.5 (n=5, A-C), E11.5 (n=4, A, 
D-E) and E12.5 (n=4, A, F-I). Scale bars; 100µm.  Statistical analysis carried 
out using the two-way ANOVA.  
 
 
Figure 94: Cardiomyocyte number in control and Rac1TnTCre hearts.  
No significant difference in cell number was observed between E15.5 control 
and Rac1TnTCre hearts (A) (n=4). However the ventricles are ballooned and 
increased in size (C compared to B) (n=4). Statistical analysis carried out using 
the unpaired t-test. Large SEM is seen in the Rac1TnTCre hearts. Statistical 
power calculations suggest the experiment is underpowered.   
 
5.3.4 Cardiomyocyte maturation is altered in Rac1TnTCre hearts 
During myocardial development, cardiomyocytes undergo maturation to 
become elongated and contractile with fully formed cell-cell junctions. Several 
markers of cardiomyocyte maturation have been identified and investigated in 
previous studies, including specific markers of compact and trabeculae 
myocardium maturation. Immunostaining and semi-quantificative PCR analysis 
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was used to investigate some of these markers in Rac1TnTCre hearts and some 
Rac1Gata5Cre hearts.  
α-SMA is expressed in all myocardial and smooth muscle cells during early 
embryonic development, as demonstrated in Figure 88. However later in 
development, as the cardiomyocytes differentiate, they gradually switch off α-
SMA expression. Trabeculae cardiomyocytes are most differentiated whilst the 
compact cardiomyocytes remain in a more immature proliferative state, as a 
result, expression is gradually restricted to the compact myocardium from E12.5 
and is mostly absent from the trabeculae by E15.5. As the compact 
cardiomyocytes undergo maturation, α-SMA expression is restricted to the 
SMCs of the coronary vessels and great vessels, with some expression in the 
OFT myocardium, which can be seen at E17.5. Anti- α-SMA IHC staining was 
carried out in Rac1TnTCre hearts at a range of ages (E11.5 to E17.5) to 
determine if cardiomyocyte maturation is affected in the absence of Rac1 
(Figure 95). In Rac1TnTCre embryos, α-SMA was expressed normally compared 
to controls at E11.5 (n=4, Figure 95A-B), and E13.5 (n=6, Figure 95C-D). The 
α-SMA expressing compact myocardium is thinner in the Rac1TnTCre E13.5 
(Figure 95C-D), E15.5 (Figure 95E-F) and E17.5 (Figure 95G-H), mutants 
compared to controls (Figure 46, n=6). The expression of α-SMA appears 
disrupted from E15.5, when it is aberrantly retained strongly in the trabeculae 
cardiomyocytes compared to reduced expression in controls (n=4) (arrows in 
Figure 95F’ and F’’). Additionally, the left compact cardiomyocytes retain strong 
expression from E15.5, which continues to E17.5 (n=4) (Figure 95F’’ and H’’). 
The retained expression in the trabeculae cardiomyocytes suggests that the 
trabeculae cardiomyocytes are not fully maturing.  
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Figure 95: α-SMA expression is disrupted at E15.5 in Rac1TnTCre hearts.  
IHC staining using anti-α-SMA on E11.5-E17.5 transverse sections of control 
and Rac1TnTCre embryos. α-SMA expression appears normal in the Rac1TnTCre 
hearts compared to controls at E11.5 (A-B) (n=4). The α-SMA expressing 
compact myocardium is thinner in the Rac1TnTCre E13.5 (C-D) (n=6), E15.5 (E-F) 
(n=4) and E17.5 (G-H) (n=4) mutants compared to controls. The expression of 
α-SMA appears disrupted from E15.5, when it is aberrantly retained strongly in 
the trabeculae cardiomyocytes compared to reduced expression in controls 
(arrows in F’ and F’’) (n=4). Additionally, the left compact cardiomyocytes retain 
strong expression from E15.5 that continues to E17.5 (arrow heads in F’’ and 
H’’) (n=4). E; embryonic day, LV; left ventricle, RV; right ventricle. Scale bars; 
A-H 500µm, A’-H’’ 100µm. 
 
Similar to α-SMA, SM22α is expressed in all cardiomyocytes early in 
development, with expression being restricted to smooth muscle cells later in 
development. As previously shown in Figure 88, SM22α is expressed normally 
in E10.5 Rac1TnTCre mutants compared to controls, with varying expression 
throughout the myocardium.    
E12.5 and E15.5 Rac1TnTCre embryos were dissected and processed for 
fluorescent IHC. Anti-SM22α antibody staining was carried out on control and 
Rac1TnTCre heart sections (Figure 96). At E12.5, strong expression of SM22α is 
restricted to the compact layer in controls with variation in the strength of 
expression between cells (Figure 96A-B). However, in Rac1TnTCre hearts, SM22α 
remains strongly expressed in some trabeculae cardiomyocytes (Figure 96C-D). 
This pattern is continued at E15.5, when SM22α is strongly expressed around 
the edges of trabeculae in the Rac1TnTCre hearts (Figure 97C-D) and is mostly 
absent in controls (Figure 97A-B). Dual staining with endomucin, an endocardial 
and coronary vein marker, and SM22α in E12.5 and E15.5 sections reveals 
strong SM22α expression in the outer layer of the trabeculae myocardium, 
underneath the endomucin-positive endocardial layer (Figure 96 and Figure 97). 
CD31, is another endothelial marker expressed in both coronary arteries and 
veins and shows reduced expression within the compact myocardium in 
Rac1TnTCre hearts. However, expression is increased around the trabeculae, 
corresponding to the areas of increased SM22α expression (Figure 98, B 
compared to D). The reduced expression of CD31 within the compact 
myocardium implies defective coronary vessel formation in Rac1TnTCre hearts 
and is discussed further in Chapter 5 Section 5.3.9.   
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Figure 96: Aberrant expression of SM22α in the trabeculae 
cardiomyocytes in E12.5 Rac1TnTCre hearts.  
IF staining with anti-SM22α, an early embryonic cardiomyocyte and smooth 
muscle marker and anti-endomucin, an endocardial marker to distinguish 
trabeculae myocardium from the compact myocardium. SM22α expression 
shows increased retention in Rac1TnTCre trabeculae cardiomyocytes compared 
to controls, particularly in the left ventricle (arrows in C and D) (n=4). Secondary 
only controls (E). E; embryonic day, LV; left ventricle, RV; right ventricle. Scale 
bars; A-D 200µm, A’-D’’’ 100µm.  
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Figure 97: Continued aberrant retention of embryonic cardiomyocyte 
markers in the trabeculae cardiomyocytes in E15.5 Rac1TnTCre hearts.  
IF staining with anti-SM22α, an early embryonic cardiomyocyte and smooth 
muscle marker and anti-endomucin, an endocardial marker to distinguish 
trabeculae myocardium from the compact myocardium. SM22α expression 
shows increased retention in Rac1TnTCre trabeculae cardiomyocytes compared 
to controls, particularly in the left ventricle (arrows in C’’’ and D’’’’) (n=4). E; 
embryonic day, LV; left ventricle, RV; right ventricle. Scale bars; A-D 200µm, A’-
D’’’ 100µm.  
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Figure 98: Disrupted localisation of SM22α and endothelial markers, 
endomucin and CD31, within the developing ventricular wall.  
IF staining with anti-SM22α, an early embryonic cardiomyocyte and smooth 
muscle marker, anti-endomucin, an endocardial marker, and CD31, an 
endothelial marker. SM22α expression shows increased retention in trabeculae 
cardiomyocytes and decreased expression within the compact myocardium in 
Rac1TnTCre compared to controls (arrows in C’’ compared to A’’) (n=4). CD31 
expression is also reduced within the compact myocardium (D compared to 
arrows in B). Endomucin positive staining is aberrantly detected within the 
compact myocardium (arrows in C’ compared to A’). E; embryonic day, LV; left 
ventricle, RV; right ventricle. Scale bars; 100µm.  
 
Since trabeculae cardiomyocytes appear to be retaining early cardiomyocyte 
markers, semi-quantitative PCR and immunofluorescent staining for some 
additional compact and trabeculae markers, Peg1, Hop and Irx3/5, was carried 
out in younger control and Rac1TnTCre hearts.   
Peg1 is initially expressed uniformly throughout the linear heart tube, but is then 
subsequently restricted to the developing myocardial trabeculae of both the 
atria and ventricles into late development. Mice lacking the Peg1 gene are 
viable and grossly normal with subtle alterations in trabeculation; an increase in 
thickness and reduction in density of the compact myocardium (King et al., 
2002). 
Hop is a small unusual homeodomain protein that is highly expressed in the 
developing heart, regulated by Nkx2.5 expression. Hop expression initiates in 
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early cardiogenesis and continues in cardiomyocytes throughout embryonic and 
postnatal development. Hop inactivation in mice results in severe myocardial 
abnormalities (Chen et al., 2002; Shin et al., 2002). Hop physically interacts with 
serum response factor (SRF) and modulates its activity by inhibiting its binding 
to DNA. SRF transcriptional regulation is involved in balancing cardiomyocyte 
proliferation and differentiation.  
Iroquois homeobox (Irx) 5 is important for postnatal cardiomyocyte 
repolarisation. In mice, Irx3 and Irx5 have redundant functions in the 
endocardium to regulate AV canal morphogenesis and OFT formation. Direct 
transcriptional repression of Bmp10 by Irx3 and Irx5 in the endocardium is 
required for ventricular septation. A postnatal deletion of Irx3 and Irx5 in the 
myocardium leads to prolongation of AV conduction, due in part to activation of 
expression of the Na(+) channel protein Nav1.5 (Gaborit et al., 2012). 
RNA was extracted from E10.5 control and Rac1TnTCre hearts and the 
synthesised cDNA was used in RT-PCR. In Rac1TnTCre hearts, expression of 
trabeculae marker Peg1 was significantly increased (p<0.05) (Figure 99, B and 
E). Additional trabeculae marker, Hop, also had a trend for increased 
expression but was not significant (Figure 99, C and E). Irx5 expression was 
unchanged in Rac1TnTCre hearts (Figure 99D-E). Peg1 and Hop are both 
myocardial markers whereas, Irx5 is an endocardial marker, suggesting that the 
maturation of the myocardium is altered in Rac1TnTCre hearts. In situ 
hybridisation for Peg1 in E10.5 control and Rac1TnTCre hearts revealed Peg1 is 
strongly expressed in the trabeculated myocardium, and to a lesser extent in 
the compact myocardium (Figure 99F-G). Rac1TnTCre hearts show subtle 
increases in expression of Peg1 within the myocardium, particularly in the 
compact layer of the LV (arrows in Figure 99, G’’ compared to F’’). This 
suggests the development of the compact myocardium is altered in Rac1TnTCre 
hearts from E10.5.  
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Figure 99: Trabeculae myocardial specific gene Peg1 is upregulated in 
Rac1TnTCre hearts.  
Semi-quantitative PCR of compact and trabeculae marker gene expression in 
control and Rac1TnTCre E10.5 hearts. Semi-quantitative PCR gel (A-D) and 
densitometry analysis (E) reveal increased expression of Peg1 in Rac1TnTCre 
hearts compared to controls, P<0.05 (n=6). Statistical analysis carried out using 
the unpaired t-test. Large SEM error bars in both control and Rac1TnTCre groups 
for HOP analysis suggest sample variability. Statistical power calculations 
suggest this experiment is underpowered and additional samples may be 
beneficial to assigning statistical significance to the trend for increased HOP 
expression in Rac1TnTCre hearts. Peg1 in situ hybridisation on E10.5 control and 
Rac1TnTCre sections (F-G). Increased expression of Peg1 in the compact layer of 
the left ventricle in Rac1TnTCre hearts compared to controls (arrows in G’’ 
compared to F’’) (n=3). LV; left ventricle, RV; right ventricle. Scale bars; F-G 
200µm, F’-G’’ 100µm.  
 
Atrial natriuretic factor (ANF) is a marker of cardiomyocyte growth and 
differentiation, and is regulated spatially, developmentally and hormonally 
(Temsah and Nemer, 2005). ANF is not expressed in the early linear heart tube; 
expression is initiated at E8.25 on the ventral side of the early looping heart 
tube. During early chamber development, ANF is more strongly expressed in 
the LV compared to RV, becoming restricted to the LV and absent from the RV 
later in development. ANF is not expressed in the AVC, OFT or the inner 
curvature of the ventricles (Christoffels et al., 2000) and is completely restricted 
to the atria after birth. E15.5 embryos were dissected, embedded and sectioned 
for immunostaining. Anti-ANF immunofluorescent staining revealed ventricular 
ANF expression is restricted to the trabeculae in both control and Rac1TnTCre 
hearts (Figure 100). Expression was most prominent in the atria and LV, 
particularly along the LV luminal edge of the IVS (Figure 100A-D). Substantially 
weaker expression was observed in the trabeculae of the RV in controls, 
(Figure 100E) however this remained prominent in Rac1TnTCre hearts (Figure 
100F). Expression appeared comparable between the LV of control and 
Rac1TnTCre hearts (Figure 100C-D). These results provide further evidence that 
the RV trabeculae are not maturing as in controls (as described in Figure 100).  
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Figure 100: Aberrant expression of ANF in the right ventricle in Rac1TnTCre 
hearts.  
IF staining with anti-ANF antibody (red) in E15.5 control and Rac1TnTCre 
transverse heart sections. Rac1TnTCre hearts display strong expression of ANF in 
the trabeculae layer of the right ventricle (arrows in F-F’) compared with no 
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expression in control hearts (E-E’) (n=4). Expression appeared comparable 
between the left ventricle of control and Rac1TnTCre hearts (C-D) (n=4). 
Secondary only control (G). LV; left ventricle, RV; right ventricle, IVS; 
interventricular septum. Scale bars; A-B 200µm, C-F’ 100µm.  
 
The abnormal trabeculae and compact myocardium development in Rac1TnTCre 
hearts highlights possibly differential development mechanisms of the right and 
left ventricles. Trabeculae formation and directionality is particularly affected in 
the LV, as is expanded trabeculae specific Peg1 expression within the compact 
myocardium. However, ANF expression is upregulated in the RV. Additonally, 
remodelling of the trabeculae appears to be absent in the RV whereas 
remodelling is abnormal in the LV. Taken together, the increase in trabeculae 
specific gene expression by qPCR, in situ hybridisation and immunostaining 
suggests that the maturation of the trabeculae myocardium is disrupted, in 
addition to the initial trabeculae formation in Rac1TnTCre hearts. Maturation of 
cardiomyocytes involves changes in cell morphology including establishment of 
the mature cytoskeleton and cell-cell adhesion junction, as well as polarisation 
of the cell. Therefore, these features were investigated in Rac1TnTCre hearts.  
5.3.5 Cytoskeleton in Rac1 deficient cardiomyocytes 
The cytoskeleton provides structural and functional integrity to the cell and is 
essential for cell contraction and also for some cellular processes, such as cell 
migration. To investigate the formation of the actin cytoskeleton in Rac1 
deficient cardiomyocytes, IF staining for multiple components of cytoskeleton 
was carried out along with TEM imaging.  
E10.5 and E11.5 embryos were dissected and processed for immunostaining. 
IF was carried out using antibodies against cardiac-actin, α-actinin and cardiac- 
Tn-I. Expression of these sarcomeric proteins was unchanged in Rac1TnTCre 
myocardium compared to controls (Figure 101 and Figure 102). In 
cardiomyocytes, cardiac actin is present as a component of the thin actin 
filaments, as well as actin microfilaments. Tn-I is also a component of the thin 
actin filaments, which are connected and stabilised in the Z-disc, through actin 
binding protein, α-actinin (Sjoblom et al., 2008). α-actinin shows expression 
within the Z-disc of cardiomyocytes at E11.5 (Figure 101A-F). Expression of α-
actinin appears unchanged in Rac1TnTCre cardiomyocytes compared to controls 
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(Figure 101D-F compared to A-C). Cardiac actin and Tn-I show similar 
expression patterns, within the thin actin filaments (Figure 101G-L and Figure 
102). Expression of Tn-I appears unchanged between control and Rac1TnTCre 
cardiomyocytes at E11.5 (Figure 101G-L). Additionally, cardiac actin expression 
is normal at E10.5 and E11.5 in Rac1TnTCre hearts (Figure 102). Therefore the 
actin cytoskeleton appears normal in Rac1TnTCre hearts by IF.  
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Figure 101: Sarcomeric proteins, α-actinin and troponin-I are expressed 
normally in Rac1TnTCre hearts.  
IF staining with anti-α-actinin and anti-troponin I antibodies in E11.5 control and 
Rac1TnTCre transverse heart sections. Control and Rac1TnTCre hearts display 
strong expression of both α-actinin (A-F) and troponin-I (G-L) within the 
cardiomyocytes of the developing myocardium at E11.5 (n=3). LV; left ventricle, 
RV; right ventricle. Scale bars; 50µm. 
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Figure 102: Sarcomeric protein cardiac-actin is expressed normally in 
Rac1TnTCre hearts.  
IF staining with anti-c-actin antibody in E10.5 and E11.5 control and Rac1TnTCre 
transverse heart sections. Control and Rac1TnTCre hearts display strong 
expression of c-actin within the cardiomyocytes of the developing myocardium 
at both E10.5 and E11.5 (n=3). LV; left ventricle, RV; right ventricle. Scale bars; 
50µm.  
 
E10.5 control and Rac1TnTCre hearts were dissected and fixed for TEM imaging. 
Hearts were processed, sectioned and stained by the Newcastle University 
Electron Microscopy Research Facility. Images were taken from the compact 
and trabeculae regions of the myocardium in one section from each heart (n=6). 
Analysis of the control TEM images revealed differences in the myofibril 
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formation in compact versus trabeculae cardiomyocytes. This is unsurprising 
since trabeculae cardiomyocytes are more differentiated than compact 
cardiomyocytes and thus have a more developed cytoskeletal structure. In the 
Rac1TnTCre hearts, the myofibrils appeared to be less well formed compared to 
controls in both the compact and trabeculae regions. The mutant myofibrils 
tended to be thinner and more fragmented (arrows in Figure 103). This 
suggests that Rac1 is involved in myofibril formation during embryonic 
cardiomyocyte maturation.  
 
 
Figure 103: Disrupted sarcomere formation in Rac1TnTCre hearts compared 
to controls.  
TEM images of trabeculae and compact myocardium regions in E10.5 control 
and Rac1TnTCre hearts. Rac1TnTCre hearts display disrupted formation of 
sarcomeres compared to controls (arrows in F and H, compared to arrows in B 
and D) (n=6).  
5.3.6 Cardiomyocyte Polarity  
Cardiomyocyte polarisation and adhesion are intrinsically linked and are 
essential for myocardial development. Like epithelial cells, cardiomyocytes 
display ABP and adhesion through AJ, TJ and desmosomes. Cardiomyocytes 
also display properties of PCP, however the role of PCP signalling in 
cardiomyocytes is not fully understood. 
To investigate if cardiomyocyte polarity is affected in Rac1TnTCre hearts, 
immunofluorescence staining was carried out for proteins associated with PCP 
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signalling and cell polarisation, as well as cell membrane staining to analyse cell 
shape and size.  
Scrib is a fellow member of the PCP signalling pathway and has been shown to 
interact with Rac1 in cardiomyocytes previously (Boczonadi et al., 2014b), and 
was therefore selected to investigate the effect of the loss of Rac1 on the PCP 
pathway. E9.5 and E12.5 embryos were dissected and processed for 
immunofluorescence. Staining using an anti-Scrib antibody confirmed that Scrib 
is expressed at the cell membrane as expected (shown in Figure 104). 
Surprisingly, Scrib expression was unchanged in Rac1TnTCre mutants at both 
E9.5 (n=3, Figure 104A-D) and E12.5 (n=3, Figure 104E-H). These results 
suggest that Scrib does not require interaction with Rac1 for localisation at the 
membrane and is unaffected in the absence of Rac1.  
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Figure 104: PCP protein, Scrib is unaffected in Rac1TnTCre hearts.  
IF staining with anti-Scrib antibody in E9.5 (A-D) and E12.5 (E-H) control and 
Rac1TnTCre transverse heart sections. Control and Rac1TnTCre hearts display 
membrane localisation of Scrib within the cardiomyocytes of the developing 
myocardium at both E9.5 (A-D) and E12.5 (E-H) (n=3). LV; left ventricle, RV; 
right ventricle. Scale bars; 50µm. 
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Wheat germ agglutinin (WGA) binds to sialic acid and N-acetylglucosaminyl 
residues both cell and nuclear membranes. Staining using an Alexa Fluor 594 
conjugate was carried out on E10.5-17.5 sections (Figure 105A-H) (n=4). WGA 
membrane staining was used to draw around cell membranes using Nikon 
elements confocal software, in order to calculate cell circularity and cell size. 
The analysis revealed that Rac1TnTCre cardiomyocytes were significantly larger 
in size compared to controls from E10.5 (Figure 105A, B and I) and remained 
consistently larger at E17.5 (Figure 105F-H, I). From E10.5 to E15.5 the 
cardiomyocytes of Rac1TnTCre ventricles have significantly increased cell area 
compared to controls, in both left and right ventricles (Figure 105I) (except at 
E12.5 the increase in cell area is only significant in the LV of Rac1TnTCre hearts, 
with no differences in the RV). For E17.5 cell area measurements, compact and 
trabeculae regions were separated. In both ventricles, b compact and 
trabeculae cardiomyocytes had significantly increased  cell areas compared to 
controls (Figure 105J). No differences in cell shape were detected, as 
calculated by circularity measurements (Figure 105K). These results suggest 
that the Rac1 deficient cardiomyocytes undergo a hypertrophic response in the 
absence of Rac1.  
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Figure 105: Cardiomyocyte hypertrophy observed from E10.5 in Rac1TnTCre 
hearts.  
E10.5-E17.5 control and Rac1TnTCre heart sections were stained with wheat 
germ agglutinin (WGA) to label the cell membrane (A-H) (n=4). Cardiomyocyte 
area and shape measurements were carried out using ImageJ. From E10.5 to 
E15.5 the cardiomyocytes of Rac1TnTCre ventricles have significantly increased 
cell area compared to controls, in both left and right ventricles (I) (except at 
E12.5 the increase in cell area is only significant in the left ventricle of 
Rac1TnTCre hearts, with no differences in the right ventricle). For E17.5 cell area 
measurements, compact and trabeculae regions were separated. In both 
ventricles, compact and trabeculae cardiomyocytes had significantly increased 
cell areas compared to controls (J). No differences in cell shape were detected, 
as calculated by circularity measurements (K). LV; left ventricle, RV; right 
ventricle, IVS; interventricular septum. Scale bars; 100µm. Statistical analysis 
carried out using a two-way ANOVA, *p<0.05.  
5.3.7 Cardiomyocyte adhesion  
Cardiomyocytes are attached to adjacent cardiomyocytes through the ICD, 
which are exclusive to cardiomyocytes (Borg et al., 1983). ICD allow connection 
and communication between cardiomyocytes and consist of desmosomes, AJ 
and gap junctions. Via immunostaining, each type of ICD component was 
investigated in Rac1TnTCre hearts, as well as additional cell-cell junctions, TJ.  
5.3.7.1 Adherens junctions  
The main proteins of the AJ in embryonic cardiomyocytes include N-cadherin 
and the cytoplasmic proteins, α- and β-catenin, to which thin actin filaments are 
attached. IF with anti-N-cadherin and anti-β-catenin antibodies revealed 
expression of both proteins at the cell membrane from E9.5. Expression of N-
cadherin in Rac1TnTCre ventricles is comparable to controls at E10.5 (n=4) and 
E11.5 (n=4) (Figure 106A-H). However, by E12.5, N-cadherin expression is 
visibly reduced in Rac1TnTCre ventricles, in both the compact and trabeculae 
myocardium (n=3) (Figure 106I-L). Expression of β-catenin in Rac1TnTCre 
ventricles is comparable to controls at E10.5 (n-4) (Figure 107A-H). However, at 
E11.5, β-catenin expression is visibly reduced and disorganised in Rac1TnTCre 
ventricles, in both the compact and trabeculae myocardium (n=4) (Figure 107I-
P). 
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Figure 106: Adherens junction protein, N-cadherin is disrupted at E11.5 in 
Rac1TnTCre hearts.  
IF staining with anti-N-cadherin antibody in E10.5 and E11.5 control and 
Rac1TnTCre transverse heart sections. Control hearts display strong expression 
of N-cadherin in the adherens junctions in cardiomyocytes of the developing 
myocardium at all ages. Expression of N-cadherin in Rac1TnTCre ventricles is 
comparable to controls at E10.5 and E11.5 (n=3). However, by E12.5, N-
cadherin expression is visibly disrupted in Rac1TnTCre ventricles, in both the 
compact and trabeculae myocardium (arrows in K’ and L’ compared to I’ and 
J’) (n=3). Secondary only control (M). LV; left ventricle, RV; right ventricle. 
Scale bars; 50µm. 
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Figure 107: Adherens junction protein, β-catenin is disrupted in Rac1TnTCre 
hearts. 
IF staining with anti-β-catenin antibody in E10.5 and E11.5 control and 
Rac1TnTCre transverse heart sections. Control hearts display strong expression 
of β-catenin in the adherens junctions in cardiomyocytes of the developing 
myocardium at all ages. Expression of β-catenin in Rac1TnTCre ventricles is 
comparable to controls at E10.5 (n=3). However at E11.5, β-catenin expression 
is visibly reduced and disorganised in Rac1TnTCre ventricles, in both the compact 
and trabeculae myocardium (arrows in K’, L’ and P’ compared to I’, J’ and N’) 
(n=3). Secondary only control (Q). LV; left ventricle, RV; right ventricle. Scale 
bars; 50µm.  
 
5.3.7.2 Gap junctions 
Cx-40 is expressed in the common ventricular chamber, particularly in the 
trabeculae at E9.5. By E10.5 there is strong Cx-40 expression in the LV in both 
trabeculae and compact layer cardiomyocytes, with no expression in the RV. 
Cx-40 is expressed in the RV at E11.5 and from E11.5-E14.5 Cx-40 is strongly 
expressed in the trabeculae layer whilst absent from the compact myocardium 
(Delorme et al., 1997). From E14.5 onwards, ventricular expression of Cx-40 
fades and it is restricted to the atria and His-Purkinje cardiac conduction system 
(Severs et al., 2001).  
Cx-43 is expressed in the compact myocardium cardiomyocytes at E9.5. From 
E11.5-E14.5 Cx-43 is strongly expressed in the trabeculae layer whilst reduced 
in the compact myocardium and co-localsises with Cx-40 (Delorme et al., 1997). 
Neither Cx-40 nor Cx-43 are expressed in the cardiac OFT at any stage of 
development. In the adult heart, Cx-43 is the main connexin that makes up the 
gap junctions of the ventricular myocardium and is essential for cell-cell 
coupling and normal cardiac function (Kolcz et al., 2002; Heinzel et al., 2005; 
Boengler et al., 2006; Boengler et al., 2007).  
IF staining was carried out with an anti-Cx-40 antibody in E9.5 and E10.5 
control and Rac1TnTCre transverse heart sections. Control and Rac1TnTCre hearts 
display strong Cx-40 in the LV trabeculae at E9.5 and throughout the LV 
myocardium at E10.5, with some expression in the RV trabeculae (Figure 108). 
Expression is comparable between control and Rac1TnTCre ventricles (n=3) 
(Figure 108).  
IF with an anti-Cx-43 antibody confirmed expression within the ICD at the cell 
membrane from E9.5. Expression of Cx-43 in Rac1TnTCre ventricles is 
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comparable to controls at E9.5 (n=3) and E10.5 (n=4) (Figure 109A-J). 
However, by E11.5 Cx-43 expression is disrupted in Rac1TnTCre ventricles, in 
both the compact and trabeculae myocardium (n=4) (Figure 109K-V).  
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Figure 108: Gap junction protein, Cx-40 is expressed normally in 
Rac1TnTCre hearts.  
IF staining with anti-Cx-40 antibody in E9.5 and E10.5 control and Rac1TnTCre 
transverse heart sections. Control and Rac1TnTCre hearts display strong Cx-40 
expression in the left ventricle trabeculae at E9.5 and throughout the left 
ventricle myocardium at E10.5 (arrows A-I) with some expression in the right 
ventricle trabeculae (arrows in J-M) (n=3). LV; left ventricle, RV; right ventricle. 
Scale bars; A-D 200µm, A’-M’ 50µm.  
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Figure 109: Gap junction protein, Cx-43 expression is disrupted at E11.5 in 
Rac1TnTCre hearts.  
IF staining with anti-Cx-43 antibody in E9.5, E10.5 and E11.5 control and 
Rac1TnTCre transverse heart sections. Rac1TnTCre hearts display strong 
expression of Cx-43 in the gap junctions in cardiomyocytes of the developing 
myocardium at E9.5 and E10.5, which is comparable to controls (A-J) (n=4). At 
E11.5, expression of Cx-43 appears disrupted with reduced or odd expression 
in both the compact and trabeculae myocardium (arrows in Q-V compared to K-
P) (n=4). Secondary only control (W). LV; left ventricle, RV; right ventricle.  
Scale bars; A-D 100µm, A’-V 50µm.  
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5.3.7.3 Desmosomes 
Desmin is part of the desmosome complex, as well as the main protein in 
desmin intermediate filaments. IF staining was carried out with an anti-Desmin 
antibody in E9.5-E12.5 control and Rac1TnTCre transverse heart sections. At 
E9.5 (n=3) and E10.5 (n=4) control and Rac1TnTCre hearts display comparably 
strong expression of Desmin in the cell-cell junctions between cardiomyocytes 
(Figure 110). At E11.5 (n=4) and E12.5 (n=3), control hearts display strong 
expression of Desmin in cardiomyocytes of the developing myocardium. 
Whereas, in Rac1TnTCre hearts, Desmin expression is strongest within the 
trabeculae and appears clumpy, compared to uniform expression throughout 
the myocardium in control hearts (Figure 111). 
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Figure 110: Desmosomal protein, Desmin is expressed normally in 
Rac1TnTCre hearts during early heart development. 
IF staining with anti-Desmin antibody in E9.5 (n=3) and E10.5 (n=4) control and 
Rac1TnTCre transverse heart sections. Control and Rac1TnTCre hearts display 
strong expression of Desmin in the cell-cell junctions in cardiomyocytes of the 
developing myocardium at all ages. LV; left ventricle, RV; right ventricle. Scale 
bars; 50µm. 
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Figure 111: Desmonsomal protein, Desmin expression is altered later in 
cardiac development in Rac1TnTCre hearts.  
IF staining with anti-Desmin antibody in E11.5 (n=4) and E12.5 (n=3) control 
and Rac1TnTCre heart sections. Control and Rac1TnTCre hearts display strong 
expression of Desmin in cardiomyocytes of the developing myocardium at all 
ages. In Rac1TnTCre hearts Desmin expression is strong and clumpy within the 
trabeculae, compared to uniform expression throughout the myocardium in 
control hearts (arrows in M-P compared to I-L). Secondary only control (Q). LV; 
left ventricle, RV; right ventricle. Scale bars; 50µm. 
 
5.3.7.4 Tight junctions 
ZO-1 is a crucial part of the TJ and is expressed normally in Rac1TnTCre hearts. 
IF staining with anti-ZO1 antibody was carried out on E9.5 and E10.5 control 
and Rac1TnTCre transverse heart sections. Control and Rac1TnTCre hearts display 
expression of ZO1 within the cell-cell junctions in cardiomyocytes of the 
developing myocardium (n=4) (Figure 112). Strong expression of ZO1 was seen 
in cell-cell junctions of the endocardium and epicardium (Figure 112).  
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Figure 112: Tight junction protein, ZO1 is expressed normally in Rac1TnTCre 
hearts.  
IF staining with anti-ZO1 antibody in E9.5 and E10.5 control and Rac1TnTCre 
transverse heart sections. Control and Rac1TnTCre hearts display expression of 
ZO1 within the cell-cell junctions in cardiomyocytes of the developing 
myocardium and no differences were observed between them (n=4). Strong 
expression of ZO1 was seen in cell-cell junctions of the endocardium and 
epicardium. LV; left ventricle, RV; right ventricle. Scale bars; A and D 200µm, B-
C’, E-N’ 50µm. 
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5.3.7.5 Microtubules 
γ-tubulin is a main component of the MTOC, which are apically expressed 
polarised cell organelles. IF staining with anti-γ-tubulin antibody was carried out 
on E11.5 control and Rac1TnTCre transverse heart sections. Control and 
Rac1TnTCre hearts display localised expression of γ-tubulin in the MTOCs in 
cardiomyocytes of the developing myocardium (Figure 113A-G). Quantification 
of the number of γ-tubulin positive MTOCs did not show any difference between 
controls and Rac1TnTCre hearts (n=4) (Figure 113H). 
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Figure 113: MTOC protein, γ-tubulin is expressed normally in Rac1TnTCre 
hearts.  
IF staining with anti-γ-tubulin antibody in E11.5 control and Rac1TnTCre 
transverse heart sections. Control and Rac1TnTCre hearts display localised 
expression of γ-tubulin in the MTOCs in cardiomyocytes of the developing 
myocardium (n=4). Quantification of the number of γ-tubulin positive MTOCs did 
not show any difference between controls and Rac1TnTCre hearts. LV; left 
ventricle, RV; right ventricle. Scale bars; 50µm. Statistical analysis carried out 
using the unpaired t-test.  
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These data suggest that cell polarity and adhesion are disrupted in Rac1TnTCre 
hearts. However, this disruption was observed at E11.5 and older stages of 
embryonic heart development, at a time when the compact myocardial and 
trabeculae defects are already apparent. This implies that the polarity and 
adhesion defects occur secondary to an unknown primary defect within the 
cardiomyocytes. Possible causes of this defect include altered gene expression 
and abnormal signalling within the myocardium and are investigated in Chapter 
5 Sections 5.3.8 and 5.3.9, respectively.   
 
Figure 114: Rac1TnTCre cardiomyocytes display disrupted cell-cell adhesion 
and desmin intermediate filaments from E11.5.  
Proteins of both AJ (yellow) and Gap junctions (purple) show reduced ICD 
expression at E11.5 in Rac1 deficient cardiomyocytes and Desmin intermediate 
filaments (red) appear clumpy in the trabecular layer of Rac1TnTCre hearts at 
E11.5.  
 
5.3.8 Gene expression in Rac1TnTCre hearts 
As discussed in Chater 5 Section 5.3.1 embryonic deletion of Rac1 in 
cardiomyocytes disrupts the development of the myocardium, particularly the 
formation and maturation of the trabeculae. The cardiomyocyte cytoskeleton 
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appears immature and trabeculae maturation markers are aberrantly 
expressed. However, the mechanism of how the lack of Rac1 leads to these 
disruptions remains unknown. Rac1 has many cellular functions including 
regulation of pathways controlling gene transcription, such as NFkB, JNK and 
MAPK signalling pathways (Perona et al., 1997; Bosco et al., 2009).  
As a result, investigation of transcriptional changes in Rac1TnTCre hearts using a 
microarray was carried out. Changes in gene expression would be expected to 
occur before phenotypic changes. Since myocardial defects in Rac1TnTCre hearts 
can be detected from E11.5, E10.5 was selected to investigate gene level 
changes. RNA was extracted from E10.5 Rac1TnTCre hearts and sent to Aros for 
analysis on an Affymetrix Mouse Transcriptome 1.0 microarray chip (n=3, 4 
hearts pooled per sample). The data was analysed using the Transcriptome 
analysis console v3.0. Genes with a significant fold change of 1.5 or more are 
listed in Table 29. 
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Gene Symbol Gene  Fold 
Change 
P-value Function 
Afp alpha fetoprotein 6.53 0.003 Foetal form of plasma 
albumin 
Apob apolipoprotein B 2.61 0.044 Component of LDL in 
plasma 
Apoa1 apolipoprotein A-I 1.85 0.040 Component of HDL in 
plasma  
Sfrp1 secreted frizzled-related 
protein 1 
1.73 0.015 Modulator of Wnt signalling 
Papss2 3-phosphoadenosine 5-
phosphosulfate 
synthase 2 
1.72 0.017 Involved in sulphation  
Trf transferrin 1.67 0.004 Plasma glycoprotein, binds 
iron 
Ttr transthyretin 1.66 0.028 Plasma protein , transports 
thyroxine and retinol 
Cyr61/ 
Ccn1 
cysteine rich protein 61 1.59 0.002 ECM-associated signalling 
LOC10105590
9 
protein transport protein 
Sec61 subunit beta-like 
1.56 0.016 Necessary for protein 
translocation in the ER 
Gm3893 predicted gene 3893 -1.53 0.027 - 
Gm15171 predicted gene 15171 -1.53 0.019 - 
Igkv17-121 immunoglobulin kappa 
variable 17-121 
-1.61 0.012 - 
Gm13432 predicted gene 13432 -1.74 0.031 - 
Table 29: Differentially expressed genes in E10.5 Rac1TnTCre hearts vs 
controls.  
Microarray analysis of E10.5 control and Rac1TnTCre hearts was carried out (n=3, 
4 hearts pooled per sample). Genes with a significant fold change of 1.5 or 
more (p<0.05).  
 
In order to validate the gene changes detected in Rac1TnTCre hearts, qPCR 
analysis was carried out on the RNA used for microarray analysis and additional 
RNA from E10.5 single heart samples. cDNA was synthesised from the RNA 
and primers were designed to amplify a region of the gene, spanning exons. 
Three genes were selected for validation via qPCR; alphafetoprotein (Afp), 
secreted frizzled related protein 1 (Sfrp1) and cysteine rich protein 61 (Ccn1). 
Afp had the largest fold change of 6.53, and therefore represented a good 
target for validation. Additional genes, Sfrp1 and Ccn1 are expressed in the 
developing heart, associated with the ECM (Jaspard et al., 2000; Mo and Lau, 
2006). qPCR analysis using the cDNA from the microarray samples showed 
Afp, Sfrp1 and Ccn1 were all significantly increased in Rac1TnTCre hearts 
compared to controls (n=3, 4 hearts pooled) (Figure 115). However, in the 
additional E10.5 single hearts, the expression of all three genes showed a trend 
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for increase but were not significant (n=6, single hearts) (Figure 115). These 
results could be due to variability amongst the single E10.5 hearts, such as 
slight differences in developmental stage/somite number. Pooling of 4 hearts 
together averages any potential outliers and allows subtle gene expression 
changes to be detected.  Statistical power calculations suggest that the single 
E10.5 heart experiment is underpowered and may benefit from additional 
samples to assign statistical significance to the trend for increased expression 
of Afp, Sfrp1 and Ccn1 in Rac1TnTCre hearts. However, the large number of extra 
samples required to demonstate these differences is both impractible and 
unethical. 
 
Figure 115: qPCR analysis of microarray target gene expression in E10.5 
Rac1TnTCre hearts.  
qPCR analysis of microarray E10.5 pooled hearts; Afp, Sfrp1 and Ccn1 were all 
significantly increased in Rac1TnTCre hearts compared to controls (n=3, 4 hearts 
pooled). However, in the additional E10.5 single hearts, the expression of all 3 
genes showed a trend for increase but were not significant (n=6, single hearts). 
Significance determined by unpaired t-test. *P<0.05. Statistical power 
calculations suggest the single E10.5 heart experiment is underpowered and 
may benefit from additional samples to assign statistical significance to the 
trend for increased expression of Afp, Sfrp1 and Ccn1 in Rac1TnTCre hearts. 
Expression normalised to housekeeping gene Gapdh. E; embryonic day.  
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Since the qPCR results using additional samples were inconclusive, slide in situ 
hybridisation was carried out to investigate gene expression patterns within the 
heart. All the known microarray targets were included in this analysis. In situ 
probes were designed to hybridise to a 400bp region of RNA. E10.5 embryos 
were dissected and processed in RNA free conditions. Hybridisation was 
carried out on control E10.5 heart sections to determine expression within the 
heart (Figure 116). No expression of Afp (Figure 116A), Apoa1 (Figure 116B), 
Apob (Figure 116C), Papss2 (Figure 116D), Trt (Figure 116E) or Ttr (Figure 
116F) was shown within the heart, therefore no further analysis of these genes 
was carried out.  
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Figure 116: In situ hybridisation of microarray targets in control E10.5 
heart sections.  
Slide in situ hybridisation using antisense probes for Afp (A), Apoa1 (B), Apob 
(C), Papss2 (D), Trf (E) and Ttr (F). No expression of any probe was observed 
within the myocardium of the ventricles at E10.5. E; embryonic day, LV; left 
ventricle, RV; right ventricle. Scale bars; A-F 200µm, A’-F’’ 100µm. 
 
Since expression of Sfrp1 and Ccn1 within the heart has previously been 
published (Jaspard et al., 2000; Mo and Lau, 2006), expression of these genes 
in Rac1TnTCre hearts was investigated. Slide in situ hybridisation was carried out 
on control and Rac1TnTCre E10.5 heart sections (n=3) using probes designed to 
hybridise to a 400bp region of RNA. Images were taken and analysed. In 
controls, Sfrp1 is expressed uniformly within the ventricular myocardium (Figure 
117), whereas Ccn1 shows punctate expression within the ventricular 
myocardium (Figure 118). Rac1TnTCre hearts appear to have increased 
expression of both Sfrp1 and Ccn1 within the myocardium (Figure 117 and 
Figure 118 respectively). Expression of both transcripts is comparable between 
left and right ventricles (Figure 117 and Figure 118).  
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Figure 117: In situ hybridisation of Sfrp1 probe in control and Rac1TnTCre 
E10.5 heart sections.  
Slide in situ hybridisation using Sfrp1 antisense probe shows strong uniform 
expression within the myocardium of the ventricles at E10.5 (A-C, G-I). 
Expression of Sfrp1 appears to be upregulated in Rac1TnTCre hearts (D-F, J-L) 
(n=3). Expression between left and right ventricles is comparable in both 
controls and in Rac1TnTCre hearts. E; embryonic day, LV; left ventricle, RV; right 
ventricle. Scale bars; 100µm. 
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Figure 118: In situ hybridisation of Ccn1 probe in control and Rac1TnTCre 
E10.5 heart sections. 
Slide in situ hybridisation using Ccn1 antisense probe shows strong punctate 
expression within the myocardium of the ventricles at E10.5 (A-C, G-I). 
Expression of Ccn1 appears to be upregulated in Rac1TnTCre hearts (D-F, J-L) 
(n=3). Expression between left and right ventricles is comparable in both 
controls and in Rac1TnTCre hearts. E; embryonic day, LV; left ventricle, RV; right 
ventricle. Scale bars; 100µm.  
 
Furthermore, in order to determine if the protein expression correlated with the 
transcript expression IF staining using antibodies against Sfrp1 and Ccn1 on 
E10.5 control and Rac1TnTCre transverse sections was carried out. Ccn1 
expression appears to be localised to both the endocardium and epicardium, 
with little to no expression within the ventricular myocardium (Figure 119A-D). 
This is in contrast to the mRNA expression pattern shown by in-situ 
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hybridisation (Figure 118). Sfrp1 appears to be expressed in all three layers of 
the developing myocardium, with strongest expression in the epicardium (Figure 
119E-J), correlating to the mRNA expression pattern shown by in situ 
hybridisation (Figure 117). Both Ccn1 and Sfrp1 protein expression appears 
comparable in Rac1TnTCre ventricles compared to controls (Figure 119).  
Through X-gal staining Mo et al. show speckled expression of Ccn1 within the 
compact myocardium similar to our in situ hybridisation analysis (Figure 118), 
however they also show intense staining on Ccn1 within the AV cushions and 
OFT cushions at E10.5 (Mo and Lau, 2006). From  Figure 119 Sfrp1 is shown to 
be strongly expressed within the myocardium at E10.5, which is in support of 
previous published data showing strong myocardial expression through 
antibody staining at E9.5 and E11.5 (Jaspard et al., 2000).  
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Figure 119: Ccn1 and Sfrp1 IF staining of E10.5 control and Rac1TnTCre 
transverse sections. 
Ccn1 expression appears to be localised to both the endocardium and 
epicardium, with little to no expression within the ventricular myocardium (A-D). 
Sfrp1 appears to be expressed in all three layers of the developing myocardium 
and is strongest in the epicardium (E-J). Both Ccn1 (C-D compared to A-B) and 
Sfrp1 (G-J compared to E-F) protein expression appears comparable in 
Rac1TnTCre ventricles compared to controls (n=4). Scale bars; A-D 100µm, E-J 
50µm.  
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The microarray analysis reveals several changes in gene expression in 
Rac1TnTCre hearts compared to controls. Investigation of expression of these 
genes in the heart excluded all but two genes from further analysis. Expression 
of Sfrp1 and Ccn1 appeared to be increased in Rac1TnTCre hearts as shown by 
slide in situ hybridisation. However, Sfrp1 and Ccn1 protein expression 
appeared unaltered in Rac1TnTCre hearts using IF. Furthermore, the microarray 
results could not be confirmed in additional E10.5 heart samples by qPCR. 
These results suggest that the small changes in gene expression initially 
detected in Rac1TnTCre hearts may be due to the nature of microarray data 
analysis and the associated false positve rate (Hariharan, 2003). This suggests 
that that deletion of Rac1 in cardiomyocytes has little effect on gene expression, 
however  due to variation in RNA samples it is possible that significant 
differences may not have been detected.  
5.3.9 The endocardium is disrupted in Rac1 myocardial mutants  
The endocardium is essential for normal myocardial development and 
interactions between the endocardium and myocardium act to regulate 
processes such as cardiomyocyte proliferation, trabeculation and coronary 
vessel formation. As shown in Section 5.3.3 proliferation and cell number is 
unchanged in Rac1TnTCre mutants, however trabeculae formation is disrupted. 
Therefore, it was hypothesised that myocardial-endocardium interactions may 
be disrupted leading to defective trabeculation, and that coronary vessel 
formation may also be disrupted in Rac1 mutant hearts. To assess this 
hypothesis, the role of the endocardium and coronary vessel formation was 
investigated in Rac1TnTCre hearts.  
To visualise the endocardium in Rac1TnTCre hearts, IF staining was carried out 
using antibodies against endocardial/endothelial markers, CD31 and 
endomucin. CD31 is expressed in all endothelial cells, including endocardial 
cells, whereas endomucin is restricted to endocardial cells and some coronary 
vein endothelial cells during embryonic cardiac development. E10.5 to E17.5 
Rac1TnTCre embryos were dissected and processed for immunostaining.  
At E12.5, CD31 expression can be seen in the endocardial cells, with the 
highest expression in the endocardium at the base of the trabeculae, as well as 
in the endothelium of sub-epicardial veins (Figure 120A). There is little to no 
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expression of CD31 within the compact myocardium at E12.5. By E15.5, CD31 
marks the endothelium of the developing coronary vessels and 
microvasculature within the compact myocardium, but also remains expressed 
in the endocardial cells covering the trabeculae (Figure 120C). The distribution 
of CD31-positive endothelial cells appeared comparable to controls at E12.5 in 
the Rac1TnTCre hearts (Figure 120, B compared to A). However, at E15.5 there 
was a marked reduction in the number of CD31-positive endothelial cells within 
the compact myocardium in Rac1TnTCre hearts compared to controls (Figure 
120, D compared to C). No large CD31-positive coronary vessels were detected 
in Rac1TnTCre hearts and the CD31-positive microvascular in the compact layer 
of E15.5 Rac1TnTCre hearts appeared reduced. Additionally, the vessels that 
have formed appeared to be developing in aberrant directions compared to 
controls (Figure 120, D compared to C). In control hearts, the CD31-positive 
endocardial cells were uniformly distributed around the trabeculae, however in 
Rac1TnTCre hearts, the CD31-positive endocardial cells appeared to be more 
concentrated at the base of the trabeculae (Figure 120, D compared to C).   
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Figure 120: CD31 IF staining of E12.5 and E15.5 control and Rac1TnTCre 
transverse sections. 
The pattern of CD31+ endothelial cells is disrupted in the Rac1TnTCre hearts (B 
and D) compared to controls (A and C), with less CD31+ vessels forming in the 
mutants compared to controls and more endothelial cells at the base of the 
trabeculae in the mutants compared to controls (n=4). Secondary only control 
(E). LV; left ventricle, RV; right ventricle. Scale bars; A-D 200µm, A’-D’’’ 100µm, 
C’’-D’’’’ 50µm. 
 
From E10.5 to E17.5, endomucin-positive endocardial cells line the trabeculae 
and highlight the distinct regions of the compact and trabeculae myocardium 
(Figure 121 and Figure 122). At E10.5 and E11.5, trabeculae form uniformly 
along the compact myocardium, and at the base of the trabeculae endocardial 
cells project into the compact myocardium (Figure 121). It has previously been 
suggested that these cells migrate into the compact myocardium and contribute 
to coronary vessel endothelium, however sufficient evidence is lacking (Wu et 
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al., 2012) and recent data suggests this may not be the case (Zhang et al., 
2016). Compared to controls, in Rac1TnTCre hearts the number of these 
projecting endocardial cells at the base of trabeculae is significantly fewer at 
E11.5 (arrows in Figure 121G-L) and shows a trend at E10.5 (arrows in Figure 
121A-F). In controls, endocardial cells at the base of the trabeculae project into 
the compact layer in between individual cardiomyocytes. As previously 
mentioned, in Rac1TnTCre hearts this was observed less often and occasionally 
endocardial cells appeared completely surrounded in compact myocardium 
(arrows in Figure 121O-P). This mutant phenotype was continued in E12.5 
Rac1TnTCre hearts, when the compact myocardial wall is significantly thinned and 
the border between compact and trabeculae myocardial is less well defined 
(Figure 122A-B). In Rac1TnTCre hearts, the trabeculae appear to undergo 
compensatory remodelling between E12.5 to E17.5 (Figure 122A-F). This is 
striking at E15.5 (Figure 122C-D) and E17.5 (Figure 122E-F), with endomucin 
positive cells appearing ‘trapped’ within the compact myocardial layer (arrows in 
Figure 122, D’’ and F’’). Additionally, the difference between the right and left 
ventricle walls from E15.5 onwards suggests there is differential remodelling 
between the two ventricles in mutant hearts. The RV remains thin with relatively 
large numbers of trabeculae compared to controls (Figure 122, D’ and F’), 
whereas the LV thickens and becomes smooth on the inner surface with 
relatively few trabeculae (Figure 122, D’’ and F’’). However, this thickened left 
ventricular wall is less densely packed than in controls and contains ‘trapped’ 
endomucin positive endocardial cells arrows in Figure 122, D’’ and F’’.   
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Figure 121: Endomucin IF staining of E10.5 and E11.5 control and 
Rac1TnTCre transverse sections.  
Immunostaining with anti-endomucin for endothelial cells with DAPI nuclear 
stain (blue) (A-P). From E10.5, endomucin positive endocardial cells line the 
trabeculae and highlight the distinct compact and trabeculae myocardial 
regions. At E10.5 and E11.5, trabeculae form uniformly along the compact 
myocardium and at the base of the trabeculae, endocardial cells project into the 
compact myocardium. Compared to controls, in Rac1TnTCre hearts the number of 
these projecting endocardial cells at the base of trabeculae is significantly fewer 
at E11.5 (arrows in G-L) and shows a trend at E10.5 (arrows in A-F) (n=4). In 
controls, endocardial cells at the base of the trabeculae project into the compact 
layer in between individual cardiomyocytes. As previously mentioned, in 
Rac1TnTCre hearts, this is observed less often and occasionally, endocardial cells 
appear surrounded in the compact myocardium (arrows in O-P). Scale bars; 
50µm.  
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Figure 122: Endomucin IF staining of E12.5, E15.5 and E17.5 control and 
Rac1TnTCre transverse sections. 
Immunostaining with anti-endomucin for endothelial cells with DAPI nuclear 
stain (blue) (A-P). In mutant Rac1TnTCre hearts the trabeculae appear to undergo 
compensatory remodelling between E12.5 to E17.5 (A-F) (n=4). This is striking 
at E15.5 (C-D) and E17.5 (E-F), with endomucin positive cells appearing 
‘trapped’ within the compact myocardial layer (arrows in D’’ and F’’). The right 
ventricle remains thin with relatively large numbers of trabeculae compared to 
controls (D’ and F’), whereas the left ventricle thickens and becomes smooth on 
the inner surface with relatively few trabeculae (D’’ and F’’), but is less densely 
packed than in controls and contains ‘trapped’ endomucin positive endocardial 
cells (arrows in D’’ and F’’). LV; left ventricle, RV; right ventricle. Scale bars; A-
F 200µm, A’-F’’ 50µm. 
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Figure 123: Endocardial abnormalities in Rac1TnTCre hearts.  
In controls, endocardial cells at the base of the trabeculae project into the compact layer in between individual cardiomyocytes. 
In Rac1TnTCre hearts this is observed less often. This mutant phenotype was continued in E12.5 Rac1TnTCre hearts, when the 
compact myocardial wall is significantly thinned and the border between compact and trabeculae myocardial is less well 
defined, additionally some endocardial cells appear trapped within the myocardial wall. In Rac1TnTCre hearts, the trabeculae 
appear to undergo compensatory remodelling between E12.5 to E17.5. This is striking at E15.5, with endomucin positive cells 
again appearing ‘trapped’ within the compact myocardial layer, particularly in the LV. Additionally, the difference between the 
right and left ventricle walls from E15.5 onwards suggests there is differential remodelling between the two ventricles in mutant 
hearts. In Rac1TnTCre hearts the RV remains thin with relatively large numbers of trabeculae compared to controls, whereas the 
LV thickens and becomes smooth on the inner surface with relatively few trabeculae. However, this thickened left ventricular 
wall is less densely packed than in controls and contains ‘trapped’ endomucin positive endocardial cells. At E12.5, CD31 
expression can be seen in the endocardial cells, with the highest expression in the endocardium at the base of the trabeculae, 
as well as in the endothelium of sub-epicardial veins. There is little to no expression of CD31 within the compact myocardium 
at E12.5. By E15.5, CD31 marks the endothelium of the developing coronary vessels and microvasculature within the compact 
myocardium, but also remains expressed in the endocardial cells covering the trabeculae. However, at E15.5 there was a 
marked reduction in the number of CD31-positive endothelial cells within the compact myocardium in Rac1TnTCre hearts 
compared to controls. No large CD31-positive coronary vessels were detected in Rac1TnTCre hearts and the CD31-positive 
microvascular in the compact layer of E15.5 Rac1TnTCre hearts appeared reduced. In control hearts, the CD31-positive 
endocardial cells were uniformly distributed around the trabeculae, however in Rac1TnTCre hearts, the CD31-positive 
endocardial cells appeared to be more concentrated at the base of the trabeculae from E12.5.   
 
 
 
 
 
 
 
 
286 
 
CD31 and endomucin immunostaining revealed reduced coronary endothelial 
cells and aberrant ‘trapped’ endocardial cells in the myocardium of Rac1TnTCre 
hearts during late stages of embryonic heart development. This phenotype 
suggests that the myocardium is undergoing abnormal compaction. Additionally, 
the number of projecting endocardial cells was reduced early in development. 
This suggests that the endocardial cells behaviour is altered during early 
myocardial development. It was therefore hypothesised that, in Rac1TnTCre 
hearts, endocardial cells are not migrating into the compact myocardium, as in 
controls, to give rise to the endothelial cells of the coronary vessels and hence 
the lack of coronary vessel formation later in development. However, the 
contribution of endocardial cells to the coronary vessels is currently debatable 
(Wu et al., 2012), and recent evidence suggests it may only be a small 
proportion of coronary endothelial cells which arise from the endocardium 
(Zhang et al., 2016). Therefore, this area of research requires further 
investigation. Since the endocardium appears disrupted during early myocardial 
development, and myocardial-endocardial interactions are known to be 
important for this process, further investigatation of endocardial cells in 
Rac1TnTCre mutants was carried out by using immunostaining for characteristic 
endothelial markers, including VE-cadherin, ERG and Nfatc1.  
VE-cadherin is found clustered at cell-cell contacts, in AJ and interacts with β-
catenin, plakoglobin and p120-catenin. VE-cadherin is required for interaction 
with the cytoskeleton and junctional strength, but can also regulate endothelial 
cell differentiation, growth, and migration. VE-cadherin appears selectively 
expressed in endocardial cells, with increased density at cell-cell junctions and 
is unaffected in Rac1TnTCre hearts (E9.5; n=3, E10.5; n=7 E11.5, n=6) (Figure 
124 and Figure 125). 
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Figure 124: VE-cadherin IF staining of E9.5 control and Rac1TnTCre 
transverse sections. 
IF staining shows strong VE-cadherin expression within the endocardium at 
E9.5, expression was comparable between controls and Rac1TnTCre hearts in 
both the left and right ventricle (n=4). LV; left ventricle, RV; right ventricle. Scale 
bars; A-B 200µm, A’-B’’’’ 50µm.  
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Figure 125: VE-cadherin IF staining of E10.5 and E11.5 control and 
Rac1TnTCre transverse sections.  
IF staining shows strong VE-cadherin expression within the endocardium at 
E10.5 and E11.5, expression was comparable between controls and Rac1TnTCre 
hearts in both the left and right ventricle (E10.5, n=4) (E11.5, n=3). LV; left 
ventricle, RV; right ventricle. Scale bars; 50µm.  
 
Nfatc1 is active in the nucleus of endocardial cells during cardiac development 
and is ‘switched off’ in migratory endocardial cells as they enter the compact 
myocardium (Ajima et al.). Staining of E10.5, E11.5 and E13.5 hearts sections 
with anti-Nfatc1 confirmed expression of Nfatc1 in all endocardial cells in both 
controls and Rac1TnTCre hearts, however there was no difference between the 
two groups  (E10.5; n=3, E11.5; n=4, E13.5 n=3) (Figure 126).  
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Figure 126: Nfatc1 IF staining of E10.5 and E11.5 control and Rac1TnTCre 
transverse sections.  
IF staining shows strong Nfatc1 expression within the nucleus of endocardial 
cells at E10.5 and E11.5, expression was comparable between controls and 
Rac1TnTCre hearts in both the left and right ventricle (n=4). LV; left ventricle, RV; 
right ventricle. Scale bars; 50µm. 
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ERG, an ETS family transcription factor, is known to be expressed in 
endothelial cells. Staining of E11.5 hearts sections with anti-ERG and anti-
endomucin confirmed expression of ERG within all endomucin-positive 
endocardial cells (Figure 127). In Rac1TnTCre hearts, as previously seen with 
endomucin IF staining (Figure 96), endocardial cells do not appear to be 
protruding into the compact myocardium as in controls and endocardial cells 
appear to be gathered at the base of trabeculae (arrows in Figure 127, C-D and 
F) and also at the ends of the trabeculae (arrows in Figure 127E) (n=4).  
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Figure 127: ERG and endomucin IF staining of E11.5 control and Rac1TnTCre transverse sections.  
IF staining shows strong ERG expression within the nucleus of endocardial cells (also stained with endomucin) at E11.5. 
Endocardial cells do not appear to be protruding into the compact myocardium as in controls and endocardial cells appear to 
be gathered at the base of trabeculae (arrows in C, D and F) and also at the ends of the trabeculae (arrows in E) (n=4). LV; 
left ventricle, RV; right ventricle. Scale bars 50µm/ 
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5.3.10 Signalling between myocardium and endocardium  
As discussed earlier, signalling between the myocardium and endocardium is 
vital for normal myocardial development. Some of the main signalling pathways 
which are active in the myocardium and endocardium during myocardial 
development include Notch signalling and VEGF signalling, and semaphorin 
signalling has also recently been implicated (Toyofuku et al., 2004b; Grego-
Bessa et al., 2007; Wu et al., 2012; D'Amato et al., 2016). It is hypotheised that 
these signalling pathways may be perturbed in Rac1 myocardial mutants. To 
investigate this some of the main proteins in these signalling pathways were 
examined in Rac1TnTCre hearts, using IF staining, in situ hybridisation and qPCR.  
5.3.10.1 Notch Signalling  
Notch 1 is activated in endocardial cells through binding of ligands delta4 and 
jagged1. Previous studies have reported that N1ICD is most strongly expressed 
in endocardial cells at the base of trabeculae. IF staining using anti-N1ICD 
shows strong staining in the endocardium at E11.5. The expression of N1ICD is 
comparable in Rac1TnTCre hearts (Figure 128, B-C compared to A). 
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Figure 128: N1ICD IF staining of E11.5 control and Rac1TnTCre transverse 
sections. 
IF staining shows strong N1ICD expression within the nucleus of endocardial 
cells at E11.5, expression was comparable between controls and Rac1TnTCre 
hearts in both the left and right ventricle (n=4). LV; left ventricle, RV; right 
ventricle. Scale bars; A-C 200µm, A’-C’’ 50µm.  
 
Hey2 is a downstream target of Notch signalling and provides a readout of 
Notch signalling in the myocardium. Hey2 expression is restricted to the 
compact myocardium within the ventricle (Leimeister et al., 1999). In situ 
hybridisation using a Hey2 probe confirmed expression of Hey2 within the 
compact myocardium with little to no expression in the trabeculae myocardium, 
at both E10.5 and E12.5. In Rac1TnTCre hearts, Hey2 expression was similarly 
limited to the compact myocardium at E10.5 (n=4) (Figure 129, B compared 
with A) and E12.5 (n=4) (Figure 129, D compared with C).  
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Figure 129: In situ hybridisation of Hey2 in E10.5 and E12.5 control and 
Rac1TnTCre hearts.  
In control hearts Hey2 expression is restricted to the compact myocardium at 
both E10.5 (A) and E12.5 (C), the expression appears unchanged in Rac1TnTCre 
hearts at both E10.5 (B) and E12.5 (D) (n=3). RV; right ventricle, LV; left 
ventricle. Scale bars; A-D 200µm, A’-D’’ 50µm.  
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These results suggest that Notch signalling between the endocardium and 
myocardium is normal in Rac1TnTCre hearts, with activated Notch expressed in 
endocardial cells, and signalling effector Hey2 expressed in the compact 
myocardium. However, as Notch signalling is known to play several roles during 
cardiac development, additional indicators of Notch signalling were investigated.  
During trabeculation, there are two parallel Notch dependent cardiac 
developmental processes. The first is the transition of primitive myocardial 
epithelium to trabeculae and compact myocardium, mediated by EphrinB2-Nrg 
signalling in the endocardium. The second involves maintenance of BMP-
dependent proliferation of trabeculae cardiomyocytes. These processes were 
investigated in Rac1TnTCre hearts.  
5.3.10.2 EphrinB2 - Neuregulin signalling pathway  
Notch signals to the EphrinB2/EphB4 ligand-receptor pair in the endocardium 
and activates expression of Nrg within the endocardium. Nrg can then signal to 
the myocardium by binding to ErbB2/4 receptors expressed in cardiomyocytes.  
qPCR was carried out on E10.5 heart cDNA to assess gene transcription 
changes in the ErbB/Nrg signalling pathway. There were no significant changes 
in Nrg, ErbB2 or ErbB4 in Rac1TnTCre hearts compared to controls (n=6) (Figure 
130).  
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Figure 130: qPCR analysis of Nrg/ErbB signalling genes in E10.5 
Rac1TnTCre hearts.  
There were no significant changes in expression of Nrg, ErbB2 or ErbB4 (n=6). 
Housekeeping gene GAPDH. Statistical analysis carried out using the unpaired 
t-test. 
 
Additionally, slide in situ hybridisation was carried out to assess localisation of 
EphB4 and Nrg1 within the endocardium and ErbB2 within the myocardium. As 
expected, EphB4 and Nrg1 are highly expressed in the endocardium at E10.5 
and E12.5, whereas ErbB2 is highly expressed in the myocardium. Expression 
of Nrg1, EphB4 and ErbB2 is unchanged in Rac1TnTCre hearts compared to 
controls (Figure 131, Figure 132 and Figure 133) (E10.5; n=3, E12.5; n=3).  
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Figure 131: In situ hybridisation of EphB4 in E10.5 and E12.5 control and  
Rac1TnTCre hearts.  
Within the ventricles, expression of EphB4 is observed in endocardial cells at 
E10.5 (arrows in A’ and A’’) and E12.5 (arrows in C’ and C’’). Expression of 
EphB4 in Rac1TnTCre hearts is comparable to controls at E10.5 (arrows in B’ and 
B’’) and E12.5 (arrows in D’ and D’’) (n=3). E; embryonic day, RV; right 
ventricle, LV; left ventricle. Scale bars; A-D 200µm, A’-D’’ 50µm.  
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Figure 132: In situ hybridisation of ErbB2 in E10.5 and E12.5 control and 
Rac1TnTCre hearts.  
Within the ventricles, expression of ErbB2 is observed in the myocardium at 
E10.5 (arrows in A’ and A’’) and E12.5 (arrows in C’ and C’’). Expression of 
ErbB2 in Rac1TnTCre hearts is comparable to controls at E10.5 (arrows in B’ and 
B’’) and E12.5 (arrows in D’ and D’’) (n=3). E; embryonic day, RV; right 
ventricle, LV; left ventricle. Scale bars; A-D 200µm, A’-D’’ 50µm. 
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Figure 133: In situ hybridisation of Nrg1 in E10.5 control and Rac1TnTCre 
hearts. 
Within the ventricles, expression of Nrg1 is observed in the endocardium at 
E10.5 (arrows in A’ and A’’). Expression of Nrg1 in Rac1TnTCre hearts is 
comparable to controls at E10.5 (arrows in B’ and B’’) (n=3). E; embryonic day, 
RV; right ventricle, LV; left ventricle. Scale bars; A-D 200µm, A’-D’’ 50µm. 
 
5.3.10.3 Maintenance of BMP10 in trabeculae myocardium   
BMP10 is required to maintain cardiomyocyte proliferative capacity after the 
onset of trabeculae cardiomyocyte differentiation and is therefore expressed 
transiently from E9.0 to E13.5, and is restricted to trabeculae cardiomyocytes 
(Neuhaus et al., 1999). 
Slide in situ hybridisation was carried out on E10.5 and E12.5 sections to 
investigate Bmp10 expression in Rac1TnTCre hearts. Bmp10 was expressed 
strongly in the trabeculae cardiomyocytes at E10.5, with weak expression in 
compact cardiomyocytes in both control hearts and Rac1TnTCre hearts. At E12.5 
Bmp10 expression remains restricted to trabeculae cardiomyocytes with no 
expression in the compact myocardium in both control and Rac1TnTCre hearts 
(Figure 134).   
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Figure 134: In situ hybridisation of Bmp10 in E10.5 and E12.5 control and 
Rac1TnTCre hearts.  
Within the ventricles, expression of Bmp10 is restricted to the trabeculated 
myocardium at E10.5 (arrows in A’ and A’’) and E12.5 (arrows in C’ and C’’). 
Expression of Bmp10 in Rac1TnTCre hearts is comparable to controls at E10.5 
(arrows in B’ and B’’) and E12.5 (arrows in D’ and D’’) (n=3). E; embryonic day, 
RV; right ventricle, LV; left ventricle. Scale bars; A-D 200µm, A’-D’’ 50µm. 
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5.3.10.4 VEGF signalling  
Myocardial VEGF binds to VEGF receptors expressed in endocardial cells to 
regulate angiogenesis; the main VEGF receptor expressed in the endocardium 
during cardiac development is VEGFR-2. To determine if VEGF-a signalling in 
the myocardium is affected in the absence of Rac1, qPCR, slide in situ 
hybridisation and IF analysis of VEGF-a was carried out in control and 
Rac1TnTCre hearts.  
E10.5 and E12.5 hearts were dissected for RNA extraction, cDNA synthesis 
was carried out and used in qPCR reactions. There was no change in Vegf-a 
expression in Rac1TnTCre hearts compared to controls at either E10.5 or E12.5 
(n=6 and n=4, respectively) (Figure 135). 
 
Figure 135: qPCR analysis of Vegf-a gene expression in Rac1TnTCre hearts. 
qPCR analysis shows cardiac expression of Vegf-a at E10.5 (n=6) and E12.5 
(n=3). No significant differences in expression were detected in Rac1TnTCre 
hearts compared to controls (P<0.05). Expression values are normalised to 
housekeeping gene GAPDH and are relative to control expression. E; 
embryonic day. Statistical analysis carried out using the unpaired t-test. 
 
Additionally, both Vegf-a and Vegfr-2 expression was analysed by slide in situ 
hybridisation in E10.5 hearts. As expected, Vegfr-2 is expressed solely in the 
endocardial cells of the ventricle at E10.5 (Figure 136A). Conversely, Vegf-a 
shows a varied expression pattern throughout the three main layers of the 
ventricle at E10.5 (Figure 136C). Expression of both the Vegf-a ligand and 
Vegfr-2 receptor is comparable to controls in Rac1TnTCre hearts (Figure 136, B 
and D, respectively).  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
E10.5 E12.5
Fo
ld
 C
h
an
ge
 in
 G
e
n
e
 E
xp
re
ss
io
n
 
Control
Rac1TnTCre
303 
 
 
Figure 136: In situ hybridisation of Vegf-a and Vegfr-2 in E10.5 control and 
Rac1TnTCre hearts.  
Within the ventricles, Vegfr-2 is expressed solely in the endocardial cells at 
E10.5 (A). Conversely, Vegf-a shows a varied expression pattern throughout 
the three main layers of the ventricle at E10.5 (C). Expression of both the Vegf-
a ligand and Vegfr-2 receptor is comparable to controls in Rac1TnTCre hearts (B 
and D, respectively) (n=3). E; embryonic day, RV; right ventricle, LV; left 
ventricle. Scale bars; A-D 200µm, A’-D’’ 100µm. 
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To further asses VEGFR-2 at the protein level, IF staining using an anti-
VEGFR-2 antibody was carried out. At E11.5 VEGFR-2 expression is restricted 
to endocardial cells within the developing ventricles. The receptor displays 
expression throughout the endocardial cell, with punctate expression in one 
region per cell. VEGFR-2 expression appeared normal in the majority of 
endocardial cells of the developing ventricles in Rac1TnTCre hearts compared to 
controls, with the exception of the endocardial cells on the surface of the 
compact myocardium, where no trabeculae have formed. In these areas the 
VEGFR-2 expression appears reduced (arrows in Figure 137D-F). This 
observation is most striking in the RV and expression in the LV is more 
comparable between controls and Rac1TnTCre hearts (arrows in Figure 137J-L).  
 
 
 
 
 
305 
 
 
Figure 137: VEGFR-2 IF staining of E11.5 control and Rac1TnTCre transverse 
sections.  
At E11.5, VEGFR-2 expression appears reduced in the endocardial cells on the 
surface of the compact myocardium where no trabeculae are forming. This 
observation is most striking in the RV (shown by arrows in D-F’) and expression 
in the LV is more comparable between controls and Rac1TnTCre hearts (J-K) 
(n=4). LV; left ventricle, RV; right ventricle. Scale bars; 50µm. 
 
5.3.10.4 Semaphorin signalling 
Plexin transmembrane receptors and their semaphorins ligands as well as co-
receptors, including Nrp1, VEGFR-2 and ErbB2, are emerging as key regulatory 
proteins during development (Gu et al., 2003; Gitler et al., 2004; Toyofuku et al., 
2004a; Liu et al., 2010; Epstein et al., 2015). Chick and mouse KO studies have 
highlighted possible roles during cardiac development and trabeculae formation. 
It is, therefore, hypothesised that semaphorin signalling may be disrupted in 
Rac1 mutant hearts. Based on literature research and reanalysis of microarray 
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data, ligands Sema3a and Sema4c, and receptor Nrp-1, represented good 
candidates to investigate in Rac1TnTCre hearts (Gu et al., 2003; Ko et al., 2005; 
Perala et al., 2005; Ieda et al., 2007). E10.5 embryos were dissected and 
processed for slide in situ hybridisation or immunostaining.  
Within the ventricles, Sema4c is expressed throughout the myocardium but is 
strongly expressed in the epicardium and some endocardial cells (Figure 138A). 
In Rac1TnTCre hearts, Sema4c expression is substantially and specifically 
reduced in the myocardium, however the expression is retained in the 
epicardium and endocardium (Figure 138B and C). This expression pattern is 
similar to that seen with Rac1 Exon4-5 probe (Figure 34). Nrp1 shows a similar 
expression pattern to Sema4c in controls (Figure 138D) and also appears 
reduced in the myocardium of Rac1TnTCre hearts (Figure 138E).  
Sema3A is strongly expressed in subendocardial regions of the trabeculae 
myocardium early in development, and is then restricted to the purkinje fibres 
later in development (Behar et al., 1996; Ieda et al., 2007). At E10.5, Sema3a 
expression appears to be restricted to endocardial cells and some epicardial 
cells (Figure 139). Expression of Sema3a is comparable between controls and 
Rac1TnTCre hearts (Figure 139).  
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Figure 138: In situ hybridisation of Sema4c and Nrp1 in E10.5 control and 
Rac1TnTCre hearts.  
Within the ventricles, Sema4c is expressed throughout the myocardium but is 
strongly expressed in the epicardium and some endocardial cells (A). In 
Rac1TnTCre hearts, Sema4c expression is reduced in the myocardium (asterisk 
in B and C, compared to asterisk in A) but the expression is retained in the 
epicardium and endocardium (arrows in B and C, compared to arrows in A) 
(n=3). Nrp1 shows a similar expression pattern to Sema4c in controls (D) and 
also appears reduced in the myocardium of Rac1TnTCre hearts (E) (n=3). E; 
embryonic day, RV; right ventricle, LV; left ventricle. Scale bars; A-D 200µm, A’-
D’’ 100µm. 
 
 
Figure 139: Sema3a IF staining of E10.5 control and Rac1TnTCre transverse 
sections.  
At E10.5, Sema3a expression appears to be restricted to endocardial cells and 
some epicardial cells. Expression of Sema3a is comparable between controls 
and Rac1TnTCre hearts (arrows in C-F compared to arrows in A-B) (n=3). LV; left 
ventricle, RV; right ventricle. Scale bars; 50µm. 
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5.3.11 Extracellular matrix 
In the heart, ECM is produced by cardiomyocytes and myocardial fibroblasts 
and consists of mainly type I, III and IV-type collagen, laminin, fibronectin and 
proteoglycans. One of the many functions of the ECM is a structural and 
signalling role during the formation and remodelling of the trabeculae. Mice 
lacking in ECM proteins fail to form trabeculae (Yamamura et al., 1997; 
Camenisch et al., 2000). It was therefore hypothesised that the composition of 
the ECM may be disrupted during trabeculae formation in Rac1TnTCre hearts. To 
investigate the composition of the ECM in Rac1TnTCre hearts, histology and 
immunofluorescent staining for main ECM proteins was carried out.   
Histology stains including Alcian blue, Sirius red, Toluidine blue and Miller’s 
elastin allow visual localisation of ECM proteins and were carried out on control 
and Rac1TnTCre wax sections (n=4).  
Miller’s elastin stains elastin in blue and counterstaining with eosin allows 
contrast imaging. Staining of E12.5 sections did not reveal any elastin in the 
developing myocardium in either controls or Rac1TnTCre hearts (Figure 140A-B). 
Toluidine blue is a basic thiazine metachromatic dye which stains nuclei in blue 
and proteoglycans and GAGs in purple. Staining of E12.5 sections did not 
reveal any GAGs in the developing myocardium in either controls or Rac1TnTCre 
hearts (Figure 140C-D). Alcian blue stains the alcianophilic proteoglycans of the 
ECM in a blueish stain and counterstaining with nuclear fast red allows contrast 
imaging. Staining of E12.5 sections showed proteoglycans within the 
subepicardial and subendocardial spaces, however there was no difference in 
expression between controls and Rac1TnTCre hearts (Figure 140E-F). Sirius red 
stains collagen I and collagen III red. Staining of E12.5 sections showed the 
collagen matrix surrounding the cardiomyocytes of the myocardium (Figure 
140G-H). In Rac1TnTCre hearts, the collagen matrix appeared disrupted and 
compared to controls (Figure 140G-H).  
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Figure 140: Miller’s Elastin, Toluidine Blue, Alcian blue and Sirius red 
histology staining of E12.5 control and Rac1TnTCre transverse sections.  
Miller’s elastin stains elastin blue and counterstaining with eosin allows contrast 
imaging (A-B). Staining of E12.5 sections did not reveal any elastin in the 
developing myocardium in either controls or Rac1TnTCre hearts (A-B) (n=4). 
Toluidine blue is a basic thiazine metachromatic dye that stains nuclei in blue 
and proteoglycans and GAGs in purple (C-D). Staining of E12.5 sections did not 
reveal any GAGs in the developing myocardium in either controls or Rac1TnTCre 
hearts (C-D) (n=4). Alcian blue stains the alcianophilic proteoglycans of the 
ECM in a blueish stain and counterstaining with nuclear fast red allows contrast 
imaging (E-F). Staining of E12.5 sections did not reveal any differences in 
proteoglycan expression within the ventricle wall in Rac1TnTCre hearts compared 
to controls (E-F) (n=4). Sirius red stains collagen I and collagen III red (G-H). 
Staining of E12.5 sections revealed disrupted collagen matrix within the 
myocardium in Rac1TnTCre hearts compared to controls (G-H) (n=4). LV; left 
ventricle, RV; right ventricle. Scale bars; A-H 200µm, A’-H’’ 50µm.  
 
The main components of the ECM include collagens, laminins and fibronectins. 
Since the Sirius Red histology staining revealed aberrant collagen expression 
within the myocardial wall at E12.5, collagen expression was investigated 
earlier at E11.5, as well as expression of crucial components of the ECM during 
cardiac development; laminin (Beck et al., 1990). and fibronectin(Astrof et al., 
2007). 
Laminin is expressed on the basal membrane of cardiomyocytes early in 
ventricular development (Figure 141). Laminin IF staining within the 
myocardium appears normal at E9.5 and E10.5 in Rac1TnTCre hearts compared 
to controls (n=4) (Figure 141A-O). However, at E11.5 laminin is aberrantly 
expressed around cardiomyocytes of the compact myocardium (n=4) (Figure 
141P-W). This aberrant expression of laminin appears to correlate with 
disrupted collagen expression at E11.5 (n=4) (Figure 142, C compared to A). 
The disrupted ECM, could explain why endomucin-positive endocardial cells 
become ‘trapped’ within the compact myocardium in Rac1TnTCre hearts (arrow in 
Figure 142, D compared to B).  
Fibronectin is expressed in the sub-epicardial matrix during early ventricular 
development (Figure 143). Fibronectin IF staining within the myocardium is 
expanded in Rac1TnTCre hearts compared to controls (n=4), with fibronectin 
expression aberrantly located in-between cardiomyocytes on the epicardial side 
of the compact myocardium (arrows in Figure 143, C-D and G-H). 
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Figure 141: Laminin IF staining of E9.5-11.5 control and Rac1TnTCre 
transverse sections.  
IF staining shows strong laminin expression in the sub-endocardium and sub-
epicardium at E9.5 (A-F) and E10.5 (G-O) in both control and Rac1TnTCre hearts. 
This expression pattern is continued at E11.5 in control hearts (P-S), however in 
Rac1TnTCre hearts, laminin appeared to be aberrantly expressed around 
individual cardiomyocytes within the compact myocardium (A-W). Expression 
was comparable in both the left and right ventricles (n=4). LV; left ventricle, RV; 
right ventricle. Scale bars; A and D 100µm, all others 50µm. 
 
 
Figure 142: Sirius red and Laminin IF staining of E11.5 control and 
Rac1TnTCre transverse sections.  
In Rac1TnTCre hearts, laminin is aberrantly expressed around individual 
cardiomyocytes within the compact myocardium (arrow heads in D compared to 
B) and endomucin appeared trapped within the compact myocardium (arrows in 
D compared to B) (n=4). Secondary only control (E). LV; left ventricle. Scale 
bars 50µm. 
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Figure 143: Fibronectin IF staining of E11.5 control and Rac1TnTCre 
transverse sections.  
Fibronectin is expressed in the sub-epicardial matrix during early ventricular 
development. Fibronectin IF staining within the myocardium is expanded in 
Rac1TnTCre hearts compared to controls (n=4), with fibronectin expression 
aberrantly located inbetween cardiomyocytes on the epicardial side of the 
compact myocardium (arrows in C-D and G-H). Secondary only control (I). LV; 
left ventricle, RV; right ventricle. Scale bars 50µm.  
5.3.12 Rac1 interactors 
Since Mena is known to interact with Rac1 in cardiomyocytes and a previous 
study suggests Mena is required for the migration of cardiomyocytes into the 
trabeculae layer (Toyofuku et al., 2004b; Ram et al., 2014), investigatation of 
Mena expression in Rac1TnTCre hearts was carried out. IF using an anti-Mena 
antibody was carried out on E10.5 transverse sections to determine if Mena 
expression was altered in Rac1TnTCre hearts. At E10.5, Mena expression 
appears to across all cell layers of the developing ventricle, including 
cardiomyocytes (Figure 144A-I’). In controls, expression of Mena is significantly 
greater in the trabeculae myocardium compared to the compact myocardium 
(Figure 144A-D’). This pattern is lost in Rac1TnTCre hearts as the expression of 
Mena in the trabeculae myocardium is similar to that of the compact 
myocardium (Figure 144E-I’). Overall expression of Mena is reduced in 
Rac1TnTCre hearts compared to controls (Figure 144, G-H compared to A-D). 
Intensity analysis using ImageJ software revealed that Rac1 is significantly 
increased in the trabeculae of control ventricles compared to the compact layer, 
however in Rac1TnTCre ventricles this difference in staining intensity is 
unchanged between the two layers of the ventricles (P<0.05) (Figure 144J). 
Therefore Mena expression in the trabeculae layer is significanly reduced in 
Rac1TnTCre hearts  as compared to controls (P<0.05) (Figure 144J). Overall 
intensity in the compact layer is reduced in Rac1TnTCre ventricles but this 
difference is not significant (Figure 144J). 
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Figure 144: Mena IF staining of E10.5 control and Rac1TnTCre transverse 
sections.  
In controls, expression of Mena is greater in the trabeculae myocardium 
compared to the compact myocardium (A-D). This pattern is lost in Rac1TnTCre 
hearts as the expression of Mena in the trabeculae myocardium is similar to that 
of the compact myocardium (F-H) (n=4). Staining intensity analysis (J). 
Expression of Mena is significantly reduced in the trabeculae layer of Rac1TnTCre 
hearts compared to controls (* P<0.05). LV; left ventricle, RV; right ventricle. 
Scale bars 50µm. Secondary only control (K). Statistical analysis carried out 
using a two-way ANOVA.  
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Additionally, Vav2 is a ubiquitously expressed GEF for Rho family GTPases 
(Abe et al., 2000). At E10.5, Vav2 expression appears across all cell layers of 
the developing ventricle but is strongest in the myocardium (Figure 145). In 
controls, expression of Vav2 is organised on the luminal side of the 
cardiomyocytes, resulting in a visible line of expression through the compact 
myocardium (arrows in Figure 145A-B). The expression pattern of Vav2 is 
disrupted in Rac1TnTCre hearts with Vav2 being expressed throughout the 
cardiomyocytes, and the observed polarity of the normal staining pattern is lost 
within the compact myocardium (Figure 145C-F). 
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Figure 145: Vav2 IF staining of E10.5 control and Rac1TnTCre transverse 
sections.  
At E10.5, Vav2 expression appears across all cell layers of the developing 
ventricle but is strongest in the myocardium. In controls, expression of Vav2 is 
organised on the luminal side of the cell, resulting in a line of expression 
observed through the compact myocardium. The expression pattern of Vav2 is 
disrupted in Rac1TnTCre hearts with Vav2 expressed throughout the cell and the 
line pattern is lost within the compact myocardium (n=4). Secondary only control 
(G). LV; left ventricle, RV; right ventricle. Scale bars 50µm.  
 
Co-immunoprecipitation (Co-IP) was carried out to confirm that Rac1 interacts 
with Vav2 in the embryonic heart. IP was performed on CD1 E15.5 whole heart 
lysate with anti-Rac1 and anti-Vav2 antibodies. The enriched protein lysates 
were run on a gel along with total heart lysate and blotted for Rac1 and Vav2 
antibodies (assistance from Kate Bailey). Expected protein size for Rac1 is 
21kDa and for Vav2 is 101kDa. The Co-IP shown in Figure 146 demonstrates 
that Rac1 and Vav2 interact in the embryonic heart. However, a negative 
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control (no antibody or a non-specific antibody) was not included in this 
experiment and therefore, a limitation of the result interpretation is that 
Rac1/Vav2 binding to the Co-IP beads rather than a physical interaction 
between the proteins cannot be ruled out.  
Rac1 and Mena Co-IP was also tried but this did not work on E15.5 hearts, 
possibly due to the Mena antibody not detecting at a low level.  
  
Figure 146: Co-IP analysis shows Rac1 and Vav1 interact in embryonic 
hearts.  
IP performed on CD1 E15.5 whole heart lysate with anti-Rac1 and anti-Vav2 
antibodies. The enriched protein lysates were run on a gel along with total heart 
lysate and blotted for Rac1 and Vav2 antibodies (assistance from Kate Bailey). 
Expected protein size for Rac1 is 21kDa and for Vav2 is 101kDa.  
 
These results suggest that Rac1 interacts with both Mena and Vav2 in 
cardiomyocytes to regulate trabeculation and compact myocardial thickening 
(Figure 147). Vav2 and Mena expression is altered at E10.5 in the absence of 
Rac1. In controls Vav2 is expressed on the luminal edge of cardiomyocytes, 
however in Rac1TnTCre hearts Rac1 is aberrantly expressed around all sides of 
the cardiomyocytes. Mena expression is strongest in the trabeculae layer in 
controls but is reduced to similar levels to the compact layer in Rac1TnTCre 
mutants.  
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Figure 147: Rac1 interacts with Mena and Vav2 to regulate early ventricular development. Vav2 and Mena expression 
is altered at E10.5 in the absence of Rac1.  
In controls Vav2 is expressed on the luminal edge of cardiomyocytes, however in Rac1TnTCre hearts Rac1 is aberrantly 
expressed around all sides of the cardiomyocytes, suggesting loss of cell polarity. Mena expression is strongest in the 
trabeculae layer in controls but is reduced to similar levels to the compact layer in Rac1TnTCre mutants. 
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5.4 Discussion  
 
The aim of this chapter was to dissect the cellular mechanisms of Rac1 in 
cardiomyocytes during the maturation of the ventricular myocardium, and to 
identify the primary cause of the myocardial defects in Rac1TnTCre hearts, as 
described in Chapter 3.  
Myocardial deletion of Rac1 during embryonic development resulted in severe 
myocardial defects including a thinned myocardial wall and sparse trabeculae 
formation. This data suggested that Rac1 plays a crucial role in the trabeculae 
development and thickening of the myocardium. It was hypothesised that 
disrupted cell polarity and/or cellular organisation leads to defective trabeculae 
formation and reduced compact myocardial proliferation. To investigate this 
hypothesis the Rac1TnTCre hearts were characterised the at the onset of 
myocardial defects and the key regulatory cellular processes involved at this 
stage of embryonic development were examined.   
Early in development, at around E9.5, trabeculae formation initiates. Trabeculae 
are found in all vertebrates and are a landmark in the initiation of ventricular 
chamber formation (Christoffels et al., 2000). In Rac1TnTCre hearts initial 
trabeculae formation appears unaffected, with trabeculae forming between 
E9.5-E10.5. This introduces a novel idea of different waves of trabeculae 
formation, and therefore it is hypothesised that Rac is involved in the ‘second’ 
wave of trabeculae formation. From E10.5, trabeculae formation is disrupted, 
with fewer trabeculae forming and large gaps in the compact myocardium that 
are lacking in trabeculation. The processes involved in trabeculation include 
cardiomyocyte proliferation, maturation, adhesion and migration and these can 
be regulated by changes in gene expression, cytoskeletal arrangements and 
signalling between the myocardium and endocardium. Since Rac1 is known to 
be involved in many of these processes, each of them were investigated in 
Rac1TnTCre hearts by various methods. In addition, the expression of two 
potential Rac1 interactors during the onset of the defects in ventricular 
myocardial development was analysed.  
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5.4.1 Rac1 deletion does not affect cardiomyocyte proliferation    
Cell cycle progression occurs normally in Rac1TnTCre cardiomyocytes compared 
to control cardiomyocytes. Cell cycle gene expression within whole hearts was 
unchanged and the percentage of cardiomyocytes undergoing proliferation and 
apoptosis was comparable between control and Rac1TnTCre cardiomyocytes. 
Rac1TnTCre hearts display a severely thinned myocardium and fewer trabeculae 
in a cross-sectional view through the ventricle, however, Rac1TnTCre hearts are 
significantly increased in size compared to control hearts and hence the total 
cell number is equal between control and Rac1TnTCre hearts at E15.5. It is 
therefore proposed that in Rac1TnTCre hearts normal levels of cardiomyocyte 
proliferation is leading to continued ballooning in the ventricles, with little 
contribution to increasing the thickness of the myocardial wall and trabeculation. 
This conclusion suggests that cardiomyocytes have disrupted proliferation 
directionality in Rac1TnTCre hearts.  
The lack of changes in either proliferation or cell death in Rac1TnTCre hearts is in 
agreement with Abu-Issa et al., who did not show any changes in proliferation 
or cell death in the myocardium of Rac1;Nkx2.5-Cre mice at E11.5, as 
determined by BrdU and TUNEL analysis respectively (Abu-Issa, 2014). 
However, they did not comment on the development of a severely thinned 
myocardium in the absence of proliferation or apoptosis differences. Leung et 
al. attributed the thinned RV myocardium in Rac1;Mef2c-Cre hearts to an 
increase in apoptosis in cardiomyocytes, with no change in cardiomyocyte 
proliferation (Leung et al., 2014). Although this analysis was carried out in E11.5 
hearts, when the cardiac phenotype was already established. Additionally, 
deletion of fellow PCP protein Scrib in cardiac progenitors caused a significantly 
thinned myocardium without any changes in pHHH3 or caspase-3 expression, 
at E10.5, before the onset of cardiac abnormalities (Boczonadi et al., 2014b).  
Rac1 is known to be involved in cell cycle regulation, for example, the 
expression of a dominant negative form of Rac1 in rat fibroblasts causes growth 
arrest in the G2/M phase of the cell cycle (Moore et al., 1997). Although this is 
the case in various cell types, Rac1 does not appear to regulate the cell cycle in 
embryonic cardiomyocytes.  
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5.4.2 Rac1 deletion disrupts cardiomyocyte maturation  
Early cardiomyocyte differentiation occurs normally in Rac1TnTCre hearts; the 
myocardium expresses classic cardiomyocyte differentiation markers α-SMA, 
MF20, α-actinin, cardiac-actin and SM22α at E9.5 and E10.5. This is similar to 
Notch1 mutants where defects in the endocardium and trabeculae myocardium 
were observed despite early ventricular myocardial differentiation being 
unaffected (Grego-Bessa et al., 2007). However, later in development, the 
maturation of the cardiomyocytes appears affected, with disrupted expression of 
SM22α and α-SMA within the compact myocardium and trabeculae 
myocardium. Rac1TnTCre cardiomyocytes fail to downregulate the expression of 
these proteins as the myocardium matures. It is speculated that the altered 
expression of SM22α and α-SMA is secondary to the abnormal development of 
the heart. Additionally, divergent maturation of the cardiomyocytes within the 
compact and trabeculae myocardium compartments is altered. Trabeculae 
marker Peg1 is abnormally expressed in the compact myocardium at E10.5. 
Peg1, a paternally imprinted gene, is preferentially expressed in the trabeculae 
cardiomyocytes and is absent from the compact myocardium, OFT and AVJ 
during cardiac development stages E9-E12 (King et al., 2002). Peg1 knockout 
mice develop subtle but consistent abnormalities in the pattern of trabeculae; 
the trabeculae are fewer, and appear thicker and more irregular (King et al., 
2002). This phenotype is a subtle version of the abnormalities that have been 
described in this thesis in Rac1TnTCre hearts. These similarities suggest that 
alterations in Peg1 expression may contribute to the abnormal trabeculae 
phenotype in Rac1TnTCre hearts. Peg1 expression was also reduced in Notch 
mutants (Grego-Bessa et al., 2007). However, a link between Rac1 and Peg1 is 
lacking, therefore altered Peg1 expression may be a downstream secondary 
effect of Rac1 deletion. An additional trabeculae marker which is disrupted in 
Rac1TnTCre hearts later in ventricular development is ANF. Expression of ANF, a 
marker of cardiomyocyte growth and differentiation, normally declines in the 
ventricle rapidly near birth whereas expression in the atrium is maintained 
(Temsah and Nemer, 2005). During early chamber development, ANF is more 
strongly expressed in the LV compared to RV, becoming restricted to the LV 
and absent from the RV later in development (Christoffels et al., 2000). 
Expression of ANF was retained in the RV of E15.5 Rac1TnTCre hearts. 
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Disrupted ANF has been reported in several other mutants with myocardial 
phenotypes. E17 Jumonji mutants exhibited a higher expression level of ANF 
than the wild type, suggesting a defect in downregulation of ANF (Lee et al., 
2000). Jumonji mutants display cardiac defects similar to Rac1TnTCre embryos; 
DORV with abnormal development of the ventricular walls. Jumonji is a nuclear 
protein that regulates proliferation and is expressed in the myocardium of the 
ventricles and OFT (Toyoda et al., 2003). ANF was also aberrantly expressed in 
Hey2 cardiomyocyte mutants and increased in Hand2 endocardial mutants that 
display VSD and hypotrabeculated ventricles (Togi et al., 2006; Xin et al., 
2007). The retained ANF expression gives further evidence of perturbed 
maturation of the myocardium.    
5.4.3 Rac1 deficient cardiomyocytes are less adhesive  
Cardiomyocyte adhesion is affected from E11.5 in the myocardium of 
Rac1TnTCre hearts. Expression of ICD proteins, including AJ proteins, gap 
junction proteins and desmosomal proteins, is reduced in between 
cardiomyocytes, suggesting reduced adhesiveness and connectivity within the 
myocardium of Rac1TnTCre hearts. Tight junctions are highly expressed in 
endothelial cells of the developing endocardium; however they are relatively 
absent in the embryonic cardiomyocytes that were investigated. Therefore, it 
was not possible to fully consider the effect of Rac1 deletion on tight junction 
formation and localisation, which may be disrupted later in embryonic 
development. The junctions of the ICD are affected subsequent to the onset of 
disrupted protein expression which contributes to the phenotype at E10.5. 
Mutations in ICD proteins can lead to cardiovascular defects (Li et al., 1996; 
Linden et al., 2001; Zhao et al., 2005), therefore the alterations observed in the 
ICD may lead to further disruption of myocardial development. This is in 
agreement with Leung et al, and Abu Issa that described altered β-catenin 
expression at E13.5 in Rac1;Mef2c-Cre hearts and at E11.5 in Rac1;Nkx2.5-
Cre cardiomyocytes in culture respectively (Abu-Issa, 2014; Leung et al., 2014). 
5.4.4 Gene expression changes are minimal in Rac1TnTCre hearts  
As determined by microarray analysis of E10.5 hearts, there were very few 
changes in gene expression levels in Rac1TnTCre hearts compared to controls. In 
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addition, the small number of changes that were detected were not able to be 
confirmed in additional hearts or at a protein level. This is unsurprising since 
Rac1 is not a transcription factor and although Rac1 is known to regulate gene 
expression through its activation of JNK and SRF (Hill et al., 1995; Minden et 
al., 1995), this may not be applicable to its role in cardiomyocytes during 
development.  
5.4.5 Cytoskeleton arrangements are disrupted in Rac1TnTCre hearts 
Rac1TnTCre cardiomyocytes have disrupted sarcomere formation; actin myofibrils 
are thin and disorganised, and Rac1 is known to regulate the actin cytoskeleton; 
Rac1 is essential in endothelial cells for regulation of the actin cytoskeleton and 
lamellipodia protrusion formation that is necessary for endothelial cell migration 
(Tan et al., 2008). Immunostaining for cardiac-actin and α-actinin did not reveal 
any visible changes in the actin cytoskeleton. However, TEM imaging detected 
thin myofibrils forming in aberrant directions in Rac1TnTCre cardiomyocytes. TEM 
is capable of significantly higher resolution images compared to fluorescent 
microscopy and therefore allows a more in-depth analysis of the actin 
cytoskeleton. Additionally, since actin myofibrils are only just beginning to form 
and align at E10.5, some cardiomyocytes displayed less developed actin 
myofibrils than others, dependent on their position in the compact and 
trabeculae myocardium. It was, therefore, difficult to investigate any disruptions 
by IF and TEM images of comparable regions of control and Rac1TnTCre 
ventricles was necessary. Similar to our findings, Leung et al. found a deficiency 
in long actin filaments in PO hearts using phallodin staining of F-actin (Leung et 
al., 2014). Disruptions of the actin filaments causes myocardial defects. For 
example, mice lacking α-tropomyosin-1, a regulatory protein of the actin thin 
filaments, develop enlarged, misshapen and non-beating hearts, with a thinned 
myocardium and fewer trabeculae (McKeown et al., 2014). This phenotype is 
similar to the Rac1TnTCre hearts and similarities within the myocardium include 
reduced striated myofibrils and smaller adherens junctions (McKeown et al., 
2014).  
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5.4.6 Disruptions to the endocardium and epicardium as a result of Rac1 
myocardial deletion  
The changes observed in myocardial maturation, adhesion and cytoskeleton, 
and directionality of compact myocardium proliferation and trabeculation appear 
to affect the development of the endocardium. Early in ventricular development, 
endocardial cells were observed trapped within the compact myocardium and 
the endocardial cells at the base of the trabeculae did not project into the 
compact myocardium as in controls. Additionally, coronary vessel formation is 
affected, with no large vessels present in the compact myocardium of 
Rac1TnTCre hearts and smaller blood vessels appear to be forming in aberrant 
directions.  
Signalling pathways between the endocardium and myocardium are crucial for 
the development of both layers during ventricular development. Some of the 
main signalling pathways, Notch, VEGF and Semaphorin, were investigated, 
however any changes in these pathways appeared secondary to the myocardial 
defects.  
The Notch signalling pathway is the main pathway thought to be responsible for 
the initiation of trabeculation, with many Notch mutants displaying severe 
trabeculation defects (Grego-Bessa et al., 2007). However, the Notch signalling 
pathway was unaffected in Rac1TnTCre hearts. N1ICD was expressed in the 
endocardium and downstream effector Hey2 was expressed in the myocardium 
as in controls. Additional Notch signalling pathway genes Nrg1/ErbB2/4 and 
Bmp10 were also unaffected. This is not surprising since initial trabeculae 
formation appears unaffected. These results therefore highlight that there is a 
novel pathway of trabeculation involving Rac1 during the second phase of 
trabeculation.  
VEGF signalling appeared normal at E10.5 with both the ligand and receptor 
expressed in the myocardium and endocardium respectively. However at E11.5, 
VEGFR-2 was reduced in the endocardium where no trabeculae were forming. 
Rac1 promotes VEGF-induced endothelial cell migration by stimulating the 
formation of lamellipodia and membrane ruffles. Inhibiting Rac1 in human 
endothelial cells using a dominant negative approach led to reduced Vegfr-2 
mRNA and protein expression (Meissner et al., 2009). In developing ventricles, 
movement and differentiation of the cardiomyocyte forming a trabeculae may 
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trigger VEGFR-2 expression in the adjacent endocardium. Therefore, VEGFR-2 
expression may be downregulated as a consequence of the lack of trabeculae 
in Rac1TnTCre hearts.   
There was no difference in the expression of Sema3a or receptor Nrp1. 
However, Sema4c was strikingly reduced in the compact myocardium, similar to 
the targeted reduction of Rac1 in the myocardium. Little has been published 
about Sema4c in the heart, but it is known to be required for myogenic terminal 
differentiation (Ko et al., 2005; Wu et al., 2007). Rac1 and Sema4C are not 
known to interact however Sema4C is linked with Rac1 GEF, Git1, in non-small-
cell lung cancer (Li et al., 2015) and expression of active Rac enhances the 
ability of Plexin-B1 to interact with fellow Sema4D, by stimulating the 
localisation of Plexin-B1 to the cell surface (Vikis et al., 2002). Rac1 is known to 
interact directly with the intracellular domain of PlexinA and PlexinB family 
members, to both regulate receptor activity and propagate downstream 
signalling processes (Vikis et al., 2000; Vikis et al., 2002; Turner et al., 2004; 
Tong and Buck, 2005; Bell et al., 2011). These studies suggest that Rac1 
deficiency affects Sema4c expression,  
In addition to the signalling pathways mentioned above, the ECM also supports 
both the endocardium and myocardium, and is crucial to signalling between the 
two layers. Several components of the ECM are disrupted in Rac1TnTCre hearts. 
Collagen, laminin and fibronectin expression all appear disturbed and increased 
inbetween cardiomyocytes. The expression pattern of collagen is altered within 
the myocardial layer, laminin is aberrantly expressed between cardiomyocytes 
of the compact layer and fibronectin expression is expanded into the compact 
layer from the subepicardium and is expressed between cardiomyocytes. In 
fibroblasts, Rac1 facilitates MMP mediated matrix remodelling and Rac1 
inhibitor prevented matrix degradation (Tovell et al., 2012). The deletion of Rac1 
could lead to the upregulation or increased secretion of ECM proteins or the 
downregulation or decreased secretion of ECM degradation proteins in 
cardiomyocytes. However, in the absence of transcriptional changes, it is 
proposed that altered cardiomyocytes cytoskeleton and adhesion leads to 
disrupted organisation of the myocardium and its surrounding ECM. The 
increased fibronectin between the myocardial and epicardial layer is indicative 
of epicardial disfunction. This along with the absence of coronary vessels in 
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Rac1TnTCre and Rac1Gata5Cre hearts and the presense of epicardial blisters in 
Rac1Gata5Cre hearts is suggestive of a secondary epicardial phenotype due to 
defects in the myocardium.  
5.4.7 Rac1 interactors 
Mena, a regulator of actin filament assembly and ICD composition, is localised 
at the ICD and Z-discs where it co-localises with numerous cytoskeletal proteins 
(Benz et al., 2013). At the ICD Mena co-localised with Cx-43, cadherin and 
vinculin. Mena associates with active Rac1 in cardiomyocytes and is increased 
in cardiomyocytes overexpressing Rac1 (Ram et al., 2014). It was shown that 
Mena is reduced in the myocardium of Rac1TnTCre hearts compared to controls 
at E10.5 and that Cx-43 expression at the ICD is altered from E11.5. These 
results imply that Rac1 and Mena interact in cardiomyocytes and that Mena 
expression is altered in the absence of Rac1. αII-Spectrin is part of the 
Mena/VASP complex and is important for formation and stability of actin 
networks in the heart. αII-spectrin KO embryos die in utero and develop 
abnormal cardiac shape, cardiac dilation and thinning of the myocardium similar 
to Rac1 myocardial mutants (Benz et al., 2013). Cardiomyocytes expressing a 
mutant version of Mena were shown to remain in the compact myocardial layer, 
suggesting Mena is required for the migration of cardiomyocytes into the 
trabeculae layer (Toyofuku et al., 2004b). It was shown that Mena is more 
highly expressed in the trabeculae cardiomyocytes as compared to those in the 
compact layer. This distinction between the expression of Mena in the 
trabeculae compared to compact myocardium is lost in the Rac1TnTCre hearts. 
These findings suggest that Mena is required for trabeculae specification and 
migration from the compact layer. In Rac1TnTCre hearts, cardiomyocytes appear 
to have lost their directionality, with less migration into the trabeculae layer and 
fewer trabeculae formed. It is concluded that Rac1-Mena interactions are 
required for the directionality of cardiomyocyte movement, both in the thickening 
of the compact layer and in the process of trabeculation.  
Vav2, an exchange factor for Rho family GTPases (Abe et al., 2000), is 
associated with active Rac1 in endothelial cells (Liu and Burridge, 2000), and 
this thesis presents novel data to show that Vav2 and Rac1 are both expressed 
in cardiomyocytes. Vav2 is known to be required for the formation of actin 
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filaments and in this Chapter it is shown that Vav2 interacts with Rac1 in the 
embryonic heart. Our analysis using IF revealed that the localisation of Vav2 is 
disrupted in E10.5 Rac1TnTCre hearts. In controls Vav2 is expressed on the 
luminal edge of cardiomyocytes, however in Rac1TnTCre hearts Vav2 is 
aberrantly expressed around all sides of the cardiomyocytes, suggesting 
disrupted cardiomyocyte polarity. 
5.4.8 Myocardial disorganisation in Rac1TnTCre is due to altered Rac1-
Mena-Vav2 interactions 
The alterations in Mena and Vav2 expression suggests a role of both of these 
proteins in the disruption of the actin cytoskeleton and disorganisation of the 
compact myocardium seen in Rac1TnTCre hearts. At E9.5 there are no 
abnormalities in Rac1TnTCre mutants. The changes in Mena and Vav2 
expression appear at E10.5, which is at the onset of subtle cardiac 
abnormalities; number and directionality of trabeculae begin to be affected and 
actin myofibril formation is disrupted. Therefore, it is proposed that Rac1-
Mena/Vav2 interactions in cardiomyocytes are involved in regulation of the actin 
filaments and ICD assembly. In the absence of these interactions, the actin 
myofibrils are disrupted; TEM imaging highlighted disrupted actin filaments at 
E10.5 (Figure 148). 
Unsurprisingly, since Mena-Rac1 interactions regulate the ICD, cardiomyocyte 
adhesion is affected at later stages of myocardial development with reduced 
ICD junctions; adhesion junctions (β-catenin, N-cadherin) and gap junctions 
(Cx-43) from E11.5. In addition, the myocardium appears disorganised with 
ECM protein expression expanded within the compact myocardium. The altered 
ECM most likely occurs as a consequence to altered cardiomyocyte adhesion 
and organisation due to disrupted Rac1/Mena interaction (Figure 148). 
The disruption of the myocardium affects the endocardium from early in 
ventricular development. As mentioned, the ECM between these two layers is 
affected with altered laminin, fibronectin and collagen expression. The 
endocardium shows reduced VEGFR-2 expression, and endocardial cells 
appear pooled at the base of the trabeculae and appeared trapped within the 
compact layer at E11.5. It is proposed that this is due to the altered ECM 
composition and reduced adhesion between cardiomyocytes. Additionally, the 
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endocardial cells do not protrude into the compact myocardium at the base of 
the trabeculae as in controls. This again could be due to the increased ECM 
surrounding the cardiomyocytes and reduced adhesion. It is hypothesised that 
the lack of these projecting endocardial cells further contribute to the altered 
directionality of the trabeculae as these endocardial cells appear to be 
supporting the trabeculae at the base. Later in development, at E15.5, the 
compact myocardium is lacking in CD31-positive coronary vessels and is 
scattered with endomucin positive cells (Figure 148). The trabeculae seem to 
undergo aberrant remodelling, possibly in order to compensate for the severely 
thinned myocardium, leading to trapping of endocardial cells within the compact 
myocardium.  
Mena appears to be required for movement of cardiomyocytes into the 
trabeculae layer through actin regulation; hence, in the absence of Rac1-Mena 
interaction in Rac1TnTCre cardiomyocytes there is reduced Mena and fewer 
trabeculae formed. The trabeculae that do form appear aberrant in shape and 
size and display altered gene expression including ANF, α-SMA and SM22α 
(Figure 148).  
In Rac1TnTCre hearts, lack of Rac1-Mena/Vav2 interaction leads to 
disorganisation of the myocardial wall, disrupting the directionality of growth of 
the myocardium. Therefore, the heart balloons in size but the compact layer is 
does not undergo thickening and trabeculae formation is reduced. Regulated 
oriented cell division may be required for the initiation or trabeculation, compact 
layer expansion and maintenance of heart shape and size, and is altered in the 
absence of Rac1-Mena-Vav2 interactions.  
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Figure 148: Rac1 interacts with Mena and Vav2 to regulate early ventricular development, which leads to disruption of 
cardiomyocyte cytoskeletion and ICD, in addtion to alterations in the endocardium and coronary vessel formation 
later in development.  
At E10.5 (A) Vav2 and Mena expression is altered in the absence of Rac1. In controls Vav2 is expressed on the luminal edge 
of cardiomyocytes, however in Rac1TnTCre hearts, Vav2 is aberrantly expressed around all sides of the cardiomyocytes, 
suggesting loss of cell polarity. Mena expression is strongest in the trabeculae layer in controls but is reduced to similar levels 
to the compact layer in Rac1TnTCre mutants. As a result of this actin myofibril disruption appears at E10.5 in both compact and 
trabeculae cardiomyocytes. At E11.5 (B), Rac1 deficient cardiomyocytes display altered ICD expression (yellow) and Desmin 
intermediate filaments (red) appear clumpy in the trabecular layer. In addition, ECM proteins laminin (blue) and fibronectin 
(green) are expanded within the compact myocardium. At E12.5 (C), some endomucin-positive cells become trapped within 
the myocardium (green) and trabeculae cardiomyocytes retain strong SM22α expression. Later in development, at E15.5 (C), 
the compact myocardium is lacking in CD31-positive coronary vessels (pink) and is scattered with endomucin positive cells 
(green), and the right ventricle trabeculae retain strong expression of ANF (orange).  
The trabeculae seem to undergo aberrant remodelling, possibly in order to compensate for the severely thinned myocardium, 
leading to trapping of endocardial cells within the compact myocardium. Additionally, the difference between the right and left 
ventricle walls from suggests there is differential remodelling between the two ventricles in mutant hearts. The RV remains thin 
with relatively large numbers of trabeculae compared to controls, whereas the LV thickens and becomes smooth on the inner 
surface with relatively few trabeculae. However, this thickened left ventricular wall is less densely packed than in controls and 
contains ‘trapped’ endomucin positive endocardial cells. 
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Chapter 6. Final Discussion 
 
6.1 Summary 
Heart development in mammals is a very complex and highly regulated 
process. When heart development is disrupted CHDs can arise. CHDs are the 
most common form of birth abnormalities and in the majority of cases the cause 
is unknown. Evidence suggests that abnormalities occurring in utero can 
predispose individuals to heart disease in adult life. Therefore, investigating the 
genetic causes of CHD is relevant to treatment of both CHD and adult CVD.  
Rac1, a member of the Rho family of small GTPases, is involved in a variety of 
cellular processes, such as cell migration, polarity, survival, morphology, 
proliferation and differentiation. Rac1 has been shown to play a critical role 
during embryonic development (Sugihara et al., 1998) and appears to be 
reactivated during CVD (de las Fuentes et al., 2012).  
During heart development, the FHF forms the linear heart tube, consisting of a 
myocardial layer with an inner endocardial layer. Over the course of embryonic 
development, the linear tube loops and septates to form the four-chambered 
heart. This process requires the addition of extra-cardiac populations including 
the PE, NCC and SHF. At the onset of this thesis, the role of Rac1 in 
endothelial cells and NCC had been investigated in previous publications (Tan 
et al., 2008; Thomas et al., 2010). The role of Rac1 in adult cardiomyocytes 
during CVD had been studied in many publications (Higuchi et al., 2003; 
Buscemi et al., 2005; Satoh et al., 2006). However, studies investigating the 
role of Rac1 in epicardial cells and cardiomyocytes during embryonic 
development were lacking. Therefore, genetically modified mice were used to 
delete Rac1 from these cell populations and investigate the role of Rac1 during 
cardiovascular development. Since the onset of this project however, two 
papers have been published investigating the role of Rac1 within 
cardiomyocytes by conditionally deleting Rac1 from cardiac mesoderm 
progenitors and SHF progenitors (Abu-Issa, 2014; Leung et al., 2014). These 
papers use Mef2c-Cre and Nkx2.5-Cre transgenic mouse lines to conditionally 
delete Rac1, which differ from our TnT-Cre mediated deletion as the Cre lines 
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include additional cell types as well as cardiomyocytes. These studies 
suggested that Rac1 is critical for cardiomyocyte polarity and adhesion during 
heart development. However, Abu-Issa provides very limited phenotyping data 
and poor quality immunostaining in cultured cardiomyocytes (Abu-Issa, 2014) 
and Leung et al. investigated gene transcriptional changes in hearts with a 
severe phenotype at E13.5, therefore the altered gene expression quantified 
could to be secondary to cellular changes (Leung et al., 2014). Additionally, 
both Abu Issa and Leung and colleagues use conditional deletions of Rac1 
which include multiple cell types, and are therefore, unable to identify the role of 
Rac1 solely in cardiomyocytes during myocardial development. Thus the role of 
Rac1 in early myocardial development remains unclear, particularly during the 
formation of the trabeculae and compaction of the myocardium. The work in this 
thesis confirms the findings of both Leung et al. and Issa; that Rac1 is required 
in cardiomyocytes for normal heart development and deletion of Rac1 results in 
cardiac abnormalities. In addition, as outlined below, this thesis gives an in 
depth evaluation of the role of Rac1 in pure epicardial and myocardial 
populations during embryonic heart development and identifies primary 
changes in cell morphology and protein expression at the onset of cardiac 
defects.  
Work in this thesis confirmed that Rac1 is expressed in the embryonic heart, 
within the myocardium, endocardium and epicardium layers. It was shown 
through several genetic mouse crosses that Rac1 is crucial in cardiomyocytes 
for myocardial development, whilst expression in the epicardium may not be 
required. Myocardial deletion of Rac1 resulted in reduced trabeculation, 
myocardial thinning and OFT alignment defects.  
Although TnT-Cre is expressed from E7.5 in Troponin-T expressing 
cardiomyocytes, early cardiomyocyte differentiation is unaffected in Rac1 
myocardial mutants. Additionally, linear heart tube formation and initial 
trabeculae formation are unaltered. These findings suggest that Rac1 is not 
required before E10.5 for cardiomyocytes differentiation and heart morphology. 
This is consistent with reports from Abu-Issa, where despite early activation of 
Nkx2.5-Cre, cardiac mesoderm specification and heart tube formation and 
looping is unaffected in Rac1Nkx2.5Cre embryos (Abu-Issa, 2014).  
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In this project the role of Rac1 has been investigated specifically in 
cardiomyocytes during early ventricular development and two key proteins have 
been identified that interact with Rac1 and show altered expression in the 
absence of Rac1. Unlike the recent publications described, in this thesis primary 
defects have been identified at the point of onset of cardiac abnormalities and 
are separated from the defects which are secondary to the original defects but 
also contribute to the phenotype in later in development. Rac1 deficient 
cardiomyocytes display aberrant expression of Rac1 interacting proteins, Vav2 
and Mena, as well as disruption of the actin cytoskeleton at E10.5. At this time, 
subtle abnormalities begin to appear in the myocardium, including reduced 
trabeculae formation and altered directionality of trabeculae. Subsequently, at 
E11.5, cardiomyocyte adhesion is affected with reduced expression of ICD 
proteins. Therefore, it is proposed from the results in this thesis, that Rac1-
Mena/Vav2 interactions in cardiomyocytes are involved in regulation of the actin 
filaments and ICD composition. Additionally the disruption of these proteins in 
Rac1 myocardial mutants leads to the myocardial disorganisation and altered 
expression of ECM proteins observed within the compact myocardium. The 
altered Rac1-Mena/Vav2 interactions and disorganisation of the myocardium in 
Rac1 myocardial mutants leads to several morphological disruptions as the 
hearts develop.  
After E10.5, trabeculae formation is affected with trabeculae forming in aberrant 
directions and large portions of smooth compact myocardium appear where no 
trabeculae have formed. The migration mechanisms of cardiomyocytes into the 
trabeculae layer remains controversial, however, Rac1 is required in endothelial 
cells for cell migration and Rac1 deficient cells displayed reduced focal 
adhesion and lamellipodia formation with unorganised cell adhesion (Tan et al., 
2008). Therefore, it is proposed that Rac1 is also required for the migration of 
cardiomyocytes into the trabeculae layer, as in endothelial cells, possibly 
through interactions with Mena. Mena has been shown to be required for 
movement of cardiomyocytes into the trabeculae layer (Toyofuku et al., 2004b), 
therefore reduced trabeculation may result from the observed reduction of Mena 
in Rac1 deficient cardiomyocytes. The trabeculae that do form appear aberrant 
in shape and size and display altered gene expression including ANF, α-SMA 
and SM22α.  
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It is proposed that the disorganisation of the myocardial wall disrupts the 
directionality of growth of the myocardium. The compact layer does not undergo 
thickening and trabeculae formation is reduced, resulting in a dilated/ballooning 
heart. Regulated oriented cell division may be required for the initiation or 
trabeculation, compact layer expansion and maintenance of heart shape and 
size. Analysis of this using antibodies against oriented expressed proteins such 
as Aurora B should be investigated to determine if this is altered in the absence 
of Rac1-Mena-Vav2 interactions.  
The disruption of the myocardium affects the development of the endocardium 
from E11.5. Endocardial cells are gathered at the base of the trabeculae and 
are trapped within the compact layer at E11.5. Additionally, the endocardial 
cells do not protrude into the compact myocardium at the base of the trabeculae 
as in controls. Later in development, the trabeculae undergo aberrant 
remodelling, in order to compensate for the severely thinned myocardium, 
leading to trapping of endocardial cells within the compact myocardium. No 
coronary vessels are seen in Rac1TnTCre hearts. The orgin of coronary 
endothelium is still controversial, however several populations have been 
documented, including the SV, epicardium and endocardium.  It is hypothesied 
that Rac1 is required in cardiomyocytes to produce a thickening compact layer  
which allows migration of endocardial cells and also formation of coronary 
vessels from the contributing sources.  
Myocardial deletion of Rac1 does not affect initial OFT formation but leads to 
defects in OFT remodelling and alignment. The DORV/OA defects arise as a 
consequence of the severe abnormalities in ventricular chamber development 
and disrupted ventricular septation. The ventricle myocardium is severely 
thinned in Rac1 myocardial mutants from E12.5, whereas, the OFT myocardium 
and IVS is relatively thick compared to control hearts. This suggests that Rac1 
is not required in cardiomyocytes for the processes occurring in the IVS or OFT 
myocardium, however it is crucial for development of the ventricular free wall 
myocardium. This also suggests, in agreement with previous data, that these 
myocardial populations develop differently (Togi et al., 2006). Mlc2v-Cre is 
highly expressed in the IVS; however there is no disruption of IVS formation in 
Rac1Mlc2v-Cre embryos, and Gata5-Cre is not expressed in the IVS but results in 
VSD similar to Rac1TnTCre hearts. Combination of results from all Cre line 
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crosses suggests Rac1 is selectively required for myocardial maturation in the 
ventricular free wall and is not required for the development of the IVS or OFT 
myocardium. Since Rac1 is expressed ubiquitously throughout the heart, this 
again suggests that these myocardial populations developed differently and 
Rac1 is specifically involved in processes in the free wall ventricular 
myocardium. In Rac1 myocardial mutants, the combination of a thinned ventricle 
myocardium with a thick developed OFT myocardium leads to abnormal heart 
shape and defective OFT positioning later in development. As correct alignment 
of the OFT requires compaction and rotation of the OFT myocardium (Bamforth 
et al., 2001; Watanabe et al., 2001; Bajolle et al., 2006), without the support of 
the ventricle myocardium, the OFT myocardium cannot correctly rotate to 
facilitate OFT alignment in Rac1 myocardial mutants. Additionally, the dilated 
and ballooned shape of the ventricles is likely to impact on atrioventricular 
septation, meaning the aorta remains associated with the RV.  
6.2 Conclusion 
Rac1 and interacting partners Vav2 and Mena are required for actin 
cytoskeleton organisation and ICD arrangement. Thus, Rac1 is required to 
maintain cardiomyocyte organisation within the compact layer of the 
myocardium, which allows orientated cell proliferation required for compact 
myocardial thickening and for the migration of cardiomyocytes into the 
trabeculae layer.  
6.3 Future work 
6.3.1 Rac1 interactions with Mena and Vav2 
The interaction between Rac1 and Mena/Vav2 in cardiomyocytes requires 
further investigation. Absence of gene expression changes from microarray 
analysis suggests that Mena and Vav2 are disrupted on a protein level. Mena is 
significantly reduced in the trabeculae layer and is subtly reduced in the 
compact layer and the cellular localisation of Vav2 is altered. Through the use 
of Co-IP, interactions between Rac1 and Vav2 within the embryonic heart has 
been confirmed. Rac1-Mena interactions were investigated using Co-IP, 
however this was unsuccessful. Since it has been published previously in 
cardiomyocytes, it is possible that this may have been due to the amount of 
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protein analysed and age of tissue investigated (Ram et al., 2014). Mena 
expression is reduced as the heart develops, therefore this analysis should be 
carried out on younger E10.5 hearts; however obtaining enough protein for a 
Co-IP can be technically difficult from such a small amount of tissue. 
Additionally, the same analysis could be carried out in isolated cardiomyocytes 
to confirm the interaction between the proteins in cardiomyocytes alone. 
Since Rac1 has a pivotal role in focal adhesion assembly, possible disruptions 
in focal adhesions in embryonic cardiomyocytes could be analysed by carrying 
out IF staining using focal adhesion protein antibodies such as vinculin, paxillin 
and PAK. The lack of reliability of the antibodies tested did not allow for 
investigation of these proteins in this thesis.  
6.3.2 Role of Rac1 in endocardial cells during ventricular development  
Using endothelial specific Cre line Tie2-Cre, Rac1 was deleted from endothelial 
cells. These embryos die at E9.5 due to developmental delay, with defective 
development of major vessels and complete lack of smaller branched vessels 
(Tan et al., 2008). Since endocardial cells represent a small sub-population of 
endothelial cell, endocardial specific deletion of Rac1 would isolate the role of 
Rac1 in the endocardium. A potential Cre mouse for this experiment is Nrp3-
Cre, as this Cre line is specific to endocardial cells and does not include 
additional endothelial sources such as the SV and epicardium (Zhang et al., 
2016).  
6.3.3 Role of Rac1 in epicardial cells during epicardium formation and 
migration of EDPCs 
The deletion of Rac1 in epicardial cells using WT1-CreERT2 did not affect 
myocardial development during embryonic development. Histology analysis did 
not reveal any cardiac abnormalities at E15.5, specifically myocardial thickening 
is not affected. Additionally the formation of the epicardium and migration of 
EPDCs was not significantly altered as observed by GFP IHC staining. 
However, this deletion may be detrimental to further myocardial and coronary 
vessel development, postnatally, or in the adult heart. Since EPDCs migrate 
into the compact myocardium and differentiate into SMC and endothelial cells of 
the coronary vessels, as well as fibroblasts, these cell populations may be 
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affected in the absence of Rac1. Differentiation markers such as SM22α for 
smooth muscle cells, CD31 for coronary endothelial cells and vimentin for 
cardiac fibroblasts, could be analysed in GFP-positive cells to determine if any 
of these differentiation processes are affected by the loss of Rac1.  
Some of the defects seen in Rac1TnTCre and Rac1Gata5Cre hearts are typical of an 
epicardial phenotype. Further studies could aim to confirm the cause of the 
epicardial defects. The work presented in this thesis suggests the epicardial 
defects are secondary to myocardial defects. However, since Rac1 delection 
was assessed indirectly with EYFP expression in Rac1Gata5Cre and Rac1WT1-
CreERT2, a role of Rac1 in epicardial cells cannot be excluded.   
6.3.4 Additional signalling pathways between the endocardium and 
myocardium  
Additional signalling pathways which may be affected between the myocardium 
and endocardium include FGF, TGF-β and Ang/Tie2 signalling. FGF ligands 
binds to FGF receptors in either a cell autonomous or non-cell autonomous 
manner. In mice, the FGF ligands are expressed in endocardial cells and FGF 
receptors are expressed in endocardial cells as well as in myocardial cells. 
Gene inactivation studies have determined that FGF signalling from endocardial 
to myocardial cells regulates proliferation of the compact myocardium and 
trabeculation, therefore FGF signalling may be reduced in Rac1TnTCre ventricles 
(Mima et al., 1995; Lavine et al., 2005; Lu et al., 2008). TGF-β signalling is 
mediated via a heterotetrameric receptor complex, composed of two TGF-β 
type II (TGFβRII) receptors and two type I (Alk5) receptors. Genetic disruptions 
of this signalling in mice has highlighted a role in ventricular development, and 
results in similar defects to those seen in Rac1TnTCre mutants; Alk5-Gata5-Cre 
mutants have a thinned myocardium with reduced cell-cell adhesion in 
epicardial cells (Sridurongrit et al., 2008; Snider et al., 2014). FKBP12 is 
associated with BMP/TGF-β signalling (Wang et al., 1996) and is expressed at 
high levels in the endocardium, myocardium, and septum.  FKBP12 deficient 
mice die between E14.5 and birth due to severe dilated cardiomyopathy and 
VSD. FKBP12 hearts had thinner left ventricular walls, hypertrophic trabeculae, 
and deep intertrabecular recesses which resembled LVNC (Shou et al., 1998). 
Angiopoietin-1 (Ang-1) is a ligand produced in the myocardium and signals to 
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the Tie2 receptor in the endocardium. This signalling is essential for 
coronary vein formation and normal ventricular maturation (Shalaby et al., 1995; 
Suri et al., 1996). Angiopoietin-1 mutants are embryonic lethal at E12.5, with an 
immature endocardium. The mutants display a ventricular phenotype similar to 
Nrg1/ErbB2/4 mutants. Cardiomyocyte-specific Ang-1 deletion results in 
defective formation of subepicardial coronary veins, but had no significant effect 
on the formation of intramyocardial coronary arteries. Ang-1 regulates 
proliferation, migration and differentiation of immature ECs derived from the SV 
(Arita et al., 2014). These signalling pathways could be investigated by the 
techniques used in this thesis; immunostaining, qPCR and in situ hybridisation.  
6.3.5 Rac1 mutations in Patients  
Patients with abnormal ventricular walls and/or DORV could be screened for 
mutations in Rac1 or interacting partners Mena and Vav2. 
6.4 Final Remarks  
In this thesis, it is shown that Rac1 interactions with Mena and Vav2 act to 
regulate crucial processes that underlie initial trabeculation and compact 
myocardial thickening. This thesis also highlights the differences between the 
development of the left and right ventricles, and therefore should be taken into 
consideration in research and clinical evaluation of the two ventricles. 
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